CN115997011A - 具有工程化衣壳的腺相关病毒 - Google Patents
具有工程化衣壳的腺相关病毒 Download PDFInfo
- Publication number
- CN115997011A CN115997011A CN202180043726.1A CN202180043726A CN115997011A CN 115997011 A CN115997011 A CN 115997011A CN 202180043726 A CN202180043726 A CN 202180043726A CN 115997011 A CN115997011 A CN 115997011A
- Authority
- CN
- China
- Prior art keywords
- seq
- capsid protein
- sequence
- amino acid
- raav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000702421 Dependoparvovirus Species 0.000 title claims abstract description 198
- 210000000234 capsid Anatomy 0.000 title abstract description 110
- 108090000565 Capsid Proteins Proteins 0.000 claims abstract description 286
- 102100023321 Ceruloplasmin Human genes 0.000 claims abstract description 286
- 210000002845 virion Anatomy 0.000 claims abstract description 277
- 210000004027 cell Anatomy 0.000 claims abstract description 228
- 238000010361 transduction Methods 0.000 claims abstract description 129
- 230000026683 transduction Effects 0.000 claims abstract description 129
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims abstract description 69
- 210000002064 heart cell Anatomy 0.000 claims abstract description 57
- 230000001965 increasing effect Effects 0.000 claims abstract description 46
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 221
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 213
- 229920001184 polypeptide Polymers 0.000 claims description 210
- 108090000623 proteins and genes Proteins 0.000 claims description 194
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 104
- 238000000034 method Methods 0.000 claims description 103
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 96
- 230000000747 cardiac effect Effects 0.000 claims description 74
- 102000040430 polynucleotide Human genes 0.000 claims description 66
- 108091033319 polynucleotide Proteins 0.000 claims description 66
- 239000002157 polynucleotide Substances 0.000 claims description 66
- 210000002216 heart Anatomy 0.000 claims description 64
- 150000007523 nucleic acids Chemical class 0.000 claims description 64
- 102000039446 nucleic acids Human genes 0.000 claims description 56
- 108020004707 nucleic acids Proteins 0.000 claims description 56
- 241000282414 Homo sapiens Species 0.000 claims description 47
- 210000001054 cardiac fibroblast Anatomy 0.000 claims description 46
- 208000015181 infectious disease Diseases 0.000 claims description 40
- 238000006467 substitution reaction Methods 0.000 claims description 40
- 239000002773 nucleotide Substances 0.000 claims description 36
- 125000003729 nucleotide group Chemical group 0.000 claims description 36
- 210000005003 heart tissue Anatomy 0.000 claims description 27
- 108010018650 MEF2 Transcription Factors Proteins 0.000 claims description 20
- 102100039229 Myocyte-specific enhancer factor 2C Human genes 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 101000586000 Homo sapiens Myocardin Proteins 0.000 claims description 16
- 102100030217 Myocardin Human genes 0.000 claims description 16
- 108010014480 T-box transcription factor 5 Proteins 0.000 claims description 16
- 102100024755 T-box transcription factor TBX5 Human genes 0.000 claims description 16
- 230000001939 inductive effect Effects 0.000 claims description 14
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 claims description 13
- 102100021380 Transcription factor GATA-4 Human genes 0.000 claims description 13
- 230000001976 improved effect Effects 0.000 claims description 12
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 claims description 11
- 210000005240 left ventricle Anatomy 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 11
- 102100022142 Achaete-scute homolog 1 Human genes 0.000 claims description 10
- 101000901099 Homo sapiens Achaete-scute homolog 1 Proteins 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 210000003494 hepatocyte Anatomy 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 229910052698 phosphorus Inorganic materials 0.000 claims description 9
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 108091060568 Mir-133 microRNA precursor family Proteins 0.000 claims description 6
- 102100038934 Myosin-7 Human genes 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 108091023685 miR-133 stem-loop Proteins 0.000 claims description 6
- 230000002463 transducing effect Effects 0.000 claims description 6
- 108091033409 CRISPR Proteins 0.000 claims description 5
- 102100031509 Fibrillin-1 Human genes 0.000 claims description 5
- 101000846893 Homo sapiens Fibrillin-1 Proteins 0.000 claims description 5
- 101000629402 Homo sapiens Mesoderm posterior protein 1 Proteins 0.000 claims description 5
- 101001030243 Homo sapiens Myosin-7 Proteins 0.000 claims description 5
- 101000694017 Homo sapiens Sodium channel protein type 5 subunit alpha Proteins 0.000 claims description 5
- 102100026822 Mesoderm posterior protein 1 Human genes 0.000 claims description 5
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 claims description 5
- 102100022437 Myotonin-protein kinase Human genes 0.000 claims description 5
- 102100027198 Sodium channel protein type 5 subunit alpha Human genes 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 4
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 claims description 4
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 claims description 4
- 102100024881 C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8 Human genes 0.000 claims description 4
- 102000014814 CACNA1C Human genes 0.000 claims description 4
- 102100034578 Desmoglein-2 Human genes 0.000 claims description 4
- 102100024108 Dystrophin Human genes 0.000 claims description 4
- 101000961044 Homo sapiens Atrial natriuretic peptide receptor 1 Proteins 0.000 claims description 4
- 101000924314 Homo sapiens Desmoglein-2 Proteins 0.000 claims description 4
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 claims description 4
- 101000982032 Homo sapiens Myosin-binding protein C, cardiac-type Proteins 0.000 claims description 4
- 101000583179 Homo sapiens Plakophilin-2 Proteins 0.000 claims description 4
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 claims description 4
- 101000844504 Homo sapiens Transient receptor potential cation channel subfamily M member 4 Proteins 0.000 claims description 4
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 claims description 4
- 102100035135 Limbin Human genes 0.000 claims description 4
- 108050003065 Limbin Proteins 0.000 claims description 4
- 102100026771 Myosin-binding protein C, cardiac-type Human genes 0.000 claims description 4
- 102000007530 Neurofibromin 1 Human genes 0.000 claims description 4
- 108010085793 Neurofibromin 1 Proteins 0.000 claims description 4
- 102100030348 Plakophilin-2 Human genes 0.000 claims description 4
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 claims description 4
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims description 4
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims description 4
- 102000057028 SOS1 Human genes 0.000 claims description 4
- 108700022176 SOS1 Proteins 0.000 claims description 4
- 101001053942 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Diphosphomevalonate decarboxylase Proteins 0.000 claims description 4
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 claims description 4
- 102100027732 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Human genes 0.000 claims description 4
- 101150100839 Sos1 gene Proteins 0.000 claims description 4
- 102000003618 TRPM4 Human genes 0.000 claims description 4
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 101000936922 Homo sapiens Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Proteins 0.000 claims description 3
- 102100034401 Sarcoplasmic/endoplasmic reticulum calcium ATPase regulator DWORF Human genes 0.000 claims description 3
- 101710112310 Sarcoplasmic/endoplasmic reticulum calcium ATPase regulator DWORF Proteins 0.000 claims description 3
- 210000005229 liver cell Anatomy 0.000 claims description 2
- 102100030281 Ectopic P granules protein 5 homolog Human genes 0.000 claims 1
- 101000938359 Homo sapiens Ectopic P granules protein 5 homolog Proteins 0.000 claims 1
- 108010067902 Peptide Library Proteins 0.000 description 396
- 102000004169 proteins and genes Human genes 0.000 description 57
- 230000014509 gene expression Effects 0.000 description 54
- 239000005090 green fluorescent protein Substances 0.000 description 47
- 108010042407 Endonucleases Proteins 0.000 description 43
- 239000000203 mixture Substances 0.000 description 41
- 210000004185 liver Anatomy 0.000 description 38
- 108010079364 N-glycylalanine Proteins 0.000 description 36
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 36
- 230000008672 reprogramming Effects 0.000 description 36
- -1 HAND2 Proteins 0.000 description 28
- 241000700605 Viruses Species 0.000 description 27
- 102100031780 Endonuclease Human genes 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 238000002347 injection Methods 0.000 description 26
- 239000007924 injection Substances 0.000 description 26
- 238000001727 in vivo Methods 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 24
- KBBFOULZCHWGJX-KBPBESRZSA-N Gly-Tyr-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)CN)O KBBFOULZCHWGJX-KBPBESRZSA-N 0.000 description 23
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 23
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 23
- SBQDRNOLGSYHQA-YUMQZZPRSA-N Lys-Ser-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SBQDRNOLGSYHQA-YUMQZZPRSA-N 0.000 description 23
- 210000000130 stem cell Anatomy 0.000 description 23
- 239000003623 enhancer Substances 0.000 description 22
- 238000000338 in vitro Methods 0.000 description 21
- 238000012384 transportation and delivery Methods 0.000 description 21
- BUANFPRKJKJSRR-ACZMJKKPSA-N Ala-Ala-Gln Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CCC(N)=O BUANFPRKJKJSRR-ACZMJKKPSA-N 0.000 description 19
- 230000035772 mutation Effects 0.000 description 19
- 238000012385 systemic delivery Methods 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 239000013598 vector Substances 0.000 description 18
- 102000004533 Endonucleases Human genes 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 108700028369 Alleles Proteins 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 230000003612 virological effect Effects 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 15
- 208000031229 Cardiomyopathies Diseases 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 238000010362 genome editing Methods 0.000 description 14
- 208000019622 heart disease Diseases 0.000 description 14
- 102000007469 Actins Human genes 0.000 description 13
- 108010085238 Actins Proteins 0.000 description 13
- 101710132601 Capsid protein Proteins 0.000 description 13
- 101710197658 Capsid protein VP1 Proteins 0.000 description 13
- NPTGGVQJYRSMCM-GLLZPBPUSA-N Gln-Gln-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NPTGGVQJYRSMCM-GLLZPBPUSA-N 0.000 description 13
- 108020005004 Guide RNA Proteins 0.000 description 13
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 13
- 101710108545 Viral protein 1 Proteins 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 238000004806 packaging method and process Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 description 12
- 108700026244 Open Reading Frames Proteins 0.000 description 12
- 210000004165 myocardium Anatomy 0.000 description 12
- 108010065781 myosin light chain 2 Proteins 0.000 description 12
- 238000010453 CRISPR/Cas method Methods 0.000 description 11
- NMCBVGFGWSIGSB-NUTKFTJISA-N Trp-Ala-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N NMCBVGFGWSIGSB-NUTKFTJISA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000002861 ventricular Effects 0.000 description 11
- 206010020772 Hypertension Diseases 0.000 description 10
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 10
- 230000002950 deficient Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- BULIVUZUDBHKKZ-WDSKDSINSA-N Gly-Gln-Asn Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BULIVUZUDBHKKZ-WDSKDSINSA-N 0.000 description 9
- 206010019280 Heart failures Diseases 0.000 description 9
- 101710081079 Minor spike protein H Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- VHRLUTIMTDOVCG-PEDHHIEDSA-N Val-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](C(C)C)N VHRLUTIMTDOVCG-PEDHHIEDSA-N 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 208000010125 myocardial infarction Diseases 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000010415 tropism Effects 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 102100027875 Homeobox protein Nkx-2.5 Human genes 0.000 description 8
- 101000632197 Homo sapiens Homeobox protein Nkx-2.5 Proteins 0.000 description 8
- 241000880493 Leptailurus serval Species 0.000 description 8
- 101710163270 Nuclease Proteins 0.000 description 8
- 102000004903 Troponin Human genes 0.000 description 8
- 108090001027 Troponin Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 8
- 239000013608 rAAV vector Substances 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 102000004987 Troponin T Human genes 0.000 description 7
- 108090001108 Troponin T Proteins 0.000 description 7
- 108010092854 aspartyllysine Proteins 0.000 description 7
- 208000029078 coronary artery disease Diseases 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 108010016686 methionyl-alanyl-serine Proteins 0.000 description 7
- 108091070501 miRNA Proteins 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 101150115978 tbx5 gene Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- OWUCNXMFJRFOFI-BQBZGAKWSA-N Asn-Gly-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O OWUCNXMFJRFOFI-BQBZGAKWSA-N 0.000 description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 description 6
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 6
- 102100036912 Desmin Human genes 0.000 description 6
- 108010044052 Desmin Proteins 0.000 description 6
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 101000958741 Homo sapiens Myosin-6 Proteins 0.000 description 6
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 6
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 description 6
- 102100038319 Myosin-6 Human genes 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- SSSFPISOZOLQNP-GUBZILKMSA-N Pro-Arg-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSFPISOZOLQNP-GUBZILKMSA-N 0.000 description 6
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 6
- 102000013534 Troponin C Human genes 0.000 description 6
- RTJPAGFXOWEBAI-SRVKXCTJSA-N Val-Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RTJPAGFXOWEBAI-SRVKXCTJSA-N 0.000 description 6
- 108010067390 Viral Proteins Proteins 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 210000004351 coronary vessel Anatomy 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 210000005045 desmin Anatomy 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 108010050848 glycylleucine Proteins 0.000 description 6
- 108010040030 histidinoalanine Proteins 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 108010034529 leucyl-lysine Proteins 0.000 description 6
- 108010051242 phenylalanylserine Proteins 0.000 description 6
- 108010015796 prolylisoleucine Proteins 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 239000013607 AAV vector Substances 0.000 description 5
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 5
- FTCGGKNCJZOPNB-WHFBIAKZSA-N Asn-Gly-Ser Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FTCGGKNCJZOPNB-WHFBIAKZSA-N 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 5
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 5
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 5
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 5
- MMGJPDWSIOAGTH-ACZMJKKPSA-N Ser-Ala-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MMGJPDWSIOAGTH-ACZMJKKPSA-N 0.000 description 5
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108010089804 glycyl-threonine Proteins 0.000 description 5
- 108010037850 glycylvaline Proteins 0.000 description 5
- 108010025306 histidylleucine Proteins 0.000 description 5
- 108010057821 leucylproline Proteins 0.000 description 5
- 230000002438 mitochondrial effect Effects 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 210000002235 sarcomere Anatomy 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 108010026333 seryl-proline Proteins 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 108010061238 threonyl-glycine Proteins 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 210000002620 vena cava superior Anatomy 0.000 description 5
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 4
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 4
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 4
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 4
- GSCLWXDNIMNIJE-ZLUOBGJFSA-N Ala-Asp-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GSCLWXDNIMNIJE-ZLUOBGJFSA-N 0.000 description 4
- KIUYPHAMDKDICO-WHFBIAKZSA-N Ala-Asp-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KIUYPHAMDKDICO-WHFBIAKZSA-N 0.000 description 4
- CZPAHAKGPDUIPJ-CIUDSAMLSA-N Ala-Gln-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CZPAHAKGPDUIPJ-CIUDSAMLSA-N 0.000 description 4
- LMFXXZPPZDCPTA-ZKWXMUAHSA-N Ala-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N LMFXXZPPZDCPTA-ZKWXMUAHSA-N 0.000 description 4
- CCDFBRZVTDDJNM-GUBZILKMSA-N Ala-Leu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CCDFBRZVTDDJNM-GUBZILKMSA-N 0.000 description 4
- VCSABYLVNWQYQE-SRVKXCTJSA-N Ala-Lys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O VCSABYLVNWQYQE-SRVKXCTJSA-N 0.000 description 4
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 4
- FEGOCLZUJUFCHP-CIUDSAMLSA-N Ala-Pro-Gln Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O FEGOCLZUJUFCHP-CIUDSAMLSA-N 0.000 description 4
- YHBDGLZYNIARKJ-GUBZILKMSA-N Ala-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N YHBDGLZYNIARKJ-GUBZILKMSA-N 0.000 description 4
- YCTIYBUTCKNOTI-UWJYBYFXSA-N Ala-Tyr-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YCTIYBUTCKNOTI-UWJYBYFXSA-N 0.000 description 4
- JNJHNBXBGNJESC-KKXDTOCCSA-N Ala-Tyr-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JNJHNBXBGNJESC-KKXDTOCCSA-N 0.000 description 4
- JQFJNGVSGOUQDH-XIRDDKMYSA-N Arg-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCN=C(N)N)N)C(O)=O)=CNC2=C1 JQFJNGVSGOUQDH-XIRDDKMYSA-N 0.000 description 4
- UHFUZWSZQKMDSX-DCAQKATOSA-N Arg-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UHFUZWSZQKMDSX-DCAQKATOSA-N 0.000 description 4
- UZGFHWIJWPUPOH-IHRRRGAJSA-N Arg-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UZGFHWIJWPUPOH-IHRRRGAJSA-N 0.000 description 4
- AYZAWXAPBAYCHO-CIUDSAMLSA-N Asn-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N AYZAWXAPBAYCHO-CIUDSAMLSA-N 0.000 description 4
- KXFCBAHYSLJCCY-ZLUOBGJFSA-N Asn-Asn-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O KXFCBAHYSLJCCY-ZLUOBGJFSA-N 0.000 description 4
- GNKVBRYFXYWXAB-WDSKDSINSA-N Asn-Glu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O GNKVBRYFXYWXAB-WDSKDSINSA-N 0.000 description 4
- FHETWELNCBMRMG-HJGDQZAQSA-N Asn-Leu-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FHETWELNCBMRMG-HJGDQZAQSA-N 0.000 description 4
- DAYDURRBMDCCFL-AAEUAGOBSA-N Asn-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N DAYDURRBMDCCFL-AAEUAGOBSA-N 0.000 description 4
- XEDQMTWEYFBOIK-ACZMJKKPSA-N Asp-Ala-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XEDQMTWEYFBOIK-ACZMJKKPSA-N 0.000 description 4
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 4
- UGKZHCBLMLSANF-CIUDSAMLSA-N Asp-Asn-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O UGKZHCBLMLSANF-CIUDSAMLSA-N 0.000 description 4
- UGIBTKGQVWFTGX-BIIVOSGPSA-N Asp-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)N)C(=O)O UGIBTKGQVWFTGX-BIIVOSGPSA-N 0.000 description 4
- PGUYEUCYVNZGGV-QWRGUYRKSA-N Asp-Gly-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PGUYEUCYVNZGGV-QWRGUYRKSA-N 0.000 description 4
- IDDMGSKZQDEDGA-SRVKXCTJSA-N Asp-Phe-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 IDDMGSKZQDEDGA-SRVKXCTJSA-N 0.000 description 4
- ZVGRHIRJLWBWGJ-ACZMJKKPSA-N Asp-Ser-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZVGRHIRJLWBWGJ-ACZMJKKPSA-N 0.000 description 4
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 4
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 4
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 4
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 4
- 101000805768 Banna virus (strain Indonesia/JKT-6423/1980) mRNA (guanine-N(7))-methyltransferase Proteins 0.000 description 4
- 101150044789 Cap gene Proteins 0.000 description 4
- 101000686790 Chaetoceros protobacilladnavirus 2 Replication-associated protein Proteins 0.000 description 4
- 101000864475 Chlamydia phage 1 Internal scaffolding protein VP3 Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 101000803553 Eumenes pomiformis Venom peptide 3 Proteins 0.000 description 4
- QYTKAVBFRUGYAU-ACZMJKKPSA-N Gln-Asp-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O QYTKAVBFRUGYAU-ACZMJKKPSA-N 0.000 description 4
- GPISLLFQNHELLK-DCAQKATOSA-N Gln-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N GPISLLFQNHELLK-DCAQKATOSA-N 0.000 description 4
- KVXVVDFOZNYYKZ-DCAQKATOSA-N Gln-Gln-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KVXVVDFOZNYYKZ-DCAQKATOSA-N 0.000 description 4
- VOLVNCMGXWDDQY-LPEHRKFASA-N Gln-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)C(=O)O VOLVNCMGXWDDQY-LPEHRKFASA-N 0.000 description 4
- OREPWMPAUWIIAM-ZPFDUUQYSA-N Gln-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)N)N OREPWMPAUWIIAM-ZPFDUUQYSA-N 0.000 description 4
- SYZZMPFLOLSMHL-XHNCKOQMSA-N Gln-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N)C(=O)O SYZZMPFLOLSMHL-XHNCKOQMSA-N 0.000 description 4
- SBCYJMOOHUDWDA-NUMRIWBASA-N Glu-Asp-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SBCYJMOOHUDWDA-NUMRIWBASA-N 0.000 description 4
- CUXJIASLBRJOFV-LAEOZQHASA-N Glu-Gly-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CUXJIASLBRJOFV-LAEOZQHASA-N 0.000 description 4
- PMSMKNYRZCKVMC-DRZSPHRISA-N Glu-Phe-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(=O)O)N PMSMKNYRZCKVMC-DRZSPHRISA-N 0.000 description 4
- DMYACXMQUABZIQ-NRPADANISA-N Glu-Ser-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O DMYACXMQUABZIQ-NRPADANISA-N 0.000 description 4
- PMNHJLASAAWELO-FOHZUACHSA-N Gly-Asp-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PMNHJLASAAWELO-FOHZUACHSA-N 0.000 description 4
- BEQGFMIBZFNROK-JGVFFNPUSA-N Gly-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)O BEQGFMIBZFNROK-JGVFFNPUSA-N 0.000 description 4
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 4
- YTSVAIMKVLZUDU-YUMQZZPRSA-N Gly-Leu-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YTSVAIMKVLZUDU-YUMQZZPRSA-N 0.000 description 4
- VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 4
- CSMYMGFCEJWALV-WDSKDSINSA-N Gly-Ser-Gln Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O CSMYMGFCEJWALV-WDSKDSINSA-N 0.000 description 4
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 4
- PNUFMLXHOLFRLD-KBPBESRZSA-N Gly-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 PNUFMLXHOLFRLD-KBPBESRZSA-N 0.000 description 4
- OCRQUYDOYKCOQG-IRXDYDNUSA-N Gly-Tyr-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 OCRQUYDOYKCOQG-IRXDYDNUSA-N 0.000 description 4
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 4
- 101000583961 Halorubrum pleomorphic virus 1 Matrix protein Proteins 0.000 description 4
- BDHUXUFYNUOUIT-SRVKXCTJSA-N His-Asp-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BDHUXUFYNUOUIT-SRVKXCTJSA-N 0.000 description 4
- HYWZHNUGAYVEEW-KKUMJFAQSA-N His-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N HYWZHNUGAYVEEW-KKUMJFAQSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- JODPUDMBQBIWCK-GHCJXIJMSA-N Ile-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O JODPUDMBQBIWCK-GHCJXIJMSA-N 0.000 description 4
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 4
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 4
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 4
- USLNHQZCDQJBOV-ZPFDUUQYSA-N Leu-Ile-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O USLNHQZCDQJBOV-ZPFDUUQYSA-N 0.000 description 4
- BMVFXOQHDQZAQU-DCAQKATOSA-N Leu-Pro-Asp Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N BMVFXOQHDQZAQU-DCAQKATOSA-N 0.000 description 4
- MPOHDJKRBLVGCT-CIUDSAMLSA-N Lys-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N MPOHDJKRBLVGCT-CIUDSAMLSA-N 0.000 description 4
- XFIHDSBIPWEYJJ-YUMQZZPRSA-N Lys-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN XFIHDSBIPWEYJJ-YUMQZZPRSA-N 0.000 description 4
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 description 4
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 4
- YRAWWKUTNBILNT-FXQIFTODSA-N Met-Ala-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YRAWWKUTNBILNT-FXQIFTODSA-N 0.000 description 4
- 102000008934 Muscle Proteins Human genes 0.000 description 4
- 108010074084 Muscle Proteins Proteins 0.000 description 4
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 4
- UNLYPPYNDXHGDG-IHRRRGAJSA-N Phe-Gln-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 UNLYPPYNDXHGDG-IHRRRGAJSA-N 0.000 description 4
- YYKZDTVQHTUKDW-RYUDHWBXSA-N Phe-Gly-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N YYKZDTVQHTUKDW-RYUDHWBXSA-N 0.000 description 4
- HQCSLJFGZYOXHW-KKUMJFAQSA-N Phe-His-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CS)C(=O)O)N HQCSLJFGZYOXHW-KKUMJFAQSA-N 0.000 description 4
- YFNOUBWUIIJQHF-LPEHRKFASA-N Pro-Asp-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O YFNOUBWUIIJQHF-LPEHRKFASA-N 0.000 description 4
- UUHXBJHVTVGSKM-BQBZGAKWSA-N Pro-Gly-Asn Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UUHXBJHVTVGSKM-BQBZGAKWSA-N 0.000 description 4
- VVAWNPIOYXAMAL-KJEVXHAQSA-N Pro-Thr-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VVAWNPIOYXAMAL-KJEVXHAQSA-N 0.000 description 4
- IMNVAOPEMFDAQD-NHCYSSNCSA-N Pro-Val-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IMNVAOPEMFDAQD-NHCYSSNCSA-N 0.000 description 4
- OOKCGAYXSNJBGQ-ZLUOBGJFSA-N Ser-Asn-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OOKCGAYXSNJBGQ-ZLUOBGJFSA-N 0.000 description 4
- UBRXAVQWXOWRSJ-ZLUOBGJFSA-N Ser-Asn-Asp Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N)C(=O)N UBRXAVQWXOWRSJ-ZLUOBGJFSA-N 0.000 description 4
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 4
- BPMRXBZYPGYPJN-WHFBIAKZSA-N Ser-Gly-Asn Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O BPMRXBZYPGYPJN-WHFBIAKZSA-N 0.000 description 4
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 4
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 4
- XKFJENWJGHMDLI-QWRGUYRKSA-N Ser-Phe-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O XKFJENWJGHMDLI-QWRGUYRKSA-N 0.000 description 4
- KZPRPBLHYMZIMH-MXAVVETBSA-N Ser-Phe-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KZPRPBLHYMZIMH-MXAVVETBSA-N 0.000 description 4
- FBLNYDYPCLFTSP-IXOXFDKPSA-N Ser-Phe-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FBLNYDYPCLFTSP-IXOXFDKPSA-N 0.000 description 4
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 4
- BDMWLJLPPUCLNV-XGEHTFHBSA-N Ser-Thr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BDMWLJLPPUCLNV-XGEHTFHBSA-N 0.000 description 4
- LVHHEVGYAZGXDE-KDXUFGMBSA-N Thr-Ala-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O)N)O LVHHEVGYAZGXDE-KDXUFGMBSA-N 0.000 description 4
- WFUAUEQXPVNAEF-ZJDVBMNYSA-N Thr-Arg-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CCCN=C(N)N WFUAUEQXPVNAEF-ZJDVBMNYSA-N 0.000 description 4
- IMDMLDSVUSMAEJ-HJGDQZAQSA-N Thr-Leu-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IMDMLDSVUSMAEJ-HJGDQZAQSA-N 0.000 description 4
- UJQVSMNQMQHVRY-KZVJFYERSA-N Thr-Met-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O UJQVSMNQMQHVRY-KZVJFYERSA-N 0.000 description 4
- IWAVRIPRTCJAQO-HSHDSVGOSA-N Thr-Pro-Trp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O IWAVRIPRTCJAQO-HSHDSVGOSA-N 0.000 description 4
- ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 description 4
- BKVICMPZWRNWOC-RHYQMDGZSA-N Thr-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)[C@@H](C)O BKVICMPZWRNWOC-RHYQMDGZSA-N 0.000 description 4
- XZLHHHYSWIYXHD-XIRDDKMYSA-N Trp-Gln-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O XZLHHHYSWIYXHD-XIRDDKMYSA-N 0.000 description 4
- YRSOERSDNRSCBC-XIRDDKMYSA-N Trp-His-Cys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CS)C(=O)O)N YRSOERSDNRSCBC-XIRDDKMYSA-N 0.000 description 4
- VPRHDRKAPYZMHL-SZMVWBNQSA-N Trp-Leu-Glu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 VPRHDRKAPYZMHL-SZMVWBNQSA-N 0.000 description 4
- UJRIVCPPPMYCNA-HOCLYGCPSA-N Trp-Leu-Gly Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N UJRIVCPPPMYCNA-HOCLYGCPSA-N 0.000 description 4
- CYDVHRFXDMDMGX-KKUMJFAQSA-N Tyr-Asn-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O CYDVHRFXDMDMGX-KKUMJFAQSA-N 0.000 description 4
- DWAMXBFJNZIHMC-KBPBESRZSA-N Tyr-Leu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O DWAMXBFJNZIHMC-KBPBESRZSA-N 0.000 description 4
- PRONOHBTMLNXCZ-BZSNNMDCSA-N Tyr-Leu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PRONOHBTMLNXCZ-BZSNNMDCSA-N 0.000 description 4
- BYAKMYBZADCNMN-JYJNAYRXSA-N Tyr-Lys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O BYAKMYBZADCNMN-JYJNAYRXSA-N 0.000 description 4
- QPZMOUMNTGTEFR-ZKWXMUAHSA-N Val-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N QPZMOUMNTGTEFR-ZKWXMUAHSA-N 0.000 description 4
- SZTTYWIUCGSURQ-AUTRQRHGSA-N Val-Glu-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SZTTYWIUCGSURQ-AUTRQRHGSA-N 0.000 description 4
- LAYSXAOGWHKNED-XPUUQOCRSA-N Val-Gly-Ser Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LAYSXAOGWHKNED-XPUUQOCRSA-N 0.000 description 4
- ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 4
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 4
- 108010051583 Ventricular Myosins Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 4
- 108010044940 alanylglutamine Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000003205 diastolic effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 4
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 4
- 108010059898 glycyl-tyrosyl-lysine Proteins 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 4
- 108010047926 leucyl-lysyl-tyrosine Proteins 0.000 description 4
- 210000000663 muscle cell Anatomy 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 4
- 230000006780 non-homologous end joining Effects 0.000 description 4
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 108010077112 prolyl-proline Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 108010071207 serylmethionine Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108010015666 tryptophyl-leucyl-glutamic acid Proteins 0.000 description 4
- 108010038745 tryptophylglycine Proteins 0.000 description 4
- 108010045269 tryptophyltryptophan Proteins 0.000 description 4
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 3
- 102100024626 5'-AMP-activated protein kinase subunit gamma-2 Human genes 0.000 description 3
- 101710137099 5'-AMP-activated protein kinase subunit gamma-2 Proteins 0.000 description 3
- 102100039819 Actin, alpha cardiac muscle 1 Human genes 0.000 description 3
- IKKVASZHTMKJIR-ZKWXMUAHSA-N Ala-Asp-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IKKVASZHTMKJIR-ZKWXMUAHSA-N 0.000 description 3
- LGFCAXJBAZESCF-ACZMJKKPSA-N Ala-Gln-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O LGFCAXJBAZESCF-ACZMJKKPSA-N 0.000 description 3
- GRPHQEMIFDPKOE-HGNGGELXSA-N Ala-His-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O GRPHQEMIFDPKOE-HGNGGELXSA-N 0.000 description 3
- NHWYNIZWLJYZAG-XVYDVKMFSA-N Ala-Ser-His Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N NHWYNIZWLJYZAG-XVYDVKMFSA-N 0.000 description 3
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 3
- LSMDIAAALJJLRO-XQXXSGGOSA-N Ala-Thr-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LSMDIAAALJJLRO-XQXXSGGOSA-N 0.000 description 3
- XSLGWYYNOSUMRM-ZKWXMUAHSA-N Ala-Val-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XSLGWYYNOSUMRM-ZKWXMUAHSA-N 0.000 description 3
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 3
- CGWVCWFQGXOUSJ-ULQDDVLXSA-N Arg-Tyr-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O CGWVCWFQGXOUSJ-ULQDDVLXSA-N 0.000 description 3
- DDPXDCKYWDGZAL-BQBZGAKWSA-N Asn-Gly-Arg Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N DDPXDCKYWDGZAL-BQBZGAKWSA-N 0.000 description 3
- MOHUTCNYQLMARY-GUBZILKMSA-N Asn-His-Gln Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N MOHUTCNYQLMARY-GUBZILKMSA-N 0.000 description 3
- FTSAJSADJCMDHH-CIUDSAMLSA-N Asn-Lys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N FTSAJSADJCMDHH-CIUDSAMLSA-N 0.000 description 3
- BKZFBJYIVSBXCO-KKUMJFAQSA-N Asn-Phe-His Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O BKZFBJYIVSBXCO-KKUMJFAQSA-N 0.000 description 3
- RVHGJNGNKGDCPX-KKUMJFAQSA-N Asn-Phe-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N RVHGJNGNKGDCPX-KKUMJFAQSA-N 0.000 description 3
- UYCPJVYQYARFGB-YDHLFZDLSA-N Asn-Phe-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O UYCPJVYQYARFGB-YDHLFZDLSA-N 0.000 description 3
- GKKUBLFXKRDMFC-BQBZGAKWSA-N Asn-Pro-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O GKKUBLFXKRDMFC-BQBZGAKWSA-N 0.000 description 3
- VHQSGALUSWIYOD-QXEWZRGKSA-N Asn-Pro-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O VHQSGALUSWIYOD-QXEWZRGKSA-N 0.000 description 3
- BEHQTVDBCLSCBY-CFMVVWHZSA-N Asn-Tyr-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BEHQTVDBCLSCBY-CFMVVWHZSA-N 0.000 description 3
- XEGZSHSPQNDNRH-JRQIVUDYSA-N Asn-Tyr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XEGZSHSPQNDNRH-JRQIVUDYSA-N 0.000 description 3
- WSWYMRLTJVKRCE-ZLUOBGJFSA-N Asp-Ala-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O WSWYMRLTJVKRCE-ZLUOBGJFSA-N 0.000 description 3
- ZLGKHJHFYSRUBH-FXQIFTODSA-N Asp-Arg-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLGKHJHFYSRUBH-FXQIFTODSA-N 0.000 description 3
- IXIWEFWRKIUMQX-DCAQKATOSA-N Asp-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O IXIWEFWRKIUMQX-DCAQKATOSA-N 0.000 description 3
- MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 3
- UQBGYPFHWFZMCD-ZLUOBGJFSA-N Asp-Asn-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O UQBGYPFHWFZMCD-ZLUOBGJFSA-N 0.000 description 3
- RDRMWJBLOSRRAW-BYULHYEWSA-N Asp-Asn-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O RDRMWJBLOSRRAW-BYULHYEWSA-N 0.000 description 3
- BKOIIURTQAJHAT-GUBZILKMSA-N Asp-Pro-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 BKOIIURTQAJHAT-GUBZILKMSA-N 0.000 description 3
- OYSYWMMZGJSQRB-AVGNSLFASA-N Asp-Tyr-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O OYSYWMMZGJSQRB-AVGNSLFASA-N 0.000 description 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- 208000002330 Congenital Heart Defects Diseases 0.000 description 3
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 3
- 102100031620 Cysteine and glycine-rich protein 3 Human genes 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 206010052337 Diastolic dysfunction Diseases 0.000 description 3
- 102100030323 Epigen Human genes 0.000 description 3
- 108010016906 Epigen Proteins 0.000 description 3
- 102100031855 Estrogen-related receptor gamma Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LJEPDHWNQXPXMM-NHCYSSNCSA-N Gln-Arg-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O LJEPDHWNQXPXMM-NHCYSSNCSA-N 0.000 description 3
- IKFZXRLDMYWNBU-YUMQZZPRSA-N Gln-Gly-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N IKFZXRLDMYWNBU-YUMQZZPRSA-N 0.000 description 3
- GNMQDOGFWYWPNM-LAEOZQHASA-N Gln-Gly-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](N)CCC(N)=O)C(O)=O GNMQDOGFWYWPNM-LAEOZQHASA-N 0.000 description 3
- NSORZJXKUQFEKL-JGVFFNPUSA-N Gln-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCC(=O)N)N)C(=O)O NSORZJXKUQFEKL-JGVFFNPUSA-N 0.000 description 3
- JKDBRTNMYXYLHO-JYJNAYRXSA-N Gln-Tyr-Leu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 JKDBRTNMYXYLHO-JYJNAYRXSA-N 0.000 description 3
- UBRQJXFDVZNYJP-AVGNSLFASA-N Gln-Tyr-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O UBRQJXFDVZNYJP-AVGNSLFASA-N 0.000 description 3
- MKRDNSWGJWTBKZ-GVXVVHGQSA-N Gln-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MKRDNSWGJWTBKZ-GVXVVHGQSA-N 0.000 description 3
- ZMXZGYLINVNTKH-DZKIICNBSA-N Gln-Val-Phe Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZMXZGYLINVNTKH-DZKIICNBSA-N 0.000 description 3
- AUTNXSQEVVHSJK-YVNDNENWSA-N Glu-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O AUTNXSQEVVHSJK-YVNDNENWSA-N 0.000 description 3
- OGNJZUXUTPQVBR-BQBZGAKWSA-N Glu-Gly-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OGNJZUXUTPQVBR-BQBZGAKWSA-N 0.000 description 3
- WVYJNPCWJYBHJG-YVNDNENWSA-N Glu-Ile-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O WVYJNPCWJYBHJG-YVNDNENWSA-N 0.000 description 3
- VGUYMZGLJUJRBV-YVNDNENWSA-N Glu-Ile-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O VGUYMZGLJUJRBV-YVNDNENWSA-N 0.000 description 3
- WGYHAAXZWPEBDQ-IFFSRLJSSA-N Glu-Val-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGYHAAXZWPEBDQ-IFFSRLJSSA-N 0.000 description 3
- XUDLUKYPXQDCRX-BQBZGAKWSA-N Gly-Arg-Asn Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O XUDLUKYPXQDCRX-BQBZGAKWSA-N 0.000 description 3
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 3
- CIMULJZTTOBOPN-WHFBIAKZSA-N Gly-Asn-Asn Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CIMULJZTTOBOPN-WHFBIAKZSA-N 0.000 description 3
- IXKRSKPKSLXIHN-YUMQZZPRSA-N Gly-Cys-Leu Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O IXKRSKPKSLXIHN-YUMQZZPRSA-N 0.000 description 3
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 3
- RIYIFUFFFBIOEU-KBPBESRZSA-N Gly-Tyr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 RIYIFUFFFBIOEU-KBPBESRZSA-N 0.000 description 3
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 description 3
- VIJMRAIWYWRXSR-CIUDSAMLSA-N His-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 VIJMRAIWYWRXSR-CIUDSAMLSA-N 0.000 description 3
- 101000959247 Homo sapiens Actin, alpha cardiac muscle 1 Proteins 0.000 description 3
- 101000920831 Homo sapiens Estrogen-related receptor gamma Proteins 0.000 description 3
- 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 description 3
- DFFTXLCCDFYRKD-MBLNEYKQSA-N Ile-Gly-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N DFFTXLCCDFYRKD-MBLNEYKQSA-N 0.000 description 3
- GAZGFPOZOLEYAJ-YTFOTSKYSA-N Ile-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N GAZGFPOZOLEYAJ-YTFOTSKYSA-N 0.000 description 3
- JTBFQNHKNRZJDS-SYWGBEHUSA-N Ile-Trp-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)O)N JTBFQNHKNRZJDS-SYWGBEHUSA-N 0.000 description 3
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 3
- STAVRDQLZOTNKJ-RHYQMDGZSA-N Leu-Arg-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STAVRDQLZOTNKJ-RHYQMDGZSA-N 0.000 description 3
- LLBQJYDYOLIQAI-JYJNAYRXSA-N Leu-Glu-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LLBQJYDYOLIQAI-JYJNAYRXSA-N 0.000 description 3
- KOSWSHVQIVTVQF-ZPFDUUQYSA-N Leu-Ile-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O KOSWSHVQIVTVQF-ZPFDUUQYSA-N 0.000 description 3
- QLDHBYRUNQZIJQ-DKIMLUQUSA-N Leu-Ile-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QLDHBYRUNQZIJQ-DKIMLUQUSA-N 0.000 description 3
- QNTJIDXQHWUBKC-BZSNNMDCSA-N Leu-Lys-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QNTJIDXQHWUBKC-BZSNNMDCSA-N 0.000 description 3
- FLNPJLDPGMLWAU-UWVGGRQHSA-N Leu-Met-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(C)C FLNPJLDPGMLWAU-UWVGGRQHSA-N 0.000 description 3
- BIZNDKMFQHDOIE-KKUMJFAQSA-N Leu-Phe-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 BIZNDKMFQHDOIE-KKUMJFAQSA-N 0.000 description 3
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 3
- IDGZVZJLYFTXSL-DCAQKATOSA-N Leu-Ser-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-DCAQKATOSA-N 0.000 description 3
- YNNPKXBBRZVIRX-IHRRRGAJSA-N Lys-Arg-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O YNNPKXBBRZVIRX-IHRRRGAJSA-N 0.000 description 3
- QUCDKEKDPYISNX-HJGDQZAQSA-N Lys-Asn-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QUCDKEKDPYISNX-HJGDQZAQSA-N 0.000 description 3
- VSRXPEHZMHSFKU-IUCAKERBSA-N Lys-Gln-Gly Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O VSRXPEHZMHSFKU-IUCAKERBSA-N 0.000 description 3
- ZXEUFAVXODIPHC-GUBZILKMSA-N Lys-Glu-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ZXEUFAVXODIPHC-GUBZILKMSA-N 0.000 description 3
- GHOIOYHDDKXIDX-SZMVWBNQSA-N Lys-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCCN)C(O)=O)=CNC2=C1 GHOIOYHDDKXIDX-SZMVWBNQSA-N 0.000 description 3
- GNLJXWBNLAIPEP-MELADBBJSA-N Lys-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCCCN)N)C(=O)O GNLJXWBNLAIPEP-MELADBBJSA-N 0.000 description 3
- IVFUVMSKSFSFBT-NHCYSSNCSA-N Lys-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN IVFUVMSKSFSFBT-NHCYSSNCSA-N 0.000 description 3
- IZJGPPIGYTVXLB-FQUUOJAGSA-N Lys-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IZJGPPIGYTVXLB-FQUUOJAGSA-N 0.000 description 3
- NJNRBRKHOWSGMN-SRVKXCTJSA-N Lys-Leu-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O NJNRBRKHOWSGMN-SRVKXCTJSA-N 0.000 description 3
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 3
- CAVRAQIDHUPECU-UVOCVTCTSA-N Lys-Thr-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAVRAQIDHUPECU-UVOCVTCTSA-N 0.000 description 3
- VWJFOUBDZIUXGA-AVGNSLFASA-N Lys-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCCCN)N VWJFOUBDZIUXGA-AVGNSLFASA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 3
- DTICLBJHRYSJLH-GUBZILKMSA-N Met-Ala-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O DTICLBJHRYSJLH-GUBZILKMSA-N 0.000 description 3
- IHITVQKJXQQGLJ-LPEHRKFASA-N Met-Asn-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N IHITVQKJXQQGLJ-LPEHRKFASA-N 0.000 description 3
- OSZTUONKUMCWEP-XUXIUFHCSA-N Met-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC OSZTUONKUMCWEP-XUXIUFHCSA-N 0.000 description 3
- OTKQHDPECKUDSB-SZMVWBNQSA-N Met-Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCSC)C(O)=O)=CNC2=C1 OTKQHDPECKUDSB-SZMVWBNQSA-N 0.000 description 3
- 208000029578 Muscle disease Diseases 0.000 description 3
- 208000009525 Myocarditis Diseases 0.000 description 3
- 102100030856 Myoglobin Human genes 0.000 description 3
- 108010062374 Myoglobin Proteins 0.000 description 3
- 102100030971 Myosin light chain 3 Human genes 0.000 description 3
- 102100026057 Myosin regulatory light chain 2, atrial isoform Human genes 0.000 description 3
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 3
- 108010047562 NGR peptide Proteins 0.000 description 3
- BRDYYVQTEJVRQT-HRCADAONSA-N Phe-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O BRDYYVQTEJVRQT-HRCADAONSA-N 0.000 description 3
- GDBOREPXIRKSEQ-FHWLQOOXSA-N Phe-Gln-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GDBOREPXIRKSEQ-FHWLQOOXSA-N 0.000 description 3
- FMMIYCMOVGXZIP-AVGNSLFASA-N Phe-Glu-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O FMMIYCMOVGXZIP-AVGNSLFASA-N 0.000 description 3
- VJLLEKDQJSMHRU-STQMWFEESA-N Phe-Gly-Met Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O VJLLEKDQJSMHRU-STQMWFEESA-N 0.000 description 3
- QRUOLOPKCOEZKU-HJWJTTGWSA-N Phe-Met-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CC=CC=C1)N QRUOLOPKCOEZKU-HJWJTTGWSA-N 0.000 description 3
- WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 3
- ZLAKUZDMKVKFAI-JYJNAYRXSA-N Phe-Pro-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O ZLAKUZDMKVKFAI-JYJNAYRXSA-N 0.000 description 3
- XNMYNGDKJNOKHH-BZSNNMDCSA-N Phe-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XNMYNGDKJNOKHH-BZSNNMDCSA-N 0.000 description 3
- CVAUVSOFHJKCHN-BZSNNMDCSA-N Phe-Tyr-Cys Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(O)=O)C1=CC=CC=C1 CVAUVSOFHJKCHN-BZSNNMDCSA-N 0.000 description 3
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 3
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 3
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- DRVIASBABBMZTF-GUBZILKMSA-N Pro-Ala-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@@H]1CCCN1 DRVIASBABBMZTF-GUBZILKMSA-N 0.000 description 3
- ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 description 3
- KTFZQPLSPLWLKN-KKUMJFAQSA-N Pro-Gln-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KTFZQPLSPLWLKN-KKUMJFAQSA-N 0.000 description 3
- FYKUEXMZYFIZKA-DCAQKATOSA-N Pro-Pro-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O FYKUEXMZYFIZKA-DCAQKATOSA-N 0.000 description 3
- NAIPAPCKKRCMBL-JYJNAYRXSA-N Pro-Pro-Phe Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NCCC1)C1=CC=CC=C1 NAIPAPCKKRCMBL-JYJNAYRXSA-N 0.000 description 3
- OWQXAJQZLWHPBH-FXQIFTODSA-N Pro-Ser-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O OWQXAJQZLWHPBH-FXQIFTODSA-N 0.000 description 3
- SEZGGSHLMROBFX-CIUDSAMLSA-N Pro-Ser-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O SEZGGSHLMROBFX-CIUDSAMLSA-N 0.000 description 3
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 3
- FIDNSJUXESUDOV-JYJNAYRXSA-N Pro-Tyr-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O FIDNSJUXESUDOV-JYJNAYRXSA-N 0.000 description 3
- ZMLRZBWCXPQADC-TUAOUCFPSA-N Pro-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 ZMLRZBWCXPQADC-TUAOUCFPSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108010079005 RDV peptide Proteins 0.000 description 3
- HVKMTOIAYDOJPL-NRPADANISA-N Ser-Gln-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVKMTOIAYDOJPL-NRPADANISA-N 0.000 description 3
- XXNYYSXNXCJYKX-DCAQKATOSA-N Ser-Leu-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O XXNYYSXNXCJYKX-DCAQKATOSA-N 0.000 description 3
- NNFMANHDYSVNIO-DCAQKATOSA-N Ser-Lys-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NNFMANHDYSVNIO-DCAQKATOSA-N 0.000 description 3
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 3
- VLMIUSLQONKLDV-HEIBUPTGSA-N Ser-Thr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VLMIUSLQONKLDV-HEIBUPTGSA-N 0.000 description 3
- QYBRQMLZDDJBSW-AVGNSLFASA-N Ser-Tyr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O QYBRQMLZDDJBSW-AVGNSLFASA-N 0.000 description 3
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 3
- KEGBFULVYKYJRD-LFSVMHDDSA-N Thr-Ala-Phe Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KEGBFULVYKYJRD-LFSVMHDDSA-N 0.000 description 3
- JMZKMSTYXHFYAK-VEVYYDQMSA-N Thr-Arg-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O JMZKMSTYXHFYAK-VEVYYDQMSA-N 0.000 description 3
- QGXCWPNQVCYJEL-NUMRIWBASA-N Thr-Asn-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QGXCWPNQVCYJEL-NUMRIWBASA-N 0.000 description 3
- JEDIEMIJYSRUBB-FOHZUACHSA-N Thr-Asp-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O JEDIEMIJYSRUBB-FOHZUACHSA-N 0.000 description 3
- OHAJHDJOCKKJLV-LKXGYXEUSA-N Thr-Asp-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O OHAJHDJOCKKJLV-LKXGYXEUSA-N 0.000 description 3
- SHOMROOOQBDGRL-JHEQGTHGSA-N Thr-Glu-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SHOMROOOQBDGRL-JHEQGTHGSA-N 0.000 description 3
- KCRQEJSKXAIULJ-FJXKBIBVSA-N Thr-Gly-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O KCRQEJSKXAIULJ-FJXKBIBVSA-N 0.000 description 3
- VYEHBMMAJFVTOI-JHEQGTHGSA-N Thr-Gly-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O VYEHBMMAJFVTOI-JHEQGTHGSA-N 0.000 description 3
- YSXYEJWDHBCTDJ-DVJZZOLTSA-N Thr-Gly-Trp Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O YSXYEJWDHBCTDJ-DVJZZOLTSA-N 0.000 description 3
- XOWKUMFHEZLKLT-CIQUZCHMSA-N Thr-Ile-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O XOWKUMFHEZLKLT-CIQUZCHMSA-N 0.000 description 3
- 235000011941 Tilia x europaea Nutrition 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102100021382 Transcription factor GATA-6 Human genes 0.000 description 3
- 102100033632 Tropomyosin alpha-1 chain Human genes 0.000 description 3
- 101710128188 Tropomyosin alpha-1 chain Proteins 0.000 description 3
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 3
- QNTBGBCOEYNAPV-CWRNSKLLSA-N Trp-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)O QNTBGBCOEYNAPV-CWRNSKLLSA-N 0.000 description 3
- YXONONCLMLHWJX-SZMVWBNQSA-N Trp-Glu-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O)=CNC2=C1 YXONONCLMLHWJX-SZMVWBNQSA-N 0.000 description 3
- WMIUTJPFHMMUGY-ZFWWWQNUSA-N Trp-Pro-Gly Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)NCC(=O)O WMIUTJPFHMMUGY-ZFWWWQNUSA-N 0.000 description 3
- SDNVRAKIJVKAGS-LKTVYLICSA-N Tyr-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N SDNVRAKIJVKAGS-LKTVYLICSA-N 0.000 description 3
- HKIUVWMZYFBIHG-KKUMJFAQSA-N Tyr-Arg-Gln Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O HKIUVWMZYFBIHG-KKUMJFAQSA-N 0.000 description 3
- JWGXUKHIKXZWNG-RYUDHWBXSA-N Tyr-Gly-Gln Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O JWGXUKHIKXZWNG-RYUDHWBXSA-N 0.000 description 3
- QFXVAFIHVWXXBJ-AVGNSLFASA-N Tyr-Ser-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O QFXVAFIHVWXXBJ-AVGNSLFASA-N 0.000 description 3
- WQOHKVRQDLNDIL-YJRXYDGGSA-N Tyr-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O WQOHKVRQDLNDIL-YJRXYDGGSA-N 0.000 description 3
- HZDQUVQEVVYDDA-ACRUOGEOSA-N Tyr-Tyr-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HZDQUVQEVVYDDA-ACRUOGEOSA-N 0.000 description 3
- QVYFTFIBKCDHIE-ACRUOGEOSA-N Tyr-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O QVYFTFIBKCDHIE-ACRUOGEOSA-N 0.000 description 3
- ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 3
- SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 description 3
- OUUBKKIJQIAPRI-LAEOZQHASA-N Val-Gln-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OUUBKKIJQIAPRI-LAEOZQHASA-N 0.000 description 3
- FOADDSDHGRFUOC-DZKIICNBSA-N Val-Glu-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N FOADDSDHGRFUOC-DZKIICNBSA-N 0.000 description 3
- QIVPZSWBBHRNBA-JYJNAYRXSA-N Val-Pro-Phe Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O QIVPZSWBBHRNBA-JYJNAYRXSA-N 0.000 description 3
- UQMPYVLTQCGRSK-IFFSRLJSSA-N Val-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N)O UQMPYVLTQCGRSK-IFFSRLJSSA-N 0.000 description 3
- JXWGBRRVTRAZQA-ULQDDVLXSA-N Val-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N JXWGBRRVTRAZQA-ULQDDVLXSA-N 0.000 description 3
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 3
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 208000028831 congenital heart disease Diseases 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 108010023942 cysteine and glycine-rich protein 3 Proteins 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 3
- 229960002768 dipyridamole Drugs 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000003981 ectoderm Anatomy 0.000 description 3
- 206010014665 endocarditis Diseases 0.000 description 3
- 210000001900 endoderm Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000004077 genetic alteration Effects 0.000 description 3
- 231100000118 genetic alteration Toxicity 0.000 description 3
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 3
- 108010077435 glycyl-phenylalanyl-glycine Proteins 0.000 description 3
- 108010081551 glycylphenylalanine Proteins 0.000 description 3
- 108010077515 glycylproline Proteins 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 108010092114 histidylphenylalanine Proteins 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 3
- 108010012058 leucyltyrosine Proteins 0.000 description 3
- 239000004571 lime Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 108010076718 lysyl-glutamyl-tryptophan Proteins 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000003716 mesoderm Anatomy 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 238000007481 next generation sequencing Methods 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 108010024607 phenylalanylalanine Proteins 0.000 description 3
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 3
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 3
- 229960002702 piroxicam Drugs 0.000 description 3
- 108010090894 prolylleucine Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229960004699 valsartan Drugs 0.000 description 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- RDWJAMWCGSWTQS-UHFFFAOYSA-N 1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-9-ol Chemical compound C1=CC=C2C(O)N(CCC3)C3=NC2=C1 RDWJAMWCGSWTQS-UHFFFAOYSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 2
- 102100032964 Alpha-actinin-2 Human genes 0.000 description 2
- 102100026277 Alpha-galactosidase A Human genes 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 244000105975 Antidesma platyphyllum Species 0.000 description 2
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- 101710095339 Apolipoprotein E Proteins 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 2
- COXMUHNBYCVVRG-DCAQKATOSA-N Arg-Leu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O COXMUHNBYCVVRG-DCAQKATOSA-N 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 2
- YRZIYQGXTSBRLT-AVGNSLFASA-N Asp-Phe-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O YRZIYQGXTSBRLT-AVGNSLFASA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102100032306 Aurora kinase B Human genes 0.000 description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000003904 Caveolin 3 Human genes 0.000 description 2
- 108090000268 Caveolin 3 Proteins 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 108010058546 Cyclin D1 Proteins 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 2
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 description 2
- 101100206166 Danio rerio tbx5a gene Proteins 0.000 description 2
- 101100191376 Dictyostelium discoideum prkag gene Proteins 0.000 description 2
- 101100028477 Drosophila melanogaster Pak gene Proteins 0.000 description 2
- 206010014522 Embolism venous Diseases 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- PITMCSLKSXHPOA-UHFFFAOYSA-N Fluo-5F Chemical compound OC(=O)CN(CC(O)=O)C1=CC=C(F)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)=CC=C1N(CC(O)=O)CC(O)=O PITMCSLKSXHPOA-UHFFFAOYSA-N 0.000 description 2
- DFCRUBKUVOJCOV-UHFFFAOYSA-N Fluo-5N Chemical compound OC(=O)CN(CC(O)=O)C1=CC=C(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)C=C1OCCOC1=CC([N+]([O-])=O)=CC=C1N(CC(O)=O)CC(O)=O DFCRUBKUVOJCOV-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 2
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 2
- UESYBOXFJWJVSB-AVGNSLFASA-N Gln-Phe-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O UESYBOXFJWJVSB-AVGNSLFASA-N 0.000 description 2
- 102100036646 Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial Human genes 0.000 description 2
- FGPLUIQCSKGLTI-WDSKDSINSA-N Gly-Ser-Glu Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O FGPLUIQCSKGLTI-WDSKDSINSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AIPUZFXMXAHZKY-QWRGUYRKSA-N His-Leu-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AIPUZFXMXAHZKY-QWRGUYRKSA-N 0.000 description 2
- BKOVCRUIXDIWFV-IXOXFDKPSA-N His-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CN=CN1 BKOVCRUIXDIWFV-IXOXFDKPSA-N 0.000 description 2
- RLAOTFTXBFQJDV-KKUMJFAQSA-N His-Phe-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CN=CN1 RLAOTFTXBFQJDV-KKUMJFAQSA-N 0.000 description 2
- JATYGDHMDRAISQ-KKUMJFAQSA-N His-Tyr-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O JATYGDHMDRAISQ-KKUMJFAQSA-N 0.000 description 2
- 101000797275 Homo sapiens Alpha-actinin-2 Proteins 0.000 description 2
- 101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 description 2
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 2
- 101000922020 Homo sapiens Cysteine and glycine-rich protein 1 Proteins 0.000 description 2
- 101000868643 Homo sapiens G2/mitotic-specific cyclin-B1 Proteins 0.000 description 2
- 101001072655 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial Proteins 0.000 description 2
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 2
- 101000977765 Homo sapiens Iroquois-class homeodomain protein IRX-4 Proteins 0.000 description 2
- 101001019104 Homo sapiens Mediator of RNA polymerase II transcription subunit 14 Proteins 0.000 description 2
- 101000629405 Homo sapiens Mesoderm posterior protein 2 Proteins 0.000 description 2
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 2
- 101000713606 Homo sapiens T-box transcription factor TBX20 Proteins 0.000 description 2
- 101000931371 Homo sapiens Zinc finger protein ZFPM2 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000031309 Hypertrophic Familial Cardiomyopathy Diseases 0.000 description 2
- JSLIXOUMAOUGBN-JUKXBJQTSA-N Ile-Tyr-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N JSLIXOUMAOUGBN-JUKXBJQTSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 2
- 102100023531 Iroquois-class homeodomain protein IRX-4 Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- OGCQGUIWMSBHRZ-CIUDSAMLSA-N Leu-Asn-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OGCQGUIWMSBHRZ-CIUDSAMLSA-N 0.000 description 2
- YWKNKRAKOCLOLH-OEAJRASXSA-N Leu-Phe-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YWKNKRAKOCLOLH-OEAJRASXSA-N 0.000 description 2
- ADJWHHZETYAAAX-SRVKXCTJSA-N Leu-Ser-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N ADJWHHZETYAAAX-SRVKXCTJSA-N 0.000 description 2
- ISHNZELVUVPCHY-ZETCQYMHSA-N Lys-Gly-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O ISHNZELVUVPCHY-ZETCQYMHSA-N 0.000 description 2
- PRSBSVAVOQOAMI-BJDJZHNGSA-N Lys-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN PRSBSVAVOQOAMI-BJDJZHNGSA-N 0.000 description 2
- DIBZLYZXTSVGLN-CIUDSAMLSA-N Lys-Ser-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O DIBZLYZXTSVGLN-CIUDSAMLSA-N 0.000 description 2
- IKXQOBUBZSOWDY-AVGNSLFASA-N Lys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N IKXQOBUBZSOWDY-AVGNSLFASA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102100026817 Mesoderm posterior protein 2 Human genes 0.000 description 2
- KBTQZYASLSUFJR-KKUMJFAQSA-N Met-Phe-Gln Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N KBTQZYASLSUFJR-KKUMJFAQSA-N 0.000 description 2
- LXCSZPUQKMTXNW-BQBZGAKWSA-N Met-Ser-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O LXCSZPUQKMTXNW-BQBZGAKWSA-N 0.000 description 2
- 208000003430 Mitral Valve Prolapse Diseases 0.000 description 2
- 101100425896 Mus musculus Tpm1 gene Proteins 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- 108010067385 Myosin Light Chains Proteins 0.000 description 2
- 102000016349 Myosin Light Chains Human genes 0.000 description 2
- 101710193416 Myosin light chain 3 Proteins 0.000 description 2
- 101710101143 Myosin light polypeptide 6 Proteins 0.000 description 2
- 101710098224 Myosin regulatory light chain 2, atrial isoform Proteins 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 2
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- MDHZEOMXGNBSIL-DLOVCJGASA-N Phe-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N MDHZEOMXGNBSIL-DLOVCJGASA-N 0.000 description 2
- SPXWRYVHOZVYBU-ULQDDVLXSA-N Phe-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CC=CC=C2)N SPXWRYVHOZVYBU-ULQDDVLXSA-N 0.000 description 2
- VIIRRNQMMIHYHQ-XHSDSOJGSA-N Phe-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N VIIRRNQMMIHYHQ-XHSDSOJGSA-N 0.000 description 2
- 108010057275 Plakophilins Proteins 0.000 description 2
- 102000003753 Plakophilins Human genes 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101100537532 Rattus norvegicus Tnni3 gene Proteins 0.000 description 2
- 102100024837 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 3 Human genes 0.000 description 2
- 101710188227 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 3 Proteins 0.000 description 2
- PZZJMBYSYAKYPK-UWJYBYFXSA-N Ser-Ala-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PZZJMBYSYAKYPK-UWJYBYFXSA-N 0.000 description 2
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 2
- IFPBAGJBHSNYPR-ZKWXMUAHSA-N Ser-Ile-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O IFPBAGJBHSNYPR-ZKWXMUAHSA-N 0.000 description 2
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 2
- VXYQOFXBIXKPCX-BQBZGAKWSA-N Ser-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CO)N VXYQOFXBIXKPCX-BQBZGAKWSA-N 0.000 description 2
- VIIJCAQMJBHSJH-FXQIFTODSA-N Ser-Met-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O VIIJCAQMJBHSJH-FXQIFTODSA-N 0.000 description 2
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 2
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 2
- 108010042291 Serum Response Factor Proteins 0.000 description 2
- 102100022056 Serum response factor Human genes 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 102000001435 Synapsin Human genes 0.000 description 2
- 108050009621 Synapsin Proteins 0.000 description 2
- 102100036833 T-box transcription factor TBX20 Human genes 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- ZUUDNCOCILSYAM-KKHAAJSZSA-N Thr-Asp-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O ZUUDNCOCILSYAM-KKHAAJSZSA-N 0.000 description 2
- FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000009190 Transthyretin Human genes 0.000 description 2
- 101710186379 Tropomyosin-1 Proteins 0.000 description 2
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- ZPFLBLFITJCBTP-QWRGUYRKSA-N Tyr-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O ZPFLBLFITJCBTP-QWRGUYRKSA-N 0.000 description 2
- YQYFYUSYEDNLSD-YEPSODPASA-N Val-Thr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O YQYFYUSYEDNLSD-YEPSODPASA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 102100020996 Zinc finger protein ZFPM2 Human genes 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010002906 aortic stenosis Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000002763 arrhythmic effect Effects 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000028956 calcium-mediated signaling Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960002155 chlorothiazide Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229960003009 clopidogrel Drugs 0.000 description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 229960004969 dalteparin Drugs 0.000 description 2
- 238000000280 densification Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000011257 dilated cardiomyopathy 1B Diseases 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 208000012955 familial cardiomyopathy Diseases 0.000 description 2
- 208000004996 familial dilated cardiomyopathy Diseases 0.000 description 2
- 201000006692 familial hypertrophic cardiomyopathy Diseases 0.000 description 2
- 208000024251 familial restrictive cardiomyopathy Diseases 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000007849 functional defect Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 2
- 108010020688 glycylhistidine Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 235000009424 haa Nutrition 0.000 description 2
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 description 2
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 208000018578 heart valve disease Diseases 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 108010036413 histidylglycine Proteins 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000004731 long QT syndrome Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 108091030789 miR-302 stem-loop Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 108010059725 myosin-binding protein C Proteins 0.000 description 2
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 108010048818 seryl-histidine Proteins 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000007847 structural defect Effects 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960005001 ticlopidine Drugs 0.000 description 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 2
- 208000004043 venous thromboembolism Diseases 0.000 description 2
- 239000000277 virosome Substances 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- XVZCXCTYGHPNEM-IHRRRGAJSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O XVZCXCTYGHPNEM-IHRRRGAJSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PDURUKZNVHEHGO-UHFFFAOYSA-N 2-[6-[bis(carboxymethyl)amino]-5-(carboxymethoxy)-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylic acid Chemical compound O1C=2C=C(N(CC(O)=O)CC(O)=O)C(OCC(=O)O)=CC=2C=C1C1=NC=C(C(O)=O)O1 PDURUKZNVHEHGO-UHFFFAOYSA-N 0.000 description 1
- DPDZHVCKYBCJHW-UHFFFAOYSA-N 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=NC(C=2C=C3OCCOC3=CC=2)=C(C=2N=CC=CC=2)N1 DPDZHVCKYBCJHW-UHFFFAOYSA-N 0.000 description 1
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- CTESJDQKVOEUOY-UHFFFAOYSA-N 4-hydroxy-3-[4-(2-hydroxyphenyl)phenyl]-6-oxo-7H-thieno[2,3-b]pyridine-5-carbonitrile Chemical compound OC1=CC=CC=C1C1=CC=C(C=2C=3C(O)=C(C#N)C(=O)NC=3SC=2)C=C1 CTESJDQKVOEUOY-UHFFFAOYSA-N 0.000 description 1
- NMBDIMPYACLUDE-UHFFFAOYSA-N 4-methyl-3-[(3-methyl-5-nitro-4-imidazolyl)thio]-1,2,4-triazole Chemical compound CN1C=NN=C1SC1=C([N+]([O-])=O)N=CN1C NMBDIMPYACLUDE-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 101150015935 ATP2 gene Proteins 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 102100032158 Adenylate cyclase type 6 Human genes 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
- UWQJHXKARZWDIJ-ZLUOBGJFSA-N Ala-Ala-Cys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(O)=O UWQJHXKARZWDIJ-ZLUOBGJFSA-N 0.000 description 1
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
- KQFRUSHJPKXBMB-BHDSKKPTSA-N Ala-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C)C(O)=O)=CNC2=C1 KQFRUSHJPKXBMB-BHDSKKPTSA-N 0.000 description 1
- XQJAFSDFQZPYCU-UWJYBYFXSA-N Ala-Asn-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N XQJAFSDFQZPYCU-UWJYBYFXSA-N 0.000 description 1
- ZIWWTZWAKYBUOB-CIUDSAMLSA-N Ala-Asp-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O ZIWWTZWAKYBUOB-CIUDSAMLSA-N 0.000 description 1
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 1
- BLGHHPHXVJWCNK-GUBZILKMSA-N Ala-Gln-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BLGHHPHXVJWCNK-GUBZILKMSA-N 0.000 description 1
- FBHOPGDGELNWRH-DRZSPHRISA-N Ala-Glu-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O FBHOPGDGELNWRH-DRZSPHRISA-N 0.000 description 1
- XYTNPQNAZREREP-XQXXSGGOSA-N Ala-Glu-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XYTNPQNAZREREP-XQXXSGGOSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- NIZKGBJVCMRDKO-KWQFWETISA-N Ala-Gly-Tyr Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NIZKGBJVCMRDKO-KWQFWETISA-N 0.000 description 1
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 1
- AWZKCUCQJNTBAD-SRVKXCTJSA-N Ala-Leu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN AWZKCUCQJNTBAD-SRVKXCTJSA-N 0.000 description 1
- BLTRAARCJYVJKV-QEJZJMRPSA-N Ala-Lys-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(O)=O BLTRAARCJYVJKV-QEJZJMRPSA-N 0.000 description 1
- DEWWPUNXRNGMQN-LPEHRKFASA-N Ala-Met-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N DEWWPUNXRNGMQN-LPEHRKFASA-N 0.000 description 1
- SYIFFFHSXBNPMC-UWJYBYFXSA-N Ala-Ser-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N SYIFFFHSXBNPMC-UWJYBYFXSA-N 0.000 description 1
- VNFSAYFQLXPHPY-CIQUZCHMSA-N Ala-Thr-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNFSAYFQLXPHPY-CIQUZCHMSA-N 0.000 description 1
- SFPRJVVDZNLUTG-OWLDWWDNSA-N Ala-Trp-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SFPRJVVDZNLUTG-OWLDWWDNSA-N 0.000 description 1
- VYMJAWXRWHJIMS-LKTVYLICSA-N Ala-Tyr-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N VYMJAWXRWHJIMS-LKTVYLICSA-N 0.000 description 1
- ZCUFMRIQCPNOHZ-NRPADANISA-N Ala-Val-Gln Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N ZCUFMRIQCPNOHZ-NRPADANISA-N 0.000 description 1
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
- 101100227798 Arabidopsis thaliana THFS gene Proteins 0.000 description 1
- KWKQGHSSNHPGOW-BQBZGAKWSA-N Arg-Ala-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(O)=O KWKQGHSSNHPGOW-BQBZGAKWSA-N 0.000 description 1
- XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 description 1
- KWTVWJPNHAOREN-IHRRRGAJSA-N Arg-Asn-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O KWTVWJPNHAOREN-IHRRRGAJSA-N 0.000 description 1
- NTAZNGWBXRVEDJ-FXQIFTODSA-N Arg-Asp-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NTAZNGWBXRVEDJ-FXQIFTODSA-N 0.000 description 1
- JSHVMZANPXCDTL-GMOBBJLQSA-N Arg-Asp-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JSHVMZANPXCDTL-GMOBBJLQSA-N 0.000 description 1
- HQIZDMIGUJOSNI-IUCAKERBSA-N Arg-Gly-Arg Chemical compound N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQIZDMIGUJOSNI-IUCAKERBSA-N 0.000 description 1
- PNIGSVZJNVUVJA-BQBZGAKWSA-N Arg-Gly-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O PNIGSVZJNVUVJA-BQBZGAKWSA-N 0.000 description 1
- NPAVRDPEFVKELR-DCAQKATOSA-N Arg-Lys-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NPAVRDPEFVKELR-DCAQKATOSA-N 0.000 description 1
- XFXZKCRBBOVJKS-BVSLBCMMSA-N Arg-Phe-Trp Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 XFXZKCRBBOVJKS-BVSLBCMMSA-N 0.000 description 1
- KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 1
- DRDWXKWUSIKKOB-PJODQICGSA-N Arg-Trp-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O DRDWXKWUSIKKOB-PJODQICGSA-N 0.000 description 1
- NMTANZXPDAHUKU-ULQDDVLXSA-N Arg-Tyr-Lys Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=C(O)C=C1 NMTANZXPDAHUKU-ULQDDVLXSA-N 0.000 description 1
- CPTXATAOUQJQRO-GUBZILKMSA-N Arg-Val-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O CPTXATAOUQJQRO-GUBZILKMSA-N 0.000 description 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
- 201000006058 Arrhythmogenic right ventricular cardiomyopathy Diseases 0.000 description 1
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- 101150010353 Ascl1 gene Proteins 0.000 description 1
- BRCVLJZIIFBSPF-ZLUOBGJFSA-N Asn-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N BRCVLJZIIFBSPF-ZLUOBGJFSA-N 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- GOVUDFOGXOONFT-VEVYYDQMSA-N Asn-Arg-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GOVUDFOGXOONFT-VEVYYDQMSA-N 0.000 description 1
- RCENDENBBJFJHZ-ACZMJKKPSA-N Asn-Asn-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RCENDENBBJFJHZ-ACZMJKKPSA-N 0.000 description 1
- LDSFSKFATNBTBV-UHFFFAOYSA-N Asn-Asn-Gly-His Chemical compound NC(=O)CC(N)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NC(C(O)=O)CC1=CN=CN1 LDSFSKFATNBTBV-UHFFFAOYSA-N 0.000 description 1
- ZWASIOHRQWRWAS-UGYAYLCHSA-N Asn-Asp-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZWASIOHRQWRWAS-UGYAYLCHSA-N 0.000 description 1
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 1
- PLVAAIPKSGUXDV-WHFBIAKZSA-N Asn-Gly-Cys Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)C(=O)N PLVAAIPKSGUXDV-WHFBIAKZSA-N 0.000 description 1
- PBSQFBAJKPLRJY-BYULHYEWSA-N Asn-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N PBSQFBAJKPLRJY-BYULHYEWSA-N 0.000 description 1
- XLHLPYFMXGOASD-CIUDSAMLSA-N Asn-His-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N XLHLPYFMXGOASD-CIUDSAMLSA-N 0.000 description 1
- NVWJMQNYLYWVNQ-BYULHYEWSA-N Asn-Ile-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O NVWJMQNYLYWVNQ-BYULHYEWSA-N 0.000 description 1
- ZMUQQMGITUJQTI-CIUDSAMLSA-N Asn-Leu-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O ZMUQQMGITUJQTI-CIUDSAMLSA-N 0.000 description 1
- HFPXZWPUVFVNLL-GUBZILKMSA-N Asn-Leu-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O HFPXZWPUVFVNLL-GUBZILKMSA-N 0.000 description 1
- JEEFEQCRXKPQHC-KKUMJFAQSA-N Asn-Leu-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JEEFEQCRXKPQHC-KKUMJFAQSA-N 0.000 description 1
- ALHMNHZJBYBYHS-DCAQKATOSA-N Asn-Lys-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ALHMNHZJBYBYHS-DCAQKATOSA-N 0.000 description 1
- JWKDQOORUCYUIW-ZPFDUUQYSA-N Asn-Lys-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JWKDQOORUCYUIW-ZPFDUUQYSA-N 0.000 description 1
- MYVBTYXSWILFCG-BQBZGAKWSA-N Asn-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N MYVBTYXSWILFCG-BQBZGAKWSA-N 0.000 description 1
- YXVAESUIQFDBHN-SRVKXCTJSA-N Asn-Phe-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O YXVAESUIQFDBHN-SRVKXCTJSA-N 0.000 description 1
- GFGUPLIETCNQGF-DCAQKATOSA-N Asn-Pro-His Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O GFGUPLIETCNQGF-DCAQKATOSA-N 0.000 description 1
- HPBNLFLSSQDFQW-WHFBIAKZSA-N Asn-Ser-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O HPBNLFLSSQDFQW-WHFBIAKZSA-N 0.000 description 1
- NPZJLGMWMDNQDD-GHCJXIJMSA-N Asn-Ser-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NPZJLGMWMDNQDD-GHCJXIJMSA-N 0.000 description 1
- SNYCNNPOFYBCEK-ZLUOBGJFSA-N Asn-Ser-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O SNYCNNPOFYBCEK-ZLUOBGJFSA-N 0.000 description 1
- NCXTYSVDWLAQGZ-ZKWXMUAHSA-N Asn-Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O NCXTYSVDWLAQGZ-ZKWXMUAHSA-N 0.000 description 1
- AMGQTNHANMRPOE-LKXGYXEUSA-N Asn-Thr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O AMGQTNHANMRPOE-LKXGYXEUSA-N 0.000 description 1
- ZAESWDKAMDVHLL-RCOVLWMOSA-N Asn-Val-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O ZAESWDKAMDVHLL-RCOVLWMOSA-N 0.000 description 1
- SYZWMVSXBZCOBZ-QXEWZRGKSA-N Asn-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)N)N SYZWMVSXBZCOBZ-QXEWZRGKSA-N 0.000 description 1
- PQKSVQSMTHPRIB-ZKWXMUAHSA-N Asn-Val-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O PQKSVQSMTHPRIB-ZKWXMUAHSA-N 0.000 description 1
- GVPSCJQLUGIKAM-GUBZILKMSA-N Asp-Arg-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O GVPSCJQLUGIKAM-GUBZILKMSA-N 0.000 description 1
- QHAJMRDEWNAIBQ-FXQIFTODSA-N Asp-Arg-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O QHAJMRDEWNAIBQ-FXQIFTODSA-N 0.000 description 1
- HMQDRBKQMLRCCG-GMOBBJLQSA-N Asp-Arg-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HMQDRBKQMLRCCG-GMOBBJLQSA-N 0.000 description 1
- FAEIQWHBRBWUBN-FXQIFTODSA-N Asp-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N)CN=C(N)N FAEIQWHBRBWUBN-FXQIFTODSA-N 0.000 description 1
- WLKVEEODTPQPLI-ACZMJKKPSA-N Asp-Gln-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O WLKVEEODTPQPLI-ACZMJKKPSA-N 0.000 description 1
- YDJVIBMKAMQPPP-LAEOZQHASA-N Asp-Glu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O YDJVIBMKAMQPPP-LAEOZQHASA-N 0.000 description 1
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 1
- XWSIYTYNLKCLJB-CIUDSAMLSA-N Asp-Lys-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O XWSIYTYNLKCLJB-CIUDSAMLSA-N 0.000 description 1
- LKVKODXGSAFOFY-VEVYYDQMSA-N Asp-Met-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LKVKODXGSAFOFY-VEVYYDQMSA-N 0.000 description 1
- QJHOOKBAHRJPPX-QWRGUYRKSA-N Asp-Phe-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 QJHOOKBAHRJPPX-QWRGUYRKSA-N 0.000 description 1
- KPSHWSWFPUDEGF-FXQIFTODSA-N Asp-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(O)=O KPSHWSWFPUDEGF-FXQIFTODSA-N 0.000 description 1
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 1
- UXRVDHVARNBOIO-QSFUFRPTSA-N Asp-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)N UXRVDHVARNBOIO-QSFUFRPTSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 201000005943 Barth syndrome Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 238000010446 CRISPR interference Methods 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 1
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 1
- 108010017954 Calcium-Transporting ATPases Proteins 0.000 description 1
- 102000004612 Calcium-Transporting ATPases Human genes 0.000 description 1
- 102100035602 Calsequestrin-2 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010051609 Cardiac Myosins Proteins 0.000 description 1
- 102000013602 Cardiac Myosins Human genes 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 101000936911 Chionoecetes opilio Sarcoplasmic/endoplasmic reticulum calcium ATPase Proteins 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- XMTDCXXLDZKAGI-ACZMJKKPSA-N Cys-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CS)N XMTDCXXLDZKAGI-ACZMJKKPSA-N 0.000 description 1
- PRXCTTWKGJAPMT-ZLUOBGJFSA-N Cys-Ala-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O PRXCTTWKGJAPMT-ZLUOBGJFSA-N 0.000 description 1
- JTNKVWLMDHIUOG-IHRRRGAJSA-N Cys-Arg-Phe Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JTNKVWLMDHIUOG-IHRRRGAJSA-N 0.000 description 1
- XRTISHJEPHMBJG-SRVKXCTJSA-N Cys-Asp-Tyr Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XRTISHJEPHMBJG-SRVKXCTJSA-N 0.000 description 1
- XTHUKRLJRUVVBF-WHFBIAKZSA-N Cys-Gly-Ser Chemical compound SC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O XTHUKRLJRUVVBF-WHFBIAKZSA-N 0.000 description 1
- BBQIWFFTTQTNOC-AVGNSLFASA-N Cys-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CS)N BBQIWFFTTQTNOC-AVGNSLFASA-N 0.000 description 1
- YNJBLTDKTMKEET-ZLUOBGJFSA-N Cys-Ser-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O YNJBLTDKTMKEET-ZLUOBGJFSA-N 0.000 description 1
- 108010090461 DFG peptide Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101100518002 Danio rerio nkx2.2a gene Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 1
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- RWUGLXXRIOWFGX-UHFFFAOYSA-N Fluo-4FF Chemical compound OC(=O)CN(CC(O)=O)C1=CC=C(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)C=C1OCCOC1=C(F)C(F)=CC=C1N(CC(O)=O)CC(O)=O RWUGLXXRIOWFGX-UHFFFAOYSA-N 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 241000974780 Furcraea necrotic streak virus Species 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 101000693916 Gallus gallus Albumin Proteins 0.000 description 1
- 102100028652 Gamma-enolase Human genes 0.000 description 1
- 102100021337 Gap junction alpha-1 protein Human genes 0.000 description 1
- 102100030525 Gap junction alpha-4 protein Human genes 0.000 description 1
- 102100030540 Gap junction alpha-5 protein Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- PNENQZWRFMUZOM-DCAQKATOSA-N Gln-Glu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O PNENQZWRFMUZOM-DCAQKATOSA-N 0.000 description 1
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 1
- DQPOBSRQNWOBNA-GUBZILKMSA-N Gln-His-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O DQPOBSRQNWOBNA-GUBZILKMSA-N 0.000 description 1
- NROSLUJMIQGFKS-IUCAKERBSA-N Gln-His-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N NROSLUJMIQGFKS-IUCAKERBSA-N 0.000 description 1
- GXMBDEGTXHQBAO-NKIYYHGXSA-N Gln-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)N)N)O GXMBDEGTXHQBAO-NKIYYHGXSA-N 0.000 description 1
- VZRAXPGTUNDIDK-GUBZILKMSA-N Gln-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N VZRAXPGTUNDIDK-GUBZILKMSA-N 0.000 description 1
- YPMDZWPZFOZYFG-GUBZILKMSA-N Gln-Leu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YPMDZWPZFOZYFG-GUBZILKMSA-N 0.000 description 1
- HSHCEAUPUPJPTE-JYJNAYRXSA-N Gln-Leu-Tyr Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HSHCEAUPUPJPTE-JYJNAYRXSA-N 0.000 description 1
- HPCOBEHVEHWREJ-DCAQKATOSA-N Gln-Lys-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HPCOBEHVEHWREJ-DCAQKATOSA-N 0.000 description 1
- SWDSRANUCKNBLA-AVGNSLFASA-N Gln-Phe-Asp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N SWDSRANUCKNBLA-AVGNSLFASA-N 0.000 description 1
- GHAXJVNBAKGWEJ-AVGNSLFASA-N Gln-Ser-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GHAXJVNBAKGWEJ-AVGNSLFASA-N 0.000 description 1
- UEILCTONAMOGBR-RWRJDSDZSA-N Gln-Thr-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UEILCTONAMOGBR-RWRJDSDZSA-N 0.000 description 1
- OEIDWQHTRYEYGG-QEJZJMRPSA-N Gln-Trp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N OEIDWQHTRYEYGG-QEJZJMRPSA-N 0.000 description 1
- SAHTWBLTLJWAQA-XIRDDKMYSA-N Gln-Trp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)N)N SAHTWBLTLJWAQA-XIRDDKMYSA-N 0.000 description 1
- SGVGIVDZLSHSEN-RYUDHWBXSA-N Gln-Tyr-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O SGVGIVDZLSHSEN-RYUDHWBXSA-N 0.000 description 1
- VCUNGPMMPNJSGS-JYJNAYRXSA-N Gln-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O VCUNGPMMPNJSGS-JYJNAYRXSA-N 0.000 description 1
- QZQYITIKPAUDGN-GVXVVHGQSA-N Gln-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N QZQYITIKPAUDGN-GVXVVHGQSA-N 0.000 description 1
- SRZLHYPAOXBBSB-HJGDQZAQSA-N Glu-Arg-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SRZLHYPAOXBBSB-HJGDQZAQSA-N 0.000 description 1
- BRKUZSLQMPNVFN-SRVKXCTJSA-N Glu-His-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BRKUZSLQMPNVFN-SRVKXCTJSA-N 0.000 description 1
- WVTIBGWZUMJBFY-GUBZILKMSA-N Glu-His-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O WVTIBGWZUMJBFY-GUBZILKMSA-N 0.000 description 1
- SUIAHERNFYRBDZ-GVXVVHGQSA-N Glu-Lys-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O SUIAHERNFYRBDZ-GVXVVHGQSA-N 0.000 description 1
- KJBGAZSLZAQDPV-KKUMJFAQSA-N Glu-Phe-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N KJBGAZSLZAQDPV-KKUMJFAQSA-N 0.000 description 1
- IDEODOAVGCMUQV-GUBZILKMSA-N Glu-Ser-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IDEODOAVGCMUQV-GUBZILKMSA-N 0.000 description 1
- VNCNWQPIQYAMAK-ACZMJKKPSA-N Glu-Ser-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O VNCNWQPIQYAMAK-ACZMJKKPSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 1
- QSDKBRMVXSWAQE-BFHQHQDPSA-N Gly-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN QSDKBRMVXSWAQE-BFHQHQDPSA-N 0.000 description 1
- CLODWIOAKCSBAN-BQBZGAKWSA-N Gly-Arg-Asp Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(O)=O CLODWIOAKCSBAN-BQBZGAKWSA-N 0.000 description 1
- TZOVVRJYUDETQG-RCOVLWMOSA-N Gly-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN TZOVVRJYUDETQG-RCOVLWMOSA-N 0.000 description 1
- XXGQRGQPGFYECI-WDSKDSINSA-N Gly-Cys-Glu Chemical compound NCC(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCC(O)=O XXGQRGQPGFYECI-WDSKDSINSA-N 0.000 description 1
- JMQFHZWESBGPFC-WDSKDSINSA-N Gly-Gln-Asp Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JMQFHZWESBGPFC-WDSKDSINSA-N 0.000 description 1
- QPDUVFSVVAOUHE-XVKPBYJWSA-N Gly-Gln-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CN)C(O)=O QPDUVFSVVAOUHE-XVKPBYJWSA-N 0.000 description 1
- IDOGEHIWMJMAHT-BYPYZUCNSA-N Gly-Gly-Cys Chemical compound NCC(=O)NCC(=O)N[C@@H](CS)C(O)=O IDOGEHIWMJMAHT-BYPYZUCNSA-N 0.000 description 1
- CQIIXEHDSZUSAG-QWRGUYRKSA-N Gly-His-His Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 CQIIXEHDSZUSAG-QWRGUYRKSA-N 0.000 description 1
- FSPVILZGHUJOHS-QWRGUYRKSA-N Gly-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CNC=N1 FSPVILZGHUJOHS-QWRGUYRKSA-N 0.000 description 1
- IUZGUFAJDBHQQV-YUMQZZPRSA-N Gly-Leu-Asn Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IUZGUFAJDBHQQV-YUMQZZPRSA-N 0.000 description 1
- LLZXNUUIBOALNY-QWRGUYRKSA-N Gly-Leu-Lys Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN LLZXNUUIBOALNY-QWRGUYRKSA-N 0.000 description 1
- JPAACTMBBBGAAR-HOTGVXAUSA-N Gly-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)CN)CC(C)C)C(O)=O)=CNC2=C1 JPAACTMBBBGAAR-HOTGVXAUSA-N 0.000 description 1
- ICUTTWWCDIIIEE-BQBZGAKWSA-N Gly-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN ICUTTWWCDIIIEE-BQBZGAKWSA-N 0.000 description 1
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 1
- IALQAMYQJBZNSK-WHFBIAKZSA-N Gly-Ser-Asn Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O IALQAMYQJBZNSK-WHFBIAKZSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- FKYQEVBRZSFAMJ-QWRGUYRKSA-N Gly-Ser-Tyr Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FKYQEVBRZSFAMJ-QWRGUYRKSA-N 0.000 description 1
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 1
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 1
- FOKISINOENBSDM-WLTAIBSBSA-N Gly-Thr-Tyr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O FOKISINOENBSDM-WLTAIBSBSA-N 0.000 description 1
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 1
- NWOSHVVPKDQKKT-RYUDHWBXSA-N Gly-Tyr-Gln Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O NWOSHVVPKDQKKT-RYUDHWBXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000700735 Ground squirrel hepatitis virus Species 0.000 description 1
- 101150031823 HSP70 gene Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102100023855 Heart- and neural crest derivatives-expressed protein 1 Human genes 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- KAXZXLSXFWSNNZ-XVYDVKMFSA-N His-Ser-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KAXZXLSXFWSNNZ-XVYDVKMFSA-N 0.000 description 1
- AHEBIAHEZWQVHB-QTKMDUPCSA-N His-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O AHEBIAHEZWQVHB-QTKMDUPCSA-N 0.000 description 1
- 101000947118 Homo sapiens Calsequestrin-2 Proteins 0.000 description 1
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 1
- 101001058231 Homo sapiens Gamma-enolase Proteins 0.000 description 1
- 101000905239 Homo sapiens Heart- and neural crest derivatives-expressed protein 1 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000573526 Homo sapiens Membrane protein MLC1 Proteins 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
- 101000635878 Homo sapiens Myosin light chain 3 Proteins 0.000 description 1
- 101001120813 Homo sapiens Myosin regulatory light chain 2, atrial isoform Proteins 0.000 description 1
- 101000603702 Homo sapiens Neurogenin-3 Proteins 0.000 description 1
- 101000720704 Homo sapiens Neuronal migration protein doublecortin Proteins 0.000 description 1
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 1
- 101000685824 Homo sapiens Probable RNA polymerase II nuclear localization protein SLC7A6OS Proteins 0.000 description 1
- 101000685712 Homo sapiens Protein S100-A1 Proteins 0.000 description 1
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 101100537779 Homo sapiens TPM2 gene Proteins 0.000 description 1
- 101000801260 Homo sapiens Troponin C, slow skeletal and cardiac muscles Proteins 0.000 description 1
- 101000851334 Homo sapiens Troponin I, cardiac muscle Proteins 0.000 description 1
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 1
- 241000883306 Huso huso Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010058222 Hypertensive cardiomyopathy Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XENGULNPUDGALZ-ZPFDUUQYSA-N Ile-Asn-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)N XENGULNPUDGALZ-ZPFDUUQYSA-N 0.000 description 1
- HDODQNPMSHDXJT-GHCJXIJMSA-N Ile-Asn-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O HDODQNPMSHDXJT-GHCJXIJMSA-N 0.000 description 1
- KFVUBLZRFSVDGO-BYULHYEWSA-N Ile-Gly-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O KFVUBLZRFSVDGO-BYULHYEWSA-N 0.000 description 1
- CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 description 1
- RIVKTKFVWXRNSJ-GRLWGSQLSA-N Ile-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N RIVKTKFVWXRNSJ-GRLWGSQLSA-N 0.000 description 1
- BBQABUDWDUKJMB-LZXPERKUSA-N Ile-Ile-Ile Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C([O-])=O BBQABUDWDUKJMB-LZXPERKUSA-N 0.000 description 1
- PFPUFNLHBXKPHY-HTFCKZLJSA-N Ile-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)O)N PFPUFNLHBXKPHY-HTFCKZLJSA-N 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- PARSHQDZROHERM-NHCYSSNCSA-N Ile-Lys-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)O)N PARSHQDZROHERM-NHCYSSNCSA-N 0.000 description 1
- AKOYRLRUFBZOSP-BJDJZHNGSA-N Ile-Lys-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N AKOYRLRUFBZOSP-BJDJZHNGSA-N 0.000 description 1
- CKRFDMPBSWYOBT-PPCPHDFISA-N Ile-Lys-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N CKRFDMPBSWYOBT-PPCPHDFISA-N 0.000 description 1
- VOCZPDONPURUHV-QEWYBTABSA-N Ile-Phe-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N VOCZPDONPURUHV-QEWYBTABSA-N 0.000 description 1
- JDCQDJVYUXNCGF-SPOWBLRKSA-N Ile-Ser-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N JDCQDJVYUXNCGF-SPOWBLRKSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100033340 Integrin beta-1-binding protein 2 Human genes 0.000 description 1
- 101710117514 Integrin beta-1-binding protein 2 Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010011185 KCNQ1 Potassium Channel Proteins 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- IBCXZJCWDGCXQT-UHFFFAOYSA-N LY 364947 Chemical compound C=1C=NC2=CC=CC=C2C=1C1=CNN=C1C1=CC=CC=N1 IBCXZJCWDGCXQT-UHFFFAOYSA-N 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- CZCSUZMIRKFFFA-CIUDSAMLSA-N Leu-Ala-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O CZCSUZMIRKFFFA-CIUDSAMLSA-N 0.000 description 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 description 1
- PNUCWVAGVNLUMW-CIUDSAMLSA-N Leu-Cys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O PNUCWVAGVNLUMW-CIUDSAMLSA-N 0.000 description 1
- KUEVMUXNILMJTK-JYJNAYRXSA-N Leu-Gln-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KUEVMUXNILMJTK-JYJNAYRXSA-N 0.000 description 1
- QDSKNVXKLPQNOJ-GVXVVHGQSA-N Leu-Gln-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O QDSKNVXKLPQNOJ-GVXVVHGQSA-N 0.000 description 1
- LAGPXKYZCCTSGQ-JYJNAYRXSA-N Leu-Glu-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LAGPXKYZCCTSGQ-JYJNAYRXSA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- FMEICTQWUKNAGC-YUMQZZPRSA-N Leu-Gly-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O FMEICTQWUKNAGC-YUMQZZPRSA-N 0.000 description 1
- SGIIOQQGLUUMDQ-IHRRRGAJSA-N Leu-His-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N SGIIOQQGLUUMDQ-IHRRRGAJSA-N 0.000 description 1
- JKSIBWITFMQTOA-XUXIUFHCSA-N Leu-Ile-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O JKSIBWITFMQTOA-XUXIUFHCSA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- JDBQSGMJBMPNFT-AVGNSLFASA-N Leu-Pro-Val Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O JDBQSGMJBMPNFT-AVGNSLFASA-N 0.000 description 1
- JIHDFWWRYHSAQB-GUBZILKMSA-N Leu-Ser-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JIHDFWWRYHSAQB-GUBZILKMSA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- IWMJFLJQHIDZQW-KKUMJFAQSA-N Leu-Ser-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IWMJFLJQHIDZQW-KKUMJFAQSA-N 0.000 description 1
- SQUFDMCWMFOEBA-KKUMJFAQSA-N Leu-Ser-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SQUFDMCWMFOEBA-KKUMJFAQSA-N 0.000 description 1
- HQBOMRTVKVKFMN-WDSOQIARSA-N Leu-Trp-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(O)=O HQBOMRTVKVKFMN-WDSOQIARSA-N 0.000 description 1
- RIHIGSWBLHSGLV-CQDKDKBSSA-N Leu-Tyr-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O RIHIGSWBLHSGLV-CQDKDKBSSA-N 0.000 description 1
- WFCKERTZVCQXKH-KBPBESRZSA-N Leu-Tyr-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O WFCKERTZVCQXKH-KBPBESRZSA-N 0.000 description 1
- RDFIVFHPOSOXMW-ACRUOGEOSA-N Leu-Tyr-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RDFIVFHPOSOXMW-ACRUOGEOSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 241001490312 Lithops pseudotruncatella Species 0.000 description 1
- 208000009378 Low Cardiac Output Diseases 0.000 description 1
- NTSPQIONFJUMJV-AVGNSLFASA-N Lys-Arg-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O NTSPQIONFJUMJV-AVGNSLFASA-N 0.000 description 1
- LMVOVCYVZBBWQB-SRVKXCTJSA-N Lys-Asp-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LMVOVCYVZBBWQB-SRVKXCTJSA-N 0.000 description 1
- VEGLGAOVLFODGC-GUBZILKMSA-N Lys-Glu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VEGLGAOVLFODGC-GUBZILKMSA-N 0.000 description 1
- OJDFAABAHBPVTH-MNXVOIDGSA-N Lys-Ile-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O OJDFAABAHBPVTH-MNXVOIDGSA-N 0.000 description 1
- WVJNGSFKBKOKRV-AJNGGQMLSA-N Lys-Leu-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVJNGSFKBKOKRV-AJNGGQMLSA-N 0.000 description 1
- TWPCWKVOZDUYAA-KKUMJFAQSA-N Lys-Phe-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O TWPCWKVOZDUYAA-KKUMJFAQSA-N 0.000 description 1
- UDXSLGLHFUBRRM-OEAJRASXSA-N Lys-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N)O UDXSLGLHFUBRRM-OEAJRASXSA-N 0.000 description 1
- MIMXMVDLMDMOJD-BZSNNMDCSA-N Lys-Tyr-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O MIMXMVDLMDMOJD-BZSNNMDCSA-N 0.000 description 1
- VKCPHIOZDWUFSW-ONGXEEELSA-N Lys-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN VKCPHIOZDWUFSW-ONGXEEELSA-N 0.000 description 1
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 1
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 description 1
- 102000009565 Lysosomal-Associated Membrane Protein 2 Human genes 0.000 description 1
- 108010009491 Lysosomal-Associated Membrane Protein 2 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- HGKJFNCLOHKEHS-FXQIFTODSA-N Met-Cys-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC(O)=O HGKJFNCLOHKEHS-FXQIFTODSA-N 0.000 description 1
- STLBOMUOQNIALW-BQBZGAKWSA-N Met-Gly-Cys Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](CS)C(O)=O STLBOMUOQNIALW-BQBZGAKWSA-N 0.000 description 1
- MYAPQOBHGWJZOM-UWVGGRQHSA-N Met-Gly-Leu Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C MYAPQOBHGWJZOM-UWVGGRQHSA-N 0.000 description 1
- JQHYVIKEFYETEW-IHRRRGAJSA-N Met-Phe-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=CC=C1 JQHYVIKEFYETEW-IHRRRGAJSA-N 0.000 description 1
- BJPQKNHZHUCQNQ-SRVKXCTJSA-N Met-Pro-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCSC)N BJPQKNHZHUCQNQ-SRVKXCTJSA-N 0.000 description 1
- PCTFVQATEGYHJU-FXQIFTODSA-N Met-Ser-Asn Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O PCTFVQATEGYHJU-FXQIFTODSA-N 0.000 description 1
- 206010070909 Metabolic cardiomyopathy Diseases 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- 108091092539 MiR-208 Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 102100021118 Microtubule-associated protein 2 Human genes 0.000 description 1
- 108091027766 Mir-143 Proteins 0.000 description 1
- 108091028684 Mir-145 Proteins 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 102100030330 Myosin regulatory light chain 12B Human genes 0.000 description 1
- 101710092698 Myosin regulatory light chain 2 Proteins 0.000 description 1
- 101710204029 Myosin-7 Proteins 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- FABQUVYDAXWUQP-UHFFFAOYSA-N N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC=CC(C=2N=C(N)N=C(NCC=3C=C4OCOC4=CC=3)C=2)=C1 FABQUVYDAXWUQP-UHFFFAOYSA-N 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 102100038553 Neurogenin-3 Human genes 0.000 description 1
- 102100025929 Neuronal migration protein doublecortin Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 101150114527 Nkx2-5 gene Proteins 0.000 description 1
- 102000001759 Notch1 Receptor Human genes 0.000 description 1
- 108010029755 Notch1 Receptor Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 102100029181 PDZ and LIM domain protein 5 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101150075928 Pax4 gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101001038535 Pelodiscus sinensis Lysozyme C Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 208000025584 Pericardial disease Diseases 0.000 description 1
- 241000042032 Petrocephalus catostoma Species 0.000 description 1
- CDNPIRSCAFMMBE-SRVKXCTJSA-N Phe-Asn-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CDNPIRSCAFMMBE-SRVKXCTJSA-N 0.000 description 1
- HGNGAMWHGGANAU-WHOFXGATSA-N Phe-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 HGNGAMWHGGANAU-WHOFXGATSA-N 0.000 description 1
- GXDPQJUBLBZKDY-IAVJCBSLSA-N Phe-Ile-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O GXDPQJUBLBZKDY-IAVJCBSLSA-N 0.000 description 1
- JKJSIYKSGIDHPM-WBAXXEDZSA-N Phe-Phe-Ala Chemical compound C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccccc1)C(O)=O JKJSIYKSGIDHPM-WBAXXEDZSA-N 0.000 description 1
- YMIZSYUAZJSOFL-SRVKXCTJSA-N Phe-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O YMIZSYUAZJSOFL-SRVKXCTJSA-N 0.000 description 1
- JXQVYPWVGUOIDV-MXAVVETBSA-N Phe-Ser-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JXQVYPWVGUOIDV-MXAVVETBSA-N 0.000 description 1
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 1
- JTKGCYOOJLUETJ-ULQDDVLXSA-N Phe-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 JTKGCYOOJLUETJ-ULQDDVLXSA-N 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 102100037444 Potassium voltage-gated channel subfamily KQT member 1 Human genes 0.000 description 1
- 102100026531 Prelamin-A/C Human genes 0.000 description 1
- KIGGUSRFHJCIEJ-DCAQKATOSA-N Pro-Asp-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O KIGGUSRFHJCIEJ-DCAQKATOSA-N 0.000 description 1
- PZSCUPVOJGKHEP-CIUDSAMLSA-N Pro-Gln-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PZSCUPVOJGKHEP-CIUDSAMLSA-N 0.000 description 1
- QNZLIVROMORQFH-BQBZGAKWSA-N Pro-Gly-Cys Chemical compound C1C[C@H](NC1)C(=O)NCC(=O)N[C@@H](CS)C(=O)O QNZLIVROMORQFH-BQBZGAKWSA-N 0.000 description 1
- AUQGUYPHJSMAKI-CYDGBPFRSA-N Pro-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 AUQGUYPHJSMAKI-CYDGBPFRSA-N 0.000 description 1
- INDVYIOKMXFQFM-SRVKXCTJSA-N Pro-Lys-Gln Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)O INDVYIOKMXFQFM-SRVKXCTJSA-N 0.000 description 1
- WLJYLAQSUSIQNH-GUBZILKMSA-N Pro-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@@H]1CCCN1 WLJYLAQSUSIQNH-GUBZILKMSA-N 0.000 description 1
- JIWJRKNYLSHONY-KKUMJFAQSA-N Pro-Phe-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JIWJRKNYLSHONY-KKUMJFAQSA-N 0.000 description 1
- WHNJMTHJGCEKGA-ULQDDVLXSA-N Pro-Phe-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WHNJMTHJGCEKGA-ULQDDVLXSA-N 0.000 description 1
- DWPXHLIBFQLKLK-CYDGBPFRSA-N Pro-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 DWPXHLIBFQLKLK-CYDGBPFRSA-N 0.000 description 1
- KBUAPZAZPWNYSW-SRVKXCTJSA-N Pro-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KBUAPZAZPWNYSW-SRVKXCTJSA-N 0.000 description 1
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 1
- KWMZPPWYBVZIER-XGEHTFHBSA-N Pro-Ser-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWMZPPWYBVZIER-XGEHTFHBSA-N 0.000 description 1
- CHYAYDLYYIJCKY-OSUNSFLBSA-N Pro-Thr-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CHYAYDLYYIJCKY-OSUNSFLBSA-N 0.000 description 1
- QHSSUIHLAIWXEE-IHRRRGAJSA-N Pro-Tyr-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O QHSSUIHLAIWXEE-IHRRRGAJSA-N 0.000 description 1
- KHRLUIPIMIQFGT-AVGNSLFASA-N Pro-Val-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHRLUIPIMIQFGT-AVGNSLFASA-N 0.000 description 1
- FIODMZKLZFLYQP-GUBZILKMSA-N Pro-Val-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FIODMZKLZFLYQP-GUBZILKMSA-N 0.000 description 1
- 102100023136 Probable RNA polymerase II nuclear localization protein SLC7A6OS Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 101800001494 Protease 2A Proteins 0.000 description 1
- 101800001066 Protein 2A Proteins 0.000 description 1
- 101710150336 Protein Rex Proteins 0.000 description 1
- 102100023097 Protein S100-A1 Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FHYUGAJXYORMHI-UHFFFAOYSA-N SB 431542 Chemical compound C1=CC(C(=O)N)=CC=C1C1=NC(C=2C=C3OCOC3=CC=2)=C(C=2N=CC=CC=2)N1 FHYUGAJXYORMHI-UHFFFAOYSA-N 0.000 description 1
- 101710109123 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FIXILCYTSAUERA-FXQIFTODSA-N Ser-Ala-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FIXILCYTSAUERA-FXQIFTODSA-N 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- WTWGOQRNRFHFQD-JBDRJPRFSA-N Ser-Ala-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WTWGOQRNRFHFQD-JBDRJPRFSA-N 0.000 description 1
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- WXUBSIDKNMFAGS-IHRRRGAJSA-N Ser-Arg-Tyr Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WXUBSIDKNMFAGS-IHRRRGAJSA-N 0.000 description 1
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 1
- CNIIKZQXBBQHCX-FXQIFTODSA-N Ser-Asp-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O CNIIKZQXBBQHCX-FXQIFTODSA-N 0.000 description 1
- SNNSYBWPPVAXQW-ZLUOBGJFSA-N Ser-Cys-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N)O SNNSYBWPPVAXQW-ZLUOBGJFSA-N 0.000 description 1
- INCNPLPRPOYTJI-JBDRJPRFSA-N Ser-Cys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N INCNPLPRPOYTJI-JBDRJPRFSA-N 0.000 description 1
- BQWCDDAISCPDQV-XHNCKOQMSA-N Ser-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)C(=O)O BQWCDDAISCPDQV-XHNCKOQMSA-N 0.000 description 1
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 description 1
- WSTIOCFMWXNOCX-YUMQZZPRSA-N Ser-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N WSTIOCFMWXNOCX-YUMQZZPRSA-N 0.000 description 1
- QGAHMVHBORDHDC-YUMQZZPRSA-N Ser-His-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CN=CN1 QGAHMVHBORDHDC-YUMQZZPRSA-N 0.000 description 1
- CLKKNZQUQMZDGD-SRVKXCTJSA-N Ser-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CN=CN1 CLKKNZQUQMZDGD-SRVKXCTJSA-N 0.000 description 1
- CAOYHZOWXFFAIR-CIUDSAMLSA-N Ser-His-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O CAOYHZOWXFFAIR-CIUDSAMLSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- VZQRNAYURWAEFE-KKUMJFAQSA-N Ser-Leu-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VZQRNAYURWAEFE-KKUMJFAQSA-N 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- JLPMFVAIQHCBDC-CIUDSAMLSA-N Ser-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N JLPMFVAIQHCBDC-CIUDSAMLSA-N 0.000 description 1
- BYCVMHKULKRVPV-GUBZILKMSA-N Ser-Lys-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O BYCVMHKULKRVPV-GUBZILKMSA-N 0.000 description 1
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 1
- LPSKHZWBQONOQJ-XIRDDKMYSA-N Ser-Lys-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N LPSKHZWBQONOQJ-XIRDDKMYSA-N 0.000 description 1
- RXSWQCATLWVDLI-XGEHTFHBSA-N Ser-Met-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RXSWQCATLWVDLI-XGEHTFHBSA-N 0.000 description 1
- AXOHAHIUJHCLQR-IHRRRGAJSA-N Ser-Met-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CO)N AXOHAHIUJHCLQR-IHRRRGAJSA-N 0.000 description 1
- NQZFFLBPNDLTPO-DLOVCJGASA-N Ser-Phe-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CO)N NQZFFLBPNDLTPO-DLOVCJGASA-N 0.000 description 1
- UGTZYIPOBYXWRW-SRVKXCTJSA-N Ser-Phe-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O UGTZYIPOBYXWRW-SRVKXCTJSA-N 0.000 description 1
- ZKBKUWQVDWWSRI-BZSNNMDCSA-N Ser-Phe-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKBKUWQVDWWSRI-BZSNNMDCSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- OVQZAFXWIWNYKA-GUBZILKMSA-N Ser-Pro-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)N OVQZAFXWIWNYKA-GUBZILKMSA-N 0.000 description 1
- CKDXFSPMIDSMGV-GUBZILKMSA-N Ser-Pro-Val Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O CKDXFSPMIDSMGV-GUBZILKMSA-N 0.000 description 1
- PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 1
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- HXPNJVLVHKABMJ-KKUMJFAQSA-N Ser-Tyr-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CO)N)O HXPNJVLVHKABMJ-KKUMJFAQSA-N 0.000 description 1
- KIEIJCFVGZCUAS-MELADBBJSA-N Ser-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)N)C(=O)O KIEIJCFVGZCUAS-MELADBBJSA-N 0.000 description 1
- PCMZJFMUYWIERL-ZKWXMUAHSA-N Ser-Val-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PCMZJFMUYWIERL-ZKWXMUAHSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000008253 Systolic Heart Failure Diseases 0.000 description 1
- DFTCYYILCSQGIZ-GCJQMDKQSA-N Thr-Ala-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O DFTCYYILCSQGIZ-GCJQMDKQSA-N 0.000 description 1
- XDARBNMYXKUFOJ-GSSVUCPTSA-N Thr-Asp-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XDARBNMYXKUFOJ-GSSVUCPTSA-N 0.000 description 1
- GCXFWAZRHBRYEM-NUMRIWBASA-N Thr-Gln-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O GCXFWAZRHBRYEM-NUMRIWBASA-N 0.000 description 1
- ONNSECRQFSTMCC-XKBZYTNZSA-N Thr-Glu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ONNSECRQFSTMCC-XKBZYTNZSA-N 0.000 description 1
- IMULJHHGAUZZFE-MBLNEYKQSA-N Thr-Gly-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IMULJHHGAUZZFE-MBLNEYKQSA-N 0.000 description 1
- JKGGPMOUIAAJAA-YEPSODPASA-N Thr-Gly-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O JKGGPMOUIAAJAA-YEPSODPASA-N 0.000 description 1
- UDNVOQMPQBEITB-MEYUZBJRSA-N Thr-His-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O UDNVOQMPQBEITB-MEYUZBJRSA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 1
- WRQLCVIALDUQEQ-UNQGMJICSA-N Thr-Phe-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WRQLCVIALDUQEQ-UNQGMJICSA-N 0.000 description 1
- KERCOYANYUPLHJ-XGEHTFHBSA-N Thr-Pro-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O KERCOYANYUPLHJ-XGEHTFHBSA-N 0.000 description 1
- YGCDFAJJCRVQKU-RCWTZXSCSA-N Thr-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O YGCDFAJJCRVQKU-RCWTZXSCSA-N 0.000 description 1
- STUAPCLEDMKXKL-LKXGYXEUSA-N Thr-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O STUAPCLEDMKXKL-LKXGYXEUSA-N 0.000 description 1
- NQQMWWVVGIXUOX-SVSWQMSJSA-N Thr-Ser-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NQQMWWVVGIXUOX-SVSWQMSJSA-N 0.000 description 1
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 1
- GRIUMVXCJDKVPI-IZPVPAKOSA-N Thr-Thr-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GRIUMVXCJDKVPI-IZPVPAKOSA-N 0.000 description 1
- LECUEEHKUFYOOV-ZJDVBMNYSA-N Thr-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)[C@@H](C)O LECUEEHKUFYOOV-ZJDVBMNYSA-N 0.000 description 1
- JAWUQFCGNVEDRN-MEYUZBJRSA-N Thr-Tyr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O JAWUQFCGNVEDRN-MEYUZBJRSA-N 0.000 description 1
- AKHDFZHUPGVFEJ-YEPSODPASA-N Thr-Val-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AKHDFZHUPGVFEJ-YEPSODPASA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 description 1
- 102100035000 Thymosin beta-4 Human genes 0.000 description 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 102100036471 Tropomyosin beta chain Human genes 0.000 description 1
- 102100033744 Troponin C, slow skeletal and cardiac muscles Human genes 0.000 description 1
- TWJDQTTXXZDJKV-BPUTZDHNSA-N Trp-Arg-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O TWJDQTTXXZDJKV-BPUTZDHNSA-N 0.000 description 1
- UKINEYBQXPMOJO-UBHSHLNASA-N Trp-Asn-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N UKINEYBQXPMOJO-UBHSHLNASA-N 0.000 description 1
- BXKWZPXTTSCOMX-AQZXSJQPSA-N Trp-Asn-Thr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BXKWZPXTTSCOMX-AQZXSJQPSA-N 0.000 description 1
- OJKVFAWXPGCJMF-BPUTZDHNSA-N Trp-Pro-Ser Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)N[C@@H](CO)C(=O)O OJKVFAWXPGCJMF-BPUTZDHNSA-N 0.000 description 1
- GSCPHMSPGQSZJT-JYBASQMISA-N Trp-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O GSCPHMSPGQSZJT-JYBASQMISA-N 0.000 description 1
- VMXLNDRJXVAJFT-JYBASQMISA-N Trp-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O VMXLNDRJXVAJFT-JYBASQMISA-N 0.000 description 1
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 1
- VTFWAGGJDRSQFG-MELADBBJSA-N Tyr-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O VTFWAGGJDRSQFG-MELADBBJSA-N 0.000 description 1
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 1
- ZNFPUOSTMUMUDR-JRQIVUDYSA-N Tyr-Asn-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZNFPUOSTMUMUDR-JRQIVUDYSA-N 0.000 description 1
- VFJIWSJKZJTQII-SRVKXCTJSA-N Tyr-Asp-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O VFJIWSJKZJTQII-SRVKXCTJSA-N 0.000 description 1
- CWQZAUYFWRLITN-AVGNSLFASA-N Tyr-Gln-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N)O CWQZAUYFWRLITN-AVGNSLFASA-N 0.000 description 1
- SLCSPPCQWUHPPO-JYJNAYRXSA-N Tyr-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SLCSPPCQWUHPPO-JYJNAYRXSA-N 0.000 description 1
- WVGKPKDWYQXWLU-BZSNNMDCSA-N Tyr-His-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CCCCN)C(=O)O)N)O WVGKPKDWYQXWLU-BZSNNMDCSA-N 0.000 description 1
- WSFXJLFSJSXGMQ-MGHWNKPDSA-N Tyr-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N WSFXJLFSJSXGMQ-MGHWNKPDSA-N 0.000 description 1
- PGEFRHBWGOJPJT-KKUMJFAQSA-N Tyr-Lys-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O PGEFRHBWGOJPJT-KKUMJFAQSA-N 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- IZFVRRYRMQFVGX-NRPADANISA-N Val-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N IZFVRRYRMQFVGX-NRPADANISA-N 0.000 description 1
- AZSHAZJLOZQYAY-FXQIFTODSA-N Val-Ala-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O AZSHAZJLOZQYAY-FXQIFTODSA-N 0.000 description 1
- VMRFIKXKOFNMHW-GUBZILKMSA-N Val-Arg-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N VMRFIKXKOFNMHW-GUBZILKMSA-N 0.000 description 1
- DNOOLPROHJWCSQ-RCWTZXSCSA-N Val-Arg-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DNOOLPROHJWCSQ-RCWTZXSCSA-N 0.000 description 1
- NWDOPHYLSORNEX-QXEWZRGKSA-N Val-Asn-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)O)N NWDOPHYLSORNEX-QXEWZRGKSA-N 0.000 description 1
- JLFKWDAZBRYCGX-ZKWXMUAHSA-N Val-Asn-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N JLFKWDAZBRYCGX-ZKWXMUAHSA-N 0.000 description 1
- YODDULVCGFQRFZ-ZKWXMUAHSA-N Val-Asp-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O YODDULVCGFQRFZ-ZKWXMUAHSA-N 0.000 description 1
- BWVHQINTNLVWGZ-ZKWXMUAHSA-N Val-Cys-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N BWVHQINTNLVWGZ-ZKWXMUAHSA-N 0.000 description 1
- OQWNEUXPKHIEJO-NRPADANISA-N Val-Glu-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N OQWNEUXPKHIEJO-NRPADANISA-N 0.000 description 1
- ZRSZTKTVPNSUNA-IHRRRGAJSA-N Val-Lys-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(O)=O ZRSZTKTVPNSUNA-IHRRRGAJSA-N 0.000 description 1
- YKNOJPJWNVHORX-UNQGMJICSA-N Val-Phe-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YKNOJPJWNVHORX-UNQGMJICSA-N 0.000 description 1
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 1
- LTTQCQRTSHJPPL-ZKWXMUAHSA-N Val-Ser-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N LTTQCQRTSHJPPL-ZKWXMUAHSA-N 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- HWNYVQMOLCYHEA-IHRRRGAJSA-N Val-Ser-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N HWNYVQMOLCYHEA-IHRRRGAJSA-N 0.000 description 1
- CEKSLIVSNNGOKH-KZVJFYERSA-N Val-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](C(C)C)N)O CEKSLIVSNNGOKH-KZVJFYERSA-N 0.000 description 1
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 1
- JAIZPWVHPQRYOU-ZJDVBMNYSA-N Val-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O JAIZPWVHPQRYOU-ZJDVBMNYSA-N 0.000 description 1
- VVIZITNVZUAEMI-DLOVCJGASA-N Val-Val-Gln Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(N)=O VVIZITNVZUAEMI-DLOVCJGASA-N 0.000 description 1
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 1
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- KLGQSVMIPOVQAX-UHFFFAOYSA-N XAV939 Chemical compound N=1C=2CCSCC=2C(O)=NC=1C1=CC=C(C(F)(F)F)C=C1 KLGQSVMIPOVQAX-UHFFFAOYSA-N 0.000 description 1
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940062352 aceon Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- MCEXQZRGUKALLT-VVEOGCPPSA-N acetyloxymethyl 2-[n-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[[6-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-2-[(e)-(5-oxo-2-sulfanylideneimidazolidin-4-ylidene)methyl]-1-benzofuran-5-yl]oxy]ethoxy]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=CC2=C1OC(\C=C\1C(NC(=S)N/1)=O)=C2 MCEXQZRGUKALLT-VVEOGCPPSA-N 0.000 description 1
- ANRZUBSJAOAXHS-UHFFFAOYSA-N acetyloxymethyl 2-[n-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[[8-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-6-methoxyquinolin-2-yl]methoxy]-4-methylanilino]acetate Chemical compound C1=CC2=CC(OC)=CC(N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C2N=C1COC1=CC(C)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O ANRZUBSJAOAXHS-UHFFFAOYSA-N 0.000 description 1
- 229940092980 adalat Drugs 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108010023957 adenylyl cyclase 6 Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 101150026213 atpB gene Proteins 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 102000011262 beta-Adrenergic Receptor Kinases Human genes 0.000 description 1
- 108010037997 beta-Adrenergic Receptor Kinases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 101150067309 bmp4 gene Proteins 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229940088498 bumex Drugs 0.000 description 1
- 229940088033 calan Drugs 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000011128 cardiac conduction Effects 0.000 description 1
- 230000007555 cardiovascular defect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 201000000015 catecholaminergic polymorphic ventricular tachycardia Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 108010015408 connexin 37 Proteins 0.000 description 1
- 108010014510 connexin 40 Proteins 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940097488 corgard Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940074654 diuril Drugs 0.000 description 1
- 101150052825 dnaK gene Proteins 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 229940087051 fragmin Drugs 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000003144 genetic modification method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010084264 glycyl-glycyl-cysteine Proteins 0.000 description 1
- 108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 1
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 1
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005986 heart dysfunction Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- 229940088024 isoptin Drugs 0.000 description 1
- ZGSXEXBYLJIOGF-BOPNQXPFSA-N iwr-1 Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=O)C(C=C1)=CC=C1N1C(=O)[C@@H]2C(C=C3)CC3[C@@H]2C1=O ZGSXEXBYLJIOGF-BOPNQXPFSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940063711 lasix Drugs 0.000 description 1
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940080288 lotrel Drugs 0.000 description 1
- 229940118179 lovenox Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- MRSJBSHLMOBYSH-UHFFFAOYSA-N m-Nisoldipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 MRSJBSHLMOBYSH-UHFFFAOYSA-N 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- NGCVJRFIBJVSFI-UHFFFAOYSA-I magnesium green Chemical compound [K+].[K+].[K+].[K+].[K+].C1=C(N(CC([O-])=O)CC([O-])=O)C(OCC(=O)[O-])=CC(NC(=O)C=2C=C3C(C4(C5=CC(Cl)=C([O-])C=C5OC5=CC([O-])=C(Cl)C=C54)OC3=O)=CC=2)=C1 NGCVJRFIBJVSFI-UHFFFAOYSA-I 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 108091028606 miR-1 stem-loop Proteins 0.000 description 1
- 108091056170 miR-499 stem-loop Proteins 0.000 description 1
- 108091050885 miR-499-1 stem-loop Proteins 0.000 description 1
- 108091038523 miR-499-2 stem-loop Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- UIAGMCDKSXEBJQ-UHFFFAOYSA-N nimodipine Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940036132 norvasc Drugs 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 108010065135 phenylalanyl-phenylalanyl-phenylalanine Proteins 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 235000013446 pixi Nutrition 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 229940089949 procardia Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 210000003742 purkinje fiber Anatomy 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 101150066583 rep gene Proteins 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- JNYSEDHQJCOWQU-UHFFFAOYSA-N stepronin Chemical compound OC(=O)CNC(=O)C(C)SC(=O)C1=CC=CS1 JNYSEDHQJCOWQU-UHFFFAOYSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002948 striated muscle cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229940081330 tena Drugs 0.000 description 1
- LQSATJAZEBYDQQ-UHFFFAOYSA-J tetrapotassium;2-[4-[bis(carboxylatomethyl)amino]-3-(carboxylatomethoxy)phenyl]-1h-indole-6-carboxylate Chemical compound [K+].[K+].[K+].[K+].C1=C(N(CC([O-])=O)CC([O-])=O)C(OCC(=O)[O-])=CC(C=2NC3=CC(=CC=C3C=2)C([O-])=O)=C1 LQSATJAZEBYDQQ-UHFFFAOYSA-J 0.000 description 1
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 1
- 108010079996 thymosin beta(4) Proteins 0.000 description 1
- 229940035248 tiazac Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960005062 tinzaparin Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000031998 transcytosis Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940054495 univasc Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- 229940099270 vasotec Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 201000003130 ventricular septal defect Diseases 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229940055010 verelan Drugs 0.000 description 1
- 229940087652 vioxx Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/075—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本公开提供了具有工程化衣壳蛋白的重组腺相关病毒(rAAV)病毒体。具体而言,本公开提供了具有工程化AAV9衣壳、AAV5/9嵌合衣壳或组合衣壳的AAV9病毒体,所述病毒体实现了在心脏细胞中增加的转导效率、增加的细胞类型选择性和/或其他期望的特性。
Description
相关申请的交叉引用
本申请要求2020年4月20日提交的美国临时专利申请序列号63/012,703的优先权权益,该专利申请的内容据此通过引用整体并入。
技术领域
本公开总体上涉及用腺相关病毒载体的基因疗法。具体而言,本公开涉及具有工程化衣壳蛋白的重组腺相关病毒病毒体。
参考序列表
本申请经由EFS-Web电子申请并且包含呈.txt格式的电子提交的序列表。该.txt文件包含创建于2021年4月13日的名为“TENA_019_01WO_SeqList_ST25.txt”且大小为~479千字节的序列表。此.txt文件中含有的序列表是说明书的一部分,并且通过引用整体并入本文。
发明背景
腺相关病毒(AAV)有希望用于基因疗法和其他生物医学应用。具体而言,AAV可以用于将基因产物递送到体外和体内的各种组织和细胞。AAV的衣壳蛋白在很大程度上决定了AAV载体的免疫原性和嗜性。
对于心脏组织,AAV亚型9(AAV9)由于能够在全身递送后转导心脏,是优选的AAV载体。虽然AAV9可以实现心脏的适度转导,但是大多数载体运输到肝脏。而且,为了在心脏中实现治疗水平的转导,需要相对高的全身剂量,这可能导致全身炎症,并进而导致毒性。
需要开发一种具有工程化衣壳蛋白的腺相关病毒,该腺相关病毒实现提高的心脏嗜性,并且任选地实现心脏组织相对于肝脏的选择性提高。本公开提供了AAV9衣壳和/或嵌合AAV5/AAV9衣壳的变体,这些衣壳形成的rAAV病毒体,与包含野生型AAV9衣壳蛋白的rAAV病毒体相比,能够更有效和/或更具选择性地转导心脏组织和/或细胞类型,可用于安全且有效的心脏基因疗法。
发明内容
在一个方面,本公开提供了重组腺相关病毒(rAAV)衣壳蛋白,该衣壳蛋白在亲本序列的VR-IV位点、VR-V位点、VR-VII位点和VR-VIII位点中的一个或多个位点处包含变体多肽序列,其中所述亲本序列包含与SEQ ID NO:463至少95%、至少98%、至少99%或100%相同的序列。在一些实施方案中,变体多肽序列是亲心性变体多肽序列。
在一些实施方案中,本公开的衣壳蛋白在亲本序列的VR-IV位点处包含变体多肽。在一些实施方案中,VR-IV位点的变体多肽具有序列:
-X1-X2-X3-X4-X5-X6-X7-X8-X9-
其中:X1是G、S或V;X2是Y、Q或I;X3是H、W、V或I;X4是K或N;X5是S、G或I;X6是G或R;X7是A、P或V;X8是A或R;并且X9是Q或D(SEQ ID NO:477)。在一些实施方案中,VR-IV位点的变体多肽包含选自SEQ ID NO:6-104的氨基酸序列。在一些实施方案中,VR-IV位点的变体多肽包含选自GYHKSGAAQ(SEQ ID NO:6)、VIIKSGAAQ(SEQ ID NO:7)、GYHKIGAAQ(SEQ ID NO:8)、SQVNGRPRD(SEQ ID NO:33)和GYHKSGVAQ(SEQ ID NO:9)的氨基酸序列。在一些实施方案中,VR-IV位点的变体多肽包含氨基酸序列GYHKSGAAQ(SEQ ID NO:6)或相对于GYHKSGAAQ(SEQID NO:6)包含至多1、2、3或4个氨基酸取代的序列。
在一些实施方案中,本公开的衣壳蛋白在亲本序列的VR-V位点处包含变体多肽。在一些实施方案中,VR-V位点的变体多肽具有序列:
-X1-X2-X3-X4-X5-X6-
其中:X1是S、L、H、N或A;X2是T、M、K、G或N;X3是S、T、M或I;X4是S、P、F、M或N;X5是F、S、P或L;并且X6是I、V或T(SEQ ID NO:474)。在一些实施方案中,VR-V位点的变体多肽包含选自SEQ ID NO:105-203的氨基酸序列。在一些实施方案中,VR-V位点的所述变体多肽包含选自LNSMLI(SEQ ID NO:105)、NGMSFT(SEQ ID NO:106)、HKTFSI(SEQ ID NO:107)和SMSNFV(SEQ ID NO:108)的氨基酸序列。在一些实施方案中,VR-V位点的变体多肽包含氨基酸序列LNSMLI(SEQ ID NO:105)或相对于LNSMLI(SEQ ID NO:105)包含至多1、2、3或4个氨基酸取代的序列。
在一些实施方案中,本公开的衣壳蛋白在亲本序列的VR-VII位点处包含变体多肽。在一些实施方案中,VR-VII位点的变体多肽具有序列:
-X1-X2-X3-X4-X5-
其中:X1是V、L、Q、C或R;X2是S、H、G、C或D;X3是Y、S、L、G或N;X4是S、L、H、Q或N;并且X5是V、I或R(SEQ ID NO:475)。在一些实施方案中,VR-VII位点的变体多肽包含选自SEQ IDNO:204-302的氨基酸序列。在一些实施方案中,VR-VII位点的变体多肽包含选自RGNQV(SEQID NO:204)、VSLNR(SEQ ID NO:205)、CDYSV(SEQ ID NO:206)和QHGHI(SEQ ID NO:207)的氨基酸序列。在一些实施方案中,VR-VII位点的变体多肽包含氨基酸序列RGNQV(SEQ IDNO:204)或相对于RGNQV(SEQ ID NO:204)包含至多1、2或3个氨基酸取代的序列。
在一些实施方案中,本公开的衣壳蛋白在亲本序列的VR-VII位点处包含变体多肽。在一些实施方案中,VR-VIII位点的变体多肽具有序列:
-X1-X2-X3-X4-
其中:X1是S、N或A;X2是V、M、N或A;X3是Y、V、S或G;并且X4是Y、T、M、G或N(SEQ IDNO:476)。在一些实施方案中,VR-VIII位点的变体多肽包含选自SEQ ID NO:303-401的氨基酸序列。在一些实施方案中,VR-VIII位点的变体多肽包含选自ANYG(SEQ ID NO:305)、NVSY(SEQ ID NO:303)、SMVN(SEQ ID NO:304)和NVGT(SEQ ID NO:306)的氨基酸序列。在一些实施方案中,VR-VIII位点的变体多肽包含氨基酸序列ANYG(SEQ ID NO:305)或相对于ANYG(SEQ ID NO:305)包含至多1或2个氨基酸取代的序列。在一些实施方案中,VR-VIII位点的变体多肽包含氨基酸序列NVSY(SEQ ID NO:303)或相对于NVSY(SEQ ID NO:303)包含至多1或2个氨基酸取代的序列。
在一个方面,本公开提供了重组腺相关病毒(rAAV)衣壳蛋白,该衣壳蛋白在亲本序列的VR-IV位点、VR-V位点、VR-VII位点和VR-VIII位点中的一个或多个位点处包含变体多肽序列,其中所述亲本序列包含与SEQ ID NO:463至少95%、至少98%、至少99%或100%相同的序列。在一些实施方案中,该衣壳蛋白包含与选自SEQ ID NO:402-410的序列至少95%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与SEQ ID NO:402至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与SEQID NO:403至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与SEQ ID NO:404至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与SEQ ID NO:406至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与SEQ ID NO:409至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与482至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与483至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与484至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与485至少95%、至少98%、至少99%或100%相同的氨基酸序列。
在一些实施方案中,该衣壳蛋白是AAV5/AAV9嵌合衣壳蛋白。在一些实施方案中,该衣壳蛋白包含来自AAV5衣壳蛋白的至少一个区段。在一些实施方案中,该衣壳蛋白包含:a)包含与SEQ ID NO:411或SEQ ID NO:412至少95%相同的序列的第一区段;b)包含与SEQID NO:413或SEQ ID NO:414至少95%相同的序列的第二区段;c)包含与SEQ ID NO:415或SEQ ID NO:416至少95%相同的序列的第三区段;d)包含与SEQ ID NO:417或SEQ ID NO:418至少95%相同的序列的第四区段;e)包含与SEQ ID NO:419或SEQ ID NO:420至少95%相同的序列的第五区段;其中至少一个区段来自AAV5衣壳蛋白且至少一个区段来自AAV9衣壳蛋白。在一些实施方案中,该嵌合衣壳蛋白包含与选自SEQ ID NO:445-462的序列至少95%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与SEQ ID NO:457至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,衣壳蛋白包含与SEQID NO:459至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与SEQ ID NO:445至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与SEQ ID NO:446至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与SEQ ID NO:447至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与SEQID NO:448至少95%、至少98%、至少99%或100%相同的氨基酸序列。
在一个方面,本公开提供了重组腺相关病毒(rAAV)衣壳蛋白,该衣壳蛋白包含与SEQ ID NO:463至少95%、至少98%、至少99%或100%相同的序列。在一些实施方案中,变体多肽序列是亲心性变体多肽序列。在一些实施方案中,该衣壳蛋白包含来自AAV5衣壳蛋白的至少一个区段。在一些实施方案中,该衣壳蛋白包含:
a)包含与SEQ ID NO:411或SEQ ID NO:412至少95%相同的序列的第一区段;
b)包含与SEQ ID NO:413或SEQ ID NO:414至少95%相同的序列的第二区段;
c)包含与SEQ ID NO:415或SEQ ID NO:416至少95%相同的序列的第三区段;
d)包含与SEQ ID NO:417或SEQ ID NO:418至少95%相同的序列的第四区段;
e)包含与SEQ ID NO:419或SEQ ID NO:420至少95%相同的序列的第五区段。
其中至少一个区段来自AAV5衣壳蛋白且至少一个区段来自AAV9衣壳蛋白。在一些实施方案中,该嵌合衣壳蛋白包含与选自SEQ ID NO:421-444的序列至少95%相同的序列。在一些实施方案中,该衣壳蛋白包含与SEQ ID NO:434至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与SEQ ID NO:438至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,该衣壳蛋白包含与SEQID NO:441至少95%、至少98%、至少99%或100%相同的氨基酸序列。
在一个方面,本公开提供了重组腺相关病毒(rAAV)病毒体,该病毒体包含本公开的衣壳蛋白和包含编码一种或多种基因产物的核苷酸序列的异源核酸。在一些实施方案中,该rAAV病毒体包含含有与SEQ ID NO:404至少95%、至少98%、至少99%或100%相同的氨基酸序列的衣壳蛋白。在一些实施方案中,该rAAV病毒体包含含有与SEQ ID NO:483至少95%、至少98%、至少99%或100%相同的氨基酸序列的衣壳蛋白。在一些实施方案中,该rAAV病毒体与包含亲本序列的AAV病毒体相比,在心脏细胞中表现出增加的转导效率。在一些实施方案中,心脏细胞位于心脏的左心室中。在一些实施方案中,该rAAV病毒体与包含亲本序列的AAV病毒体相比,在诱导多能干细胞来源的心肌细胞(iPS-CM)中表现出增加的转导效率。在一些实施方案中,该rAAV病毒体与包含亲本序列的AAV病毒体相比,在人心脏成纤维细胞(hCF)中表现出增加的转导效率。在一些实施方案中,该rAAV病毒体在100,000的感染复数(MOI)下在iPS-CM细胞中表现出增加至少2倍的转导效率。在一些实施方案中,该rAAV病毒体在75,000的感染复数(MOI)下在iPS-CM细胞中表现出增加至少2倍的转导效率。在一些实施方案中,该rAAV病毒体在C57BL/6J小鼠中表现出增加至少2倍的心脏转导效率,其中该小鼠被注射2.5E+11vg/只小鼠的病毒体剂量。在一些实施方案中,该rAAV病毒体在C57BL/6J小鼠中表现出增加至少1.5倍的心脏转导效率,其中该小鼠被注射2E+11vg/只小鼠的病毒体剂量。在一些实施方案中,该rAAV病毒体在C57BL/6J小鼠中表现出增加至少2倍的心脏转导效率,其中该小鼠被注射1E+11vg/只小鼠的病毒体剂量。在一些实施方案中,该rAAV病毒体与包含亲本序列的AAV病毒体相比,在肝细胞中表现出增加的转导效率。在一些实施方案中,该rAAV病毒体与包含亲本序列的AAV病毒体相比,表现出改善的NAb逃避。在一些实施方案中,该rAAV病毒体表现出该rAAV病毒体对心脏细胞比对肝细胞的选择性增加。在一些实施方案中,该rAAV病毒体表现出该rAAV病毒体对iPS-CM细胞比对肝细胞的选择性增加。
在一个方面,本公开提供了包含本公开的rAAV病毒体和药学上可接受的载剂的药物组合物。
在一个方面,本公开提供了编码本公开的衣壳蛋白的多核苷酸。在一些实施方案中,该多核苷酸包含编码衣壳蛋白的序列,该衣壳蛋白包含与SEQ ID NO:404至少95%、至少98%、至少99%或100%相同的氨基酸序列。在一些实施方案中,该多核苷酸包含编码衣壳蛋白的序列,该衣壳蛋白包含与SEQ ID NO:483至少95%、至少98%、至少99%或100%相同的氨基酸序列。
在一个方面,本公开提供了转导心脏细胞的方法,这些方法包括使心脏细胞与本公开的rAAV病毒体接触,其中该rAAV病毒体转导心脏细胞。在一些实施方案中,该心脏细胞是心肌细胞。在一些实施方案中,该rAAV病毒体与包含AAV9衣壳蛋白序列的AAV病毒体相比,在细胞中表现出增强的转导效率。在一些实施方案中,该rAAV病毒体与包含AAV9衣壳蛋白序列的AAV病毒体相比在75,000的感染复数(MOI)下在细胞中表现出增加至少2倍的转导效率。
在一个方面,本公开提供了将一种或多种基因产物递送至心脏细胞的方法,这些方法包括使心脏细胞与本公开的rAAV病毒体接触。在一些实施方案中,该心脏细胞是心肌细胞。
在一个方面,本公开提供了治疗有此需要的受试者的心脏病理的方法,这些方法包括向受试者施用治疗有效量的本公开的rAAV病毒体或本公开的药物组合物,其中该rAAV病毒体转导心脏组织。在一些实施方案中,该rAAV病毒体包含含有编码一种或多种基因产物的核苷酸序列的异源核酸。在一些实施方案中,该一种或多种基因产物包括MYBPC3、DWORF、KCNH2、TRPM4、DSG2、PKP2和/或ATP2A2。在一些实施方案中,该一种或多种基因产物包括CACNA1C、DMD、DMPK、EPG5、EVC、EVC2、FBN1、NF1、SCN5A、SOS1、NPR1、ERBB4、VIP、MYH7和/或Cas9。在一些实施方案中,该一种或多种基因产物包括MYOCD、ASCL1、GATA4、MEF2C、TBX5、miR-133和/或MESP1。
在一个方面,本公开提供了包含本公开的药物组合物和使用说明书的试剂盒。
附图说明
图1描绘了AAV9衣壳,突出了选定的AAV9可变区(VR-IV、VR-V、VR-VII和VR-VIII位点)中的氨基酸。
图2示出了定向进化选择策略和变体表征的示意图。文库生成后,每个文库在hiPSC-CMs中进行一轮选择且在小鼠模型中进行两轮选择。通过评价病毒系统递送后的体外转导(hiPSC-CMs)和体内转导(心脏和肝脏)来表征每个文库的前几种变体。针对逃避人NAb抑制的能力对前几种变体变体进行筛选。
图3示出了三轮文库筛选后VR修饰的文库的图示。示出了亲本病毒文库中以及在三轮选择后VR-IV(图3A)、VR-V(图3B)、VR-VII(图3C)和VR-VIII(图3D)的文库复杂性的图示,其中图像中的每个读段与图像中的一个像素相关。基于序列的疏水性,为蛋白质序列给予独特的颜色,并且相同序列的读段聚集在一起。
图4描绘了定向进化后在VR-IV(图4A)、VR-V(图4B)、VR-VII(图4C)和VR-VIII(图4D)位点中鉴定的蛋白质基序。
图5显示与AAV9相比,AAV VR-IV修饰的变体表现出优异的hiPSC-CM转导。人IPSC来源的心肌细胞以100,000的MOI用AAV9或包装泛表达GFP报告基因的各种进化衣壳变体感染。感染后三天,通过流式细胞术对GFP表达进行定量。与AAV9相比,CR9-01(129倍)、CR9-07(16倍)和CR9-13(9倍)展示出显著改善的转导,而CR9-10、CR9-13和CR9-14显示出转导适度增加。图的下半部分示出了AAV9和CR9-01的代表性图像,示出了转导的显著增加。
图6示出了新型AAV变体的体内表征。在C57BL/6J中以2.5x1011vg/只小鼠(每组n=2-3只小鼠)在眶后注射包装在新型衣壳中的AAV9:CAG-GFP或CAG-GFP。图6A显示,如通过ELISA测定,CR9-07、CR9-10、CR9-13和CR9-14表现出显著高于AAV9的心脏转导(p<0.05,单因素方差分析(One-way ANOVA);邓尼特多重比较检验(Dunnett’s multiple comparisontest))。图6B示出了对于前几种转导变体而言心脏的代表性横截面。图6C显示,与AAV9相比,CR9-10和CR9-14展示出显著降低的肝脏嗜性(p<0.03,单因素方差分析;邓尼特多重比较检验)。图6D示出了对于前几种变体而言肝脏的代表性IHC图像。
图7A-图7C示出了新型AAV变体对针对汇集的人IgG的NAb抑制的易感性。图7A是评估在0-600·g/mL范围内的不同剂量的汇集的人IgG(~2000名患者)下的中和抗体逃避的实验设计的图解说明。图7B示出了剂量反应曲线,展示在IgG浓度高于300·g/mL时,CR9-07和CR9-13的中和作用降低。图7C显示,与AAV9相比,CR9-07和CR9-13具有显著降低的中和作用(p<0.0001,单因素方差分析;邓尼特多重比较检验)
图8示出了通过DNA改组生成AAV5/9嵌合文库的视觉描绘。对AAV9进行密码子修饰以提高与AAV5的同源性,并通过DNA酶I消化将两个Cap基因片段化,并基于两个Cap基因之间的部分同源性经由PCR重新组装。
图9显示AAV5/9嵌合文库的文库复杂性在一轮体内筛选后显著降低。图示描绘了单个AAV嵌合体的序列。
图10示出了前几种AAV5/9嵌合体的体外表征。图10A示出了在75,000的MOI下hiPSC-CMs的转导效率。与AAV9相比,ZC44表现出改善的hiPSC-CM转导。图10B示出了在1mg/mL汇集的人IgG下对前几种AAV5/9嵌合体的NAb逃避的评价。与AAV9相比,ZC44显示出增强的NAb逃避。
图11示出了嵌合AAV变体的体内表征。在C57BL/6J中以2x1011vg/只小鼠(每组n=3只小鼠)在眶后注射包装在嵌合衣壳中的AAV9:CAG-GFP或CAG-GFP。注射后14天,收获心脏(图11A)和肝脏(图11B)并且评估GFP表达以评价转染效率和特异性。与野生型AAV9相比,ZC40和ZC47展示出改善的心脏特异性。
图12描绘了通过组合前几种AAV5/9嵌合体和AAV9 VR修饰的变体来生成组合AAV变体。
图13示出了对VR修饰的和组合AAV衣壳变体的可制造性的评估。进行中等规模的载体生产以评估AAV衣壳变体的可制造性。与AAV9相比,CR9-07、CR9-10和TN40-14具有改善的可制造性。
图14证明组合AAV变体具有显著改善的hiPSC-CM转导。人IPSC来源的心肌细胞以100,000的MOI用AAV9或包装泛表达GFP报告基因的各种组合衣壳变体感染。感染后五天,使用Cytation 5细胞成像读取器对GFP表达进行定量。与AAV9相比,TN44-07和TN47-07具有显著改善的hiPSC-CMs转导(>15倍)。
图15示出了新型AAV变体的体内表征结果。在C57BL/6J中以1x1011 vg/只小鼠(每组n=4只小鼠)在眶后注射包装在新型衣壳中的AAV9:CAG-GFP或CAG-GFP。注射后14天,收获心脏和肝脏并评估GFP表达。图15A示出了在心脏中每种衣壳变体的转导效率。图15B示出了在肝脏中每种衣壳变体的转导效率。图15C示出了在心脏中的转导效率/在肝脏中的转导效率的比率。与AAV9相比,TN44-07和TN47-10展示出增强的心脏转导,而TN47-14从肝脏脱靶并且具有比AAV9明显更高的心脏与肝脏转导比率。
图16示出了对前几种组合衣壳变体的人NAb逃避的评价。所有组合AAV衣壳变异体展示出在汇集的人IgG中对中和抗体的逃避提高,其中TN44-07是最隐蔽的衣壳,与AAV9相比,具有非常显著的NAb中和减少(p=0.0002,t检验,Welch校正)。
图17A示出了在以标准AAV9衣壳为基准的食蟹猴左心室中具有不同工程化衣壳的rAAV病毒体的相对转导。两种衣壳变体TN3和TN6在左心室转导中表现出显著的改善。图17B示出了在肝脏中衣壳变体的转导图谱。与AAV9相比,大多数衣壳变体展示出降低的肝脏嗜性。图17C示出了相对于AAV9衣壳归一化的心脏与肝脏的相对转导比率。与AAV9相比,TN3揭示心脏对肝脏的特异性增加了5倍。
具体实施方式
本公开提供了重组腺相关病毒(rAAV)病毒体。具体而言,本公开提供了工程化衣壳蛋白(包括嵌合衣壳蛋白)、鉴定工程化衣壳蛋白的方法和使用工程化衣壳蛋白的方法。本文公开的鉴定新衣壳蛋白的方法广泛应用于任何血清型的AAV,包括嵌合衣壳蛋白。另外,它们可以应用于迭代改善由这种方法或其他方法产生突变的衣壳蛋白。一般而言,本公开的方法涉及制备cap基因多核苷酸形式的AAV衣壳的随机或半随机文库,制备包含此类衣壳的AAV病毒体(通过将cap基因文库并入到AAV基因组中,或者反式提供该基因文库,诸如在转染到包装系中的质粒上),正向或负向选择AAV病毒体,并回收cap基因用于测序。在一些实施方案中,回收和测序包括纳米孔测序。可以使用其他高通量测序或下一代测序(NGS)方法。
在一些实施方案中,本公开提供了重组腺相关病毒(rAAV)病毒体,这些病毒体包含:
a)如本文所述的衣壳蛋白;和
b)包含编码一种或多种基因产物的核苷酸序列的异源核酸。
在一些实施方案中,本文公开的rAAV病毒体包含如本文公开的AAV9衣壳蛋白。在一些实施方案中,本文公开的rAAV病毒体包含如本文公开的嵌合AAV5/AAV9衣壳蛋白。在一些实施方案中,本文公开的rAAV病毒体包含如本文公开的组合衣壳蛋白。
在一些实施方案中,该AAV9衣壳蛋白包含与SEQ ID NO:1具有至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%同一性的序列,如下所示。VP1、VP2和VP3的N端残基以及VR位点(VR-IV、VR-V、VR-VII和VR-VIII)在下面的全长VP1(SEQ ID NO:1)的序列中示出。
VP1-->
MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLVP2-->
EPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIG
VP3-->
EPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLID
VR-IV VR-VQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNS EFAWP
VR-VII GASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIK
VR-VIII
TTNPVATESYGQVATNHQSAQAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL(SEQ ID NO:1)
在VR位点具有变体多肽序列的衣壳蛋白
在一个方面,本公开提供了AAV9衣壳蛋白,其中该衣壳蛋白相对于亲本序列在亲本序列的一个或多个位点包含变体多肽序列。在一些实施方案中,亲本序列的该一个或多个位点选自由VR-IV位点、VR-V位点、VR-VII位点和VR-VIII位点组成的组。如上面SEQ IDNO:1中所标记的,VR-IV位点介于亲本序列中的残基452与残基460之间(“NGSGQNQQT”,SEQID NO:2);VR-V位点介于亲本序列中的残基497与残基502之间(“NNSEFA”,SEQ ID NO:3);VR-VII位点介于亲本序列中的残基549与残基553之间(“GRDNV”,SEQ ID NO:4);VR-VIII位点介于亲本序列中的残基586与残基589之间(“SAQA”,SEQ ID NO:5)。在一些实施方案中,该AAV9衣壳蛋白包含与SEQ ID NO:1具有至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%同一性的序列,不包括VR-IV位点、VR-V位点、VR-VII位点和/或VR-VIII位点。在一些实施方案中,该AAV9衣壳蛋白在亲本序列的VR-IV位点、VR-V位点、VR-VII位点和VR-VIII位点中的一个或多个位点处包含变体多肽序列,其中该亲本序列包含与SEQID NO:463至少80%、至少85%、至少90%、至少95%、至少98%、至少99%或100%相同的序列。(在SEQ ID NO:463中,将标记为“X”的氨基酸残基从序列同一性计算中排除。)
在一些实施方案中,该AAV9衣壳蛋白包含变体多肽序列,该变体多肽序列是合理设计的;通过诱变引入的;或者是通过在一个或多个位点产生随机密码子使用的序列文库而随机化的。本公开的衣壳蛋白包括通过定向进化,接着测序鉴定为富集的任何变体多肽序列,如实施例中所示,但不限于此。不限于任何特定的取代位点,在一些实施方案中,选自由VR-IV位点、VR-V位点、VR-VII位点和VR-VIII位点组成的组的一个或多个位点具有如本文所述的氨基酸取代。
在一些实施方案中,本公开的衣壳蛋白在VR-IV位点处包含变体多肽序列。在一些实施方案中,整个VR-IV位点(“NGSGQNQQT”,SEQ ID NO:2)被下式的肽取代:
-(X)n-
其中n为7-11,并且X表示20种标准氨基酸中的任何一种(SEQ ID NO:478)。
在一些实施方案中,该VR-IV位点的变体多肽序列为:
-X1-X2-X3-X4-X5-X6-X7-X8-X9-。
在一些实施方案中,该VR-IV位点的变体多肽序列为:
-X1-X2-X3-X4-X5-X6-X7-X8-X9-
其中X1是G、S或V;X2是Y、Q或I;X3是H、W、V或I;X4是K或N;X5是S、G或I;X6是G或R;X7是A、P或V;X8是A或R;和/或X9是Q或D(SEQ ID NO:477)。
在一些实施方案中,该VR-IV位点的变体多肽序列包含选自以下的序列或由选自以下的序列组成:GYHKSGAAQ(SEQ ID NO:6)、VIIKSGAAQ(SEQ ID NO:7)、GYHKIGAAQ(SEQ IDNO:8)、GYHKSGVAQ(SEQ ID NO:9)、VYHKSGAAQ(SEQ ID NO:10)、GYHKISAAQ(SEQ ID NO:11)、TTVPSSSRY(SEQ ID NO:12)、VIIRVVRLS(SEQ ID NO:13)、TVLGQNQQT(SEQ ID NO:14)、IYHKSGAAQ(SEQ ID NO:15)、TVLDKNQQT(SEQ ID NO:16)、YSGTDVRYK(SEQ ID NO:17)、VTASGKEHR(SEQ ID NO:18)、GYRKSGAAQ(SEQ ID NO:19)、NRTVSNGSE(SEQ ID NO:20)、TVLDRINKT(SEQ ID NO:21)、TGVGHLTSA(SEQ ID NO:22)、GYHKGGAAQ(SEQ ID NO:23)、VIAKSGAAQ(SEQ ID NO:24)、GYHKSGAAH(SEQ ID NO:25)、FIIKSGAAQ(SEQ ID NO:26)、GYHKVVRLS(SEQ ID NO:27)、GATRSAVES(SEQ ID NO:28)、TVSGQNQQT(SEQ ID NO:29)、LSHKSGAAQ(SEQ ID NO:30)、SSSGQNQQT(SEQ ID NO:31)、SGSGQNQQT(SEQ ID NO:32)、SQVNGRPRD(SEQ ID NO:33)、GYHKEWCGS(SEQ ID NO:34)、VVSSKSLNS(SEQ ID NO:35)、GYHKSGAAP(SEQ ID NO:36)、DASSREKVR(SEQ ID NO:37)、SYHKSGAAQ(SEQ ID NO:38)、TANGSQKYL(SEQ ID NO:39)、VIIRVGAAQ(SEQ ID NO:40)、SSTNKISTA(SEQ ID NO:41)、TVLDRIQQT(SEQ ID NO:42)、GYHKSGAVQ(SEQ ID NO:43)、TVLDQNQQT(SEQ ID NO:44)、VNMSSPIKT(SEQ ID NO:45)、AAYNSNSAF(SEQ ID NO:46)、GYHKSGAAR(SEQ ID NO:47)、VIIRVVRLQ(SEQ ID NO:48)、RFWTQNQQT(SEQ ID NO:49)、SSPRASSAL(SEQ ID NO:50)、IIIRVVRLS(SEQ ID NO:51)、KSSNLTAMP(SEQ ID NO:52)、NLNSDRHSA(SEQ ID NO:53)、LSLKSGAAQ(SEQ ID NO:54)、TVLDRNQQT(SEQ ID NO:55)、GSERVSNSG(SEQ ID NO:56)、VIAKIGAAQ(SEQ ID NO:57)、VYHKIGAAQ(SEQ ID NO:58)、LSYKSGAAQ(SEQ ID NO:59)、STVSQPVRT(SEQ ID NO:60)、GHHKSGAAQ(SEQ ID NO:61)、YAGIDPRYH(SEQ ID NO:62)、DRSRKSMCD(SEQ ID NO:63)、VIIRSGAAQ(SEQ ID NO:64)、GYHKSGGSA(SEQ ID NO:65)、VIIKIGAAQ(SEQ ID NO:66)、GYHKVVQLS(SEQ ID NO:67)、VIIKLVAAQ(SEQ ID NO:68)、KVSSHSVCD(SEQ ID NO:69)、GYHKRVRLS(SEQ ID NO:70)、GYHKSSAAQ(SEQ ID NO:71)、GYRKIGAAQ(SEQ ID NO:72)、GYHKSGAAC(SEQ ID NO:73)、GYRQSGAAQ(SEQ ID NO:74)、VIIKLIAAQ(SEQ ID NO:75)、VIIRVVRAQ(SEQ ID NO:76)、GYHKSGAAW(SEQ ID NO:77)、GYHKSGAVS(SEQ ID NO:78)、GYHKEWCSS(SEQ ID NO:79)、SSSSNRLAD(SEQ ID NO:80)、SNNSSSAKF(SEQ ID NO:81)、VKLSSTSSS(SEQ ID NO:82)、GYHKEWCAQ(SEQ ID NO:83)、AGSGQNQQT(SEQ ID NO:84)、NPHGTATYL(SEQ ID NO:85)、NGSGQNQHT(SEQ ID NO:86)、GYHKVGAAQ(SEQ ID NO:87)、VIIRVVRLK(SEQ ID NO:88)、NSIPSTSKW(SEQ ID NO:89)、VIIRVVQLQ(SEQ ID NO:90)、SQVNGRPQD(SEQ ID NO:91)、NGSGQDQQT(SEQ ID NO:92)、GLNSSDRRL(SEQ ID NO:93)、IYHKIGAAQ(SEQ ID NO:94)、YHKSGAAQL(SEQ ID NO:95)、YSGTDVQYK(SEQ ID NO:96)、LGSGQNQQT(SEQ ID NO:97)、PVSSGADRR(SEQ ID NO:98)、EHSTKLNAC(SEQ ID NO:99)、NGSDRINKR(SEQ ID NO:100)、VIIKGGAAQ(SEQ ID NO:101)、GYHRVVRLS(SEQ ID NO:102)、VIIRVVRLL(SEQ ID NO:103)和VILKSGAAQ(SEQ ID NO:104)。
在一些实施方案中,VR-IV位点的变体多肽序列包含与SEQ ID NO:6-104之一至少约60%、70%、80%、90%或100%相同的多肽序列,基本上由该多肽序列组成或由该多肽序列组成。
在一些实施方案中,VR-IV位点的变体多肽序列包含与GYHKSGAAQ(SEQ ID NO:6)至少约60%、70%、80%、90%或100%相同的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-IV位点的变体多肽序列包含由相对于GYHKSGAAQ(SEQ ID NO:6)的至多1、2、3或4个氨基酸取代组成的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-IV位点的变体多肽序列包含由相对于GYHKSGAAQ(SEQ ID NO:6)的至多1、2、3或4个保守性氨基酸取代组成的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-IV位点的变体多肽序列是GYHKSGAAQ(SEQ ID NO:6)。
在一些实施方案中,VR-IV位点的变体多肽序列包含与SQVNGRPRD(SEQ ID NO:33)至少约60%、70%、80%、90%或100%相同的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-IV位点的变体多肽序列包含由相对于SQVNGRPRD(SEQ ID NO:33)的至多1、2、3或4个氨基酸取代组成的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-IV位点的变体多肽序列包含由相对于SQVNGRPRD(SEQ ID NO:33)的至多1、2、3或4个保守性氨基酸取代组成的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-IV位点的变体多肽序列是SQVNGRPRD(SEQ ID NO:33)。
在一些实施方案中,本公开的衣壳蛋白在VR-V位点处包含变体多肽序列。在一些实施方案中,整个VR-V位点(“NNSEFA”,SEQ ID NO:3)被下式的肽取代:
-(X)n-
其中n为4-8,并且X表示20种标准氨基酸中的任何一种(SEQ ID NO:479)。
在一些实施方案中,该VR-V位点的变体多肽序列为:
-X1-X2-X3-X4-X5-X6-
在一些实施方案中,该VR-V位点的变体多肽序列为:
-X1-X2-X3-X4-X5-X6-
其中X1是S、L、H、N或A;X2是T、M、K、G或N;X3是S、T、M或I;X4是S、P、F、M或N;X5是F、S、P或L;并且X6是I、V或T(SEQ ID NO:474)。
在一些实施方案中,VR-V位点的变体多肽序列包含选自以下的序列或由选自以下的序列组成:LNSMLI(SEQ ID NO:105)、NGMSFT(SEQ ID NO:106)、HKTFSI(SEQ ID NO:107)、SMSNFV(SEQ ID NO:108)、ATIPPI(SEQ ID NO:109)、SSTHFD(SEQ ID NO:110)、NNQFSY(SEQID NO:111)、NMGHYS(SEQ ID NO:112)、SKQMFQ(SEQ ID NO:113)、WPSAGV(SEQ ID NO:114)、NGGYQC(SEQ ID NO:115)、STSPIV(SEQ ID NO:116)、SQSGLW(SEQ ID NO:117)、VNSQFS(SEQID NO:118)、SGIEFR(SEQ ID NO:119)、SASKFT(SEQ ID NO:120)、QLNWTS(SEQ ID NO:121)、SMGFPV(SEQ ID NO:122)、SSFMGL(SEQ ID NO:123)、GSNFHV(SEQ ID NO:124)、DMTLYA(SEQID NO:125)、MGCLFT(SEQ ID NO:126)、ALAFNS(SEQ ID NO:127)、SKFLFA(SEQ ID NO:128)、QDAGLL(SEQ ID NO:129)、QDASLL(SEQ ID NO:130)、RDDMFS(SEQ ID NO:131)、LSRCFQ(SEQID NO:132)、LSRDFQ(SEQ ID NO:133)、QGLTPV(SEQ ID NO:134)、QWDVFT(SEQ ID NO:135)、PRVSFA(SEQ ID NO:136)、QSYYNP(SEQ ID NO:137)、RASHLG(SEQ ID NO:138)、IILFVP(SEQID NO:139)、IISFSY(SEQ ID NO:140)、LDSMLI(SEQ ID NO:141)、NIGHYS(SEQ ID NO:142)、NRMSFT(SEQ ID NO:143)、NGMSFA(SEQ ID NO:144)、IILLLP(SEQ ID NO:145)、RMRSLL(SEQID NO:146)、RRRCRF(SEQ ID NO:147)、PKQMFQ(SEQ ID NO:148)、LMSNFV(SEQ ID NO:149)、GASHLG(SEQ ID NO:150)、CASISW(SEQ ID NO:151)、SMTTFR(SEQ ID NO:152)、AAIPPI(SEQID NO:153)、PGCESL(SEQ ID NO:154)、SMGFAC(SEQ ID NO:155)、FLPSLM(SEQ ID NO:156)、NGISFT(SEQ ID NO:157)、ESSRWA(SEQ ID NO:158)、QLYFVP(SEQ ID NO:159)、SSNFHV(SEQID NO:160)、LEFMLI(SEQ ID NO:161)、QFDSFD(SEQ ID NO:162)、SPVFAC(SEQ ID NO:163)、VRLIFD(SEQ ID NO:164)、NGMSFI(SEQ ID NO:165)、LLFPPI(SEQ ID NO:166)、GAGVTG(SEQID NO:167)、QWMSFT(SEQ ID NO:168)、SIGFPV(SEQ ID NO:169)、RMQSLL(SEQ ID NO:170)、TSALQV(SEQ ID NO:171)、SLTHFD(SEQ ID NO:172)、QELPFL(SEQ ID NO:173)、LYFLLP(SEQID NO:174)、LSFFFA(SEQ ID NO:175)、LSRIFQ(SEQ ID NO:176)、DEVILF(SEQ ID NO:177)、RAGVAG(SEQ ID NO:178)、NGMSLP(SEQ ID NO:179)、PFEDFQ(SEQ ID NO:180)、QYGSLF(SEQID NO:181)、NYTFVL(SEQ ID NO:182)、MSGYQC(SEQ ID NO:183)、NYAFVP(SEQ ID NO:184)、RAGVTG(SEQ ID NO:185)、WNSMLI(SEQ ID NO:186)、IRRFSI(SEQ ID NO:187)、NGMSFY(SEQID NO:188)、IIQFSY(SEQ ID NO:189)、NGCLFT(SEQ ID NO:190)、RDASLL(SEQ ID NO:191)、ADSMLI(SEQ ID NO:192)、VDSQFS(SEQ ID NO:193)、SIGNFV(SEQ ID NO:194)、NGMSLL(SEQID NO:195)、NYTFVP(SEQ ID NO:196)、IRRLVF(SEQ ID NO:197)、PMSNFV(SEQ ID NO:198)、LWVFPV(SEQ ID NO:199)、VRLHFD(SEQ ID NO:200)、SMSNLF(SEQ ID NO:201)、STSLIV(SEQID NO:202)和HKTFGI(SEQ ID NO:203)。
在一些实施方案中,VR-V位点的变体多肽序列包含与SEQ ID NO:105-203之一至少约60%、70%、80%、90%或100%相同的多肽序列,基本上由该多肽序列组成或由该多肽序列组成。
在一些实施方案中,VR-V位点的变体多肽序列包含与LNSMLI(SEQ ID NO:105)至少约60%、70%、80%、90%或100%相同的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-V位点的变体多肽序列包含由相对于LNSMLI(SEQ ID NO:105)的至多1、2、3或4个氨基酸取代组成的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-V位点的变体多肽序列包含由相对于LNSMLI(SEQ ID NO:105)的至多1、2、3或4个保守性氨基酸取代组成的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-V位点的变体多肽序列是LNSMLI(SEQ ID NO:105)。
在一些实施方案中,本公开的衣壳蛋白在VR-VII位点处包含变体多肽序列。在一些实施方案中,整个VR-VII位点(“GRDNV”,SEQ ID NO:4)被下式的肽取代:
-(X)n-
其中n为3-7,并且X表示20种标准氨基酸中的任何一种(SEQ ID NO:480)。
在一些实施方案中,该VR-VII位点的变体多肽序列为:
-X1-X2-X3-X4-X5-
在一些实施方案中,该VR-VII位点的变体多肽序列为:
-X1-X2-X3-X4-X5-
其中X1是V、L、Q、C或R;X2是S、H、G、C或D;X3是Y、S、L、G或N;X4是S、L、H、Q或N;并且X5是V、I或R(SEQ ID NO:475)。
在一些实施方案中,VR-VII位点的变体多肽序列包含选自以下的序列或由选自以下的序列组成:RGNQV(SEQ ID NO:204)、VSLNR(SEQ ID NO:205)、CDYSV(SEQ ID NO:206)、QHGHI(SEQ ID NO:207)、LCSLV(SEQ ID NO:208)、PTIYV(SEQ ID NO:209)、DVIHI(SEQ IDNO:210)、AEFYA(SEQ ID NO:211)、NSVVC(SEQ ID NO:212)、VRSNC(SEQ ID NO:213)、LANNI(SEQ ID NO:214)、NLQFM(SEQ ID NO:215)、EFRDL(SEQ ID NO:216)、DFGSL(SEQ ID NO:217)、VTNYC(SEQ ID NO:218)、WNTNA(SEQ ID NO:219)、TESTC(SEQ ID NO:220)、SGAAV(SEQID NO:221)、GGCDI(SEQ ID NO:222)、SGSVV(SEQ ID NO:223)、SSNAC(SEQ ID NO:224)、YNTTV(SEQ ID NO:225)、SKCLA(SEQ ID NO:226)、SAYTV(SEQ ID NO:227)、VRDTV(SEQ IDNO:228)、WRSMV(SEQ ID NO:229)、AYHGV(SEQ ID NO:230)、GMNTI(SEQ ID NO:231)、AETSL(SEQ ID NO:232)、TLVYV(SEQ ID NO:233)、NHDWI(SEQ ID NO:234)、TVGIV(SEQ ID NO:235)、SLPTV(SEQ ID NO:236)、TGILC(SEQ ID NO:237)、TDTYI(SEQ ID NO:238)、LPVTY(SEQID NO:239)、GDVYI(SEQ ID NO:240)、LYGTV(SEQ ID NO:241)、GCEFI(SEQ ID NO:242)、SAGLL(SEQ ID NO:243)、IKSNI(SEQ ID NO:244)、VTTSL(SEQ ID NO:245)、AVTSV(SEQ IDNO:246)、RDIHI(SEQ ID NO:247)、SAISL(SEQ ID NO:248)、VASTC(SEQ ID NO:249)、IKGLL(SEQ ID NO:250)、GSYHT(SEQ ID NO:251)、RIGFV(SEQ ID NO:252)、NDIYI(SEQ ID NO:253)、AVSCV(SEQ ID NO:254)、QHNLL(SEQ ID NO:255)、VSSCV(SEQ ID NO:256)、LNLDV(SEQID NO:257)、LGATI(SEQ ID NO:258)、PVLCV(SEQ ID NO:259)、SARHI(SEQ ID NO:260)、RATLI(SEQ ID NO:261)、PYNHA(SEQ ID NO:262)、IGDSI(SEQ ID NO:263)、SPMLC(SEQ IDNO:264)、YDSTL(SEQ ID NO:265)、ALKHV(SEQ ID NO:266)、ADLLT(SEQ ID NO:267)、NNGHL(SEQ ID NO:268)、INSEV(SEQ ID NO:269)、SNKTT(SEQ ID NO:270)、GSTGL(SEQ ID NO:271)、DSDMI(SEQ ID NO:272)、TSNFI(SEQ ID NO:273)、RNFTT(SEQ ID NO:274)、SHKYS(SEQID NO:275)、VSDIV(SEQ ID NO:276)、RVVQA(SEQ ID NO:277)、AACAV(SEQ ID NO:278)、RGRQI(SEQ ID NO:279)、AVANI(SEQ ID NO:280)、AGYDL(SEQ ID NO:281)、LSEAA(SEQ IDNO:282)、MSNYL(SEQ ID NO:283)、NFSDN(SEQ ID NO:284)、SCCDV(SEQ ID NO:285)、LASSV(SEQ ID NO:286)、PDHAV(SEQ ID NO:287)、KFDII(SEQ ID NO:288)、NSSSA(SEQ ID NO:289)、HTMHV(SEQ ID NO:290)、TLSYC(SEQ ID NO:291)、ADTHR(SEQ ID NO:292)、SMYSV(SEQID NO:293)、SVNLV(SEQ ID NO:294)、MSGHL(SEQ ID NO:295)、KISDT(SEQ ID NO:296)、TGLLA(SEQ ID NO:297)、AWTTS(SEQ ID NO:298)、GGALI(SEQ ID NO:299)、SCIEV(SEQ IDNO:300)、PPVIC(SEQ ID NO:301)和GTYNL(SEQ ID NO:302)。
在一些实施方案中,VR-VII位点的变体多肽序列包含与SEQ ID NO:204-302之一至少约60%、70%、80%、90%或100%相同的多肽序列,基本上由该多肽序列组成或由该多肽序列组成。
在一些实施方案中,VR-VII位点的变体多肽序列包含与RGNQV(SEQ ID NO:204)至少约60%、70%、80%、90%或100%相同的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-VII位点的变体多肽序列包含由相对于RGNQV(SEQ ID NO:204)的至多1、2、3或4个氨基酸取代组成的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-VII位点的变体多肽序列包含由相对于RGNQV(SEQ ID NO:204)的至多1、2、3或4个保守性氨基酸取代组成的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-VII位点的变体多肽序列是RGNQV(SEQ ID NO:204)。
在一些实施方案中,本公开的衣壳蛋白在VR-VII位点处包含变体多肽序列。在一些实施方案中,整个VR-VIII位点(“SAQA”,SEQ ID NO:5)被下式的肽取代:
-(X)n-
其中n为2-6,并且X表示20种标准氨基酸中的任何一种(SEQ ID NO:481)。
在一些实施方案中,该VR-VIII位点的变体多肽序列为:
-X1-X2-X3-X4-
在一些实施方案中,该VR-VIII位点的变体多肽序列为:
-X1-X2-X3-X4-
其中X1是S、N或A;X2是V、M、N或A;X3是Y、V、S或G;并且X4是Y、T、M、G或N(SEQ ID NO:476)。
在一些实施方案中,VR-VIII位点的变体多肽序列包含选自以下的序列或由选自以下的序列组成:NVSY(SEQ ID NO:303)、SMVN(SEQ ID NO:304)、ANYG(SEQ ID NO:305)、NVGT(SEQ ID NO:306)、SAYM(SEQ ID NO:307)、EKVT(SEQ ID NO:308)、TTPG(SEQ ID NO:309)、GVYS(SEQ ID NO:310)、SYVG(SEQ ID NO:311)、LQYN(SEQ ID NO:312)、DPAK(SEQ IDNO:313)、THFS(SEQ ID NO:314)、IGGV(SEQ ID NO:315)、SSWN(SEQ ID NO:316)、SVYV(SEQID NO:317)、TLNG(SEQ ID NO:318)、NTSN(SEQ ID NO:319)、VQYA(SEQ ID NO:320)、DQYR(SEQ ID NO:321)、MPVS(SEQ ID NO:322)、SAQA(SEQ ID NO:323)、MTVA(SEQ ID NO:324)、TVMG(SEQ ID NO:325)、FSSI(SEQ ID NO:326)、SLRL(SEQ ID NO:327)、SAMG(SEQ ID NO:328)、YIKL(SEQ ID NO:329)、LMTM(SEQ ID NO:330)、QVHL(SEQ ID NO:331)、YNSV(SEQ IDNO:332)、CVIS(SEQ ID NO:333)、RLDG(SEQ ID NO:334)、AIMV(SEQ ID NO:335)、GTTG(SEQID NO:336)、ASYT(SEQ ID NO:337)、LHVG(SEQ ID NO:338)、LQFA(SEQ ID NO:339)、VRGD(SEQ ID NO:340)、NVMI(SEQ ID NO:341)、SLYG(SEQ ID NO:342)、GTVG(SEQ ID NO:343)、FNSV(SEQ ID NO:344)、TRLG(SEQ ID NO:345)、LKVL(SEQ ID NO:346)、SIRV(SEQ ID NO:347)、KIQG(SEQ ID NO:348)、QILG(SEQ ID NO:349)、QRDA(SEQ ID NO:350)、EAVR(SEQ IDNO:351)、AITV(SEQ ID NO:352)、KESI(SEQ ID NO:353)、LMVN(SEQ ID NO:354)、INLS(SEQID NO:355)、GQVS(SEQ ID NO:356)、TSLL(SEQ ID NO:357)、SSTL(SEQ ID NO:358)、YEKF(SEQ ID NO:359)、DGKL(SEQ ID NO:360)、QVYS(SEQ ID NO:361)、QKEG(SEQ ID NO:362)、ARDM(SEQ ID NO:363)、DNFR(SEQ ID NO:364)、SHGL(SEQ ID NO:365)、VSVN(SEQ ID NO:366)、GLKD(SEQ ID NO:367)、QPVF(SEQ ID NO:368)、VYSM(SEQ ID NO:369)、VMAQ(SEQ IDNO:370)、FVGM(SEQ ID NO:371)、WSTP(SEQ ID NO:372)、SYPV(SEQ ID NO:373)、TTYS(SEQID NO:374)、TVTT(SEQ ID NO:375)、KDKT(SEQ ID NO:376)、YREL(SEQ ID NO:377)、LSHF(SEQ ID NO:378)、SPGT(SEQ ID NO:379)、LMGT(SEQ ID NO:380)、AASL(SEQ ID NO:381)、FSNN(SEQ ID NO:382)、QARL(SEQ ID NO:383)、YHIA(SEQ ID NO:384)、ARQD(SEQ ID NO:385)、VAYT(SEQ ID NO:386)、TPSY(SEQ ID NO:387)、MILH(SEQ ID NO:388)、LGNV(SEQ IDNO:389)、TSIS(SEQ ID NO:390)、TMVY(SEQ ID NO:391)、LVVG(SEQ ID NO:392)、SPLY(SEQID NO:393)、YKSE(SEQ ID NO:394)、FTRL(SEQ ID NO:395)、VSYN(SEQ ID NO:396)、ERTP(SEQ ID NO:397)、FRSE(SEQ ID NO:398)、NYTE(SEQ ID NO:399)、QTIN(SEQ ID NO:400)和DVHR(SEQ ID NO:401)。
在一些实施方案中,VR-VIII位点的变体多肽序列包含与SEQ ID NO:303-401之一至少约60%、70%、80%、90%或100%相同的多肽序列,基本上由该多肽序列组成或由该多肽序列组成。
在一些实施方案中,VR-VIII位点的变体多肽序列包含与ANYG(SEQ ID NO:305)至少约60%、70%、80%、90%或100%相同的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-VIII位点的变体多肽序列包含由相对于ANYG(SEQ ID NO:305)的至多1、2或3个氨基酸取代组成的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-VIII位点的变体多肽序列包含由相对于ANYG(SEQ ID NO:305)的至多1、2或3个保守性氨基酸取代组成的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-VIII位点的变体多肽序列是ANYG(SEQ ID NO:305)。
在一些实施方案中,VR-VIII位点的变体多肽序列包含与NVSY(SEQ ID NO:303)至少约60%、70%、80%、90%或100%相同的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-VIII位点的变体多肽序列包含由相对于NVSY(SEQ ID NO:303)的至多1、2或3个氨基酸取代组成的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-VIII位点的变体多肽序列包含由相对于NVSY(SEQ ID NO:303)的至多1、2或3个保守性氨基酸取代组成的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,VR-VIII位点的变体多肽序列是NVSY(SEQ ID NO:303)。
在一些实施方案中,该衣壳蛋白包含与SEQ ID NO:402-410和464-468之一至少80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同的多肽序列或其功能片段,基本上由该多肽序列或其功能片段组成,或由该多肽序列或其功能片段组成。
表1.衣壳蛋白序列
嵌合AAV5/AAV9衣壳
本公开还提供了重组腺相关病毒(rAAV)衣壳蛋白,该衣壳蛋白包含与SEQ ID NO:463至少80%、至少85%、至少90%、至少95%、至少98%、至少99%或100%相同的序列。(在SEQ ID NO:463中,将标记为“X”的氨基酸残基从序列同一性计算中排除。)在一些实施方案中,衣壳蛋白是AAV5/AAV9嵌合衣壳蛋白。在一些实施方案中,AAV5/AAV9嵌合衣壳蛋白序列与AAV9衣壳蛋白序列(SEQ ID NO:1)超过约50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、96%、97%、98%、99%或99.5%相同。在一些实施方案中,AAV5/AAV9嵌合衣壳蛋白序列的C端500个残基与AAV9衣壳蛋白序列(SEQ ID NO:1)的C端500个残基至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同。在一些实施方案中,与AAV9衣壳蛋白序列(SEQ ID NO:1)的Q688等效的位置的残基在嵌合衣壳蛋白中是赖氨酸(K)。
在一些实施方案中,该嵌合衣壳蛋白包含至少1、2、3、4、5个或更多个源自AAV5衣壳蛋白的多肽区段。在一些实施方案中,该嵌合衣壳蛋白包含至少1、2、3、4、5个或更多个源自AAV9衣壳蛋白的多肽区段。在一些实施方案中,至少一种多肽区段源自AAV5衣壳蛋白并且至少一种多肽区段源自AAV9衣壳蛋白。
在一些实施方案中,该嵌合衣壳蛋白N端的前250个残基包含一个或多个AAV5衣壳来源的多肽区段。在一些实施方案中,该嵌合衣壳蛋白N端的前225个残基包含一个或多个AAV5衣壳来源的多肽区段。在一些实施方案中,该嵌合衣壳蛋白N端的前200个残基包含一个或多个AAV5衣壳来源的多肽区段。在一些实施方案中,该嵌合衣壳蛋白N端的前150个残基包含一个或多个AAV5衣壳来源的多肽区段。在一些实施方案中,该嵌合衣壳蛋白N端的前100个残基包含一个或多个AAV5衣壳来源的多肽区段。在一些实施方案中,该嵌合衣壳蛋白N端的前50个残基包含一个或多个AAV5衣壳来源的多肽区段。在一些实施方案中,该一个或多个AAV5衣壳来源的多肽区段中的每个多肽区段与相应的AAV5衣壳序列具有至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%的序列同一性。
在一些实施方案中,该嵌合衣壳蛋白的残基50-250包含一个或多个AAV5衣壳来源的多肽区段。在一些实施方案中,该嵌合衣壳蛋白的残基50-200包含一个或多个AAV5衣壳来源的多肽区段。在一些实施方案中,该嵌合衣壳蛋白的残基50-150包含一个或多个AAV5衣壳来源的多肽区段。在一些实施方案中,该嵌合衣壳蛋白的残基100-250包含一个或多个AAV5衣壳来源的多肽区段。在一些实施方案中,该嵌合衣壳蛋白的残基100-200包含一个或多个AAV5衣壳来源的多肽区段。在一些实施方案中,该嵌合衣壳蛋白的残基150-250包含一个或多个AAV5衣壳来源的多肽区段。在一些实施方案中,该一个或多个AAV5衣壳来源的多肽区段中的每个多肽区段与相应的AAV5衣壳序列具有至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%的序列同一性。
在一些实施方案中,该嵌合衣壳蛋白C端的最后100个残基包含一个或多个AAV5衣壳来源的多肽区段。在一些实施方案中,该嵌合衣壳蛋白C端的最后50个残基包含一个或多个AAV5衣壳来源的多肽区段。在一些实施方案中,该一个或多个AAV5衣壳来源的多肽区段中的每个多肽区段与相应的AAV5衣壳序列具有至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%的序列同一性。在一些实施方案中,该嵌合衣壳蛋白,如上所述,在该嵌合衣壳蛋白的N端或其附近包含一个或多个AAV5衣壳来源的多肽区段,并且如本段落所述,在该嵌合衣壳蛋白的C端或其附近包含一个或多个AAV5衣壳来源的多肽区段。
在一些实施方案中,该嵌合衣壳蛋白按N端到C端的顺序包含第一多肽区段,该第一多肽区段具有与SEQ ID NO:411至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同或与SEQ ID NO:412至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同的序列;第二多肽区段,该第二多肽区段具有与SEQ ID NO:413至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同或与SEQ ID NO:414至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同的序列;第三多肽区段,该第三多肽区段具有与SEQ ID NO:415至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同或与SEQ ID NO:416至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同的序列;第四多肽区段,该第四多肽区段具有与SEQ ID NO:417至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同或与SEQ ID NO:418至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同的序列;和第五多肽区段,该第五多肽区段具有与SEQ ID NO:419至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同或与SEQ ID NO:420至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同的序列。在一些实施方案中,至少一种多肽区段源自AAV5衣壳蛋白并且至少一种多肽区段源自AAV9衣壳蛋白。
AAV9来源的多肽区段1:
MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGY(SEQ ID NO:411)
AAV5来源的多肽区段1的序列:
MSFVDHPPDWLEEVGEGLREFLGLEAGPPKPKPNQQHQDQARGLVLPGY(SEQ ID NO:412)
AAV9来源的多肽区段2的序列:
KYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLK(SEQ ID NO:413)
AAV5来源的多肽区段2的序列:
NYLGPGNGLDRGEPVNRADEVAREHDISYNEQLE(SEQ ID NO:414)
AAV9来源的多肽区段3的序列:
AGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEP(SEQ ID NO:415)
AAV5来源的多肽区段3的序列:
AGDNPYLKYNHADAEFQEKLADDTSFGGNLGKAVFQAKKRVLEP(SEQ ID NO:416)
AAV9来源的多肽区段4的序列:
LGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMASGGGAPVA(SEQ ID NO:417)
AAV5来源的多肽区段4的序列:
FGLVEEGAKTAPTGKRIDDHFPKRKKARTEEDSKPSTSSDAEAGPSGSQQLQIPAQPASSLGADTMSAGGGGPLG(SEQ ID NO:418)
AAV9来源的多肽区段5的序列:
DNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTgrdnvDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL(SEQ ID NO:419)
具有Q688K突变的AAV9来源的多肽区段5的序列:
DNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTgrdnvDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELKKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL(SEQ ID NO:420)
在一些实施方案中,该嵌合衣壳蛋白包含与SEQ ID NO:421-444之一至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同的多肽序列或其功能片段,基本上由该多肽序列或其功能片段组成,或由该多肽序列或其功能片段组成。
表2.衣壳蛋白序列
组合衣壳蛋白
在一个方面,本公开提供了组合衣壳蛋白。如本文所用,“组合衣壳蛋白”是指如本公开中描述的AAV5/AAV9嵌合衣壳蛋白,该嵌合衣壳蛋白进一步相对于嵌合亲本序列在一个或多个位点包含氨基酸变异。在一些实施方案中,嵌合亲本序列的该一个或多个位点选自与AAV9衣壳蛋白的VR-IV位点、VR-V位点、VR-VII位点和VR-VIII位点等效的那些位点。
本公开的组合衣壳蛋白包括如实施例中所示但不限于实施例中所示鉴定的任何变体多肽序列。不限于任何特定的实例,在一些实施方案中,该组合衣壳蛋白包含嵌合AAV5/AAV9衣壳蛋白骨架,并且进一步在一个或多个位点处包含变体多肽序列,该一个或多个位点选自与如本文所述的AAV9衣壳蛋白的VR-IV位点、VR-V位点、VR-VII位点和VR-VIII位点等效的那些位点。
在一些实施方案中,该组合衣壳蛋白按N端到C端的顺序包含第一多肽区段,该第一多肽区段具有与SEQ ID NO:411至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同或与SEQ ID NO:412至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同的序列;第二多肽区段,该第二多肽区段具有与SEQ ID NO:413至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同或与SEQ ID NO:414至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同的序列;第三多肽区段,该第三多肽区段具有与SEQ ID NO:415至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同或与SEQ ID NO:416至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同的序列;第四多肽区段,该第四多肽区段具有与SEQ ID NO:417至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同或与SEQ ID NO:418至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同的序列;和第五多肽区段,该第五多肽区段具有与SEQ ID NO:419至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同或与SEQ ID NO:420至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同的序列(这里,与AAV9衣壳蛋白的VR-IV位点、VR-V位点、VR-VII位点和VR-VIII位点等效的区域从第五多肽区段的序列同一性计算中排除)。在一些实施方案中,该组合衣壳蛋白在亲本序列的VR-IV位点、VR-V位点、VR-VII位点和VR-VIII位点中的一个或多个位点处包含变体多肽序列,其中该亲本序列包含与SEQ ID NO:463至少80%、至少85%、至少90%、至少95%、至少98%、至少99%或100%相同的序列。(在SEQ ID NO:463中,将标记为“X”的氨基酸残基从序列同一性计算中排除。)
在一些实施方案中,至少一种多肽区段源自AAV5衣壳蛋白并且至少一种多肽区段源自AAV9衣壳蛋白。
在一些实施方案中,该组合衣壳蛋白进一步在一个或多个位点处包含变体多肽序列,该一个或多个位点选自与AAV9衣壳蛋白的VR-IV位点、VR-V位点、VR-VII位点和VR-VIII位点等效的那些位点。
在一些实施方案中,该组合衣壳蛋白在与AAV9衣壳蛋白的VR-IV位点等效的位点处具有变体多肽序列,该变体多肽序列包含与GYHKSGAAQ(SEQ ID NO:6)至少约60%、70%、80%、90%或100%相同的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,在与AAV9衣壳蛋白的VR-IV位点等效的位点处的变体多肽序列包含由相对于GYHKSGAAQ(SEQ ID NO:6)的至多1、2、3或4个保守性氨基酸取代组成的序列,基本上由该序列组成或由该序列组成。
在一些实施方案中,组合衣壳蛋白在与AAV9衣壳蛋白的VR-V位点等效的位点处具有变体多肽序列,该变体多肽序列包含与LNSMLI(SEQ ID NO:105)至少约60%、70%、80%、90%或100%相同的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,在与AAV9衣壳蛋白的VR-V位点等效的位点处的变体多肽序列包含由相对于LNSMLI(SEQ ID NO:105)的至多1、2、3或4个保守性氨基酸取代组成的序列,基本上由该序列组成或由该序列组成。
在一些实施方案中,该组合衣壳蛋白在与AAV9衣壳蛋白的VR-VIII位点等效的位点处具有变体多肽序列,该变体多肽序列包含与ANYG(SEQ ID NO:305)或NVSY(SEQ ID NO:303)至少约60%、70%、80%、90%或100%相同的序列,基本上由该序列组成或由该序列组成。在一些实施方案中,在与AAV9衣壳蛋白的VR-VIII位点等效的位点处的变体多肽序列包含由相对于ANYG(SEQ ID NO:305)或NVSY(SEQ ID NO:303)的至多1、2、3或4个保守性氨基酸取代组成的序列,基本上由该序列组成或由该序列组成。
在一些实施方案中,与AAV9衣壳蛋白序列(SEQ ID NO:1)的Q688等效的位置的残基在组合衣壳蛋白中是赖氨酸(K)。
在一些实施方案中,该组合衣壳蛋白包含与SEQ ID NO:445-462之一至少约80%、85%、90%、95%、96%、97%、98%、99%、99.5%或100%相同的多肽序列或其功能片段,基本上由该多肽序列或其功能片段组成,或由该多肽序列或其功能片段组成。
表3.衣壳蛋白序列
另外的突变
可以并入另外的氨基酸取代,例如,以进一步提高转导效率或组织选择性。示例性的非限制性取代包括但不限于在基于AAV5或AAV9的衣壳中相对于AAV5序列的S651A、T578A或T582A。
在一些实施方案中,在基于AAV5或AAV9的衣壳中,该衣壳蛋白包含相对于AAV5序列选自S651A、T578A、T582A、K251R、Y709F、Y693F或S485A的突变。在一些实施方案中,在基于AAV5或AAV9的衣壳中,该衣壳蛋白包含相对于AAV5序列选自K251R、Y709F、Y693F或S485A的突变。
转导效率、嗜性和NAb逃避
可以使用本领域已知的方法或实施例中描述的那些方法来测定转导效率。在一些实施方案中,具有工程化衣壳蛋白的rAAV病毒体与包含亲本序列的AAV病毒体相比,在心脏细胞中表现出增加的转导效率。
在一些实施方案中,该rAAV病毒体与包含亲本序列的AAV病毒体相比,在人心脏成纤维细胞(hCF)中表现出增加的转导效率。在一些实施方案中,人心脏成纤维细胞位于心脏的左心室中。
在一些实施方案中,该rAAV病毒体在100,000的感染复数(MOI)下在hCF细胞中表现出增加至少2、3、4、5、6、7、8、9、10、11、12、13、14或15倍的转导效率。在一些实施方案中,该rAAV病毒体在100,000的感染复数(MOI)下在hCF细胞中表现出增加约2倍至约16倍、约2倍至约14倍、约2倍至约12倍、约2倍至约10倍、约2倍至约8倍、约2倍至约6倍、约2倍至约4倍或约2倍至约3倍的转导效率。在一些实施方案中,该rAAV病毒体在100,000的感染复数(MOI)下在hCF细胞中表现出增加至少2、3、4、5、6、7、8、9、10、11、12、13、14或15倍的转导效率。在一些实施方案中,该rAAV病毒体在100,000的感染复数(MOI)下在hCF细胞中表现出增加约20%至30%、约30%至40%、约40%至50%、约50%至80%、约80%至100%、约100%至125%、约125%至150%、约150%至175%或约175%至200%的转导效率。
在一些实施方案中,该rAAV病毒体在1,000的感染复数(MOI)下在hCF细胞中表现出增加至少2、3、4、5、6、7、8、9、10、11、12、13、14或15倍的转导效率。在一些实施方案中,该rAAV病毒体在1,000的感染复数(MOI)下在hCF细胞中表现出增加约2倍至约16倍、约2倍至约14倍、约2倍至约12倍、约2倍至约10倍、约2倍至约8倍、约2倍至约6倍、约2倍至约4倍或约2倍至约3倍的转导效率。在一些实施方案中,该rAAV病毒体在1,000的感染复数(MOI)下在hCF细胞中表现出增加约20%至30%、约30%至40%、约40%至50%、约50%至80%、约80%至100%、约100%至125%、约125%至150%、约150%至175%或约175%至200%的转导效率。
在一些实施方案中,该rAAV病毒体与包含亲本序列的AAV病毒体相比,在诱导多能干细胞来源的心肌细胞(iPS-CM)中表现出增加的转导效率。
在一些实施方案中,该rAAV病毒体在100,000的感染复数(MOI)下在iPS-CM细胞中表现出增加至少2、3、4、5、6、7、8、9、10、11、12、13、14或15倍的转导效率。在一些实施方案中,该rAAV病毒体在100,000的感染复数(MOI)下在iPS-CM细胞中表现出增加约2倍至约16倍、约2倍至约14倍、约2倍至约12倍、约2倍至约10倍、约2倍至约8倍、约2倍至约6倍、约2倍至约4倍或约2倍至约3倍的转导效率。在一些实施方案中,该rAAV病毒体在100,000的感染复数(MOI)下在iPS-CM细胞中表现出增加约20%至30%、约30%至40%、约40%至50%、约50%至80%、约80%至100%、约100%至125%、约125%至150%、约150%至175%或约175%至200%的转导效率。
在一些实施方案中,该rAAV病毒体在75,000的感染复数(MOI)下在iPS-CM细胞中表现出增加至少2、3、4、5、6、7、8、9、10、11、12、13、14或15倍的转导效率。在一些实施方案中,该rAAV病毒体在75,000的感染复数(MOI)下在iPS-CM细胞中表现出增加约2倍至约16倍、约2倍至约14倍、约2倍至约12倍、约2倍至约10倍、约2倍至约8倍、约2倍至约6倍、约2倍至约4倍或约2倍至约3倍的转导效率。在一些实施方案中,该rAAV病毒体在75,000的感染复数(MOI)下在iPS-CM细胞中表现出增加约20%至30%、约30%至40%、约40%至50%、约50%至80%、约80%至100%、约100%至125%、约125%至150%、约150%至175%或约175%至200%的转导效率。
在一些实施方案中,该rAAV病毒体在1,000的感染复数(MOI)下在iPS-CM细胞中表现出增加至少2、3、4、5、6、7、8、9、10、11、12、13、14或15倍的转导效率。在一些实施方案中,该rAAV病毒体在1,000的感染复数(MOI)下在iPS-CM细胞中表现出增加约2倍至约16倍、约2倍至约14倍、约2倍至约12倍、约2倍至约10倍、约2倍至约8倍、约2倍至约6倍、约2倍至约4倍或约2倍至约3倍的转导效率。在一些实施方案中,该rAAV病毒体在1,000的感染复数(MOI)下在iPS-CM细胞中表现出增加约20%至30%、约30%至40%、约40%至50%、约50%至80%、约80%至100%、约100%至125%、约125%至150%、约150%至175%或约175%至200%的转导效率。
在一些实施方案中,包含本公开的工程化衣壳蛋白的rAAV病毒体与包含亲本序列的AAV病毒体相比,在心脏中表现出增加的转导效率。在一些实施方案中,通过给C57BL/6J小鼠注射由本公开的工程化衣壳蛋白包封的AAV9:CAG-GFP或CAG-GFP来监测在心脏中的转导效率。在一些实施方案中,注射剂量为2.5E+11vg/只小鼠。在一些实施方案中,注射剂量为2E+11vg/只小鼠。在一些实施方案中,注射剂量为1E+11vg/只小鼠。在一些实施方案中,该rAAV病毒体表现出增加至少2、3、4、5、6、7、8、9、10、11、12、13、14或15倍的转导效率。在一些实施方案中,该rAAV病毒体在心脏中表现出增加约2倍至约16倍、约2倍至约14倍、约2倍至约12倍、约2倍至约10倍、约2倍至约8倍、约2倍至约6倍、约2倍至约4倍或约2倍至约3倍的转导效率。在一些实施方案中,该rAAV病毒体在心脏中表现出增加约20%至30%、约30%至40%、约40%至50%、约50%至80%、约80%至100%、约100%至125%、约125%至150%、约150%至175%或约175%至200%的转导效率。
在一些实施方案中,包含本公开的工程化衣壳蛋白的rAAV病毒体与包含亲本序列的AAV病毒体相比,在肝细胞中表现出降低的转导效率。在一些实施方案中,通过给C57BL/6J小鼠注射由本公开的工程化衣壳蛋白包封的AAV9:CAG-GFP或CAG-GFP来监测肝脏转导效率。在一些实施方案中,注射剂量为2.5E+11vg/只小鼠。在一些实施方案中,注射剂量为2E+11vg/只小鼠。在一些实施方案中,注射剂量为1E+11vg/只小鼠。在一些实施方案中,该rAAV病毒体表现出降低至少2、3、4、5、6、7、8、9、10、11、12、13、14或15倍的转导效率。在一些实施方案中,该rAAV病毒体在心脏中表现出降低约2倍至约16倍、约2倍至约14倍、约2倍至约12倍、约2倍至约10倍、约2倍至约8倍、约2倍至约6倍、约2倍至约4倍或约2倍至约3倍的转导效率。在一些实施方案中,该rAAV病毒体在肝脏中表现出降低约20%至30%、约30%至40%、约40%至50%、约50%至80%或约80%至100%的转导效率。
与包含亲本序列的AAV病毒体相比,对于包含本公开的工程化衣壳蛋白的rAAV病毒体,当一种细胞/组织/器官类型相对于另一种细胞/组织/器官类型的转导效率的比率增加时,对细胞类型和/或组织/器官类型的选择性增加。在一些实施方案中,包含工程化衣壳蛋白的rAAV病毒体表现出对iPS-CM细胞比对肝细胞的选择性增加。在一些实施方案中,包含工程化衣壳蛋白的rAAV病毒体当体内注射时,表现出对心脏比对肝脏的选择性增加。在一些实施方案中,包含工程化衣壳蛋白的rAAV病毒体当体内注射时,表现出对心脏左心室比对肝脏的选择性增加。
在一些实施方案中,包含工程化衣壳蛋白的rAAV病毒体表现出对iPS-CM细胞比对肝细胞和/或对心脏比对肝脏的选择性增加至少2、3、4、5、6、7、8、9、10、11、12、13、14或15倍。在一些实施方案中,包含工程化衣壳蛋白的rAAV病毒体表现出对iPS-CM细胞比对肝细胞和/或对心脏比对肝脏的选择性增加约2倍至约16倍、约2倍至约14倍、约2倍至约12倍、约2倍至约10倍、约2倍至约8倍、约2倍至约6倍、约2倍至约4倍或约2倍至约3倍。在一些实施方案中,包含工程化衣壳蛋白的rAAV病毒体表现出对iPS-CM细胞比对肝细胞和/或对心脏比对肝脏的选择性增加约20%至30%、约30%至40%、约40%至50%、约50%至80%、约80%至100%、约100%至125%、约125%至150%、约150%至175%或约175%至200%。
在一些实施方案中,包含本公开的工程化衣壳蛋白的rAAV病毒体与包含亲本序列的AAV病毒体相比,表现出逃避人NAb(中和抗体)的能力提高。在一些实施方案中,逃避人NAb的能力经由NAb抑制测定来测量。NAb抑制测定的非限制性实例在本公开的实施例部分有所描述。在一些实施方案中,通过将AAV病毒体与汇集的人NAb(例如,IgG)一起孵育,然后以预定MOI处理靶细胞来进行NAb抑制测定,并测量与没有与汇集的人NAb一起孵育的AAV病毒体相比转导效率的降低。较低的NAb抑制表明AAV病毒体逃避人NAb的能力提高。在一些实施方案中,包含工程化衣壳蛋白的rAAV病毒体表现出逃避人NAb的能力提高至少2、3、4、5、6、7、8、9、10、11、12、13、14或15倍。在一些实施方案中,包含工程化衣壳蛋白的rAAV病毒体表现出逃避人NAb的能力提高约2倍至约16倍、约2倍至约14倍、约2倍至约12倍、约2倍至约10倍、约2倍至约8倍、约2倍至约6倍、约2倍至约4倍或约2倍至约3倍。在一些实施方案中,包含工程化衣壳蛋白的rAAV病毒体表现出逃避人NAb的能力提高约20%至30%、约30%至40%、约40%至50%、约50%至80%、约80%至100%、约100%至125%、约125%至150%、约150%至175%或约175%至200%。
编码衣壳蛋白的多核苷酸可包含含有野生型cap基因的天然密码子或选择为编码相同蛋白的替代密码子的序列。插入的密码子使用可以变化。选择适当的核苷酸序列并得到替代核苷酸序列以编码本公开的任何衣壳蛋白在本领域技术人员的技术范围内。蛋白质序列的反向翻译可以使用宿主生物的密码子使用表,即针对人类的真核密码子使用进行。
在一些实施方案中,本公开提供了编码AAV9来源的衣壳蛋白的多核苷酸,该衣壳蛋白包含与SEQ ID NO:402-410和464-468中的任一者至少80%、85%、90%、95%、99%或100%相同的序列。
在一些实施方案中,本公开提供了编码AAV5/AAV9嵌合衣壳蛋白的多核苷酸,该衣壳蛋白包含与SEQ ID NO:421-444中的任一者至少80%、85%、90%、95%、99%或100%相同的序列。
在一些实施方案中,本公开提供了编码组合衣壳蛋白的多核苷酸,该衣壳蛋白包含与SEQ ID NO:445-462中的任一者至少80%、85%、90%、95%、99%或100%相同的序列。
在一些实施方案中,本公开提供了AAV9、AAV5/AAV9嵌合或组合衣壳蛋白,该衣壳蛋白包含与选自SEQ ID NO:402-410、421-462、464-468的经修饰的衣壳至少80%、85%、90%、95%、99%或100%相同的序列,其中具有指定同一性百分比水平的氨基酸取代(任选地保守性取代)是耐受的。
基因产物
在一些实施方案中,本公开的rAAV病毒体包含异源核酸,该异源核酸包含编码选自以下的一种或多种基因产物的核苷酸序列:MYBPC3、KCNH2、TRPM4、DSG2、ATP2A2、CACNA1C、DMD、DMPK、EPG5、EVC、EVC2、FBN1、NF1、SCN5A、SOS1、NPR1、ERBB4、VIP、MYH7,或其突变体、变体或片段。
在一些实施方案中,本公开的rAAV病毒体包含异源核酸,该异源核酸包含编码选自ASCL1、MYOCD、MEF2C和TBX5的一种或多种基因产物的核苷酸序列。在一些实施方案中,本公开的rAAV病毒体包含异源核酸,该异源核酸包含编码选自以下的一种或多种基因产物的核苷酸序列:ASCL1、MYOCD、MEF2C、AND TBX5、CCNB1、CCND1、CDK1、CDK4、AURKB、OCT4、BAF60C、ESRRG、GATA4、GATA6、HAND2、IRX4、ISLL、MESP1、MESP2、NKX2.5、SRF、TBX20、ZFPM2和MIR-133。
在一些实施方案中,本公开的rAAV病毒体包含异源核酸,该异源核酸包含编码选自MYBPC3、DWORF、KCNH2、TRPM4、DSG2、PKP2和ATP2A2的一种或多种基因产物的核苷酸序列。
在一些实施方案中,本公开的rAAV病毒体包含异源核酸,该异源核酸包含编码选自以下的一种或多种基因产物的核苷酸序列:CACNA1C、DMD、DMPK、EPG5、EVC、EVC2、FBN1、NF1、SCN5A、SOS1、NPR1、ERBB4、VIP、MYH7和Cas9。
在一些实施方案中,本公开的rAAV病毒体包含异源核酸,该异源核酸包含编码选自MYOCD、ASCL1、GATA4、MEF2C、TBX5、miR-133和MESP1的一种或多种基因产物的核苷酸序列。
定义
除非上下文另有说明,否则本发明的特征可以任何组合使用。可以排除或省略所阐述的任何特征或特征组合。在单独的实施方案中描述的本发明的某些特征也可以在单个实施方案中以组合提供。在单个实施方案中描述的本发明的特征也可以单独提供或者以任何合适的子组合提供。本文公开了实施方案的所有组合,如同单独公开每个组合一样。本文公开了实施方案和要素的所有子组合,如同单独公开每个此类子组合一样。
除非另有定义,否则本文使用的所有技术和科学术语具有与本发明所属领域的普通技术人员通常理解的相同含义。仅仅是为了读者方便,将详细描述分成几个部分,并且任何部分中发现的公开内容都可以与另一部分中的公开内容组合。尽管类似于或等同于本文所述那些的任何方法和材料也可用于本发明的实践或测试,但现在描述了示例性的方法和材料。本文提到的所有出版物都通过引用并入,以公开和描述与引用的出版物相关的方法和/或材料。对出版物的提及并不是承认该出版物是现有技术。
除非上下文另有明确规定,否则单数形式“一”、“一个(种)”和“该(所述)”包括复数指代物。例如,对“重组AAV病毒体”的提及包括多个此类病毒体,而对“心脏细胞”的提及包括一个或多个心脏细胞。
连词“和/或”意指“和”和“或”两者,并且由“和/或”连接的列表涵盖所列项目中的一项或多项的所有可能组合。
术语“载体”是指包含待递送至细胞的多核苷酸或蛋白质的大分子或分子复合物。
“AAV”是腺相关病毒的缩写。该术语包括AAV的所有亚型,除非指明了亚型,并且包括天然存在的形式和重组形式。缩写“rAAV”指重组腺相关病毒。“AAV”包括AAV或任何亚型。“AAV5”是指AAV亚型5。“AAV9”是指AAV亚型9。AAV各种血清型的基因组序列,以及天然反向末端重复序列(ITR)、Rep蛋白和衣壳亚基的序列可以在文献或公共数据库诸如GenBank中找到。参见,例如,GenBank登录号NC_002077(AAV1)、AF063497(AAV1)、NC_001401(AAV2)、AF043303(AAV2)、NC_001729(AAV3)、NC_001829(AAV4)、U89790(AAV4)、NC_006152(AAV5)、AF513851(AAV7)、AF513852(AAV8)、NC_006261(AAV8)和AY530579(AAV9)。描述AAV的出版物包括Srivistava等人(1983)J.Virol.45:555;Chiorini等人(1998)J.Virol.71:6823;Chiorini等人(1999)J.Virol.73:1309;Bantel-Schaal等人(1999)J.Virol.73:939;Xiao等人(1999)J.Virol.73:3994;Muramatsu等人(1996)Virol.221:208;Shade等人(1986)J.Virol.58:921;Gao等人(2002)Proc.Nat.Acad.Sci.USA 99:11854;Moris等人(2004)Virology 33:375-383;国际专利公开号WO2018/222503A1、WO2012/145601A2、WO2000/028061A2、WO1999/61601A2和WO1998/11244A2;美国专利申请号15/782,980和15/433,322;和美国专利号10,036,016、9,790,472、9,737,618、9,434,928、9,233,131、8,906,675、7,790,449、7,906,111、7,718,424、7,259,151、7,198,951、7,105,345、6,962,815、6,984,517和6,156,303。
如本领域中所用的“AAV载体”或“rAAV载体”是指包装到rAAV病毒体中的DNA或者是指rAAV病毒体本身,这取决于上下文。如本文所用,除非上下文另外显而易见,否则rAAV载体是指包含多核苷酸序列的核酸(通常为质粒),该多核苷酸序列能够被包装到rAAV病毒体中,但具有rAAV病毒体的衣壳或其他蛋白质。通常,rAAV载体包含异源多核苷酸序列(即,非AAV来源的多核苷酸)和一个或两个位于该异源多核苷酸序列侧翼的AAV反向末端重复序列(ITR)。两个ITR中只有一个可以被包装到rAAV中,而所得rAAV病毒体的感染性仍然可以保持。参见Wu等人(2010)Mol Ther.18:80。rAAV载体可以设计成产生单链(ssAAV)或自身互补(scAAV)。参见McCarty D.(2008)Mo.Ther.16:1648-1656;WO2001/11034;WO2001/92551;WO2010/129021。
“rAAV病毒体”是指包含至少一种病毒衣壳蛋白(例如VP1)和包壳的rAAV载体(或其片段),包括衣壳蛋白的胞外病毒颗粒。
为了简洁和清楚起见,本公开涉及“一种衣壳蛋白”或“多种衣壳蛋白”本领域技术人员理解,此类提及是指VP1、VP2或VP3,或者VP1、VP2和VP3的组合。如同在野生型AAV和大多数重组表达系统中一样,VP1、VP2和VP3从相同的开放阅读框表达,对编码VP3的序列的工程改造不可避免地改变了VP1和VP2的C端结构域的序列。也可以从不同的开放阅读框表达衣壳蛋白,在这种情况下,所得rAAV病毒体的衣壳可以含有野生型衣壳蛋白和工程化衣壳蛋白的混合物,以及不同的工程化衣壳蛋白的混合物。
如本文所用的术语“反向末端重复序列”或“ITR”是指因其对称性而如此命名的AAV病毒顺式元件。这些元件对于AAV基因组的有效倍增是必不可少的。不受理论的束缚,据信ITR功能不可或缺的最小元件是Rep结合位点和末端分解位点加上允许发夹形成的可变回文序列。本公开考虑到产生AAV基因组的替代方法可能存在或者可能被预期开发为与本公开的衣壳蛋白相容。
“辅助病毒功能”是指辅助病毒基因组中编码的允许AAV复制和包装的功能。
“包装”是指引起rAAV病毒体组装的一系列细胞内事件,包括rAAV载体的包壳。AAV“rep”和“cap”基因是指编码腺相关病毒的复制和包壳蛋白的多核苷酸序列。AAVrep和cap在本文中称为AAV“包装基因”包装需要辅助病毒本身,或者在重组系统中更常见的是,需要由无辅助病毒系统(即一个或多个辅助质粒)提供的辅助病毒功能。
AAV的“辅助病毒”是指允许AAV(例如野生型AAV)被哺乳动物细胞复制和包装的病毒。辅助病毒可以是腺病毒、疱疹病毒或痘病毒,诸如牛痘。
“感染性”病毒体或病毒颗粒是指包含适当组装的病毒衣壳并且能够将多核苷酸组分递送到该病毒体对其具有嗜性的细胞中的病毒体或病毒颗粒。该术语不一定暗指病毒的任何复制能力。
“感染性”是指对病毒体感染细胞的能力的度量。感染性可以表示为感染性病毒颗粒与总病毒颗粒的比率。感染性通常相对于特定的细胞类型测定。感染性可以在体内或在体外测量。测定感染性病毒颗粒与总病毒颗粒的比率的方法是本领域已知的。参见,例如,Grainger等人(2005)Mol.Ther.11:S337(描述了TCID50感染性滴度测定);和Zolotukhin等人(1999)Gene Ther.6:973。
术语“亲本衣壳”或“亲本序列”是指颗粒衣壳或序列所来源的参考序列。除非另有说明,否则亲本序列是指与工程化衣壳蛋白血清型相同的野生型衣壳蛋白的序列。
“有复制能力的”病毒(例如有复制能力的AAV)是指一种感染性的病毒,并且也能够在受感染的细胞中(即在辅助病毒或辅助病毒功能的存在下)复制。在一些实施方案中,本公开的rAAV病毒体包含缺乏rep基因或rep和cap基因两者的基因组,因此是不能复制的。
除非另有说明,否则本公开的实践将采用组织培养、免疫学、分子生物学、细胞生物学和重组DNA的常规技术,这些技术都在本领域的技术范围内。参见,例如,Sambrook和Russell编辑(2001)Molecular Cloning:A Laboratory Manual,第3版;Ausubel等人编辑(2007)Current Protocols in Molecular Biology;Methods in Enzymology(AcademicPress,Inc.,N.Y.);MacPherson等人(1991)PCR 1:A Practical Approach(IRL Press atOxford University Press);MacPherson等人(1995)PCR 2:A Practical Approach;Harlow和Lane编辑(1999)Antibodies,A Laboratory Manual;Freshney(2005)Culture ofAnimal Cells:A Manual of Basic Technique,第5版;Gait编辑(1984)OligonucleotideSynthesis;美国专利号4,683,195;Hames和Higgins编辑(1984)Nucleic AcidHybridization;Anderson(1999)Nucleic Acid Hybridization;Hames和Higgins编辑(1984)Transcription and Translation;IRL Press(1986)Immobilized Cells andEnzymes;Perbal(1984)A Practical Guide to Molecular Cloning;Miller和Calos编辑(1987)Gene Transfer Vectors for Mammalian Cells(Cold Spring HarborLaboratory);Makrides编辑(2003)Gene Transfer and Expression in MammalianCells;Mayer和Walker编辑(1987)Immunochemical Methods in Cell and MolecularBiology(Academic Press,London);Herzenberg等人编辑(1996)Weir’s Handbook ofExperimental Immunology;Manipulating the Mouse Embryo:A Laboratory Manual,第3版(2002)Cold Spring Harbor Laboratory Press;Sohail(2004)Gene Silencing by RNAInterference:Technology and Application(CRC Press);以及Sell(2013)Stem CellsHandbook。
术语“核酸”和“多核苷酸”可互换使用并且是指任何长度的核苷酸的聚合形式,核苷酸是脱氧核糖核苷酸或核糖核苷酸,或其类似物。多核苷酸的非限制性实例包括线性和环状核酸、信使RNA(mRNA)、cDNA、重组多核苷酸、载体、探针和引物。除非另有说明或要求,否则本文所述的本发明的作为多核苷酸的任何实施方案涵盖双链形式和已知或预测会构成双链形式的两种互补单链形式中的每一种互补单链形式。
术语“多肽”和“蛋白质”在本文中可互换使用并且是指任何长度的氨基酸的聚合形式以及具有经修饰的肽骨架的多肽,氨基酸可包括遗传编码的和非遗传编码的氨基酸、化学或生物化学修饰或衍生的氨基酸。这些术语还涵盖已经被修饰的氨基酸聚合物;例如二硫键形成、糖基化、脂质化、磷酸化或与标记组分缀合。
术语“肽”是指短的多肽,例如具有约4个至30个氨基酸残基的肽。
术语“分离的”意指与细胞组成部分和病毒体、细胞、组织、多核苷酸、肽、多肽或蛋白质在自然界中通常缔合在其中的其他组成部分分开。例如,分离的细胞是与不同表型或基因型的组织或细胞中分开的细胞。
如本文所用,“序列同一性”或“同一性”是指感兴趣的序列和参考序列之间相同的氨基酸数目的百分比。通常,同一性是通过将感兴趣的序列与参考序列进行比对,确定比对的序列之间相同的氨基酸数目,将该数目除以参考序列中的氨基酸总数,并将结果乘以100得到百分比来确定的。序列可以用各种计算机程序进行比对,诸如在ncbi.nlm.nih.gov可获得的BLAST。其他比对技术在Methods in Enzymology,第266卷:Computer Methods forMacromolecular Sequence Analysis(1996);和Meth.Mol.Biol.70:173-187(1997);J.Mol.Biol.48:44中有描述。技术人员能够根据各种因素选择适当的比对方法,这些因素包括序列长度、趋异以及相对于参考序列是否存在插入或缺失。
应用于多核苷酸的“重组”意指多核苷酸是克隆、限制或连接步骤的各种组合以及其他程序的产物,这些程序产生与自然界中发现的多核苷酸不同的构建体,或者意指多核苷酸由合成的寡核苷酸组装而成。“重组”蛋白是由重组多肽产生的蛋白质。重组病毒体是包含重组多核苷酸和/或重组蛋白,例如重组衣壳蛋白的病毒体。
“基因”是指含有能够在被转录和翻译后编码特定蛋白质的至少一个开放阅读框的多核苷酸。“基因产物”是由特定基因表达产生的分子。基因产物可以包括但不限于多肽、蛋白质、适体、干扰RNA或mRNA。基因编辑系统(例如CRISPR/Cas系统)可以描述为形成该系统所需的一种基因产物或几种基因产物(例如Cas蛋白和指导RNA)。
“短发夹RNA”或shRNA是用于表达siRNA的多核苷酸构建体。
“控制元件”或“控制序列”是参与分子相互作用的核苷酸序列,该核苷酸序列有助于多核苷酸的功能调控,包括多核苷酸的复制、加倍、转录、剪接、翻译或降解。该调控可以影响该过程的频率、速度或特异性,并且本质上可以是增强的或抑制的。控制元件包括转录调控序列,诸如启动子和/或增强子。
“启动子”是在某些条件下能够结合RNA聚合酶并启动通常位于启动子下游(3’方向)的编码区的转录的DNA序列。如本文所用的术语“组织特异性启动子”是指在特定器官或组织诸如心脏组织的细胞中可操作的启动子。
“操作性地连接”或“可操作地连接”是指遗传元件的并置,其中元件处于容许它们以预期方式操作的关系。例如,如果启动子帮助启动编码序列的转录,则该启动子是操作性地连接到编码区。只要保持这种功能关系,启动子和编码区之间就可能存在居间残基。
“表达载体”是包含编码感兴趣的基因产物的编码序列的载体,该载体用于实现基因产物在靶细胞中的表达。表达载体包含与编码序列操作性连接的控制元件,以促进基因产物的表达。
术语“表达盒”是指包含编码感兴趣的基因产物的编码序列的异源多核苷酸,该异源多核苷酸用于实现基因产物在靶细胞中的表达。除非另有说明,否则AAV载体的表达盒包括介于(不包括)ITR之间的多核苷酸。
如本文所用的术语“基因递送”或“基因转移”是指将外来核酸序列例如DNA可靠地插入宿主细胞中的方法或系统。此类方法可以引起非整合的转移的DNA的瞬时表达、染色体外复制和转移的复制子(例如,游离体)的表达,或者转移的遗传物质整合到宿主细胞的基因组DNA中。
“异源”意指源自基因型不同于与其比较的实体的其余部分的实体。例如,通过基因工程技术引入到源自不同物种的质粒或载体中的多核苷酸是异源多核苷酸。从其天然编码序列中移出并操作性地连接到并非天然发现与之连接的编码序列的启动子是异源启动子。因此,例如,包含异源核酸的rAAV是包含通常不包含在天然存在的AAV中的核酸的rAAV。
术语“遗传改变”和“遗传修饰”(及其语法变体)在本文中可互换用于指其中除了通过有丝分裂或减数分裂之外,将遗传元件(例如,多核苷酸)引入细胞中的过程。该元件对于该细胞可以是异源的,或者它可以是细胞中已经存在的元件的附加拷贝或改良型式。例如,通过本领域已知的任何方法,诸如电穿孔、磷酸钙沉淀或与多核苷酸-脂质体复合物接触,用重组质粒或其他多核苷酸转染细胞,可以实现遗传改变。遗传改变也可以例如通过载体的转导或感染来实现。
如果在体外细胞的长期培养期间多核苷酸序列可用于执行其功能,则称细胞被该序列“稳定地”改变、转导、遗传修饰或转化。通常,此类细胞是“可遗传地”改变的(遗传修饰的),因为引入了改变的细胞的后代也可遗传的遗传改变。
术语“转染”如本文所用,指细胞对外源核酸分子的摄取。当外源核酸已经被引入细胞膜内部时,细胞就已经被“转染”。许多转染技术通常是本领域已知的。参见,例如,Graham等人(1973)Virology,52:456,Sambrook等人(1989)Molecular Cloning,alaboratory manual,Cold Spring Harbor Laboratories,New York,Davis等人(1986)Basic Methods in Molecular Biology,Elsevier和Chu等人(1981)Gene 13:197。此类技术可用于将一种或多种外源核酸分子导入合适的宿主细胞中。
术语“转导”如本文所用,是指通过重组病毒体将外源核酸转移到细胞中,与野生型病毒体的“感染”大不相同。当关于重组病毒体使用感染时,术语“转导”和“感染”是同义的,因此“感染性”和“转导效率”是等同的,并且可以使用类似的方法测定。
除非另有说明,否则所有医学术语都被给予医学专业人员所用术语的普通含义,例如在Harrison’s Principles of Internal Medicine,第15版,其通过引用整体并入本文用于所有目的,特别是关于心脏或心血管疾病、病症、病状和功能障碍的章节。
“治疗”定义为用药剂作用于疾病、病症或病状,以减轻或改善该疾病、病症或病状和/或其症状的有害影响或任何其他不期望的影响。
当与本发明的组合物结合使用时,“施用”等是指直接施用(由医学专业人员施用给受试者或由受试者自己施用)和/或间接施用(给患者开组合物的处方)。通常,施用有效量,该量可由本领域技术人员确定。可以使用任何施用方法。向受试者施用可以通过例如静脉内、动脉内、肌内、血管内或心肌内递送来实现。
如本文所用,关于组合物的量的术语“有效量”等是指足以诱导所需生理结果(例如,细胞重编程或疾病治疗)的量。有效量可以分一次或多次施用、施加或剂量进行施用。此类递送取决于许多变量,包括要使用单个剂量单位的时间、组合物的生物利用度、施用途径等。然而,应当理解,用于任何特定受试者的组合物(例如,rAAV病毒体)的具体量取决于多种因素,包括所采用的特定药剂的活性,受试者的年龄、体重、总体健康状况、性别和饮食,施用时间,排泄速率,组合物的组合、所治特定疾病的严重程度和施用形式。
术语“个体”、“受试者”和“患者”在本文中可互换使用并且是指哺乳动物,包括但不限于人和非人灵长类动物(例如,猿猴);哺乳类运动动物(例如,马);哺乳类农场动物(例如,绵羊、山羊等);哺乳类宠物(例如,狗、猫等);和啮齿动物(例如,小鼠、大鼠等)。
术语“心脏病理”或“心脏功能障碍”可互换使用并且是指心脏泵血功能的任何损伤。这包括例如收缩性损伤、舒张能力损伤(有时称为舒张功能障碍)、心脏瓣膜功能异常或不正常、心肌疾病(有时称为心肌病),诸如心绞痛、心肌缺血和/或以心肌供血不足为特征的梗塞的疾病,诸如淀粉样变性和血色素沉着症的浸润性疾病,整体或局部肥大(诸如可能发生在某些种类的心肌病或系统性高血压中)以及心室之间的异常联通。
如本文所用,术语“心肌病”是指直接影响心肌的任何疾病或功能障碍。疾病或病症的病因可以是,例如,炎性、代谢性、毒性、浸润性、纤维形成性、血液性、遗传性或来源不明的。公认的两种基本形式是(1)原发型,由不明原因的心肌疾病组成;和(2)继发型,由已知原因的心肌疾病或与涉及其他器官系统的疾病相关的心肌疾病组成。“特异性心肌病”是指与某些系统性或心脏病症相关的心脏病;实例包括高血压性心肌病和代谢性心肌病。心肌病包括扩张型心肌病(DCM),一种左心室和/或右心室收缩泵功能受损的病症,导致进行性心脏增大;肥厚型心肌病,以无明显原因诸如高血压或主动脉狭窄的左心室肥厚为特征;和限制性心肌病,以异常的舒张功能和阻碍心室充盈的心室壁过硬为特征。心肌病还包括左心室致密化不全、心律失常性右心室心肌病和心律失常性右心室发育不良。
“心力衰竭”是指这样一种病理状态,其中心脏功能的异常造成心脏不能以与代谢组织的需求相当的速率泵送血液和/或仅允许心脏从异常升高的舒张期容积泵送血液。心力衰竭包括收缩性和舒张性衰竭。心力衰竭患者被分为心输出量低的患者(通常继发于缺血性心脏病、高血压、扩张性心肌病和/或瓣膜或心包疾病)和心输出量升高的患者(通常是由甲状腺机能亢进、贫血、妊娠、动静脉瘘、脚气病和佩吉特氏病(Paget’s disease)引起)。心力衰竭包括射血分数降低的心力衰竭(HFrEF)和射血分数保持的心力衰竭(HFpEF)。
本文采用短语“药学上可接受的”是指在合理的医学判断范围内,适合与人和动物组织接触使用,而没有过度的毒性、刺激、过敏反应或其他问题或并发症,与合理的效益/风险比相称的那些化合物、材料、组合物和/或剂型。
如本文所用的术语“纯化”是指已经在减少或消除不相关的材料(即杂质,包括从中获得材料的天然材料)的存在的条件下分离的材料。例如,纯化的rAAV载体DNA优选基本上不含细胞或培养组分,包括组织培养组分、污染物等。
在受损心脏组织的上下文中如本文所用的术语“再生”等应当被给予其普通含义,并且还应当指在已经受损的,例如由于缺血、梗塞、再灌注或其他疾病而受损的心脏或心脏组织中生长和/或发育出新的心脏组织的过程。在一些实施方案中,心脏组织再生包括心肌细胞的生成。
如本文所用的术语“治疗性基因”是指这样的基因,当表达时,对其所存在的细胞或组织,或对表达该基因的哺乳动物赋予有益作用。有益效果的实例包括改善病状或疾病的体征或症状,预防或抑制病状或疾病,或赋予所需特征。治疗性基因包括部分或完全纠正细胞或哺乳动物中的遗传缺陷的基因。
如本文所用,术语“功能性心肌细胞”是指能够发送或接收电信号的分化的心肌细胞。在一些实施方案中,如果心肌细胞表现出电生理学特性,诸如动作电位和/或Ca2+瞬变,则称其为功能性心肌细胞。
如本文所用,“分化的非心脏细胞”可以指不能分化成成年生物体的所有细胞类型(即,不是多潜能细胞),并且是除心脏谱系以外的细胞谱系(例如,神经元谱系或结缔组织谱系)的细胞。分化细胞包括但不限于多能细胞、寡能细胞、单能细胞、祖细胞和终末分化细胞。在特定实施方案中,相对于潜能较高的细胞,潜能较低的细胞被认为是“分化的”。
“体细胞”是形成生物主体的细胞。体细胞包括构成生物体的器官、皮肤、血液、骨骼和结缔组织的细胞,但不包括生殖细胞。
如本文所用,术语“全能”意指细胞形成生物体所有细胞谱系的能力。例如,在哺乳动物中,只有接合子和第一次卵裂期的卵裂球是全能性的。
如本文所用,术语“多潜能”意指细胞形成主体或体细胞所有谱系的能力。例如,胚胎干细胞是一种类型的多潜能干细胞,能够从外胚层、中胚层和内胚层这三个胚层中的每个胚层形成细胞。多潜能细胞可以通过其标志物诸如Nanog和Rex1的表达来识别。
如本文所用,术语“多能”是指成体干细胞形成一个谱系的多种细胞类型的能力。例如,造血干细胞能够形成血细胞谱系的所有细胞,例如,淋巴细胞和骨髓细胞。
如本文所用,术语“寡能”是指成体干细胞分化成仅几种不同的细胞类型的能力。例如,淋巴或骨髓干细胞能够分别形成淋巴或骨髓谱系的细胞。
如本文所用,术语“单能”是指细胞形成单个细胞类型的能力。例如,精原干细胞只能形成精细胞。
如本文所用,术语“重编程”或“转分化”是指从不同类型的细胞(例如,成纤维细胞)生成某个谱系的细胞(例如,心脏细胞),而没有使细胞去分化为表现出多潜能干细胞特征的细胞的中间过程。
如本文所用,术语“心脏细胞”是指存在于心脏中,提供心脏功能,诸如心脏收缩或供血,或以其他方式用于维持心脏结构的任何细胞。如本文所用的心脏细胞涵盖心脏的心外膜、心肌或心内膜中存在的细胞。心脏细胞还包括,例如,心脏肌细胞或心肌细胞,以及心血管细胞,诸如冠状动脉或静脉的细胞。心脏细胞的其他非限制性实例包括上皮细胞、内皮细胞、成纤维细胞、心脏干细胞或祖细胞、心脏传导细胞和心脏起搏细胞,这些细胞构成心肌、血管和心脏细胞支持结构。心脏细胞可以源自干细胞,包括例如胚胎干细胞或诱导多潜能干细胞。
如本文所用的术语“心肌细胞”是指在哺乳动物心脏中天然发现的含肌节的横纹肌细胞,与骨骼肌细胞完全不同。心肌细胞的特征在于表达特化分子例如如,蛋白质如肌球蛋白重链、肌球蛋白轻链、心脏α-肌动蛋白。如本文所用的术语“心肌细胞”是伞式术语,包括任何心肌细胞亚群或心肌细胞亚型,例如,心房、心室和起搏心肌细胞。
术语“心肌细胞样细胞”旨在意指与心肌细胞共有特征,但可能不共有所有特征的细胞。例如,心肌样细胞可能在某些心脏基因的表达上不同于心肌细胞。
术语“培养”或“细胞培养”是指在人工体外环境中维持细胞。“细胞培养系统”在本文中用于指细胞群可以单层或悬浮生长的培养条件。“培养基”在本文中用于指用于细胞培养、生长或增殖的营养液。培养基可以通过功能特性来表征,诸如但不限于将细胞维持在特定状态(例如,多潜能状态、静止状态等),使细胞成熟-在一些情况下,特别是促进祖细胞分化成特定谱系的细胞(例如,心肌细胞)的能力。
如本文所用,术语“表达”是指多核苷酸转录成mRNA的过程和/或转录的mRNA随后翻译成肽、多肽或蛋白质的过程。如果多核苷酸源自基因组DNA,则表达可以包括mRNA在真核细胞中的剪接。基因的表达水平可以通过测量细胞或组织样品中mRNA或蛋白质的量来测定。
术语“诱导心肌细胞”或缩写“iCM”是指已经转化为心肌细胞(和/或心肌细胞样细胞)的非心肌细胞(及其后代)。本公开的方法可以与现在已知或以后发现的用于生成诱导心肌细胞的任何方法结合使用,例如,以增强其他技术。
如本文所用的术语“诱导多潜能干细胞来源的心肌细胞”是指已经分化为心肌样细胞的人诱导多潜能干细胞。制备iPS-CM细胞的示例性方法由Karakikes等人CircRes.2015年6月19日;117(1):80–88提供。
如本文所用的术语“人心脏成纤维细胞”和“小鼠心脏成纤维细胞”分别是指从人或小鼠的成体心脏的心室中分离的,并在离体培养中维持的原代细胞。
如本文所用的术语“非心肌细胞”是指细胞制剂中不符合如本文所定义和使用的“心肌细胞”标准的任何细胞或细胞群。非心肌细胞的非限制性实例包括体细胞、心脏成纤维细胞、非心脏成纤维细胞、心脏祖细胞和干细胞。
如本文所用,“重编程”包括转分化、去分化等。
如本文所用,术语“重编程效率”是指样品中成功重编程为心肌细胞的细胞数目相对于样品中细胞总数的比例。
如本文所用,术语“重编程因子”包括引入以便在细胞中表达,以帮助细胞从一种细胞类型重编程为另一种细胞类型的因子。例如,重编程因子可以包括转录因子,与其他转录因子和/或小分子组合,能够将心脏成纤维细胞重编程为诱导心肌细胞。除非从上下文中另外明确,否则重编程因子是指可由AAV递送的多核苷酸编码的多肽。重编程因子也可以包括小分子。
术语“干细胞”是指具有自我更新和生成分化后代的能力的细胞。术语“多潜能干细胞”是指可以产生全部三个胚层(内胚层、中胚层和外胚层)的细胞,但不具有产生完整生物体的能力的干细胞。
如本文所用,关于多肽或核酸序列的术语“其等效物”是指不同于参考多肽或核酸序列,但保留基本特性(例如,生物活性)的多肽或核酸。多核苷酸的典型变体在核苷酸序列上不同于另一参考多核苷酸。变体的核苷酸序列的变化可能会改变或者可能不会改变参考多核苷酸编码的多肽的氨基酸序列。核苷酸变化可在参考序列编码的多肽中产生氨基酸取代、缺失、添加、融合和截短。通常,差异是有限的,以致参考多肽和变体的序列总体上非常相似,并且在许多区域是相同的。
如本文所用,术语“祖细胞”是指致力于分化成特定类型的细胞或形成特定类型的组织的细胞。像干细胞一样,祖细胞可以进一步分化成一种或多种细胞,但比干细胞更成熟,以致其分化能力更受限/更有限。
术语“遗传修饰”是指在引入新的核酸(即,细胞的外源核酸)后,在细胞中诱导的永久或瞬时遗传变化。通过将新的核酸并入到心脏细胞的基因组中,或者通过将新的核酸瞬时或稳定维持为染色体外元件,可以实现遗传变化。在细胞是真核细胞的情况下,可以通过将核酸引入细胞的基因组中来实现永久遗传变化。合适的遗传修饰方法包括病毒感染、转染、缀合、原生质体融合、电穿孔、粒子枪技术、磷酸钙沉淀、直接显微注射等。
术语“干细胞”是指具有自我更新和生成分化后代的能力的细胞。术语“多潜能干细胞”是指可以产生全部三个胚层(内胚层、中胚层和外胚层)的细胞,但不具有产生完整生物体的能力的干细胞。在一些实施方案中,用于诱导心肌细胞表型的组合物可用于细胞群以诱导重编程。在其他实施方案中,组合物诱导心肌细胞表型。
术语“诱导多潜能干细胞”应被给予其普通含义,并且还应指已经重编程以表现出至少一种多潜能特征的分化的哺乳动物体细胞(例如,成体体细胞,诸如皮肤)。参见,例如,Takahashi等人(2007)Cell131(5):861-872,Kim等人(2011)Proc.Natl.Acad.Sci.108(19):7838-7843,Sell(2013)Stem Cells Handbook。
术语“转导效率”是指经至少一个AAV基因组转导的细胞的百分比。例如,如果将1x106个细胞暴露于病毒,并且确定0.5x106个细胞含有至少一个拷贝的AAV基因组,则转导效率为50%。用于确定转导效率的说明性方法是流式细胞术。例如,当AAV基因组包含编码绿色荧光蛋白(GFP)的多核苷酸时,GFP+细胞的百分比是转导效率的量度。
术语“选择性”是指一种细胞类型相对于另一种细胞类型或相对于所有其他细胞类型的转导效率的比率。
术语“感染性”是指AAV病毒体感染细胞,尤其是体内细胞的能力。因此感染性至少是生物分布和中和抗体逃逸的函数。
除非另有说明,否则说明书全篇使用的缩写具有以下含义:AAV,腺相关病毒;rAAV,重组腺相关病毒;AHCF,成人心脏成纤维细胞;APCF,成年猪心脏成纤维细胞;a-MHC-GFP,α-肌球蛋白重链绿色荧光蛋白;CF,心脏成纤维细胞;cm,厘米;CO,心输出量;EF,射血分数;FΑCS,荧光激活细胞分选;GFP,绿色荧光蛋白;GMT,Gata4、Mef2c和Tbx5;GMTc,Gata4、Mef2c、Tbx5、TGF-βi、WNTi;GO,基因本体;hCF,人心脏成纤维细胞;iCM,诱导心肌细胞;kg,千克;μg,微克;μl,微升;mg,毫克;ml,毫升;MI,心肌梗塞;msec,毫秒;min,分钟;MyAMT,心肌蛋白、Ascl1、Mef2c和Tbx5;MyA,心肌蛋白和Ascl1;MyMT,心肌蛋白、Mef2c和Tbx5;MyMTc,心肌蛋白、Mef2c、Tbx5、TGF-βi、WNTi;MRI,磁共振成像;PBS,磷酸盐缓冲盐水;PBST,磷酸盐缓冲盐水triton;PFA,多聚甲醛;qPCR,定量聚合酶链反应;qRT-PCR,定量逆转录聚合酶链反应;RNA,核糖核酸;RNA-seq,RNA测序;RT-PCR,逆转录聚合酶链反应;sec,秒;SV,搏出量;TGF-β,转化生长因子β;TGF-βi,转化生长因子β抑制剂;WNT,无翼-Int;WNTi,无翼-Int抑制剂;YFP,黄色荧光蛋白;4F,Gata4、Mef2c、TBX5和心肌蛋白;4Fc,Gata4、Mef2c、TBX5和心肌蛋白+TGF-βi和WNTi;7F,Gata4、Mef2c和Tbx5,Essrg,心肌蛋白、Zfpm2和Mesp1;7Fc,Gata4、Mef2c和Tbx5,Essrg,心肌蛋白、Zfpm2和Mesp1+TGF-β和WNTi。
术语“保守性氨基酸取代”是指与被取代的残基具有相似侧链物理特性的氨基酸残基的取代。保守性取代包括极性残基取代极性残基、非极性残基取代非极性残基、疏水性残基取代疏水性残基、小残基取代小残基和大残基取代大残基。保守性取代还包括以下组内的取代:{S,T}、{A,G}、{F,Y}、{R,H,K,N,E}、{S,T,N,Q}、{C,U,G,P,A}和{A,V,I,L,M,F,Y,W}。
组合物
鉴定具有可用于基因疗法的特性的衣壳变体的努力包括将AAV2和AAV5 cap基因的DNA改组,如美国专利号9,233,131中所述;以及如国际专利申请号WO2012/145601A2和WO2018/222503A1中描述的定向进化。这些文件的公开内容在此并入用于所有目的,特别是对于制备和使用AAV病毒体的方法和对于其中公开的多核苷酸序列和基因产物,以及对于可用于治疗心脏疾病或病症的转录因子的组合而言。
AAV衣壳由AAV的cap基因编码,该基因也称为右侧开放阅读框(ORF)(与左侧ORF,rep不同)。代表性AAV衣壳的结构在各种出版物中有描述,包括Xie等人(2002)Proc.Natl.Acad.Sci USA 99:10405-1040(AAV2);Govindasamy等人(2006)J.Virol.80:11556-11570(AAV4);Nam等人(2007)J.Virol.81:12260-12271(AAV8)和Govindasamy等人(2013)J.Virol.87:11187-11199(AAV5)。
AAV衣壳含有三种病毒蛋白(VP)即VP1、VP2和VP3的60个拷贝(总共),预测比率为1:1:10,以T=1的二十面体对称型排列。这三种VP是从相同的mRNA翻译的,VP1除了在其C端区域含有完整的VP2序列外,还含有一个独特的N端结构域。VP2除了在其C端含有VP3,还含有一个额外的N端序列。在大多数晶体结构中,只观察到所有衣壳蛋白共同的C端多肽序列(~530个氨基酸)。VP1的N端独特区、VP1-VP2重叠区和VP3的前14至16个N端残基被认为主要是无序的。冷冻电子显微镜术和图像重建数据表明,在完整的AAV衣壳中,VP1和VP2蛋白的N端区域位于衣壳内部并且是受体和抗体结合不可及的。因此,受体附着和转导表型通常由VP1、VP2和VP3的共同C端结构域内的氨基酸序列决定。
在一些实施方案中,该一个或多个氨基酸插入、取代或缺失处于AAV衣壳蛋白的GH环或IV环中,例如,处于AAV衣壳蛋白的GH环或IV环的溶剂可及部分中。对于AAV衣壳的GH环/IV环,参见例如,van Vliet等人(2006)Mol.Ther.14:809;Padron等人(2005)Virol.79:5047;和Shen等人(2007)Mol.Ther.15:1955。在一些实施方案中,“亲本”AAV衣壳蛋白是野生型AAV5衣壳蛋白。在一些实施方案中,“亲本”AAV衣壳蛋白是嵌合AAV衣壳蛋白。各种AAV衣壳蛋白的氨基酸序列是本领域已知的。参见,例如,AAV1的GenBank登录号NP_049542;AAV4的GenBank登录号NP_044927;AAV5的GenBank登录号AAD13756;AAV6的GenBank登录号AAB95450;AAV7的GenBank登录号YP_077178;AAV 8的GenBank登录号YP_077180;AAV9的GenBank登录号AAS99264和AAV10的GenBank登录号AAT46337。例如,参见,Santiago-Ortiz等人(2015)Gene Ther.22:934中的预测祖先AAV衣壳。
腺相关病毒(AAV)是一种复制缺陷型细小病毒,其单链DNA基因组长度为约4.7kb,包括两个145个核苷酸的反向末端重复序列(ITR)。有多种AAV血清型。AAV血清型基因组的核苷酸序列是已知的。例如,在GenBank登录号AF085716中提供了AAV5基因组。AAV的生命周期和遗传学在Muzyczka,Current Topics in Microbiology and Immunology,158:97-129(1992)中有综述。假型rAAV的产生在例如WO 01/83692中公开。也考虑了其他类型的rAAV变体,例如具有衣壳突变的rAAV。参见,例如,Marsic等人,Molecular Therapy,22(11):1900-1909(2014)。说明性的AAV载体在以下提供:US 7,105,345;US 15/782,980;US 7,259,151;US 6,962,815;US 7,718,424;US 6,984,517;US 7,718,424;US 6,156,303;US 8,524,446;US 7,790,449;US 7,906,111;US 9,737,618;US App 15/433,322;US 7,198,951,每个专利通过引用整体并入用于所有目的。
本公开的rAAV病毒体包含含有编码一种或多种基因产物的核苷酸序列的异源核酸。基因产物可以是多肽或RNA,或者两者。当基因产物是多肽时,核苷酸序列编码任选地具有一个或多个内含子的信使RNA,该信使RNA翻译成基因产物多肽。核苷酸序列可以编码一种、两种、三种或更多种基因产物(但是数目受到rAAV病毒体包装容量的限制,通常为约5.2kb)。基因产物可以操作性地连接到一个启动子(对于单个转录单位而言)或一个以上的启动子。使用内部核糖体进入信号(IRES)或自切割肽(例如,2A肽)也可以产生多种基因产物。
在一些实施方案中,基因产物是多肽。在一些实施方案中,多肽基因产物是诱导心脏成纤维细胞重编程以生成诱导心肌细胞样细胞(iCM)的多肽。在一些实施方案中,多肽基因产物是增强心脏细胞功能的多肽。在一些实施方案中,多肽基因产物是提供在心脏细胞中缺失或有缺陷的功能的多肽。在一些实施方案中,多肽基因产物是基因组编辑核酸内切酶。
在一些实施方案中,基因产物包含与异源多肽融合的融合蛋白。在一些实施方案中,基因产物包含与提供亚细胞定位的氨基酸序列融合的基因组编辑核酸酶,即,融合配偶体是亚细胞定位序列(例如,一个或多个靶向细胞核的核定位信号(NLS)、两个或多个NLS、三个或多个NLS等)。
一般而言,通过将病毒DNA或RNA构建体引入“生产细胞”或“包装细胞”系中而产生病毒载体。包装细胞系包括但不限于任何容易转染的细胞系。包装细胞系可以基于HEK291、293T细胞、NIH3T3、COS、HeLa或Sf9细胞系。包装细胞系的实例包括但不限于:Sf9(CRL-1711TM)。用于生成rAAV病毒体的示例性包装细胞系和方法由国际专利公开号WO2017075627、WO2015/031686、WO2013/063379、WO2011/020710、WO2009/104964、WO2008/024998、WO2003/042361和WO1995/013392;美国专利号US9441206B2、US8679837和US7091029B2提供。
在一些实施方案中,基因产物是功能性心脏蛋白。在一些实施方案中,基因产物是基因组编辑核酸内切酶(任选地具有指导RNA、单指导RNA和/或修复模板),该基因组编辑核酸内切酶将非功能性心脏蛋白置换或修复为功能性心脏蛋白。功能性心脏蛋白包括但不限于心脏肌钙蛋白T;心脏肌节蛋白;β-肌球蛋白重链;肌球蛋白心室必需轻链1;肌球蛋白心室调控轻链2;心脏a-肌动蛋白;a-原肌球蛋白;心脏肌钙蛋白I;心脏肌球蛋白结合蛋白C;四个半LIM蛋白1;肌联蛋白;5’-AMP-活化蛋白激酶亚基γ-2;肌钙蛋白I 3型、肌球蛋白轻链2、肌动蛋白α心肌1;心脏LIM蛋白;小窝蛋白3(CAV3);半乳糖苷酶α(GLA);溶酶体相关膜蛋白2(LAMP2);线粒体转运RNA甘氨酸(MTTG);线粒体转运RNA异亮氨酸(MTTI);线粒体转运RNA赖氨酸(MTTK);线粒体转运RNA谷氨酰胺(MTTQ);肌球蛋白轻链3(MYL3);肌钙蛋白C(TNNC1);转甲状腺素蛋白(TTR);肌内质网钙-ATP酶2a(SERCA2a);基质源性因子-1(SDF-1);腺苷酸环化酶6(AC6);β-ARKct(β-肾上腺素能受体激酶C端);成纤维细胞生长因子(FGF);血小板源性生长因子(PDGF);血管内皮生长因子(VEGF);肝细胞生长因子;缺氧诱导生长因子;胸腺素β4(TMSB4X);一氧化氮合酶-3(NOS3);unocartin 3(UCN3);melusin;载脂蛋白E(ApoE);超氧化物歧化酶(SOD);和S100A1(一种小的钙结合蛋白;参见,例如Ritterhoff和Most(2012)Gene Ther.19:613;Kraus等人(2009)Mol.Cell.Cardiol.47:445)。
在一些实施方案中,基因产物是其表达补充基因中造成遗传病症的缺陷的基因产物。本公开提供了包含编码以下的一种或多种物质的多核苷酸的rAAV病毒体—例如,用于但不限于括号中所示的病症,或用于由以下的每种引起的其他病症:TAZ(Barth综合征);FXN(弗里德希氏共济失调);CASQ2(CPVT);FBN1(Marfan);RAF1和SOS1s(Noonan);SCN5A(Brugada);KCNQ1和KCNH2s(长QT综合征);DMPK(强直性肌营养不良1);LMNA(肢带型肌营养不良1B型);JUP(Naxos);TGFBR2(Loeys-Dietz);EMD(X连锁EDMD);和ELN(SV主动脉瓣狭窄)。在一些实施方案中,rAAV病毒体包含编码以下的一种或多种的多核苷酸:心脏肌钙蛋白T(TNNT2);BAG家族分子伴侣调节因子3(BAG3);肌球蛋白重链(MYH7);原肌球蛋白1(TPM1);肌球蛋白结合蛋白C(MYBPC3);5’-AMP-活化蛋白激酶亚基γ-2(PRKAG2);肌钙蛋白I 3型(TNNI3);肌联蛋白(TTN);肌球蛋白轻链2(MYL2);肌动蛋白α心肌1(ACTC1);电压门控钾离子通道,KQT样亚家族,成员1(KCNQ1);桥粒斑菲素蛋白(plakophilin)2(PKP2);肌细胞增强因子2c(MEF2C);和心脏LIM蛋白(CSRP3)。
在一些实施方案中,本公开的基因产物是多肽重编程因子。重编程因子作为将一种细胞类型转化为另一种细胞类型的手段是理想的。使用本领域技术人员可获得的任何方法,可以使非心肌细胞在体外或体内分化成心肌细胞。例如,参见以下描述的方法:Ieda等人(2010)Cell 142:375-386;Christoforou等人(2013)PLoS ONE8:e63577;Addis等人(2013)J.Mol.Cell Cardiol.60:97-106;Jayawardena等人(2012)Circ.Res.110:1465-1473;Nam Y等人(2003)PNAS USA 110:5588-5593;Wada R等人(2013)PNAS USA 110:12667-12672;和Fu J等人(2013)Stem Cell Reports 1:235-247。
在心脏方面,重编程因子能够直接或通过中间细胞类型将心脏成纤维细胞转化为心肌细胞。具体而言,直接重编程是可能的,或者通过首先将成纤维细胞转化为多潜能或全能干细胞来重编程。此类多潜能干细胞被称为诱导多潜能干(iPS)细胞。随后转化为心肌细胞(CM)的iPS细胞被称为iPS-CM细胞。在实例中,在体外源自心脏成纤维细胞的iPS-CM用于体内选择感兴趣的衣壳蛋白。本公开还设想使用所公开的衣壳蛋白依次在体外,但尤其是在体内生成iPS-CM细胞,作为治疗性基因治疗方案的一部分。诱导心肌细胞样(iCM)细胞是指直接重编程为心肌细胞的细胞。
诱导心肌细胞表达一种或多种心肌细胞特异性标志物,其中心肌细胞特异性标志物包括但不限于心脏肌钙蛋白I、心脏肌钙蛋白C、原肌球蛋白、小窝蛋白-3、肌球蛋白重链、肌球蛋白轻链-2a、肌球蛋白轻链-2v、兰尼碱受体、肌节a-肌动蛋白、Nkx2.5、连接蛋白43和心房利钠因子。诱导心肌细胞也可以表现出肌节结构。诱导心肌细胞表现出心肌细胞特异性基因的表达增加:ACTC1(心脏a-肌动蛋白)、ACTN2(肌动蛋白a2)、MYH6(a-肌球蛋白重链)、RYR2(兰尼碱受体2)、MYL2(肌球蛋白调节轻链2,心室同种型)、MYL7(肌球蛋白调节轻链,心房同种型)、TNNT2(心脏肌钙蛋白T 2型)和NPPA(利钠肽前体A型)、PLN(受磷蛋白)。与iCM来源的成纤维细胞相比,成纤维细胞标志物诸如Colla2(胶原蛋白la2)的表达在诱导心肌细胞中下调。
涉及多肽重编程因子的重编程方法(在一些情况下由连同rAAV一起提供的小分子重编程因子补充)包括US2018/0112282A1、WO2018/005546、WO2017/173137、US2016/0186141、US2016/0251624、US2014/0301991和US2013/0216503A1中描述的那些,其整体并入,特别是对于公开的重编程方法和因子。
在一些实施方案中,使用一种或多种重编程因子将心脏细胞重编程为诱导心肌细胞样(iCM)细胞,该一种或多种重编程因子调节一种或多种感兴趣的多核苷酸或蛋白质的表达,诸如无刚毛鳞甲同系物1(ASCL1)、肌钙蛋白(MYOCD)、肌细胞特异性增强因子2C(MEF2C)和/或T-box转录因子5(TBX5)。在一些实施方案中,该一种或多种重编程因子作为编码一种或多种感兴趣的多核苷酸或蛋白质的多核苷酸(例如,RNA、mRNA或DNA多核苷酸)提供。在一些实施方案中,该一种或多种重编程因子作为蛋白质提供。
在一些实施方案中,该重编程因子是能够增加一种或多种感兴趣的多核苷酸或蛋白质的表达的微小RNA或微小RNA拮抗剂、siRNA或小分子。在一些实施方案中,感兴趣的多核苷酸或蛋白质的表达随微小RNA或微小RNA拮抗剂的表达而增加。例如,Oct多肽的内源性表达可以通过引入微小RNA-302(miR-302)或通过增加miR-302的表达来增加。参见,例如,Hu等人,Stem Cells 31(2):259-68(2013),其通过引用整体并入本文。因此,miRNA-302可以是内源性Oct多肽表达的诱导因子。miRNA-302可以单独引入或与编码Oct多肽的核酸一起引入。在一些实施方案中,合适的核酸基因产物是微小RNA。合适的微小RNA包括,例如,mir-1、mir-133、mir-208、mir-143、mir-145和mir-499。
在一些实施方案中,本公开的方法包括在施用小分子重编程因子之前、期间或之后施用本公开的rAAV病毒体。在一些实施方案中,小分子重编程因子是选自由以下组成的组的小分子:SB431542、LDN-193189、地塞米松、LY364947、D4476、杨梅酮、IWR1、XAV939、二十二碳六烯酸(DHA)、S-亚硝基-TV-乙酰青霉胺(SNAP)、Hh-Agl.5、前列地尔、克罗卡林、MNITMT、A769662、视黄酸对羟基苯胺、二溴十烃季铵、硝苯地平、吡罗昔康、杆菌肽、氨曲南、盐酸骆驼蓬酚、酰胺-C2(A7)、Ph-C12(CIO)、mCF3-C-7(J5)、G856-7272(A473)、5475707或它们的任何组合。
在一些实施方案中,基因产物包括重编程因子,这些重编程因子调节选自ASCL1、MYOCD、MEF2C和TBX5的一种或多种感兴趣的蛋白质的表达。在一些实施方案中,基因产物包括选自以下的一种或多种重编程因子:ASCL1、MYOCD、MEF2C、AND TBX5、CCNB1、CCND1、CDK1、CDK4、AURKB、OCT4、BAF60C、ESRRG、GATA4、GATA6、HAND2、IRX4、ISLL、MESP1、MESP2、NKX2.5、SRF、TBX20、ZFPM2和miR-133。
在一些实施方案中,基因产物包括GATA4、MEF2C和TBX5(即,GMT)。在一些实施方案中,基因产物包括MYOCD、MEF2C和TBX5(即,MyMT)。在一些实施方案中,基因产物包括MYOCD、ASCL1、MEF2C和TBX5(即,MyAMT)。在一些实施方案中,基因产物包括MYOCD和ASCL1(即,MyA)。在一些实施方案中,基因产物包括GATA4、MEF2C、TBX5和MYOCD(即,4F)。在其他实施方案中,基因产物包括GATA4、MEF2C、TBX5、ESSRG、MYOCD、ZFPM2和MESP1(即,7F)。在一些实施方案中,基因产物包括ASCL1、MEF2C、GATA4、TBX5、MYOCD、ESRRG和MESPL中的一种或多种。
在一些实施方案中,rAAV病毒体在体外或在体内生成心脏肌细胞。心肌细胞或心脏肌细胞是构成心肌的肌肉细胞。每个心肌细胞都含有肌原纤维,肌原纤维是肌节的长链,即肌肉细胞的收缩单位。心肌细胞显示的条纹类似于骨骼肌细胞上的条纹,但与多核骨骼细胞不同,多核骨骼细胞仅包含一个细胞核。心肌细胞具有高的线粒体密度,这允许它们快速产生ATP,从而对疲劳具有很高的抵抗力。成熟心肌细胞可以表达以下心脏标志物中的一种或多种:α-肌动蛋白、MLC2v、MY20、cMHC、NKX2-5、GATA4、cTNT、cTNI、MEF2C、MLC2a或它们的任何组合。在一些实施方案中,成熟心肌细胞表达NKX2-5、MEF2C或它们的组合。在一些实施方案中,心脏祖细胞表达早期心脏祖细胞标志物,诸如GATA4、ISL1或它们的组合。
在一些实施方案中,基因产物是多核苷酸。在一些实施方案中,如下所述,基因产物是能够与RNA导向的核酸内切酶结合的指导RNA。在一些实施方案中,基因产物是能够降低例如心脏细胞中的mRNA和/或多肽基因产物水平的抑制性核酸。例如,在一些实施方案中,多核苷酸基因产物是能够选择性灭活由引起心脏疾病或病症的等位基因编码的转录物的干扰RNA。例如,该等位基因是肌球蛋白重链7,心肌β(MYH7)等位基因,该等位基因包含导致肥厚型心肌病的突变。其他实例包括例如,选择性灭活由引起肥厚型心肌病(HCM)、扩张型心肌病(DCM)或左心室致密化不全(LVNC)的等位基因编码的转录物的干扰RNA,其中该等位基因是MYL3(肌球蛋白轻链3,碱性、心室、骨骼缓慢型)、MYH7、TNNI3(肌钙蛋白I 3型(心脏))、TNNT2(肌钙蛋白T 2型(心脏))、TPMl(原肌球蛋白1(α))或包含引起HCM、引起DCM或引起LVNC的突变的ACTCl等位基因。参见,例如,美国专利公开号2016/0237430中导致心脏病的突变的实例。
在一些实施方案中,基因产物是编码多肽的RNA。在一些实施方案中,基因产物是干扰RNA。在一些实施方案中,基因产物是适体。在一些实施方案中,基因产物是多肽。在一些实施方案中,基因产物是治疗性多肽,例如,提供临床益处的多肽。在一些实施方案中,基因产物是提供了基因功能的位点特异性敲除的位点特异性核酸酶。在一些实施方案中,基因产物是提供了对靶核酸的修饰的RNA导向的核酸内切酶。在一些实施方案中,基因产物是:i)提供了对靶核酸的修饰的RNA导向的核酸内切酶;和ii)包含与靶核酸中的靶序列结合的第一区段和与RNA导向的核酸内切酶结合的第二区段的指导RNA。在一些实施方案中,基因产物是:i)提供了对靶核酸的修饰的RNA导向的核酸内切酶;ii)包含与靶核酸中的第一靶序列结合的第一区段和与RNA导向的核酸内切酶结合的第二区段的第一指导RNA;和iii)包含与靶核酸中的第二靶序列结合的第一区段和与RNA导向的核酸内切酶结合的第二区段的第一指导RNA。
在本公开的rAAV病毒体中编码异源基因产物的核苷酸序列可以与启动子可操作地连接。例如,在本公开的rAAV病毒体中编码异源基因产物的核苷酸序列可以与组成型启动子、可调控启动子或心脏细胞特异性启动子可操作地连接。合适的组成型启动子包括人延伸因子1α亚基(EFlα)启动子、β-肌动蛋白启动子、α-肌动蛋白启动子、β-葡萄糖醛酸酶启动子、CAG启动子、超级核心启动子和泛素启动子。在一些实施方案中,在本公开的rAAV病毒体中编码异源基因产物的核苷酸序列与心脏特异性转录调控元件(TRE)可操作地连接,其中心脏特异性TRE包括启动子和增强子。合适的心脏特异性TRE包括但不限于源自以下基因的TRE:肌球蛋白轻链-2(MLC-2)、a-肌球蛋白重链(a-MHC)、结蛋白(desmin)、AE3、心脏肌钙蛋白C(cTnC)和心脏肌动蛋白。Franz等人(1997)Cardiovasc.Res.35:560-566;Robbins等人(1995)Ann.NY.Acad.Sci.752:492-505;Linn等人(1995)Circ.Res.76:584-591;Parmacek等人(1994)Mol.Cell.Biol.14:1870-1885;Hunter等人(1993)Hypertension 22:608-617;和Sartorelli等人(1992)Proc.Natl.Acad.Sci.USA 89:4047-4051。另参见,Pacak等人(2008)Genet Vaccines Ther.6:13。在一些实施方案中,启动子是α-MHC启动子、MLC-2启动子或cTnT启动子。
编码基因产物的多核苷酸与启动子和/或增强子可操作地连接以促进基因产物的表达。根据所用的宿主/载体系统,许多合适的转录和翻译控制元件中的任一种,包括组成型和诱导型启动子、转录增强子元件、转录终止子等可用于rAAV病毒体中(例如,Bitter等人(1987)Methods in Enzymology,153:516-544)。
对于每种多核苷酸可以采用单独的启动子和/或增强子。在一些实施方案中,对于单个开放阅读框中的两个或多个多核苷酸使用相同的启动子和/或增强子。采用这种遗传元件构型的载体称为“多顺反子性的”。多顺反子载体的一个说明性实例包含可操作地连接到包含两个或更多个通过2A区连接的多核苷酸的单个开放阅读框的增强子和启动子,由此开放阅读框的表达引起多种多肽共同翻译生成。据信2A区通过密码子跳跃介导多种多肽序列的生成;然而,本公开还涉及多顺反子载体,多顺反子载体采用翻译后切割从相同多核苷酸生成两种或多种感兴趣的蛋白质。通过引用并入本文的US20040265955A1中提供了说明性的2A序列、载体和相关方法。
合适的真核启动子(在真核细胞中有功能的启动子)的非限制性实例包括CMV、CMV立即早期启动子、HSV胸苷激酶、早期和晚期SV40、来自逆转录病毒的长末端重复序列(LTR)和小鼠金属硫蛋白-I。在一些实施方案中,将使用能够赋予心脏特异性表达的启动子。合适的心脏特异性启动子的非限制性实例包括结蛋白(Des)、α-肌球蛋白重链(α-MHC)、肌球蛋白轻链2(MLC-2)、心脏肌钙蛋白T(cTnT)和心脏肌钙蛋白C(cTnC)。合适的神经元特异性启动子的非限制性实例包括突触蛋白I(SYN)、钙/钙调蛋白依赖性蛋白激酶II、微管蛋白αI、神经元特异性烯醇化酶和血小板源性生长因子β链启动子以及通过将巨细胞病毒增强子(E)融合到那些神经元特异性启动子上得到的杂合启动子。
用于驱动表达重编程因子的合适启动子的实例包括但不限于逆转录病毒长末端重复(LTR)元件;组成型启动子,诸如CMV、HSV1-TK、SV40、EF-la、β-肌动蛋白、磷酸甘油激酶(PGK);诱导型启动子,诸如含有Tet操纵子元件的那些启动子;心脏特异性启动子,诸如结蛋白(DES)、α-肌球蛋白重链(a-MHC)、肌球蛋白轻链2(MLC-2)、心脏肌钙蛋白T(cTnT)和心脏肌钙蛋白C(cTnC);神经特异性启动子,诸如巢蛋白、神经元核(NeuN)、微管相关蛋白2(MAP2)、βIII微管蛋白、神经元特异性烯醇化酶(NSE)、少突胶质细胞谱系(Oligl/2)和胶质原纤维酸性蛋白(GFAP);和胰腺特异性启动子,诸如Pax4、Nkx2.2、Ngn3、胰岛素、胰高血糖素和生长抑素。
在一些实施方案中,多核苷酸可操作地连接到细胞类型特异性转录调控元件(TRE),其中TRE包括启动子和增强子。合适的TRE包括但不限于源自以下基因的TRE:肌球蛋白轻链-2、a-肌球蛋白重链、AE3、心脏肌钙蛋白C和心脏肌动蛋白。Franz等人(1997)Cardiovasc.Res.35:560-566;Robbins等人(1995)Ann.N.Y.Acad.Sci.752:492-505;Linn等人(1995)Circ.Res.76:584-591;Parmacek等人(1994)Cell.Biol.14:1870-1885;Hunter等人(1993)Hypertension 22:608-617;和Sartorelli等人(1992)PNAS USA 89:4047-4051。
启动子可以是与基因或核酸区段天然缔合的启动子。类似地,对于RNA(例如,微小RNA),启动子可以是与微小RNA基因(例如,miRNA-302基因)天然缔合的启动子。此类天然缔合的启动子可以称为“天然启动子”并且可以通过分离位于编码区段和/或外显子上游的5’非编码序列来获得。类似地,增强子可以是与核酸序列天然缔合的增强子。然而,增强子可以位于该序列的下游或上游。
可替代地,通过将编码核酸区段置于重组启动子或异源启动子的控制下将获得某些优势,重组启动子或异源启动子是指在其自然环境中通常不与核酸缔合的启动子。重组增强子或异源增强子也指在其自然环境中通常不与核酸序列缔合的增强子。此类启动子或增强子可以包括其他基因的启动子或增强子,和从任何其他原核细胞、病毒细胞或真核细胞分离的启动子或增强子,以及非“天然存在的”,即含有不同转录调控区的不同元件,和/或改变表达的突变的启动子或增强子。除了合成产生启动子和增强子的核酸序列以外,还可以使用重组克隆和/或核酸扩增技术(包括PCR)结合本文公开的组合物来产生序列(参见美国专利号4,683,202、美国专利号5,928,906,每个专利均通过引用并入本文)。
所采用的启动子可以是组成型的、诱导型的、发育特异性的、组织特异性的,和/或在适当条件下可用于指导核酸区段的高水平表达。例如,启动子可以是组成型启动子,诸如CMV启动子、CMV巨细胞病毒立即早期启动子、CAG启动子、EF-1α启动子、HSV1-TK启动子、SV40启动子、β-肌动蛋白启动子、PGK启动子或它们的组合。可使用的真核启动子的实例包括但不限于组成型启动子,例如病毒启动子诸如CMV、SV40和RSV启动子,以及可调控启动子,例如诱导型启动子或阻抑型启动子诸如tet启动子、hsp70启动子和受CRE调控的合成启动子。在某些实施方案中,细胞类型特异性启动子用于驱动特定细胞类型中重编程因子的表达。可用于本文所述的方法的合适的细胞类型特异性启动子的实例包括但不限于He等人(2006),Human Gene Therapy 17:949-959中描述的合成巨噬细胞特异性启动子;粒细胞和巨噬细胞特异性溶菌酶M启动子(参见,例如,Faust等人(2000),Blood 96(2):719-726);和骨髓特异性CD11b启动子(参见,例如,Dziennis等人(1995),Blood 85(2):319-329)。可以采用的启动子的其他实例包括人EF1α延伸因子启动子、CMV巨细胞病毒立即早期启动子、CAG鸡白蛋白启动子、与本文所述的任何病毒载体缔合的病毒启动子或与本文所述的任何启动子同源的启动子(例如,来自另一物种)。可以使用的原核启动子的实例包括但不限于SP6、T7、T5、tac、bla、trp、gal、lac或麦芽糖启动子。
在一些实施方案中,内部核糖体进入位点(IRES)元件可用于产生多基因或多顺反子信息。IRES元件能够绕过5′-甲基化Cap依赖性翻译的核糖体扫描模型并在内部位点处开始翻译(Pelletier和Sonenberg,Nature 334(6180):320-325(1988))。已经描述了来自小核糖核酸病毒家族的两个成员(脊髓灰质炎和脑心肌炎)的IRES元件(Pelletier和Sonenberg,Nature 334(6180):320-325(1988)),以及来自哺乳动物信息的IRES(Macejak和Samow,Nature 353:90-94(1991))。IRES元件可以与异源开放阅读框连接。多个开放阅读框可以一起转录,每个开放阅读框由一个IRES分开,产生多顺反子信息。由于IRES元件,每个开放阅读框都可以是核糖体可及的以进行有效翻译。使用单个启动子/增强子转录单个信息可以有效地表达多个基因(参见美国专利号5,925,565和5,935,819,通过引用并入本文)。
在一些实施方案中,核苷酸序列可操作地连接到聚腺苷酸化序列。合适的聚腺苷酸化序列包括牛生长激素聚A信号序列(bGHpolyA)和短的聚A信号序列。任选地,本公开的rAAV载体包含土拨鼠转录后调控元件(WPRE)。在一些实施方案中,编码基因产物的多核苷酸通过包括所谓的自切割肽,例如P2A肽的序列连接。
在一些实施方案中,基因产物包含提供基因功能的位点特异性敲除的位点特异性核酸内切酶,例如,其中核酸内切酶敲除与心脏疾病或病症相关的等位基因。例如,当显性等位基因编码基因的缺陷拷贝的情况下,该基因为野生型时是心脏结构蛋白和/或提供正常的心脏功能,位点特异性核酸内切酶可以靶向缺陷等位基因并敲除缺陷等位基因。在一些实施方案中,位点特异性核酸内切酶是RNA导向的核酸内切酶。
除了敲除缺陷等位基因以外,位点特异性核酸酶也可用于刺激与供体DNA的同源重组,该供体DNA编码由缺陷等位基因编码的蛋白质的功能拷贝。例如,主题rAAV病毒体可用于递送敲除缺陷等位基因的位点特异性核酸内切酶和缺陷等位基因(或其片段)的功能拷贝,引起缺陷等位基因的修复,从而提供功能性心脏蛋白(例如,功能性肌钙蛋白等)的产生。在一些实施方案中,主题rAAV病毒体包含编码位点特异性核酸内切酶的异源核苷酸序列和编码缺陷等位基因的功能拷贝的异源核苷酸序列,其中功能拷贝编码功能性心脏蛋白。功能性心脏蛋白质包括例如肌钙蛋白、氯离子通道等。
适合使用的位点特异性核酸内切酶包括,例如锌指核酸酶(ZFN);大范围核酸酶;和转录激活因子样效应核酸酶(TALEN),其中此类位点特异性核酸内切酶是非天然存在的并且经修饰以靶向特定基因。此类位点特异性核酸酶可以工程改造以切割基因组内的特定位置,然后非同源末端连接可以修复断裂,同时使几个核苷酸插入或缺失。此类位点特异性核酸内切酶(也称为“INDEL”)然后将蛋白质抛出框架并有效地敲除基因。参见,例如,美国专利公开号2011/0301073。合适的位点特异性核酸内切酶包括工程改造的大范围核酸酶,重新工程改造的归巢核酸内切酶。合适的核酸内切酶包括I-Tevl核酸酶。合适的大范围核酸酶包括I-Scel(参见,例如,Bellaiche等人(1999)Genetics 152:1037);和I-Crel(参见,例如,Heath等人(1997)Nature Sructural Biology 4:468)。适合使用的位点特异性核酸内切酶包括CRISPRi系统和基于Cas9的SAM系统。
在一些实施方案中,基因产物是RNA导向的核酸内切酶。在一些实施方案中,基因产物包括包含编码RNA导向的核酸内切酶的核苷酸序列的RNA。在一些实施方案中,基因产物是指导RNA,例如,单指导RNA。在一些实施方案中,基因产物是:1)指导RNA;和2)RNA导向的核酸内切酶。指导RNA可以包含:a)与RNA导向的核酸内切酶结合的蛋白质结合区;和b)与靶核酸结合的区域。RNA导向的核酸内切酶在本文中也称为“基因组编辑核酸酶”。
合适的基因组编辑核酸酶的实例是CRISPR/Cas核酸内切酶(例如,2类CRISPR/Cas核酸内切酶,诸如II型、V型或VI型CRISPR/Cas核酸内切酶)。合适的基因组编辑核酸酶是CRISPR/Cas核酸内切酶(例如,2类CRISPR/Cas核酸内切酶,诸如II型、V型或VI型CRISPR/Cas核酸内切酶)。在一些实施方案中,基因产物包括2类CRISPR/Cas核酸内切酶。在一些实施方案中,基因产物包括2类II型CRISPR/Cas核酸内切酶(例如,Cas9蛋白)。在一些实施方案中,基因产物包括2类V型CRISPR/Cas核酸内切酶(例如,Cpfl蛋白、C2cl蛋白或C2c3蛋白)。在一些实施方案中,基因产物包括2类VI型CRISPR/Cas核酸内切酶(例如,C2c2蛋白;也被称为“Casl3a”蛋白)。在一些实施方案中,基因产物包括CasX蛋白。在一些实施方案中,基因产物包括CasY蛋白。
使用方法
在一些实施方案中,本公开提供了鉴定AAV衣壳蛋白的方法,这些衣壳蛋白赋予rAAV病毒体在靶细胞中增加的转导效率。这些方法包括:提供rAAV病毒体群体,它们的rAAV基因组包含编码变体AAV衣壳蛋白的cap多核苷酸文库;任选地使该群体与非靶细胞接触足够长的时间,以容许不需要的rAAV病毒体附着到非靶细胞上;使该群体与靶细胞接触足够长的时间,以容许rAAV病毒体将cap多核苷酸转导到靶细胞中;以及对来自靶细胞的cap多核苷酸进行测序,从而鉴定赋予在靶细胞中增加的转导效率的AAV衣壳蛋白。在一些实施方案中,该方法还包括通过使rAAV病毒体群体与非靶细胞接触足够长的时间以容许rAAV病毒体附着到非靶细胞上来消耗rAAV病毒体群体。在实施例中提供了此类鉴定方法的非限制性实例。
本公开提供了使用rAAV病毒体在体外生成心肌细胞和/或心肌细胞样细胞的方法。将选定的起始细胞用rAAV转导并任选地在足以转化起始细胞跨越谱系和/或分化界限以形成心脏祖细胞和/或心肌细胞的时间和条件下暴露于小分子重编程因子(转导之前、期间或之后)。在一些实施方案中,起始细胞是成纤维细胞。在一些实施方案中,起始细胞表达一种或多种指示分化表型的标志物。起始细胞转化为心脏祖细胞和心肌细胞的时间可以变化。例如,起始细胞可以在用一种或多种感兴趣的多核苷酸或蛋白质处理后孵育,直到心脏或心肌细胞标志物表达。此类心脏或心肌细胞标志物可包括以下标志物中的任一种:α-GATA4、TNNT2、MYH6、RYR2、NKX2-5、MEF2C、ANP、肌动蛋白、MLC2v、MY20、cMHC、ISL1、cTNT、cTNI和MLC2a,或它们的任何组合。在一些实施方案中,诱导心肌细胞对一种或多种神经元细胞标志物呈阴性。此类神经元细胞标志物可以包括以下标志物中的任一种:DCX、TUBB3、MAP2和ENO2。
可以继续孵育,直到起始细胞表达心脏祖细胞标志物。此类心脏祖细胞标志物包括GATA4、TNNT2、MYH6、RYR2或它们的组合。心脏祖细胞标志物诸如GATA4、TNNT2、MYH6、RYR2或它们的组合可在本文所述的组合物中开始孵育细胞后约8天、或约9天、或约10天、或约11天、或约12天、或约14天、或约15天、或约16天、或约17天、或约18天、或约19天、或约20天表达。可以进行细胞的进一步孵育,直到出现晚期心脏祖细胞标志物诸如NKX2-5、MEF2C或它们的组合的表达。
重编程效率可以根据心肌细胞标志物来测量。此类多潜能性标志包括但不限于心肌细胞标志蛋白和mRNA的表达、心肌细胞形态和电生理表型。心肌细胞标志物的非限制性实例包括α-肌聚糖、心房利钠肽(ANP)、骨形态发生蛋白4(BMP4)、连接蛋白37、连接蛋白40、crypto、结蛋白、GATA4、GATA6、MEF2C、MYH6、肌球蛋白重链、NKX2.5、TBX5和肌钙蛋白T。
可以通过常规的生物化学或免疫化学方法(例如,酶联免疫吸附测定、免疫组织化学测定等)检测心肌细胞特异性的各种标志物的表达。可替代地,可以评估编码心肌细胞特异性标志物的核酸的表达。编码心肌细胞特异性标志物的核酸在细胞中的表达可以通过逆转录聚合酶链反应(RT-PCR)或杂交分析来确认,这些方法是过去常用于扩增、检测和分析编码任何标志物蛋白的mRNA的分子生物学方法。编码心肌细胞特异性标志物的核酸序列是已知的并且可通过公共数据库诸如GenBank获得。因此,很容易确定用作引物或探针所需的标志物特异性序列。
心肌细胞表现出一些心脏特异性的电生理特性。一种电特征是动作电位,该动作电位是持续短暂的事件,其中每个心脏细胞的内部和外部之间的电位差沿着一致的轨迹上升和下降。心肌细胞的另一电生理学特征是细胞溶质游离Ca2+浓度的周期性变化,称为Ca2+瞬变,其用于调控心肌细胞的收缩和舒张。可以检测和评价这些特征,以评估细胞群是否已经被重编程为心肌细胞。
本公开提供了一种将基因产物递送至心脏细胞,例如心脏成纤维细胞的方法。这些方法通常包括用rAAV病毒体感染心脏细胞(例如,心脏成纤维细胞),其中由存在于rAAV病毒体中的异源核酸编码的基因产物在心脏细胞(例如,心脏成纤维细胞)中产生。将基因产物递送至心脏细胞(例如,心脏成纤维细胞)可提供对心脏疾病或病症的治疗。将基因产物递送至心脏细胞(例如,心脏成纤维细胞)可以提供从心脏成纤维细胞生成诱导心肌细胞样(iCM)细胞。将基因产物递送至心脏细胞(例如,心脏成纤维细胞)可以提供对心脏细胞(例如,心脏成纤维细胞)的基因组的编辑。
在一些实施方案中,感染或转导心脏细胞(例如,心脏成纤维细胞)在体外进行。在一些实施方案中,感染或转导心脏细胞(例如,心脏成纤维细胞)在体外进行;并且将感染/转导的心脏细胞(例如,心脏成纤维细胞)引入(例如,输入或植入)有此需要的个体中,例如,直接引入有此需要的个体的心脏组织中。对于体外转导,待递送至细胞的rAAV病毒体的有效量为约105至约1013个rAAV病毒体。本领域的普通技术人员通过建立剂量反应曲线的常规试验,可以容易地建立其他有效剂量。
在一些实施方案中,感染心脏细胞(例如,心脏成纤维细胞)在体内进行。例如,在一些实施方案中,将有效量的本公开的rAAV病毒体直接施用到有此需要的个体的心脏组织中。“有效量”将落在相对较宽的范围内,该范围可以通过实验和/或临床试验来确定。例如,对于体内注射,即直接注射到心脏组织中,治疗有效剂量将为以下数量级:约106至约1015个本公开的rAAV病毒体,例如约105至1012个本公开的rAAV病毒体。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过心外膜的心肌内注射施用。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过冠状动脉的血管递送施用。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过上腔静脉的系统递送施用。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过外周静脉的系统递送施用。
例如,将本公开的rAAV病毒体的约104至约105、约105至约106、约106至约107、约106至约107、约107至约108、约108至约109、约109至约1010、约1010至约1011、至约1011、约1011至约1012、约1012至约1013、约1013至约1014、约1014至约1015个基因组拷贝或超过1015个基因组拷贝施用于个体,例如,直接施用于个体的心脏组织,或经由另一途径施用。施用于个体的rAAV病毒体的数目可以用个体每千克(kg)体重的病毒基因组(vg)来表示。在一些实施方案中,本公开的rAAV病毒体的有效量为约102vg/kg至104vg/kg、约104vg/kg至约106vg/kg、约106vg/kg至约108vg/kg、约108vg/kg至约1010vg/kg、约1010vg/kg至约1012vg/kg、约1012vg/kg至约1014vg/kg、约1014vg/kg至约1016vg/kg、约1016vg/kg至约1018vg/kg或超过1018vg/kg。
在一些实施方案中,有效量的本公开的rAAV病毒体经由通过心外膜的心肌内注射施用。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过冠状动脉的血管递送施用。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过上腔静脉的系统递送施用。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过外周静脉的系统递送施用。
在一些实施方案中,可以采用一次以上的施用(例如,两次、三次、四次或更多次施用)来实现所需水平的基因表达。在一些实施方案中,以不同的间隔,例如,每天、每周、每月两次、每月、每3个月、每6个月、每年等,施用多于一次的施用。在一些实施方案中,在1个月至2个月、2个月至4个月、4个月至8个月、8个月至12个月、1年至2年、2年至5年或超过5年的时间段内施用多次施用。
本公开提供了对心脏成纤维细胞进行重编程以生成诱导心肌细胞样细胞(iCM)的方法。该方法通常包括用本公开的rAAV病毒体感染心脏成纤维细胞,其中该rAAV病毒体包含异源核酸,该异源核酸包含编码一种或多种重编程因子的核苷酸序列。
通过常规的生物化学或免疫化学方法(例如,酶联免疫吸附测定、免疫组织化学测定等)检测心肌细胞特异性的各种标志物的表达。可替代地,可以评估编码心肌细胞特异性标志物的核酸的表达。编码心肌细胞特异性标志物的核酸在细胞中的表达可以通过逆转录聚合酶链反应(RT-PCR)或杂交分析来确认,这些方法是过去常用于扩增、检测和分析编码任何标志物蛋白的mRNA的分子生物学方法。编码心肌细胞特异性标志物的核酸序列是已知的并且可通过公共数据库诸如GenBank获得;因此,很容易确定用作引物或探针所需的标志物特异性序列。
诱导心肌细胞也可以表现出自发性收缩。可以使用标准的电生理学方法(例如,膜片钳)来确定诱导心肌细胞是否表现出自发性收缩。
在一些实施方案中,诱导心肌细胞可以表现出自发性Ca2+振荡。Ca2+振荡可以使用标准方法,例如使用多种钙敏感性染料中的任何一种检测,细胞内Ca2+离子检测染料包括但不限于fura-2、bis-fura 2、indo-1、Quin-2、Quin-2 AM、Benzothiaza-1、Benzothiaza-2、indo-5F、Fura-FF、BTC、Mag-Fura-2、Mag-Fura-5、Mag-Indo-1、fluo-3、rhod-2、rhod-3、fura-4F、fura-5F、fura-6F、fluo-4、fluo-5F、fluo-5N、俄勒冈绿488BAPTA、钙绿、钙黄绿素、Fura-C18、钙绿-C18、钙橙、钙深红、钙绿-5N、镁绿、俄勒冈绿488BAPTA-1、俄勒冈绿488BAPTA-2、X-rhod-1、Fura红、Rhod-5F、Rhod-5N、X-Rhod-5N、Mag-Rhod-2、Mag-X-Rhod-1、Fluo-5N、Fluo-5F、Fluo-4FF、Mag-Fluo-4、水母发光蛋白、葡聚糖缀合物或任何这些染料的任何其他衍生物等(参见,例如,Molecular Probes,Eugene的目录或互联网网站,另参见Nuccitelli编辑,Methods in Cell Biology,第40卷:A Practical Guide to the Studyof Calcium in Living Cells,Academic Press(1994);Lambert编辑,Calcium SignalingProtocols(Methods in Molecular Biology第114卷),Humana Press(1999);W.T.Mason编辑,Fluorescent and Luminescent Probes for Biological Activity.A PracticalGuide to Technology for Quantitative Real-Time Analysis,Second Ed,AcademicPress(1999);Calcium Signaling Protocols(Methods in Molecular Biology),2005,D.G.Lamber编辑,Humana Press.)。
在一些实施方案中,iCM在体外生成;并且将iCM引入个体中,例如,将iCM植入有此需要的个体的心脏组织中。本公开的方法可以包括体外感染心脏成纤维细胞群,以生成iCMs群体;并将iCMs群体植入有此需要的个体的心脏组织中。
在一些实施方案中,iCM在体内生成。例如,在一些实施方案中,对个体施用包含异源核酸的本公开的rAAV病毒体,该异源核酸包含编码一种或多种重编程因子的核苷酸序列。在一些实施方案中,将rAAV病毒体直接施用于有此需要的个体的心脏组织中。在一些实施方案中,将包含异源核酸的本公开的rAAV病毒体的约106至约105、约105至约109、约109至约1010、约1010至约1011、约1011至约1012、约1012至约1013、约1013至约1014、约1014至约1015个基因组拷贝或超过1015个基因组拷贝施用于个体,例如直接施用于个体的心脏组织或经由另一施用途径施用,该异源核酸包含编码一种或多种重编程因子的核苷酸序列。施用于个体的rAAV病毒体的数目可以用个体每千克(kg)体重的病毒基因组(vg)来表示。在一些实施方案中,本公开的rAAV病毒体的有效量为约102vg/kg至104vg/kg、约104vg/kg至约106vg/kg、约106vg/kg至约108vg/kg、约108vg/kg至约1010vg/kg、约1010vg/kg至约1012vg/kg、约1012vg/kg至约1014vg/kg、约1014vg/kg至约1014vg/kg、约1014vg/kg至约1016vg/kg或超过1016vg/kg。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过心外膜的心肌内注射施用。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过冠状动脉的血管递送施用。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过上腔静脉的系统递送施用。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过外周静脉的系统递送施用。
本公开提供了修饰(“编辑”)心脏细胞的基因组的方法。本公开提供了修饰(“编辑”)心脏成纤维细胞的基因组的方法。本公开提供了修饰(“编辑”)心肌细胞的基因组的方法。这些方法通常包括用本公开的rAAV病毒体感染心脏细胞(例如,心脏成纤维细胞或心肌细胞),其中该rAAV病毒体包含异源核酸,该异源核酸包含编码基因组编辑核酸内切酶的核苷酸序列。在一些实施方案中,该方法包括用本公开的rAAV病毒体感染心脏成纤维细胞或心肌细胞,其中该rAAV病毒体包含异源核酸,该异源核酸包含编码RNA导向的基因组编辑核酸内切酶的核苷酸序列。在一些实施方案中,该方法包括用本公开的rAAV病毒体感染心脏成纤维细胞或心肌细胞,其中该rAAV病毒体包含异源核酸,该异源核酸包含编码以下的核苷酸序列:i)RNA导向的基因组编辑核酸内切酶;和ii)一种或多种指导RNA。在一些实施方案中,该方法包括用本公开的rAAV病毒体感染心脏成纤维细胞或心肌细胞,其中该rAAV病毒体包含异源核酸,该异源核酸包含编码以下的核苷酸序列:i)RNA导向的基因组编辑核酸内切酶;ii)指导RNA;和iii)供体模板DNA。合适的RNA导向的基因组编辑核酸内切酶如上所述。
在一些实施方案中,感染心脏细胞(例如,心脏成纤维细胞;心肌细胞)在体外进行。在一些实施方案中,感染心脏细胞(例如,心脏成纤维细胞;心肌细胞)在体外进行;并且将感染的心脏细胞(例如,心脏成纤维细胞)引入(例如,植入)有此需要的个体中,例如,直接引入有此需要的个体的心脏组织中。对于体外转导,待递送至细胞的rAAV病毒体的有效量将为约105至约1013个rAAV病毒体的数量级。本领域的普通技术人员通过建立剂量反应曲线的常规试验,可以容易地建立其他有效剂量。
在一些实施方案中,感染心脏细胞(例如,心脏成纤维细胞;心肌细胞)在体内进行。例如,在一些实施方案中,将有效量的本公开的rAAV病毒体直接施用到有此需要的个体的心脏组织中。“有效量”将落在相对较宽的范围内,该范围可以通过实验和/或临床试验来确定。例如,对于体内注射,即直接注射到心脏组织中,治疗有效剂量将为以下数量级:约106至约1015个本公开的rAAV病毒体,例如约1011至1012个本公开的rAAV病毒体。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过心外膜的心肌内注射施用。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过冠状动脉的血管递送施用。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过上腔静脉的系统递送施用。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过外周静脉的系统递送施用。
例如,将本公开的rAAV病毒体的约106至约107、约107至约108、约108至约109、约109至约1010、约1010至约1011、约1011至约1012、约1012至约1013、约1013至约1014、约1014至约1015个基因组拷贝或超过1015个基因组拷贝施用于个体,例如直接施用于个体的心脏组织。施用于个体的rAAV病毒体的数目可以用个体每千克(kg)体重的病毒基因组(vg)来表示。在一些实施方案中,本公开的rAAV病毒体的有效量为约102vg/kg至104vg/kg、约104vg/kg至约106vg/kg、约106vg/kg至约108vg/kg、约108vg/kg至约1010vg/kg、约1010vg/kg至约1012vg/kg、约1012vg/kg至约1014vg/kg、约1014vg/kg至约1016vg/kg、约1016vg/kg至约1018vg/kg或超过1018vg/kg。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过心外膜的心肌内注射施用。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过冠状动脉的血管递送施用。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过上腔静脉的系统递送施用。在一些实施方案中,有效量的本公开的rAAV病毒体经由通过外周静脉的系统递送施用。
在一些实施方案中,基因组编辑包括同源定向修复(HDR)。在一些实施方案中,HDR校正心脏成纤维细胞或心肌细胞中内源靶核酸的缺陷,其中该缺陷与心脏成纤维细胞或心肌细胞,或心脏成纤维细胞或心肌细胞的组分的结构和/或功能缺陷相关或导致所述缺陷。
在一些实施方案中,基因组编辑包括非同源末端连接(NHEJ)。在一些实施方案中,NHEJ消去心脏成纤维细胞或心肌细胞中内源靶核酸的缺陷,其中该缺陷与心脏成纤维细胞或心肌细胞,或心脏成纤维细胞或心肌细胞的组分的结构和/或功能缺陷相关或导致所述缺陷。
用于编辑心脏细胞基因组的本公开方法可用于校正引起心脏疾病或病症的各种遗传缺陷中的任何遗传缺陷。感兴趣的突变包括以下基因中的一个或多个基因的突变:心肌肌钙蛋白T(TNNT2);肌球蛋白重链(MYH7);原肌球蛋白1(TPM1);肌球蛋白结合蛋白C(MYBPC3);5’-AMP-活化蛋白激酶亚基γ-2(PRKAG2);肌钙蛋白I 3型(TNNI3);肌联蛋白(TTN);肌球蛋白轻链2(MYL2);肌动蛋白α心肌1(ACTC1);电压门控钾离子通道,KQT样亚家族,成员1(KCNQ1);桥粒斑菲素蛋白(plakophilin)2(PKP2);肌细胞增强因子2c(MEF2C);和心脏LIM蛋白(CSRP3)。感兴趣的具体突变包括但不限于MYH7 R663H突变;TNNT2 R173W;PKP2 2013delC突变;PKP2 Q617X突变;和KCNQ1G269S错义突变。感兴趣的突变包括以下基因中的一个或多个基因的突变:MYH6、ACTN2、SERCA2、GATA4、TBX5、MYOCD、NKX2-5、NOTCH1、MEF2C、HAND2和HAND1。在一些实施方案中,感兴趣的突变包括以下基因中的突变:MEF2C、TBX5和MYOCD。可用本公开的方法治疗的心脏疾病和病症包括冠心病、心肌病、心内膜炎、先天性心血管缺陷和充血性心力衰竭。可用本公开的方法治疗的心脏疾病和病症包括肥厚型心肌病;瓣膜性心脏病;心肌梗塞;充血性心力衰竭;长QT综合征;房性心律失常;室性心律失常;舒张性心力衰竭;收缩性心力衰竭;心脏瓣膜疾病;心脏瓣膜钙化;左心室不致密化;室间隔缺损;和局部缺血。
治疗方法
本公开提供了一种治疗有此需要的受试者的心脏病理的方法,该方法包括向受试者施用治疗有效量的包含rAAV病毒体的药物组合物,其中该rAAV病毒体转导心脏组织。
需要使用本公开的组合物和方法进行治疗的受试者包括但不限于具有先天性心脏缺陷的个体、患有退行性肌肉疾病的个体、患有导致缺血性心脏组织的病状的个体(例如,患有冠状动脉疾病的个体)等。在一些实例中,一种方法可用于治疗退行性肌肉疾病或病状(例如,家族性心肌病、扩张型心肌病、肥厚型心肌病、限制性心肌病或冠状动脉疾病导致的缺血性心肌病)。在一些实例中,主题方法可用于治疗患有心脏或心血管疾病或病症的个体,例如心血管疾病、动脉瘤、心绞痛、心律失常、动脉粥样硬化、脑血管意外(中风)、脑血管疾病、先天性心脏病、充血性心力衰竭、心肌炎、冠状动脉瓣膜病、扩张型动脉疾病、舒张功能障碍、心内膜炎、高血压(high blood pressure/hypertension)、心肌病、肥厚型心肌病、限制性心肌病、冠状动脉疾病导致的缺血性心肌病、二尖瓣脱垂、心肌梗塞(心脏病发作)或静脉血栓栓塞。
适于使用本公开的组合物、细胞和方法进行治疗的受试者包括患有心脏病状(包括但不限于导致缺血性心脏组织的疾病)的个体(例如,哺乳动物受试者,诸如人、非人灵长类动物、家养哺乳动物、实验非人哺乳类受试者(诸如小鼠、大鼠)等)(例如,患有冠状动脉疾病的个体)。
在一些实施方案中,适合治疗的个体患有心脏或心血管疾病或病状,例如心血管疾病、动脉瘤、心绞痛、心律失常、动脉粥样硬化、脑血管意外(中风)、脑血管疾病、先天性心脏病、充血性心力衰竭、心肌炎、冠状动脉瓣膜疾病、扩张型动脉疾病、舒张功能障碍、心内膜炎、高血压(high blood pressure/hypertension)、心肌病、肥厚型心肌病、限制性心肌病、冠状动脉疾病导致的缺血性心肌病、二尖瓣脱垂、心肌梗塞(心脏病发作)或静脉血栓栓塞。在一些实例中,适合用主题方法治疗的个体包括患有退行性肌肉疾病,例如家族性心肌病、扩张型心肌病、肥厚型心肌病、限制性心肌病或冠状动脉疾病导致的缺血性心肌病的个体。
例如,心脏病理可以选自由充血性心力衰竭、心肌梗塞、心脏局部缺血、心肌炎和心律失常组成的组。在一些实施方案中,受试者是糖尿病患者。在一些实施方案中,受试者是非糖尿病患者。在一些实施方案中,受试者患有糖尿病性心肌病。
对于治疗,本公开的rAAV病毒体和/或其药物组合物可以局部或全身施用。rAAV病毒体可以通过注射、导管、可植入装置等引入。rAAV病毒体可以在对细胞没有不利影响的任何生理上可接受的赋形剂或载剂中施用。例如,本公开的rAAV病毒体和/或其药物组合物可以静脉内或通过心内途径(例如,心外膜或心肌内)施用。将本公开的rAAV病毒体和/或其药物组合物施用于受试者,特别是人类受试者的方法包括注射或输注药物组合物(例如,包含rAAV病毒体的组合物)。注射可以包括直接肌肉注射,输注可以包括血管内输注。可以将rAAV病毒体或药物组合物插入到递送装置中,该递送装置便于通过注射引入到受试者中。此类递送装置包括用于将细胞和流体注射到受体受试者体内的管,例如导管。这些管可另外包括针头,例如注射器,通过针头可将本发明的细胞引入受试者的所需位置。
在一些实施方案中,rAAV病毒体通过皮下、静脉内、肌内、腹膜内或心内注射或通过心内导管插入法施用。在一些实施方案中,rAAV病毒体通过直接心肌内注射或经血管施用进行施用。在一些实施方案中,rAAV病毒体通过直接心肌内注射、顺行冠状动脉内注射、逆行注射、经心内膜心肌注射或分子心脏手术伴循环递送(MCARD)进行施用。
rAAV病毒体可以以不同的形式插入此类递送装置,例如注射器中。rAAV病毒体可以以药物组合物的形式供给。此类组合物可以包括在足够无菌的条件下制备的用于人类施用的等渗赋形剂。对于药物配制的一般原理,读者可参考G.Morstyn和W.Sheridan编辑的Cell Therapy:Stem Cell Transplantation,GeneTherapy,and CellularImmunotherapy,Cambridge University Press,1996;和Hematopoietic StemCellTherapy,E.D.Ball,J.Lister和P.Law,Churchill Livingstone,2000。组合物中赋形剂和任何伴随组成成分的选择可以适于优化通过所采用的途径和/或装置进行的施用。
重组AAV可以局部或全身施用。通过选择本公开的适当衣壳蛋白,重组AAV可工程改造以靶向特定细胞类型。为了确定AAV病毒体组合物的各种治疗性施用方案和剂量的适合性,可以首先在合适的动物模型中测试rAAV病毒体。在一个水平上,评估重组AAV在体内感染靶细胞的能力。还可以评估重组AAV,以确定它是否迁移到靶组织,它们是否在宿主中诱导免疫反应,或者确定要施用的rAAV病毒体的适当数目或剂量。根据待治疗的疾病,可能期望或不期望重组AAV产生免疫反应。通常,如果需要重复施用病毒体,则如果病毒体无免疫原性是有利的。为了测试的目的,rAAV病毒体组合物可以施用于免疫缺陷动物(诸如裸鼠,或通过化学或辐射致使免疫缺陷的动物)。可以在感染一段时间后收获靶组织或细胞并进行评估,以确定这些组织或细胞是否已经被感染,以及是否已经在靶组织或细胞中诱导了所需表型(例如诱导心肌细胞)。
重组AAV病毒体可以通过各种途径施用,包括但不限于直接注射到心脏中或心脏导管插入。可替代地,rAAV病毒体可以全身施用,诸如通过静脉输注。当使用直接注射时,可以通过心内直视手术或微创手术进行。在一些实施方案中,通过注射或输注将重组病毒递送至心包腔。注射或输注的重组病毒可通过多种方法进行追踪。例如,用可检测标记(诸如绿色荧光蛋白或β-半乳糖苷酶)标记或表达可检测标记的重组AAV可以容易地被检测到。重组AAV可以工程改造以使靶细胞表达标志物蛋白,诸如表面表达的蛋白或荧光蛋白。可替代地,重组AAV对靶细胞的感染可以通过它们对细胞标志物的表达来检测,该细胞标志物不被用于测试的动物表达(例如,将细胞注射到实验动物中时,具有人特异性抗原)。靶细胞的存在和表型可以通过荧光显微镜(例如,绿色荧光蛋白或β-半乳糖苷酶)、免疫组织化学(例如,使用针对人抗原的抗体)、ELISA(使用针对人抗原的抗体)或使用引物和杂交条件的RT-PCR分析来评估,所述引物和杂交条件导致扩增对指示心脏表型的RNA具有特异性。
药物组合物
本公开提供了包含本公开的rAAV病毒体的药物组合物。该药物组合物可以包括药学上可接受的载剂、稀释剂、赋形剂和缓冲液中的一种或多种。在一些实施方案中,药学上可接受的载剂、稀释剂、赋形剂或缓冲液适合在人类中使用。此类赋形剂、载剂、稀释剂和缓冲液包括可以施用而没有过度毒性的任何药剂。药学上可接受的赋形剂包括但不限于液体,诸如水、盐水、甘油和乙醇。其中可以包括药学上可接受的盐,例如无机酸盐,诸如盐酸盐、氢溴酸盐、磷酸盐、硫酸盐等;以及有机酸的盐,诸如乙酸盐、丙酸盐、丙二酸盐、苯甲酸盐等。另外,辅助物质,诸如pH缓冲物质可以存在于此类媒介物中。多种药学上可接受的赋形剂是本领域已知的,本文无需详细讨论。药学上可接受的赋形剂已经在各种出版物中有充分描述,包括,例如,A.Gennaro(2000)Remington:TheScience and PracticeofPharmacy,第20版,Lippincott,Williams,&Wilkins;Pharmaceutical Dosage Forms andDrug Delivery Systems(1999)H.C.Ansel等人编辑,第7版,Lippincott,Williams,&Wilkins;和Handbook of Pharmaceutical Excipients(2000)A.H.Kibbe等人编辑,第3版Amer.Pharmaceutical Assoc。
为了制备该组合物,根据需要或期望,生成并纯化rAAV病毒体。rAAV可以与药学上可接受的载剂混合或悬浮在其中。可以将这些rAAV调节到适当浓度,并且任选地与其他药剂组合。单位剂量中包含的rAAV病毒体和/或其他药剂的浓度可以广泛变化。本领域技术人员可以优化施用的剂量和次数。例如,可以施用约102-1010个载体基因组(vg)。在一些实施方案中,剂量为至少约102vg、约103vg、约104vg、约105vg、约106vg、约107vg、约108vg、约109vg、约1010vg或更多个载体基因组。化合物的日剂量也可以变化。此类日剂量的范围可以是,例如,至少约102vg/天、约103vg/天、约104vg/天至约105vg/天、约106vg/天、约107vg/天、约108vg/天、约109vg/天、约1010vg/天,或每天更多个载体基因组。
在某些实施方案中,通过施用一种或多种抗炎剂,例如抗炎类固醇或非类固醇抗炎药(NSAID)来增强治疗方法。
用于本发明的抗炎类固醇包括皮质类固醇,且尤其是具有糖皮质激素活性的那些,例如地塞米松和泼尼松。用于本发明的非类固醇抗炎药(NSAID)通常通过阻断引起炎症和疼痛的前列腺素、环加氧酶-1(COX-1)和/或环加氧酶-2(COX-2)的产生而起作用。传统的NSAID通过阻断COX-1和COX-2两者而起作用。COX-2选择性抑制剂仅阻断COX-2酶。在某些实施方案中,NSAID是COX-2选择性抑制剂,例如塞来昔布罗非昔布(Vioxx)和伐地昔布(B extra)。在某些实施方案中,抗炎剂是NSAID前列腺素抑制剂,例如吡罗昔康(Piroxicam)。
用于治疗的rAAV病毒体的量不仅随所选择的特定载剂而变化,而且随施用途径、所治疗病状的性质以及患者的年龄和状况而变化。最终,医护人员可以决定合适的剂量。可以将药物组合物与适当比率的每种化合物配制成单一单位剂型,在有或没有细胞的情况下施用。细胞或载体可以单独提供,并且与化合物组合物的液体溶液混合,或者单独施用。
重组AAV可以配制用于肠胃外施用(例如,通过注射,例如快速浓注或连续输注),并且可以在安瓿、预装注射器、小体积输注容器或添加有防腐剂的多剂量容器中以单位剂量形式呈现。药物组合物可以采取在油性或水性媒介物中的悬浮液、溶液或乳液的形式,并且可以含有配方试剂,诸如悬浮剂、稳定剂和/或分散剂。合适的载剂包括盐水溶液、磷酸盐缓冲盐水和本领域常用的其他材料。
组合物还可以含有其他成分,诸如可用于治疗心脏疾病、病状和损伤的药剂,例如抗凝血剂(例如,达肝素(法安明(fragmin))、达那肝素(orgaran)、依诺肝素(lovenox)、肝素、亭扎肝素(innohep)和/或华法林(香豆素))、抗血小板剂(例如,阿司匹林(aspirin)、噻氯匹啶(ticlopidine)、氯吡格雷(clopidogrel)或潘生丁(dipyridamole))、血管紧张素转化酶抑制剂(例如,贝那普利(Lotensin)、卡托普利(Capoten)、依那普利(Vasotec)、福辛普利(Monopril)、赖诺普利(Prinivil,Zestril)、莫西普利(Univasc)、培哚普利(Aceon)、喹那普利(Accupril)、雷米普利(Altace)和/或群多普利(Mavik))、血管紧张素受体阻滞剂(例如,坎地沙坦(Atacand)、依普沙坦(Teveten)、厄贝沙坦(Avapro)、洛沙坦(Cozaar)、替米沙坦(Micardis)和/或缬沙坦(Diovan))、β阻滞剂(例如,醋丁洛尔(Sectral)、阿替洛尔(Tenormin)、倍他洛尔(Kerlone)、比索洛尔/双氢氯噻嗪(Ziac)、比索洛尔(Zebeta)、卡替洛尔(Cartrol)、美托洛尔(Lopressor,Toprol XL)、纳多洛尔(Corgard)、普萘洛尔(Inderal)、索他洛尔(Betapace)和/或噻吗洛尔(Blocadren))、钙通道阻滞剂(例如,氨氯地平(Norvasc,Lotrel)、苄普地尔(Vascor)、地尔硫卓(Cardizem,Tiazac)、非洛地平(Plendil)、硝苯地平(Adalat,Procardia)、尼莫地平(Nimotop)、尼索地平(Sular)、维拉帕米(Calan,Isoptin,Verelan)、利尿剂(例如,阿米洛利(Midamor)、布美他尼(Bumex)、氯噻嗪(Diuril)、氯噻酮(Hygroton)、速尿灵(Lasix)、氢氯噻嗪(Esidrix,Hydrodiuril)、吲达帕胺(Lozol)和/或螺内酯(Aldactone))、血管舒张药(例如,硝酸异山梨酯(Isordil)、奈西立肽(Natrecor)、肼苯哒嗪(Apresoline)、硝酸盐和/或米诺地尔)、他汀类、烟酸、吉非罗齐(gemfibrozil)、氯贝丁酯(clofibrate)、地高辛(Digoxin)、洋地黄毒苷(Digitoxin)、拉诺辛(Lanoxin)或它们的任何组合。
还可以包括其他药剂,诸如抗菌剂、抗微生物剂、抗病毒剂、生物反应调节剂、生长因子;免疫调节剂、单克隆抗体和/或防腐剂。本发明的组合物也可以连同其他形式的疗法一起使用。
本文所述的rAAV病毒体可施用于受试者以治疗疾病或病症。此类组合物可以以单剂量、多剂量、连续或间歇的方式,这取决于例如受者的生理状况,施用的目的是为了应对创伤性损伤还是为了更持久的治疗目的,以及熟练从业者已知的其他因素。本发明的化合物和组合物的施用可以在预选时间段内基本上是连续的,或者可以是一系列间隔剂量的形式。考虑局部和全身施用。在一些实施方案中,实现了rAAV病毒体的局部化递送。在一些实施方案中,rAAV病毒体的局部化递送用于在心脏内生成细胞群。在一些实施方案中,此类局部化群体作为心脏的“起搏细胞”起作用。在一些实施方案中,rAAV病毒体用于生成、再生、修复、置换和/或恢复窦房(SA)结、房室(AV)结、希斯氏束和/或浦肯野纤维中的一种或多种。
为了控制张力,水性药物组合物可以包含生理盐,诸如钠盐。优选氯化钠(NaCl),其可以以1mg/ml至20mg/ml存在。可能存在的其他盐包括氯化钾、磷酸二氢钾、脱水磷酸二钠、氯化镁和氯化钙。
组合物可以包括一种或多种缓冲液。典型的缓冲液包括:磷酸盐缓冲液;Tris缓冲液;硼酸盐缓冲液;琥珀酸盐缓冲液;组氨酸缓冲液;或柠檬酸盐缓冲液。通常将包括浓度在5-20mM范围的缓冲液。组合物的pH通常将介于5至8之间,更典型地介于6至8之间,例如介于6.5至7.5之间,或者介于7.0至7.8之间。
该组合物优选是无菌的。该组合物优选无谷蛋白。该组合物优选是无热原的。
在一些实施方案中,包含细胞的组合物可以包括防冻剂。防冻剂的非限制性实例包括乙二醇(例如,乙二醇、丙二醇和甘油)、二甲基亚砜(DMSO)、甲酰胺、蔗糖、海藻糖、葡萄糖及它们的任何组合。
以下类型的化合物中的一种或多种也可以存在于具有rAAV病毒体的组合物中:WNT激动剂、GSK3抑制剂、TGF-β信号传导抑制剂、表观遗传修饰剂、LSD1抑制剂、腺苷酸环化酶激动剂或它们的任何组合。
试剂盒
本文描述了多种试剂盒,这些试剂盒包括本文描述的任何组合物(例如rAAV病毒体)。该试剂盒可包括本文所述的任何组合物,这些组合物混合在一起或单独包装,并且为干燥形式或水合形式。本文所述的rAAV病毒体和/或其他药剂可以单独包装到离散的小瓶、瓶子或其他容器中。可替代地,本文所述的rAAV病毒体和/或药剂中的任一种可以包装在一起作为单一组合物,或者作为两种或多种可以一起使用或单独使用的组合物。本文所述的化合物和/或药剂可以以适当的比率和/或量包装,以促进所选细胞跨越分化边界转化,以形成心脏祖细胞和/或心肌细胞。
该试剂盒可包括施用那些组合物、化合物和/或药剂的说明书。此类说明书可以提供本申请全篇描述的信息。rAAV病毒体或药物组合物可以以递送装置的形式提供在任何试剂盒内。可替代地,递送装置可以单独包括在试剂盒中,并且说明书可以描述在向受试者施用之前如何组装递送装置。
任何试剂盒还可以包括注射器、导管、解剖刀、用于样品或细胞收集的无菌容器、稀释剂、药学上可接受的载剂等。试剂盒可提供其他因子,诸如本文在前一部分或本申请其他部分中针对组合物描述的任何辅助因子或药物。
以下非限制性实施例说明了开发本发明所涉及的一些实验工作。
实施例
实施例1:可变区修饰的AAV9衣壳的鉴定
文库生成和AAV选择
在图1中示出了AAV9衣壳上的可变区(VR-IV、VR-V、VR-VII和VR-VIII位点)。如图2所示,采用文库筛选策略,通过随机改变AAV9衣壳每个位点内的残基来产生高度多样化的文库,以鉴定对心脏组织具有改善的转导效率和/或选择性的AAV变体。简言之,为每个可变区生成单独的文库,以及由所有VR修饰的文库的组合组成的文库。这些文库独立地经受三轮定向进化。第一轮进化在hiPSC-CMs中进行,以便选择人类嗜性变体。剩下的两轮定向进化通过在αMHC-Cre小鼠中全身递送文库来进行,以便选择在全身递送后可以穿过心脏内皮屏障并转导心肌细胞的亲心性变体。在三轮定向进化后,每个文库表现出不同水平的收敛,如图3A-3D和图4A-4D所示。
确认体外和体内转导效率增加
首先评估来自每个文库的前几种变体在体外转导人iPSC-CM的能力。以100,000的MOI用包装泛表达GFP报告基因的每种变体感染细胞。与AAV9相比,VR-IV修饰的AAV衣壳表现出显著增强的hiPSC-CM转导,CR9-01展示出转导效率增加129倍(图5)。随后,在体内评估变体在全身递送后转导心脏的能力。为此,给C57BL/6J小鼠注射2.5E+11vg/只小鼠的AAV9:CAG-GFP或由新型衣壳变体包封的CAG-GFP。注射后七天,处死动物,回收心脏和肝脏,通过ELISA进行GFP表达分析。与AAV9相比,来自每个文库的变体展示出增加的心脏转导(图6A-图6B)。大多数心脏转导增加的变体也表现出降低的肝脏嗜性(图6C-6D),导致鉴定出具有提高的心脏特异性的衣壳。最后,评估了表现最好的AAV衣壳变体逃避人NAbs的能力。在以100,000的MOI处理HEK293T细胞之前,包装CAG-GFP的变体与递增浓度的汇集人IgG一起孵育30分钟。感染后四十八小时,通过流式细胞术评估GFP表达(图7A)。与未修饰的AAV9相比,两种变体CR9-07和CR9-13展示出改善的NAb逃避(图7B-图7C)。
实施例2:AAV5/9嵌合衣壳的鉴定
使用衣壳改组来鉴定具有提高的心肌细胞嗜性的AAV5/9嵌合蛋白变体。如图8所示,生成AAV5/9嵌合文库,以鉴定具有AAV5和AAV9的有利特性(降低的肝脏嗜性、低NAb易感性、转胞吞和/或心脏转导)的嵌合体。在一轮体内选择后,文库复杂性显著降低,产生少于100种在全身递送亲本文库后能够转导心脏的变体(图9)。大多数交叉事件发生在衣壳的VP1区内,大多数变体具有AAV9优势VP3区。hiPSC-CMs然后以75,000的MOI用AAV9:CAG-GFP或由嵌合AAV5/9衣壳包封的CAG-GFP感染。感染后七十二小时,收获细胞,并使用流式细胞术评价每种衣壳的转导效率(图10A)。与AAV9相比,ZC44在hiPSC-CM细胞中表现出转导效率提高。
评估AAV5/9嵌合衣壳逃避人NAbs的能力。这里,在以100,000的MOI处理HEK293T细胞之前,包装CAG-GFP的变体与1mg/mL的汇集人IgG一起孵育30分钟。感染后48小时,通过流式细胞术评估GFP表达。除了增加的转导效率之外,与AAV9相比,ZC44显示出对NAbs的易感性降低(图10B)。
在体内评估前几种嵌合变体在全身递送后转导心脏和肝脏的能力。给C57BL/6J小鼠注射2E+11vg/只小鼠的AAV9:CAG-GFP或由新型衣壳变体包封的CAG-GFP。注射后十四天,处死动物,回收心脏和肝脏,通过ELISA进行GFP表达分析。与AAV9相比,ZC47展示出增加的心脏转导;ZC40、ZC44和ZC49保留了在体内转导心脏组织的能力,与亲本AAV9相当(图11A)。Z40、Z41、Z46和Z47各自表现出肝脏脱靶,这由全身递送后肝脏转导的显著减少所证明(图11B)。
实施例3:组合衣壳的鉴定
可变区修饰的衣壳和嵌合衣壳内的修饰组合生成另外的组合衣壳变体。总共生成18种含有AAV5来源的VP1序列和经修饰的可变区的组合变体(图12)。产生中等规模的载体生产以评估AAV衣壳变体的可制造性(图13)。然后如下评价hiPSC-CMs中组合变体的转导效率:用AAV9:CAG-GFP或包装CAG-GFP的组合AAV衣壳以75,000的MOI感染细胞。感染后5天,收获细胞,并使用Cytation 5细胞成像阅读器评价每种衣壳的转导效率。TN44-07和TN47-07展示出优于AAV9的转导(>15倍)(图14)。
在体内评估组合变体在全身递送后转导心脏的能力。给C57BL/6J小鼠注射1E+11vg/只小鼠的AAV9:CAG-GFP或包装相同转基因盒的组合衣壳变体。注射后十四天,处死动物,回收心脏和肝脏,通过ELISA进行GFP表达分析。TN44-07和TN47-10,与AAV9相比显示出心脏转导的改善;TN47-14以与AAV9相似的水平转导心脏(图15A)。值得注意的是,TN47-14失去了对肝脏的几乎所有嗜性,这由肝脏中GFP表达的高度显著降低所证明(图15B)。与AAV9相比,TN47-10和TN47-14在全身递送后都具有改善的心脏与肝脏转导比率(图15C)。还评价了选择的组合衣壳变体的人NAb逃避。在不存在或存在(600ug/mL)来自~2500名患者的汇集人IgG的情况下,将AAV9或包装CAG-GFP的衣壳变体在37℃下孵育30分钟。孵育后,将病毒与HEK293T细胞以100,000的MOI孵育。第二天,补充培养基并且将细胞再孵育24小时以允许GFP充分表达。通过流式细胞术对GFP表达进行定量并将转导相对于无IgG对照归一化。所有这些组合AAV衣壳变体(TN44-07、TN47-07、TN47-10、TN47-13和TN47-14)在汇集的人IgG中都展示出对中和抗体的逃避改善。其中,含有TN44-07组合衣壳的病毒体是最隐蔽的,与AAV9相比具有非常显著的NAb中和减少(p=0.0002,t-检验,Welch校正)(图16)。
实施例4:在非人灵长类动物中进行测试
在雄性食蟹猴(Macaca fascicularis)中在以1x1012 vg/kg的剂量静脉递送包装CAG-GFP的每种衣壳后,评估由一组工程化衣壳介导的重组AAV的转导(n=3/组)。给药后三十天,对动物实施安乐死并收获器官用于特异性转导的分析。
为了以高通量方式评价新型工程化衣壳变体的器官特异性转导图谱,采用了使用RNA条形码测序的方法。为每种衣壳(两种亲本和12种新型变体)赋予独特的条形码,该条形码置于泛表达GFP的盒(CAG-GFP)的3’-UTR。通过实验确定每个选择的条形码对蛋白质表达/RNA稳定性没有影响。为每种衣壳单独制造rAAV,以便将条形码连接到衣壳上,并且将所有rAAV制剂以相同浓度汇集在一起。雄性食蟹猴(2-5岁)以1x1013vg/kg的汇集病毒文库给药(n=3)或用HBSS进行虚假处理(n=1)。注射日期后三十天,处死动物,并收集组织用于RNA分析。使用Illumina NextSeq550和自定义python脚本,通过GFP条形码转录物的下一代测序来确定每个条形码的相对丰度。每个组织的条形码的相对表达相对于AAV9进行归一化。结果示于图17中。
评估含有工程化衣壳的rAAV在动物的左心室和肝脏中的转导。与AAV9相比,TN3和TN6工程化衣壳在左心室中显示出最高的转导(图17A)。虽然TN6工程化衣壳显示出与AAV9同等的肝脏转导,但TN3相对于AAV9在肝脏中显示出显著更少的转导(图17B)。在图17C中示出了每种工程化衣壳的左心室(LV)与肝脏的转导比率。TN3工程化衣壳显示出最有利的转导图谱。它具有高LV转导,同时在肝脏中保持低转导。由于在肝脏中的脱靶转导引起的rAAV诱导的毒性在临床应用中可能是挑战,TN3工程化衣壳显示出的转导图谱可以克服这一限制。通过分析由该组工程化衣壳在一系列组织中介导的rAAV转导,生成了较广泛的转导图谱(图17D)。
<110> 特纳亚治疗股份有限公司(Tenaya Therapeutics Inc.)
<120> 具有工程化衣壳的腺相关病毒
<130> TENA-019/01WO 334682-2113
<150> US 63/012,703
<151> 2020-04-20
<160> 485
<170> PatentIn版本3.5
<210> 1
<211> 736
<212> PRT
<213> 依赖性细小病毒属腺相关病毒血清型9
<400> 1
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 2
<211> 9
<212> PRT
<213> 依赖性细小病毒属腺相关病毒血清型9
<400> 2
Asn Gly Ser Gly Gln Asn Gln Gln Thr
1 5
<210> 3
<211> 6
<212> PRT
<213> 依赖性细小病毒属腺相关病毒血清型9
<400> 3
Asn Asn Ser Glu Phe Ala
1 5
<210> 4
<211> 5
<212> PRT
<213> 依赖性细小病毒属腺相关病毒血清型9
<400> 4
Gly Arg Asp Asn Val
1 5
<210> 5
<211> 4
<212> PRT
<213> 依赖性细小病毒属腺相关病毒血清型9
<400> 5
Ser Ala Gln Ala
1
<210> 6
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 6
Gly Tyr His Lys Ser Gly Ala Ala Gln
1 5
<210> 7
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 7
Val Ile Ile Lys Ser Gly Ala Ala Gln
1 5
<210> 8
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 8
Gly Tyr His Lys Ile Gly Ala Ala Gln
1 5
<210> 9
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 9
Gly Tyr His Lys Ser Gly Val Ala Gln
1 5
<210> 10
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 10
Val Tyr His Lys Ser Gly Ala Ala Gln
1 5
<210> 11
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 11
Gly Tyr His Lys Ile Ser Ala Ala Gln
1 5
<210> 12
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 12
Thr Thr Val Pro Ser Ser Ser Arg Tyr
1 5
<210> 13
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 13
Val Ile Ile Arg Val Val Arg Leu Ser
1 5
<210> 14
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 14
Thr Val Leu Gly Gln Asn Gln Gln Thr
1 5
<210> 15
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 15
Ile Tyr His Lys Ser Gly Ala Ala Gln
1 5
<210> 16
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 16
Thr Val Leu Asp Lys Asn Gln Gln Thr
1 5
<210> 17
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 17
Tyr Ser Gly Thr Asp Val Arg Tyr Lys
1 5
<210> 18
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 18
Val Thr Ala Ser Gly Lys Glu His Arg
1 5
<210> 19
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 19
Gly Tyr Arg Lys Ser Gly Ala Ala Gln
1 5
<210> 20
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 20
Asn Arg Thr Val Ser Asn Gly Ser Glu
1 5
<210> 21
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 21
Thr Val Leu Asp Arg Ile Asn Lys Thr
1 5
<210> 22
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 22
Thr Gly Val Gly His Leu Thr Ser Ala
1 5
<210> 23
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 23
Gly Tyr His Lys Gly Gly Ala Ala Gln
1 5
<210> 24
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 24
Val Ile Ala Lys Ser Gly Ala Ala Gln
1 5
<210> 25
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 25
Gly Tyr His Lys Ser Gly Ala Ala His
1 5
<210> 26
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 26
Phe Ile Ile Lys Ser Gly Ala Ala Gln
1 5
<210> 27
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 27
Gly Tyr His Lys Val Val Arg Leu Ser
1 5
<210> 28
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 28
Gly Ala Thr Arg Ser Ala Val Glu Ser
1 5
<210> 29
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 29
Thr Val Ser Gly Gln Asn Gln Gln Thr
1 5
<210> 30
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 30
Leu Ser His Lys Ser Gly Ala Ala Gln
1 5
<210> 31
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 31
Ser Ser Ser Gly Gln Asn Gln Gln Thr
1 5
<210> 32
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 32
Ser Gly Ser Gly Gln Asn Gln Gln Thr
1 5
<210> 33
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 33
Ser Gln Val Asn Gly Arg Pro Arg Asp
1 5
<210> 34
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 34
Gly Tyr His Lys Glu Trp Cys Gly Ser
1 5
<210> 35
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 35
Val Val Ser Ser Lys Ser Leu Asn Ser
1 5
<210> 36
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 36
Gly Tyr His Lys Ser Gly Ala Ala Pro
1 5
<210> 37
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 37
Asp Ala Ser Ser Arg Glu Lys Val Arg
1 5
<210> 38
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 38
Ser Tyr His Lys Ser Gly Ala Ala Gln
1 5
<210> 39
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 39
Thr Ala Asn Gly Ser Gln Lys Tyr Leu
1 5
<210> 40
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 40
Val Ile Ile Arg Val Gly Ala Ala Gln
1 5
<210> 41
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 41
Ser Ser Thr Asn Lys Ile Ser Thr Ala
1 5
<210> 42
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 42
Thr Val Leu Asp Arg Ile Gln Gln Thr
1 5
<210> 43
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 43
Gly Tyr His Lys Ser Gly Ala Val Gln
1 5
<210> 44
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 44
Thr Val Leu Asp Gln Asn Gln Gln Thr
1 5
<210> 45
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 45
Val Asn Met Ser Ser Pro Ile Lys Thr
1 5
<210> 46
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 46
Ala Ala Tyr Asn Ser Asn Ser Ala Phe
1 5
<210> 47
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 47
Gly Tyr His Lys Ser Gly Ala Ala Arg
1 5
<210> 48
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 48
Val Ile Ile Arg Val Val Arg Leu Gln
1 5
<210> 49
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 49
Arg Phe Trp Thr Gln Asn Gln Gln Thr
1 5
<210> 50
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 50
Ser Ser Pro Arg Ala Ser Ser Ala Leu
1 5
<210> 51
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 51
Ile Ile Ile Arg Val Val Arg Leu Ser
1 5
<210> 52
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 52
Lys Ser Ser Asn Leu Thr Ala Met Pro
1 5
<210> 53
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 53
Asn Leu Asn Ser Asp Arg His Ser Ala
1 5
<210> 54
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 54
Leu Ser Leu Lys Ser Gly Ala Ala Gln
1 5
<210> 55
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 55
Thr Val Leu Asp Arg Asn Gln Gln Thr
1 5
<210> 56
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 56
Gly Ser Glu Arg Val Ser Asn Ser Gly
1 5
<210> 57
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 57
Val Ile Ala Lys Ile Gly Ala Ala Gln
1 5
<210> 58
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 58
Val Tyr His Lys Ile Gly Ala Ala Gln
1 5
<210> 59
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 59
Leu Ser Tyr Lys Ser Gly Ala Ala Gln
1 5
<210> 60
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 60
Ser Thr Val Ser Gln Pro Val Arg Thr
1 5
<210> 61
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 61
Gly His His Lys Ser Gly Ala Ala Gln
1 5
<210> 62
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 62
Tyr Ala Gly Ile Asp Pro Arg Tyr His
1 5
<210> 63
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 63
Asp Arg Ser Arg Lys Ser Met Cys Asp
1 5
<210> 64
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 64
Val Ile Ile Arg Ser Gly Ala Ala Gln
1 5
<210> 65
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 65
Gly Tyr His Lys Ser Gly Gly Ser Ala
1 5
<210> 66
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 66
Val Ile Ile Lys Ile Gly Ala Ala Gln
1 5
<210> 67
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 67
Gly Tyr His Lys Val Val Gln Leu Ser
1 5
<210> 68
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 68
Val Ile Ile Lys Leu Val Ala Ala Gln
1 5
<210> 69
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 69
Lys Val Ser Ser His Ser Val Cys Asp
1 5
<210> 70
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 70
Gly Tyr His Lys Arg Val Arg Leu Ser
1 5
<210> 71
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 71
Gly Tyr His Lys Ser Ser Ala Ala Gln
1 5
<210> 72
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 72
Gly Tyr Arg Lys Ile Gly Ala Ala Gln
1 5
<210> 73
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 73
Gly Tyr His Lys Ser Gly Ala Ala Cys
1 5
<210> 74
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 74
Gly Tyr Arg Gln Ser Gly Ala Ala Gln
1 5
<210> 75
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 75
Val Ile Ile Lys Leu Ile Ala Ala Gln
1 5
<210> 76
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 76
Val Ile Ile Arg Val Val Arg Ala Gln
1 5
<210> 77
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 77
Gly Tyr His Lys Ser Gly Ala Ala Trp
1 5
<210> 78
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 78
Gly Tyr His Lys Ser Gly Ala Val Ser
1 5
<210> 79
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 79
Gly Tyr His Lys Glu Trp Cys Ser Ser
1 5
<210> 80
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 80
Ser Ser Ser Ser Asn Arg Leu Ala Asp
1 5
<210> 81
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 81
Ser Asn Asn Ser Ser Ser Ala Lys Phe
1 5
<210> 82
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 82
Val Lys Leu Ser Ser Thr Ser Ser Ser
1 5
<210> 83
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 83
Gly Tyr His Lys Glu Trp Cys Ala Gln
1 5
<210> 84
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 84
Ala Gly Ser Gly Gln Asn Gln Gln Thr
1 5
<210> 85
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 85
Asn Pro His Gly Thr Ala Thr Tyr Leu
1 5
<210> 86
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 86
Asn Gly Ser Gly Gln Asn Gln His Thr
1 5
<210> 87
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 87
Gly Tyr His Lys Val Gly Ala Ala Gln
1 5
<210> 88
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 88
Val Ile Ile Arg Val Val Arg Leu Lys
1 5
<210> 89
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 89
Asn Ser Ile Pro Ser Thr Ser Lys Trp
1 5
<210> 90
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 90
Val Ile Ile Arg Val Val Gln Leu Gln
1 5
<210> 91
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 91
Ser Gln Val Asn Gly Arg Pro Gln Asp
1 5
<210> 92
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 92
Asn Gly Ser Gly Gln Asp Gln Gln Thr
1 5
<210> 93
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 93
Gly Leu Asn Ser Ser Asp Arg Arg Leu
1 5
<210> 94
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 94
Ile Tyr His Lys Ile Gly Ala Ala Gln
1 5
<210> 95
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 95
Tyr His Lys Ser Gly Ala Ala Gln Leu
1 5
<210> 96
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 96
Tyr Ser Gly Thr Asp Val Gln Tyr Lys
1 5
<210> 97
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 97
Leu Gly Ser Gly Gln Asn Gln Gln Thr
1 5
<210> 98
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 98
Pro Val Ser Ser Gly Ala Asp Arg Arg
1 5
<210> 99
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 99
Glu His Ser Thr Lys Leu Asn Ala Cys
1 5
<210> 100
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 100
Asn Gly Ser Asp Arg Ile Asn Lys Arg
1 5
<210> 101
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 101
Val Ile Ile Lys Gly Gly Ala Ala Gln
1 5
<210> 102
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 102
Gly Tyr His Arg Val Val Arg Leu Ser
1 5
<210> 103
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 103
Val Ile Ile Arg Val Val Arg Leu Leu
1 5
<210> 104
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 104
Val Ile Leu Lys Ser Gly Ala Ala Gln
1 5
<210> 105
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 105
Leu Asn Ser Met Leu Ile
1 5
<210> 106
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 106
Asn Gly Met Ser Phe Thr
1 5
<210> 107
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 107
His Lys Thr Phe Ser Ile
1 5
<210> 108
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 108
Ser Met Ser Asn Phe Val
1 5
<210> 109
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 109
Ala Thr Ile Pro Pro Ile
1 5
<210> 110
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 110
Ser Ser Thr His Phe Asp
1 5
<210> 111
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 111
Asn Asn Gln Phe Ser Tyr
1 5
<210> 112
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 112
Asn Met Gly His Tyr Ser
1 5
<210> 113
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 113
Ser Lys Gln Met Phe Gln
1 5
<210> 114
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 114
Trp Pro Ser Ala Gly Val
1 5
<210> 115
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 115
Asn Gly Gly Tyr Gln Cys
1 5
<210> 116
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 116
Ser Thr Ser Pro Ile Val
1 5
<210> 117
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 117
Ser Gln Ser Gly Leu Trp
1 5
<210> 118
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 118
Val Asn Ser Gln Phe Ser
1 5
<210> 119
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 119
Ser Gly Ile Glu Phe Arg
1 5
<210> 120
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 120
Ser Ala Ser Lys Phe Thr
1 5
<210> 121
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 121
Gln Leu Asn Trp Thr Ser
1 5
<210> 122
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 122
Ser Met Gly Phe Pro Val
1 5
<210> 123
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 123
Ser Ser Phe Met Gly Leu
1 5
<210> 124
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 124
Gly Ser Asn Phe His Val
1 5
<210> 125
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 125
Asp Met Thr Leu Tyr Ala
1 5
<210> 126
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 126
Met Gly Cys Leu Phe Thr
1 5
<210> 127
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 127
Ala Leu Ala Phe Asn Ser
1 5
<210> 128
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 128
Ser Lys Phe Leu Phe Ala
1 5
<210> 129
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 129
Gln Asp Ala Gly Leu Leu
1 5
<210> 130
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 130
Gln Asp Ala Ser Leu Leu
1 5
<210> 131
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 131
Arg Asp Asp Met Phe Ser
1 5
<210> 132
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 132
Leu Ser Arg Cys Phe Gln
1 5
<210> 133
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 133
Leu Ser Arg Asp Phe Gln
1 5
<210> 134
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 134
Gln Gly Leu Thr Pro Val
1 5
<210> 135
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 135
Gln Trp Asp Val Phe Thr
1 5
<210> 136
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 136
Pro Arg Val Ser Phe Ala
1 5
<210> 137
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 137
Gln Ser Tyr Tyr Asn Pro
1 5
<210> 138
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 138
Arg Ala Ser His Leu Gly
1 5
<210> 139
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 139
Ile Ile Leu Phe Val Pro
1 5
<210> 140
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 140
Ile Ile Ser Phe Ser Tyr
1 5
<210> 141
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 141
Leu Asp Ser Met Leu Ile
1 5
<210> 142
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 142
Asn Ile Gly His Tyr Ser
1 5
<210> 143
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 143
Asn Arg Met Ser Phe Thr
1 5
<210> 144
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 144
Asn Gly Met Ser Phe Ala
1 5
<210> 145
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 145
Ile Ile Leu Leu Leu Pro
1 5
<210> 146
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 146
Arg Met Arg Ser Leu Leu
1 5
<210> 147
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 147
Arg Arg Arg Cys Arg Phe
1 5
<210> 148
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 148
Pro Lys Gln Met Phe Gln
1 5
<210> 149
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 149
Leu Met Ser Asn Phe Val
1 5
<210> 150
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 150
Gly Ala Ser His Leu Gly
1 5
<210> 151
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 151
Cys Ala Ser Ile Ser Trp
1 5
<210> 152
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 152
Ser Met Thr Thr Phe Arg
1 5
<210> 153
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 153
Ala Ala Ile Pro Pro Ile
1 5
<210> 154
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 154
Pro Gly Cys Glu Ser Leu
1 5
<210> 155
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 155
Ser Met Gly Phe Ala Cys
1 5
<210> 156
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 156
Phe Leu Pro Ser Leu Met
1 5
<210> 157
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 157
Asn Gly Ile Ser Phe Thr
1 5
<210> 158
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 158
Glu Ser Ser Arg Trp Ala
1 5
<210> 159
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 159
Gln Leu Tyr Phe Val Pro
1 5
<210> 160
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 160
Ser Ser Asn Phe His Val
1 5
<210> 161
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 161
Leu Glu Phe Met Leu Ile
1 5
<210> 162
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 162
Gln Phe Asp Ser Phe Asp
1 5
<210> 163
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 163
Ser Pro Val Phe Ala Cys
1 5
<210> 164
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 164
Val Arg Leu Ile Phe Asp
1 5
<210> 165
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 165
Asn Gly Met Ser Phe Ile
1 5
<210> 166
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 166
Leu Leu Phe Pro Pro Ile
1 5
<210> 167
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 167
Gly Ala Gly Val Thr Gly
1 5
<210> 168
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 168
Gln Trp Met Ser Phe Thr
1 5
<210> 169
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 169
Ser Ile Gly Phe Pro Val
1 5
<210> 170
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 170
Arg Met Gln Ser Leu Leu
1 5
<210> 171
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 171
Thr Ser Ala Leu Gln Val
1 5
<210> 172
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 172
Ser Leu Thr His Phe Asp
1 5
<210> 173
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 173
Gln Glu Leu Pro Phe Leu
1 5
<210> 174
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 174
Leu Tyr Phe Leu Leu Pro
1 5
<210> 175
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 175
Leu Ser Phe Phe Phe Ala
1 5
<210> 176
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 176
Leu Ser Arg Ile Phe Gln
1 5
<210> 177
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 177
Asp Glu Val Ile Leu Phe
1 5
<210> 178
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 178
Arg Ala Gly Val Ala Gly
1 5
<210> 179
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 179
Asn Gly Met Ser Leu Pro
1 5
<210> 180
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 180
Pro Phe Glu Asp Phe Gln
1 5
<210> 181
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 181
Gln Tyr Gly Ser Leu Phe
1 5
<210> 182
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 182
Asn Tyr Thr Phe Val Leu
1 5
<210> 183
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 183
Met Ser Gly Tyr Gln Cys
1 5
<210> 184
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 184
Asn Tyr Ala Phe Val Pro
1 5
<210> 185
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 185
Arg Ala Gly Val Thr Gly
1 5
<210> 186
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 186
Trp Asn Ser Met Leu Ile
1 5
<210> 187
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 187
Ile Arg Arg Phe Ser Ile
1 5
<210> 188
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 188
Asn Gly Met Ser Phe Tyr
1 5
<210> 189
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 189
Ile Ile Gln Phe Ser Tyr
1 5
<210> 190
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 190
Asn Gly Cys Leu Phe Thr
1 5
<210> 191
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 191
Arg Asp Ala Ser Leu Leu
1 5
<210> 192
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 192
Ala Asp Ser Met Leu Ile
1 5
<210> 193
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 193
Val Asp Ser Gln Phe Ser
1 5
<210> 194
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 194
Ser Ile Gly Asn Phe Val
1 5
<210> 195
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 195
Asn Gly Met Ser Leu Leu
1 5
<210> 196
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 196
Asn Tyr Thr Phe Val Pro
1 5
<210> 197
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 197
Ile Arg Arg Leu Val Phe
1 5
<210> 198
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 198
Pro Met Ser Asn Phe Val
1 5
<210> 199
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 199
Leu Trp Val Phe Pro Val
1 5
<210> 200
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 200
Val Arg Leu His Phe Asp
1 5
<210> 201
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 201
Ser Met Ser Asn Leu Phe
1 5
<210> 202
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 202
Ser Thr Ser Leu Ile Val
1 5
<210> 203
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 203
His Lys Thr Phe Gly Ile
1 5
<210> 204
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 204
Arg Gly Asn Gln Val
1 5
<210> 205
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 205
Val Ser Leu Asn Arg
1 5
<210> 206
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 206
Cys Asp Tyr Ser Val
1 5
<210> 207
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 207
Gln His Gly His Ile
1 5
<210> 208
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 208
Leu Cys Ser Leu Val
1 5
<210> 209
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 209
Pro Thr Ile Tyr Val
1 5
<210> 210
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 210
Asp Val Ile His Ile
1 5
<210> 211
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 211
Ala Glu Phe Tyr Ala
1 5
<210> 212
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 212
Asn Ser Val Val Cys
1 5
<210> 213
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 213
Val Arg Ser Asn Cys
1 5
<210> 214
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 214
Leu Ala Asn Asn Ile
1 5
<210> 215
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 215
Asn Leu Gln Phe Met
1 5
<210> 216
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 216
Glu Phe Arg Asp Leu
1 5
<210> 217
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 217
Asp Phe Gly Ser Leu
1 5
<210> 218
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 218
Val Thr Asn Tyr Cys
1 5
<210> 219
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 219
Trp Asn Thr Asn Ala
1 5
<210> 220
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 220
Thr Glu Ser Thr Cys
1 5
<210> 221
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 221
Ser Gly Ala Ala Val
1 5
<210> 222
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 222
Gly Gly Cys Asp Ile
1 5
<210> 223
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 223
Ser Gly Ser Val Val
1 5
<210> 224
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 224
Ser Ser Asn Ala Cys
1 5
<210> 225
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 225
Tyr Asn Thr Thr Val
1 5
<210> 226
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 226
Ser Lys Cys Leu Ala
1 5
<210> 227
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 227
Ser Ala Tyr Thr Val
1 5
<210> 228
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 228
Val Arg Asp Thr Val
1 5
<210> 229
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 229
Trp Arg Ser Met Val
1 5
<210> 230
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 230
Ala Tyr His Gly Val
1 5
<210> 231
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 231
Gly Met Asn Thr Ile
1 5
<210> 232
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 232
Ala Glu Thr Ser Leu
1 5
<210> 233
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 233
Thr Leu Val Tyr Val
1 5
<210> 234
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 234
Asn His Asp Trp Ile
1 5
<210> 235
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 235
Thr Val Gly Ile Val
1 5
<210> 236
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 236
Ser Leu Pro Thr Val
1 5
<210> 237
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 237
Thr Gly Ile Leu Cys
1 5
<210> 238
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 238
Thr Asp Thr Tyr Ile
1 5
<210> 239
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 239
Leu Pro Val Thr Tyr
1 5
<210> 240
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 240
Gly Asp Val Tyr Ile
1 5
<210> 241
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 241
Leu Tyr Gly Thr Val
1 5
<210> 242
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 242
Gly Cys Glu Phe Ile
1 5
<210> 243
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 243
Ser Ala Gly Leu Leu
1 5
<210> 244
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 244
Ile Lys Ser Asn Ile
1 5
<210> 245
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 245
Val Thr Thr Ser Leu
1 5
<210> 246
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 246
Ala Val Thr Ser Val
1 5
<210> 247
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 247
Arg Asp Ile His Ile
1 5
<210> 248
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 248
Ser Ala Ile Ser Leu
1 5
<210> 249
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 249
Val Ala Ser Thr Cys
1 5
<210> 250
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 250
Ile Lys Gly Leu Leu
1 5
<210> 251
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 251
Gly Ser Tyr His Thr
1 5
<210> 252
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 252
Arg Ile Gly Phe Val
1 5
<210> 253
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 253
Asn Asp Ile Tyr Ile
1 5
<210> 254
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 254
Ala Val Ser Cys Val
1 5
<210> 255
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 255
Gln His Asn Leu Leu
1 5
<210> 256
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 256
Val Ser Ser Cys Val
1 5
<210> 257
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 257
Leu Asn Leu Asp Val
1 5
<210> 258
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 258
Leu Gly Ala Thr Ile
1 5
<210> 259
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 259
Pro Val Leu Cys Val
1 5
<210> 260
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 260
Ser Ala Arg His Ile
1 5
<210> 261
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 261
Arg Ala Thr Leu Ile
1 5
<210> 262
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 262
Pro Tyr Asn His Ala
1 5
<210> 263
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 263
Ile Gly Asp Ser Ile
1 5
<210> 264
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 264
Ser Pro Met Leu Cys
1 5
<210> 265
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 265
Tyr Asp Ser Thr Leu
1 5
<210> 266
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 266
Ala Leu Lys His Val
1 5
<210> 267
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 267
Ala Asp Leu Leu Thr
1 5
<210> 268
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 268
Asn Asn Gly His Leu
1 5
<210> 269
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 269
Ile Asn Ser Glu Val
1 5
<210> 270
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 270
Ser Asn Lys Thr Thr
1 5
<210> 271
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 271
Gly Ser Thr Gly Leu
1 5
<210> 272
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 272
Asp Ser Asp Met Ile
1 5
<210> 273
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 273
Thr Ser Asn Phe Ile
1 5
<210> 274
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 274
Arg Asn Phe Thr Thr
1 5
<210> 275
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 275
Ser His Lys Tyr Ser
1 5
<210> 276
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 276
Val Ser Asp Ile Val
1 5
<210> 277
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 277
Arg Val Val Gln Ala
1 5
<210> 278
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 278
Ala Ala Cys Ala Val
1 5
<210> 279
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 279
Arg Gly Arg Gln Ile
1 5
<210> 280
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 280
Ala Val Ala Asn Ile
1 5
<210> 281
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 281
Ala Gly Tyr Asp Leu
1 5
<210> 282
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 282
Leu Ser Glu Ala Ala
1 5
<210> 283
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 283
Met Ser Asn Tyr Leu
1 5
<210> 284
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 284
Asn Phe Ser Asp Asn
1 5
<210> 285
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 285
Ser Cys Cys Asp Val
1 5
<210> 286
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 286
Leu Ala Ser Ser Val
1 5
<210> 287
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 287
Pro Asp His Ala Val
1 5
<210> 288
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 288
Lys Phe Asp Ile Ile
1 5
<210> 289
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 289
Asn Ser Ser Ser Ala
1 5
<210> 290
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 290
His Thr Met His Val
1 5
<210> 291
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 291
Thr Leu Ser Tyr Cys
1 5
<210> 292
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 292
Ala Asp Thr His Arg
1 5
<210> 293
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 293
Ser Met Tyr Ser Val
1 5
<210> 294
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 294
Ser Val Asn Leu Val
1 5
<210> 295
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 295
Met Ser Gly His Leu
1 5
<210> 296
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 296
Lys Ile Ser Asp Thr
1 5
<210> 297
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 297
Thr Gly Leu Leu Ala
1 5
<210> 298
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 298
Ala Trp Thr Thr Ser
1 5
<210> 299
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 299
Gly Gly Ala Leu Ile
1 5
<210> 300
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 300
Ser Cys Ile Glu Val
1 5
<210> 301
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 301
Pro Pro Val Ile Cys
1 5
<210> 302
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 302
Gly Thr Tyr Asn Leu
1 5
<210> 303
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 303
Asn Val Ser Tyr
1
<210> 304
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 304
Ser Met Val Asn
1
<210> 305
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 305
Ala Asn Tyr Gly
1
<210> 306
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 306
Asn Val Gly Thr
1
<210> 307
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 307
Ser Ala Tyr Met
1
<210> 308
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 308
Glu Lys Val Thr
1
<210> 309
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 309
Thr Thr Pro Gly
1
<210> 310
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 310
Gly Val Tyr Ser
1
<210> 311
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 311
Ser Tyr Val Gly
1
<210> 312
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 312
Leu Gln Tyr Asn
1
<210> 313
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 313
Asp Pro Ala Lys
1
<210> 314
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 314
Thr His Phe Ser
1
<210> 315
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 315
Ile Gly Gly Val
1
<210> 316
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 316
Ser Ser Trp Asn
1
<210> 317
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 317
Ser Val Tyr Val
1
<210> 318
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 318
Thr Leu Asn Gly
1
<210> 319
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 319
Asn Thr Ser Asn
1
<210> 320
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 320
Val Gln Tyr Ala
1
<210> 321
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 321
Asp Gln Tyr Arg
1
<210> 322
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 322
Met Pro Val Ser
1
<210> 323
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 323
Ser Ala Gln Ala
1
<210> 324
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 324
Met Thr Val Ala
1
<210> 325
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 325
Thr Val Met Gly
1
<210> 326
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 326
Phe Ser Ser Ile
1
<210> 327
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 327
Ser Leu Arg Leu
1
<210> 328
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 328
Ser Ala Met Gly
1
<210> 329
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 329
Tyr Ile Lys Leu
1
<210> 330
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 330
Leu Met Thr Met
1
<210> 331
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 331
Gln Val His Leu
1
<210> 332
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 332
Tyr Asn Ser Val
1
<210> 333
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 333
Cys Val Ile Ser
1
<210> 334
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 334
Arg Leu Asp Gly
1
<210> 335
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 335
Ala Ile Met Val
1
<210> 336
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 336
Gly Thr Thr Gly
1
<210> 337
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 337
Ala Ser Tyr Thr
1
<210> 338
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 338
Leu His Val Gly
1
<210> 339
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 339
Leu Gln Phe Ala
1
<210> 340
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 340
Val Arg Gly Asp
1
<210> 341
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 341
Asn Val Met Ile
1
<210> 342
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 342
Ser Leu Tyr Gly
1
<210> 343
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 343
Gly Thr Val Gly
1
<210> 344
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 344
Phe Asn Ser Val
1
<210> 345
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 345
Thr Arg Leu Gly
1
<210> 346
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 346
Leu Lys Val Leu
1
<210> 347
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 347
Ser Ile Arg Val
1
<210> 348
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 348
Lys Ile Gln Gly
1
<210> 349
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 349
Gln Ile Leu Gly
1
<210> 350
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 350
Gln Arg Asp Ala
1
<210> 351
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 351
Glu Ala Val Arg
1
<210> 352
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 352
Ala Ile Thr Val
1
<210> 353
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 353
Lys Glu Ser Ile
1
<210> 354
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 354
Leu Met Val Asn
1
<210> 355
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 355
Ile Asn Leu Ser
1
<210> 356
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 356
Gly Gln Val Ser
1
<210> 357
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 357
Thr Ser Leu Leu
1
<210> 358
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 358
Ser Ser Thr Leu
1
<210> 359
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 359
Tyr Glu Lys Phe
1
<210> 360
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 360
Asp Gly Lys Leu
1
<210> 361
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 361
Gln Val Tyr Ser
1
<210> 362
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 362
Gln Lys Glu Gly
1
<210> 363
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 363
Ala Arg Asp Met
1
<210> 364
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 364
Asp Asn Phe Arg
1
<210> 365
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 365
Ser His Gly Leu
1
<210> 366
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 366
Val Ser Val Asn
1
<210> 367
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 367
Gly Leu Lys Asp
1
<210> 368
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 368
Gln Pro Val Phe
1
<210> 369
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 369
Val Tyr Ser Met
1
<210> 370
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 370
Val Met Ala Gln
1
<210> 371
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 371
Phe Val Gly Met
1
<210> 372
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 372
Trp Ser Thr Pro
1
<210> 373
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 373
Ser Tyr Pro Val
1
<210> 374
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 374
Thr Thr Tyr Ser
1
<210> 375
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 375
Thr Val Thr Thr
1
<210> 376
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 376
Lys Asp Lys Thr
1
<210> 377
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 377
Tyr Arg Glu Leu
1
<210> 378
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 378
Leu Ser His Phe
1
<210> 379
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 379
Ser Pro Gly Thr
1
<210> 380
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 380
Leu Met Gly Thr
1
<210> 381
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 381
Ala Ala Ser Leu
1
<210> 382
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 382
Phe Ser Asn Asn
1
<210> 383
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 383
Gln Ala Arg Leu
1
<210> 384
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 384
Tyr His Ile Ala
1
<210> 385
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 385
Ala Arg Gln Asp
1
<210> 386
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 386
Val Ala Tyr Thr
1
<210> 387
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 387
Thr Pro Ser Tyr
1
<210> 388
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 388
Met Ile Leu His
1
<210> 389
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 389
Leu Gly Asn Val
1
<210> 390
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 390
Thr Ser Ile Ser
1
<210> 391
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 391
Thr Met Val Tyr
1
<210> 392
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 392
Leu Val Val Gly
1
<210> 393
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 393
Ser Pro Leu Tyr
1
<210> 394
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 394
Tyr Lys Ser Glu
1
<210> 395
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 395
Phe Thr Arg Leu
1
<210> 396
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 396
Val Ser Tyr Asn
1
<210> 397
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 397
Glu Arg Thr Pro
1
<210> 398
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 398
Phe Arg Ser Glu
1
<210> 399
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 399
Asn Tyr Thr Glu
1
<210> 400
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 400
Gln Thr Ile Asn
1
<210> 401
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 计算机生成的肽文库序列
<400> 401
Asp Val His Arg
1
<210> 402
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 402
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Ser Gln Val Asn Gly Arg Pro Arg Asp Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 403
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 403
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Gly Tyr His Lys Ser Gly Ala Ala Gln Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 404
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 404
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ala Asn Tyr Gly Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 405
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 405
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Gly Tyr His Lys Ser Gly Ala Ala Gln Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Asn Val Ser Tyr Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 406
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 406
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Leu Asn Ser Met Leu Ile Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 407
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 407
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Gly Tyr His Lys Ser Gly Ala Ala Gln Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ala Asn Tyr Gly Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 408
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 408
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Gly Tyr His Lys Ser Gly Ala Ala Gln Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Gln Asp Ala Ser Leu Leu Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 409
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 409
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Gly Tyr His Lys Ser Gly Ala Ala Gln Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Gly Met Ser Phe Thr Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 410
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 410
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Leu Asn Ser Met Leu Ile Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ala Asn Tyr Gly Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 411
<211> 50
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 411
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr
50
<210> 412
<211> 49
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 412
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr
<210> 413
<211> 34
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 413
Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro Val Asn
1 5 10 15
Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp Gln Gln
20 25 30
Leu Lys
<210> 414
<211> 34
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 414
Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val Asn
1 5 10 15
Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu Gln
20 25 30
Leu Glu
<210> 415
<211> 44
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 415
Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp Ala Glu Phe
1 5 10 15
Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly Asn Leu Gly Arg
20 25 30
Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
35 40
<210> 416
<211> 44
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 416
Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp Ala Glu Phe
1 5 10 15
Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn Leu Gly Lys
20 25 30
Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
35 40
<210> 417
<211> 84
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 417
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
1 5 10 15
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
20 25 30
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
35 40 45
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
50 55 60
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
65 70 75 80
Ala Pro Val Ala
<210> 418
<211> 75
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 418
Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg
1 5 10 15
Ile Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp
20 25 30
Ser Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser
35 40 45
Gln Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp
50 55 60
Thr Met Ser Ala Gly Gly Gly Gly Pro Leu Gly
65 70 75
<210> 419
<211> 524
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 419
Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser Gly Asn Trp
1 5 10 15
His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr
20 25 30
Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile
35 40 45
Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly
50 55 60
Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His
65 70 75 80
Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe
85 90 95
Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu
100 105 110
Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn Asn Leu Thr Ser
115 120 125
Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu
130 135 140
Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe
145 150 155 160
Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala
165 170 175
Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met
180 185 190
Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val
195 200 205
Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met
210 215 220
Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn
225 230 235 240
Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser Val Ala Gly Pro
245 250 255
Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr
260 265 270
Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn Asn Asn Ser Glu
275 280 285
Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser
290 295 300
Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys Glu Gly Glu Asp
305 310 315 320
Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr
325 330 335
Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile Thr Asn Glu Glu
340 345 350
Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser Tyr Gly Gln Val
355 360 365
Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln Thr Gly Trp Val
370 375 380
Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val
385 390 395 400
Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn
405 410 415
Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met Lys His Pro Pro
420 425 430
Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr
435 440 445
Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr
450 455 460
Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser
465 470 475 480
Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser
485 490 495
Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val Tyr Ser Glu Pro
500 505 510
Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
515 520
<210> 420
<211> 524
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 420
Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser Gly Asn Trp
1 5 10 15
His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr
20 25 30
Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile
35 40 45
Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly
50 55 60
Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His
65 70 75 80
Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe
85 90 95
Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu
100 105 110
Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn Asn Leu Thr Ser
115 120 125
Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu
130 135 140
Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe
145 150 155 160
Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala
165 170 175
Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met
180 185 190
Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val
195 200 205
Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met
210 215 220
Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn
225 230 235 240
Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser Val Ala Gly Pro
245 250 255
Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr
260 265 270
Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn Asn Asn Ser Glu
275 280 285
Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser
290 295 300
Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys Glu Gly Glu Asp
305 310 315 320
Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr
325 330 335
Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile Thr Asn Glu Glu
340 345 350
Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser Tyr Gly Gln Val
355 360 365
Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln Thr Gly Trp Val
370 375 380
Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val
385 390 395 400
Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn
405 410 415
Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met Lys His Pro Pro
420 425 430
Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr
435 440 445
Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr
450 455 460
Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Lys Lys Glu Asn Ser
465 470 475 480
Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser
485 490 495
Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val Tyr Ser Glu Pro
500 505 510
Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
515 520
<210> 421
<211> 726
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 421
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Phe
115 120 125
Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg Ile
130 135 140
Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp Ser
145 150 155 160
Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser Gln
165 170 175
Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp Thr
180 185 190
Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly Ala
195 200 205
Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Thr Trp
210 215 220
Met Gly Asp Arg Val Val Thr Lys Ser Thr Arg Thr Trp Ala Leu Pro
225 230 235 240
Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly
245 250 255
Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly
260 265 270
Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp
275 280 285
Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn
290 295 300
Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn Gly
305 310 315 320
Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Thr
325 330 335
Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu Gly
340 345 350
Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly
355 360 365
Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser Phe
370 375 380
Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn
385 390 395 400
Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser Tyr
405 410 415
Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln
420 425 430
Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln
435 440 445
Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val Gln
450 455 460
Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser
465 470 475 480
Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala
485 490 495
Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly Pro
500 505 510
Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser
515 520 525
Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val Asp
530 535 540
Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn
545 550 555 560
Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln Ser
565 570 575
Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile Leu
580 585 590
Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile
595 600 605
Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu
610 615 620
Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile Lys
625 630 635 640
Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys
645 650 655
Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu
660 665 670
Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu
675 680 685
Ile Gln Tyr Thr Asn Asn Tyr Asn Asp Pro Gln Phe Val Asp Phe Ala
690 695 700
Pro Asp Ser Thr Gly Glu Tyr Arg Thr Thr Arg Pro Ile Gly Thr Arg
705 710 715 720
Tyr Leu Thr Arg Pro Leu
725
<210> 422
<211> 725
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 422
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro
50 55 60
Val Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn
65 70 75 80
Glu Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125
Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg
130 135 140
Ile Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp
145 150 155 160
Ser Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser
165 170 175
Gln Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp
180 185 190
Thr Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly
195 200 205
Ala Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Thr
210 215 220
Trp Met Gly Asp Arg Val Val Thr Lys Ser Thr Arg Thr Trp Val Leu
225 230 235 240
Pro Ser Tyr Asn Asn His Gln Tyr Arg Glu Ile Lys Ser Gly Ser Val
245 250 255
Asp Gly Ser Asn Ala Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly
260 265 270
Tyr Phe Asp Phe Asn Arg Phe His Ser His Trp Ser Pro Arg Asp Trp
275 280 285
Gln Arg Leu Ile Asn Asn Tyr Trp Gly Phe Arg Pro Arg Ser Leu Arg
290 295 300
Val Lys Ile Phe Asn Ile Gln Val Lys Glu Val Thr Val Gln Asp Ser
305 310 315 320
Thr Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Thr
325 330 335
Asp Asp Asp Tyr Gln Leu Pro Tyr Val Val Gly Asn Gly Thr Glu Gly
340 345 350
Cys Leu Pro Ala Phe Pro Pro Gln Val Phe Thr Leu Pro Gln Tyr Gly
355 360 365
Tyr Ala Thr Leu Asn Arg Asp Asn Thr Glu Asn Pro Thr Glu Arg Ser
370 375 380
Ser Phe Phe Cys Leu Glu Tyr Phe Pro Ser Lys Met Leu Arg Thr Gly
385 390 395 400
Asn Asn Phe Glu Phe Thr Tyr Asn Phe Glu Glu Val Pro Phe His Ser
405 410 415
Ser Phe Ala Pro Ser Gln Asn Leu Phe Lys Leu Ala Asn Pro Leu Val
420 425 430
Asp Gln Tyr Leu Tyr Arg Phe Val Ser Thr Asn Asn Thr Gly Gly Val
435 440 445
Gln Phe Asn Lys Asn Leu Ala Gly Arg Tyr Ala Asn Thr Tyr Lys Asn
450 455 460
Trp Phe Pro Gly Pro Met Gly Arg Thr Gln Gly Trp Asn Leu Gly Ser
465 470 475 480
Gly Val Asn Arg Ala Ser Val Ser Ala Phe Ala Thr Thr Asn Arg Met
485 490 495
Glu Leu Glu Gly Ala Ser Tyr Gln Val Pro Pro Gln Pro Asn Gly Met
500 505 510
Thr Asn Asn Leu Gln Gly Ser Asn Thr Tyr Ala Leu Glu Asn Thr Met
515 520 525
Ile Phe Asn Ser Gln Pro Ala Asn Pro Gly Thr Thr Ala Thr Tyr Leu
530 535 540
Glu Gly Asn Met Leu Ile Thr Ser Glu Ser Glu Thr Gln Pro Val Asn
545 550 555 560
Arg Val Ala Tyr Asn Val Gly Gly Gln Met Ala Thr Asn Asn Gln Ser
565 570 575
Ser Thr Thr Ala Pro Ala Thr Gly Thr Tyr Asn Leu Gln Glu Ile Val
580 585 590
Pro Gly Ser Val Trp Met Glu Arg Asp Val Tyr Leu Gln Gly Pro Ile
595 600 605
Trp Ala Lys Ile Pro Glu Thr Gly Ala His Phe His Pro Ser Pro Ala
610 615 620
Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Met Met Leu Ile Lys
625 630 635 640
Asn Thr Pro Val Pro Gly Asn Ile Thr Ser Phe Ser Asp Val Pro Val
645 650 655
Ser Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Thr Val Glu Met
660 665 670
Glu Trp Glu Leu Lys Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile
675 680 685
Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val
690 695 700
Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr
705 710 715 720
Leu Thr Arg Asn Leu
725
<210> 423
<211> 725
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 423
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Phe
115 120 125
Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Thr Gly Lys Arg Ile
130 135 140
Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp Ser
145 150 155 160
Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser Gln
165 170 175
Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp Thr
180 185 190
Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly Ala
195 200 205
Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Thr Trp
210 215 220
Met Gly Asp Arg Val Val Thr Lys Ser Thr Arg Thr Trp Val Leu Pro
225 230 235 240
Ser Tyr Asn Asn His Gln Tyr Arg Glu Ile Lys Ser Gly Ser Val Asp
245 250 255
Gly Ser Asn Ala Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr
260 265 270
Phe Asp Phe Asn Arg Phe His Ser His Trp Ser Pro Arg Asp Trp Gln
275 280 285
Arg Leu Ile Asn Asn Tyr Trp Gly Phe Arg Pro Arg Ser Leu Arg Val
290 295 300
Lys Ile Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val
305 310 315 320
Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp
325 330 335
Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys
340 345 350
Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr
355 360 365
Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr
370 375 380
Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe
385 390 395 400
Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala
405 410 415
His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr
420 425 430
Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln
435 440 445
Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly
450 455 460
Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr
465 470 475 480
Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser
485 490 495
Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala
500 505 510
Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly
515 520 525
Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala
530 535 540
Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro
545 550 555 560
Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala
565 570 575
Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro
580 585 590
Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp
595 600 605
Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met
610 615 620
Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn
625 630 635 640
Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu
645 650 655
Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile
660 665 670
Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile
675 680 685
Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val
690 695 700
Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr
705 710 715 720
Leu Thr Arg Asn Leu
725
<210> 424
<211> 727
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 424
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125
Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg
130 135 140
Ile Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp
145 150 155 160
Ser Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser
165 170 175
Gln Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp
180 185 190
Thr Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly
195 200 205
Ala Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Thr
210 215 220
Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu
225 230 235 240
Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser
245 250 255
Gly Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp
260 265 270
Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp
275 280 285
Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu
290 295 300
Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn
305 310 315 320
Gly Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe
325 330 335
Thr Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu
340 345 350
Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr
355 360 365
Gly Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser
370 375 380
Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn
385 390 395 400
Asn Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser
405 410 415
Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp
420 425 430
Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn
435 440 445
Gln Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val
450 455 460
Gln Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val
465 470 475 480
Ser Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly
485 490 495
Ala Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly
500 505 510
Pro Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu
515 520 525
Ser Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val
530 535 540
Asp Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr
545 550 555 560
Asn Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln
565 570 575
Ser Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile
580 585 590
Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro
595 600 605
Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro
610 615 620
Leu Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile
625 630 635 640
Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp
645 650 655
Lys Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val
660 665 670
Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro
675 680 685
Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe
690 695 700
Ala Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr
705 710 715 720
Arg Tyr Leu Thr Arg Asn Leu
725
<210> 425
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 425
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Thr Val Glu Met Glu Trp Glu Leu Lys
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Asn Asn
690 695 700
Tyr Asn Asp Pro Gln Phe Val Asp Phe Ala Pro Asp Ser Thr Gly Glu
705 710 715 720
Tyr Arg Thr Thr Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu
725 730 735
<210> 426
<211> 726
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 426
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Phe
115 120 125
Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg Ile
130 135 140
Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp Ser
145 150 155 160
Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser Gln
165 170 175
Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp Thr
180 185 190
Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly Ala
195 200 205
Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Thr Trp
210 215 220
Met Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro
225 230 235 240
Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly
245 250 255
Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly
260 265 270
Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp
275 280 285
Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn
290 295 300
Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn Gly
305 310 315 320
Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Thr
325 330 335
Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu Gly
340 345 350
Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly
355 360 365
Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser Phe
370 375 380
Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn
385 390 395 400
Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser Phe
405 410 415
Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln
420 425 430
Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln
435 440 445
Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val Gln
450 455 460
Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser
465 470 475 480
Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala
485 490 495
Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly Pro
500 505 510
Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser
515 520 525
Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val Asp
530 535 540
Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn
545 550 555 560
Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln Ser
565 570 575
Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile Leu
580 585 590
Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile
595 600 605
Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu
610 615 620
Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile Lys
625 630 635 640
Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys
645 650 655
Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu
660 665 670
Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu
675 680 685
Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala
690 695 700
Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg
705 710 715 720
Tyr Leu Thr Arg Asn Leu
725
<210> 427
<211> 726
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 427
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Phe
115 120 125
Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg Ile
130 135 140
Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp Ser
145 150 155 160
Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser Gln
165 170 175
Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp Thr
180 185 190
Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly Ala
195 200 205
Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Gln Trp
210 215 220
Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro
225 230 235 240
Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly
245 250 255
Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly
260 265 270
Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp
275 280 285
Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn
290 295 300
Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn Gly
305 310 315 320
Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Thr
325 330 335
Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu Gly
340 345 350
Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly
355 360 365
Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser Phe
370 375 380
Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn
385 390 395 400
Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser Tyr
405 410 415
Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln
420 425 430
Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln
435 440 445
Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val Gln
450 455 460
Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser
465 470 475 480
Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala
485 490 495
Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly Pro
500 505 510
Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser
515 520 525
Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val Asp
530 535 540
Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn
545 550 555 560
Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln Ser
565 570 575
Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile Leu
580 585 590
Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile
595 600 605
Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu
610 615 620
Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile Lys
625 630 635 640
Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys
645 650 655
Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu
660 665 670
Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu
675 680 685
Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala
690 695 700
Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg
705 710 715 720
Tyr Leu Thr Arg Asn Leu
725
<210> 428
<211> 726
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 428
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Phe
115 120 125
Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg Ile
130 135 140
Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp Ser
145 150 155 160
Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser Gln
165 170 175
Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp Thr
180 185 190
Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly Ala
195 200 205
Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Gln Trp
210 215 220
Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro
225 230 235 240
Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly
245 250 255
Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly
260 265 270
Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp
275 280 285
Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn
290 295 300
Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn Gly
305 310 315 320
Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Thr
325 330 335
Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu Gly
340 345 350
Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly
355 360 365
Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser Phe
370 375 380
Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn
385 390 395 400
Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser Tyr
405 410 415
Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln
420 425 430
Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln
435 440 445
Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val Gln
450 455 460
Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser
465 470 475 480
Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala
485 490 495
Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly Pro
500 505 510
Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser
515 520 525
Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val Asp
530 535 540
Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn
545 550 555 560
Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln Ser
565 570 575
Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile Leu
580 585 590
Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile
595 600 605
Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu
610 615 620
Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile Lys
625 630 635 640
Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys
645 650 655
Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu
660 665 670
Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu
675 680 685
Ile Gln Tyr Thr Asn Asn Tyr Asn Asp Pro Gln Phe Val Asp Phe Ala
690 695 700
Pro Asp Ser Thr Gly Glu Tyr Arg Thr Thr Arg Pro Ile Gly Thr Arg
705 710 715 720
Tyr Leu Thr Arg Pro Leu
725
<210> 429
<211> 727
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 429
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg
130 135 140
Ile Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp
145 150 155 160
Ser Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser
165 170 175
Gln Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp
180 185 190
Thr Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly
195 200 205
Ala Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Thr
210 215 220
Trp Met Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu
225 230 235 240
Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser
245 250 255
Gly Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp
260 265 270
Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp
275 280 285
Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu
290 295 300
Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn
305 310 315 320
Gly Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe
325 330 335
Thr Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu
340 345 350
Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr
355 360 365
Gly Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser
370 375 380
Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn
385 390 395 400
Asn Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser
405 410 415
Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp
420 425 430
Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn
435 440 445
Gln Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val
450 455 460
Gln Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val
465 470 475 480
Ser Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly
485 490 495
Ala Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly
500 505 510
Pro Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu
515 520 525
Ser Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val
530 535 540
Asp Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr
545 550 555 560
Asn Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln
565 570 575
Ser Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile
580 585 590
Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro
595 600 605
Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro
610 615 620
Leu Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile
625 630 635 640
Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp
645 650 655
Lys Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Thr Val
660 665 670
Glu Met Glu Trp Glu Leu Lys Lys Glu Asn Ser Lys Arg Trp Asn Pro
675 680 685
Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe
690 695 700
Ala Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr
705 710 715 720
Arg Tyr Leu Thr Arg Asn Leu
725
<210> 430
<211> 726
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 430
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125
Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg
130 135 140
Ile Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp
145 150 155 160
Ser Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser
165 170 175
Gln Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp
180 185 190
Thr Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly
195 200 205
Ala Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Thr
210 215 220
Trp Met Gly Asp Arg Val Val Thr Lys Ser Thr Arg Thr Trp Val Leu
225 230 235 240
Pro Ser Tyr Asn Asn His Gln Tyr Arg Glu Ile Lys Ser Gly Ser Val
245 250 255
Asp Gly Ser Asn Ala Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly
260 265 270
Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp
275 280 285
Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn
290 295 300
Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn Gly
305 310 315 320
Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Thr
325 330 335
Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu Gly
340 345 350
Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly
355 360 365
Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser Phe
370 375 380
Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn
385 390 395 400
Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser Tyr
405 410 415
Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln
420 425 430
Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln
435 440 445
Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val Gln
450 455 460
Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser
465 470 475 480
Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala
485 490 495
Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly Pro
500 505 510
Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser
515 520 525
Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val Asp
530 535 540
Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn
545 550 555 560
Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln Ser
565 570 575
Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile Leu
580 585 590
Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile
595 600 605
Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu
610 615 620
Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile Lys
625 630 635 640
Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys
645 650 655
Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu
660 665 670
Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu
675 680 685
Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala
690 695 700
Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg
705 710 715 720
Tyr Leu Thr Arg Asn Leu
725
<210> 431
<211> 726
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 431
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Phe
115 120 125
Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg Ile
130 135 140
Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp Ser
145 150 155 160
Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser Gln
165 170 175
Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp Thr
180 185 190
Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly Ala
195 200 205
Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Thr Trp
210 215 220
Met Gly Asp Arg Val Val Thr Lys Ser Thr Arg Thr Trp Ala Leu Pro
225 230 235 240
Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly
245 250 255
Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly
260 265 270
Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp
275 280 285
Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn
290 295 300
Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn Gly
305 310 315 320
Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Thr
325 330 335
Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu Gly
340 345 350
Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly
355 360 365
Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser Phe
370 375 380
Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn
385 390 395 400
Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser Tyr
405 410 415
Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln
420 425 430
Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln
435 440 445
Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val Gln
450 455 460
Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser
465 470 475 480
Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala
485 490 495
Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly Pro
500 505 510
Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser
515 520 525
Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val Asp
530 535 540
Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn
545 550 555 560
Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln Ser
565 570 575
Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile Leu
580 585 590
Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile
595 600 605
Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu
610 615 620
Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile Lys
625 630 635 640
Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys
645 650 655
Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu
660 665 670
Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu
675 680 685
Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala
690 695 700
Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg
705 710 715 720
Tyr Leu Thr Arg Asn Leu
725
<210> 432
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 432
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro
50 55 60
Val Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn
65 70 75 80
Glu Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
210 215 220
Ser Gly Asp Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Lys Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Thr Val Glu Met Glu Trp Glu Leu Lys
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Asn Asn
690 695 700
Tyr Asn Asp Pro Gln Phe Val Asp Phe Ala Pro Asp Ser Thr Gly Glu
705 710 715 720
Tyr Arg Thr Thr Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 433
<211> 735
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 433
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp Gln
65 70 75 80
Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro Leu
115 120 125
Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg Pro
130 135 140
Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly Lys
145 150 155 160
Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr Gly
165 170 175
Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala
180 185 190
Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly Ala
195 200 205
Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser
210 215 220
Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile Thr
225 230 235 240
Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr
245 250 255
Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn Ala
260 265 270
Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285
His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300
Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320
Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn Asn
325 330 335
Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu Pro
340 345 350
Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp Gly
370 375 380
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu Phe
405 410 415
Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys
435 440 445
Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser Val
450 455 460
Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro Gly
465 470 475 480
Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn Asn
485 490 495
Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn Gly
500 505 510
Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys Glu
515 520 525
Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly Lys
530 535 540
Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile Thr
545 550 555 560
Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser Tyr
565 570 575
Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln Thr
580 585 590
Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp
595 600 605
Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr
610 615 620
Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met Lys
625 630 635 640
His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp
645 650 655
Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr Gln
660 665 670
Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys
675 680 685
Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Asn Asn Tyr
690 695 700
Asn Asp Pro Gln Phe Val Asp Phe Ala Pro Asp Ser Thr Gly Glu Tyr
705 710 715 720
Arg Thr Thr Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu
725 730 735
<210> 434
<211> 735
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 434
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Leu
115 120 125
Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg Pro
130 135 140
Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly Lys
145 150 155 160
Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr Gly
165 170 175
Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala
180 185 190
Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly Ala
195 200 205
Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser
210 215 220
Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile Thr
225 230 235 240
Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr
245 250 255
Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn Ala
260 265 270
Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285
His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300
Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320
Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn Asn
325 330 335
Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu Pro
340 345 350
Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp Gly
370 375 380
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu Phe
405 410 415
Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys
435 440 445
Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser Val
450 455 460
Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro Gly
465 470 475 480
Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn Asn
485 490 495
Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn Gly
500 505 510
Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys Glu
515 520 525
Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly Lys
530 535 540
Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile Thr
545 550 555 560
Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser Tyr
565 570 575
Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln Thr
580 585 590
Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp
595 600 605
Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr
610 615 620
Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met Lys
625 630 635 640
His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp
645 650 655
Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr Gln
660 665 670
Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Lys Lys
675 680 685
Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr
690 695 700
Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val Tyr
705 710 715 720
Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 435
<211> 726
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 435
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Phe
115 120 125
Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg Ile
130 135 140
Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp Ser
145 150 155 160
Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser Gln
165 170 175
Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp Thr
180 185 190
Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly Ala
195 200 205
Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Thr Trp
210 215 220
Met Gly Asp Arg Val Val Thr Lys Ser Thr Arg Thr Trp Ala Leu Pro
225 230 235 240
Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly
245 250 255
Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly
260 265 270
Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp
275 280 285
Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn
290 295 300
Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn Gly
305 310 315 320
Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Thr
325 330 335
Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu Gly
340 345 350
Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly
355 360 365
Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser Phe
370 375 380
Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn
385 390 395 400
Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser Tyr
405 410 415
Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln
420 425 430
Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln
435 440 445
Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val Gln
450 455 460
Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser
465 470 475 480
Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala
485 490 495
Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly Pro
500 505 510
Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser
515 520 525
Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val Asp
530 535 540
Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn
545 550 555 560
Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln Ser
565 570 575
Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile Leu
580 585 590
Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile
595 600 605
Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu
610 615 620
Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile Lys
625 630 635 640
Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys
645 650 655
Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu
660 665 670
Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu
675 680 685
Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala
690 695 700
Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg
705 710 715 720
Tyr Leu Thr Arg Asn Leu
725
<210> 436
<211> 726
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 436
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Phe
115 120 125
Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg Ile
130 135 140
Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp Ser
145 150 155 160
Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser Gln
165 170 175
Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp Thr
180 185 190
Met Ser Ala Gly Gly Gly Ala Pro Val Ala Asp Asn Asn Glu Gly Ala
195 200 205
Asp Gly Val Gly Ser Ser Ser Gly Asn Trp His Cys Asp Ser Gln Trp
210 215 220
Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro
225 230 235 240
Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly
245 250 255
Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly
260 265 270
Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp
275 280 285
Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn
290 295 300
Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn Gly
305 310 315 320
Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Thr
325 330 335
Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu Gly
340 345 350
Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly
355 360 365
Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser Phe
370 375 380
Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn
385 390 395 400
Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser Tyr
405 410 415
Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln
420 425 430
Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln
435 440 445
Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val Gln
450 455 460
Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser
465 470 475 480
Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala
485 490 495
Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly Pro
500 505 510
Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser
515 520 525
Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val Asp
530 535 540
Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn
545 550 555 560
Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln Ser
565 570 575
Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile Leu
580 585 590
Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile
595 600 605
Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu
610 615 620
Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile Lys
625 630 635 640
Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys
645 650 655
Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu
660 665 670
Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu
675 680 685
Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala
690 695 700
Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg
705 710 715 720
Tyr Leu Thr Arg Asn Leu
725
<210> 437
<211> 726
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 437
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro Val
50 55 60
Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp Gln
65 70 75 80
Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Phe
115 120 125
Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg Ile
130 135 140
Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp Ser
145 150 155 160
Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser Gln
165 170 175
Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp Thr
180 185 190
Met Ser Ala Gly Gly Gly Ala Pro Val Ala Asp Asn Asn Glu Gly Ala
195 200 205
Asp Gly Val Gly Ser Ser Ser Gly Asn Trp His Cys Asp Ser Gln Trp
210 215 220
Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro
225 230 235 240
Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly
245 250 255
Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly
260 265 270
Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp
275 280 285
Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn
290 295 300
Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn Gly
305 310 315 320
Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Thr
325 330 335
Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu Gly
340 345 350
Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly
355 360 365
Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser Phe
370 375 380
Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn
385 390 395 400
Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser Tyr
405 410 415
Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln
420 425 430
Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln
435 440 445
Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val Gln
450 455 460
Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser
465 470 475 480
Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala
485 490 495
Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly Pro
500 505 510
Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser
515 520 525
Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val Asp
530 535 540
Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn
545 550 555 560
Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln Ser
565 570 575
Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile Leu
580 585 590
Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile
595 600 605
Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu
610 615 620
Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile Lys
625 630 635 640
Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys
645 650 655
Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu
660 665 670
Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu
675 680 685
Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala
690 695 700
Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg
705 710 715 720
Tyr Leu Thr Arg Asn Leu
725
<210> 438
<211> 727
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 438
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg
130 135 140
Ile Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp
145 150 155 160
Ser Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser
165 170 175
Gln Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp
180 185 190
Thr Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Glu Gly
195 200 205
Ala Asp Gly Val Gly Ser Ser Ser Gly Asn Trp His Cys Asp Ser Gln
210 215 220
Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu
225 230 235 240
Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser
245 250 255
Gly Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp
260 265 270
Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp
275 280 285
Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu
290 295 300
Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn
305 310 315 320
Gly Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe
325 330 335
Thr Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu
340 345 350
Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr
355 360 365
Gly Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser
370 375 380
Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn
385 390 395 400
Asn Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser
405 410 415
Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp
420 425 430
Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn
435 440 445
Gln Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val
450 455 460
Gln Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val
465 470 475 480
Ser Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly
485 490 495
Ala Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly
500 505 510
Pro Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu
515 520 525
Ser Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val
530 535 540
Asp Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr
545 550 555 560
Asn Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln
565 570 575
Ser Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile
580 585 590
Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro
595 600 605
Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro
610 615 620
Leu Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile
625 630 635 640
Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp
645 650 655
Lys Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val
660 665 670
Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro
675 680 685
Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe
690 695 700
Ala Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr
705 710 715 720
Arg Tyr Leu Thr Arg Asn Leu
725
<210> 439
<211> 727
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 439
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125
Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg
130 135 140
Ile Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp
145 150 155 160
Ser Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser
165 170 175
Gln Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp
180 185 190
Thr Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly
195 200 205
Ala Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Thr
210 215 220
Trp Met Gly Asp Arg Val Val Thr Thr Ser Thr Arg Thr Trp Ala Leu
225 230 235 240
Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser
245 250 255
Gly Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp
260 265 270
Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp
275 280 285
Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu
290 295 300
Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn
305 310 315 320
Gly Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe
325 330 335
Thr Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu
340 345 350
Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr
355 360 365
Gly Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser
370 375 380
Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn
385 390 395 400
Asn Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser
405 410 415
Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp
420 425 430
Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn
435 440 445
Gln Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val
450 455 460
Gln Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val
465 470 475 480
Ser Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly
485 490 495
Ala Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly
500 505 510
Pro Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu
515 520 525
Ser Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val
530 535 540
Asp Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr
545 550 555 560
Asn Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln
565 570 575
Ser Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile
580 585 590
Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro
595 600 605
Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro
610 615 620
Leu Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile
625 630 635 640
Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp
645 650 655
Lys Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val
660 665 670
Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro
675 680 685
Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe
690 695 700
Ala Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr
705 710 715 720
Arg Tyr Leu Thr Arg Asn Leu
725
<210> 440
<211> 735
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 440
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro Leu
115 120 125
Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg Pro
130 135 140
Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly Lys
145 150 155 160
Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr Gly
165 170 175
Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala
180 185 190
Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly Ala
195 200 205
Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser
210 215 220
Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile Thr
225 230 235 240
Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr
245 250 255
Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn Ala
260 265 270
Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285
His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300
Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320
Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn Asn
325 330 335
Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu Pro
340 345 350
Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp Gly
370 375 380
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu Phe
405 410 415
Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys
435 440 445
Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser Val
450 455 460
Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro Gly
465 470 475 480
Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn Asn
485 490 495
Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn Gly
500 505 510
Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys Glu
515 520 525
Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly Lys
530 535 540
Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile Thr
545 550 555 560
Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser Tyr
565 570 575
Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln Thr
580 585 590
Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp
595 600 605
Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr
610 615 620
Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met Lys
625 630 635 640
His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp
645 650 655
Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr Gln
660 665 670
Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys
675 680 685
Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr
690 695 700
Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val Tyr
705 710 715 720
Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 441
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 441
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro
50 55 60
Val Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn
65 70 75 80
Glu Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 442
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 442
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 443
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 443
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 444
<211> 735
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 444
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp Gln
65 70 75 80
Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro Leu
115 120 125
Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg Pro
130 135 140
Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly Lys
145 150 155 160
Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr Gly
165 170 175
Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala
180 185 190
Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly Ala
195 200 205
Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser
210 215 220
Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile Thr
225 230 235 240
Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr
245 250 255
Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn Ala
260 265 270
Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285
His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300
Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320
Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn Asn
325 330 335
Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu Pro
340 345 350
Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp Gly
370 375 380
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu Phe
405 410 415
Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys
435 440 445
Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser Val
450 455 460
Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro Gly
465 470 475 480
Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn Asn
485 490 495
Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn Gly
500 505 510
Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys Glu
515 520 525
Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly Lys
530 535 540
Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile Thr
545 550 555 560
Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser Tyr
565 570 575
Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln Thr
580 585 590
Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp
595 600 605
Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr
610 615 620
Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met Lys
625 630 635 640
His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp
645 650 655
Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr Gln
660 665 670
Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys
675 680 685
Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Asn Asn Tyr
690 695 700
Asn Asp Pro Gln Phe Val Asp Phe Ala Pro Asp Ser Thr Gly Glu Tyr
705 710 715 720
Arg Thr Thr Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu
725 730 735
<210> 445
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 445
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro
50 55 60
Val Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn
65 70 75 80
Glu Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Gly Tyr His Lys Ser Gly Ala Ala Gln Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 446
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 446
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro
50 55 60
Val Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn
65 70 75 80
Glu Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ala Asn Tyr Gly Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 447
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 447
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro
50 55 60
Val Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn
65 70 75 80
Glu Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Gly Tyr His Lys Ser Gly Ala Ala Gln Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Asn Val Ser Tyr Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 448
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 448
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro
50 55 60
Val Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn
65 70 75 80
Glu Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Leu Asn Ser Met Leu Ile Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 449
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 449
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro
50 55 60
Val Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn
65 70 75 80
Glu Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Gly Tyr His Lys Ser Gly Ala Ala Gln Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ala Asn Tyr Gly Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 450
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 450
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro
50 55 60
Val Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn
65 70 75 80
Glu Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Leu Asn Ser Met Leu Ile Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ala Asn Tyr Gly Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 451
<211> 735
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 451
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Leu
115 120 125
Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg Pro
130 135 140
Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly Lys
145 150 155 160
Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr Gly
165 170 175
Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala
180 185 190
Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly Ala
195 200 205
Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser
210 215 220
Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile Thr
225 230 235 240
Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr
245 250 255
Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn Ala
260 265 270
Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285
His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300
Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320
Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn Asn
325 330 335
Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu Pro
340 345 350
Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp Gly
370 375 380
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu Phe
405 410 415
Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys
435 440 445
Thr Ile Gly Tyr His Lys Ser Gly Ala Ala Gln Leu Lys Phe Ser Val
450 455 460
Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro Gly
465 470 475 480
Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn Asn
485 490 495
Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn Gly
500 505 510
Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys Glu
515 520 525
Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly Lys
530 535 540
Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile Thr
545 550 555 560
Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser Tyr
565 570 575
Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln Thr
580 585 590
Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp
595 600 605
Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr
610 615 620
Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met Lys
625 630 635 640
His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp
645 650 655
Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr Gln
660 665 670
Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Lys Lys
675 680 685
Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr
690 695 700
Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val Tyr
705 710 715 720
Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 452
<211> 735
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 452
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Leu
115 120 125
Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg Pro
130 135 140
Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly Lys
145 150 155 160
Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr Gly
165 170 175
Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala
180 185 190
Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly Ala
195 200 205
Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser
210 215 220
Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile Thr
225 230 235 240
Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr
245 250 255
Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn Ala
260 265 270
Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285
His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300
Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320
Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn Asn
325 330 335
Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu Pro
340 345 350
Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp Gly
370 375 380
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu Phe
405 410 415
Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys
435 440 445
Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser Val
450 455 460
Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro Gly
465 470 475 480
Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn Asn
485 490 495
Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn Gly
500 505 510
Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys Glu
515 520 525
Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly Lys
530 535 540
Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile Thr
545 550 555 560
Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser Tyr
565 570 575
Gly Gln Val Ala Thr Asn His Gln Ala Asn Tyr Gly Gln Ala Gln Thr
580 585 590
Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp
595 600 605
Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr
610 615 620
Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met Lys
625 630 635 640
His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp
645 650 655
Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr Gln
660 665 670
Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Lys Lys
675 680 685
Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr
690 695 700
Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val Tyr
705 710 715 720
Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 453
<211> 735
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 453
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Leu
115 120 125
Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg Pro
130 135 140
Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly Lys
145 150 155 160
Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr Gly
165 170 175
Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala
180 185 190
Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly Ala
195 200 205
Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser
210 215 220
Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile Thr
225 230 235 240
Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr
245 250 255
Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn Ala
260 265 270
Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285
His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300
Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320
Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn Asn
325 330 335
Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu Pro
340 345 350
Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp Gly
370 375 380
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu Phe
405 410 415
Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys
435 440 445
Thr Ile Gly Tyr His Lys Ser Gly Ala Ala Gln Leu Lys Phe Ser Val
450 455 460
Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro Gly
465 470 475 480
Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn Asn
485 490 495
Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn Gly
500 505 510
Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys Glu
515 520 525
Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly Lys
530 535 540
Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile Thr
545 550 555 560
Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser Tyr
565 570 575
Gly Gln Val Ala Thr Asn His Gln Asn Val Ser Tyr Gln Ala Gln Thr
580 585 590
Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp
595 600 605
Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr
610 615 620
Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met Lys
625 630 635 640
His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp
645 650 655
Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr Gln
660 665 670
Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Lys Lys
675 680 685
Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr
690 695 700
Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val Tyr
705 710 715 720
Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 454
<211> 735
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 454
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Leu
115 120 125
Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg Pro
130 135 140
Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly Lys
145 150 155 160
Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr Gly
165 170 175
Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala
180 185 190
Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly Ala
195 200 205
Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser
210 215 220
Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile Thr
225 230 235 240
Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr
245 250 255
Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn Ala
260 265 270
Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285
His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300
Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320
Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn Asn
325 330 335
Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu Pro
340 345 350
Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp Gly
370 375 380
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu Phe
405 410 415
Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys
435 440 445
Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser Val
450 455 460
Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro Gly
465 470 475 480
Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn Leu
485 490 495
Asn Ser Met Leu Ile Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn Gly
500 505 510
Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys Glu
515 520 525
Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly Lys
530 535 540
Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile Thr
545 550 555 560
Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser Tyr
565 570 575
Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln Thr
580 585 590
Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp
595 600 605
Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr
610 615 620
Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met Lys
625 630 635 640
His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp
645 650 655
Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr Gln
660 665 670
Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Lys Lys
675 680 685
Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr
690 695 700
Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val Tyr
705 710 715 720
Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 455
<211> 735
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 455
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Leu
115 120 125
Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg Pro
130 135 140
Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly Lys
145 150 155 160
Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr Gly
165 170 175
Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala
180 185 190
Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly Ala
195 200 205
Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser
210 215 220
Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile Thr
225 230 235 240
Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr
245 250 255
Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn Ala
260 265 270
Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285
His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300
Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320
Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn Asn
325 330 335
Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu Pro
340 345 350
Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp Gly
370 375 380
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu Phe
405 410 415
Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys
435 440 445
Thr Ile Gly Tyr His Lys Ser Gly Ala Ala Gln Leu Lys Phe Ser Val
450 455 460
Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro Gly
465 470 475 480
Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn Asn
485 490 495
Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn Gly
500 505 510
Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys Glu
515 520 525
Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly Lys
530 535 540
Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile Thr
545 550 555 560
Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser Tyr
565 570 575
Gly Gln Val Ala Thr Asn His Gln Ala Asn Tyr Gly Gln Ala Gln Thr
580 585 590
Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp
595 600 605
Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr
610 615 620
Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met Lys
625 630 635 640
His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp
645 650 655
Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr Gln
660 665 670
Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Lys Lys
675 680 685
Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr
690 695 700
Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val Tyr
705 710 715 720
Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 456
<211> 735
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 456
Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu
1 5 10 15
Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys
20 25 30
Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly
35 40 45
Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val
50 55 60
Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu
65 70 75 80
Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
85 90 95
Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn
100 105 110
Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Leu
115 120 125
Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg Pro
130 135 140
Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly Lys
145 150 155 160
Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr Gly
165 170 175
Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala
180 185 190
Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly Ala
195 200 205
Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser
210 215 220
Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile Thr
225 230 235 240
Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr
245 250 255
Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn Ala
260 265 270
Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285
His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300
Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320
Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn Asn
325 330 335
Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu Pro
340 345 350
Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp Gly
370 375 380
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu Phe
405 410 415
Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys
435 440 445
Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser Val
450 455 460
Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro Gly
465 470 475 480
Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn Leu
485 490 495
Asn Ser Met Leu Ile Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn Gly
500 505 510
Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys Glu
515 520 525
Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly Lys
530 535 540
Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile Thr
545 550 555 560
Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser Tyr
565 570 575
Gly Gln Val Ala Thr Asn His Gln Ala Asn Tyr Gly Gln Ala Gln Thr
580 585 590
Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp
595 600 605
Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr
610 615 620
Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met Lys
625 630 635 640
His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp
645 650 655
Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr Gln
660 665 670
Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Lys Lys
675 680 685
Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr
690 695 700
Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val Tyr
705 710 715 720
Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 457
<211> 727
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 457
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg
130 135 140
Ile Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp
145 150 155 160
Ser Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser
165 170 175
Gln Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp
180 185 190
Thr Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Glu Gly
195 200 205
Ala Asp Gly Val Gly Ser Ser Ser Gly Asn Trp His Cys Asp Ser Gln
210 215 220
Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu
225 230 235 240
Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser
245 250 255
Gly Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp
260 265 270
Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp
275 280 285
Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu
290 295 300
Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn
305 310 315 320
Gly Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe
325 330 335
Thr Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu
340 345 350
Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr
355 360 365
Gly Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser
370 375 380
Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn
385 390 395 400
Asn Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser
405 410 415
Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp
420 425 430
Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Gly Tyr His Lys Ser Gly
435 440 445
Ala Ala Gln Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val
450 455 460
Gln Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val
465 470 475 480
Ser Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly
485 490 495
Ala Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly
500 505 510
Pro Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu
515 520 525
Ser Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val
530 535 540
Asp Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr
545 550 555 560
Asn Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln
565 570 575
Ser Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile
580 585 590
Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro
595 600 605
Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro
610 615 620
Leu Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile
625 630 635 640
Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp
645 650 655
Lys Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val
660 665 670
Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro
675 680 685
Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe
690 695 700
Ala Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr
705 710 715 720
Arg Tyr Leu Thr Arg Asn Leu
725
<210> 458
<211> 727
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 458
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg
130 135 140
Ile Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp
145 150 155 160
Ser Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser
165 170 175
Gln Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp
180 185 190
Thr Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Glu Gly
195 200 205
Ala Asp Gly Val Gly Ser Ser Ser Gly Asn Trp His Cys Asp Ser Gln
210 215 220
Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu
225 230 235 240
Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser
245 250 255
Gly Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp
260 265 270
Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp
275 280 285
Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu
290 295 300
Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn
305 310 315 320
Gly Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe
325 330 335
Thr Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu
340 345 350
Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr
355 360 365
Gly Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser
370 375 380
Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn
385 390 395 400
Asn Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser
405 410 415
Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp
420 425 430
Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn
435 440 445
Gln Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val
450 455 460
Gln Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val
465 470 475 480
Ser Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly
485 490 495
Ala Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly
500 505 510
Pro Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu
515 520 525
Ser Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val
530 535 540
Asp Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr
545 550 555 560
Asn Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln
565 570 575
Ser Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile
580 585 590
Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro
595 600 605
Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro
610 615 620
Leu Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile
625 630 635 640
Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp
645 650 655
Lys Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val
660 665 670
Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro
675 680 685
Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe
690 695 700
Ala Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr
705 710 715 720
Arg Tyr Leu Thr Arg Asn Leu
725
<210> 459
<211> 727
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 459
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg
130 135 140
Ile Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp
145 150 155 160
Ser Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser
165 170 175
Gln Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp
180 185 190
Thr Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Glu Gly
195 200 205
Ala Asp Gly Val Gly Ser Ser Ser Gly Asn Trp His Cys Asp Ser Gln
210 215 220
Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu
225 230 235 240
Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser
245 250 255
Gly Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp
260 265 270
Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp
275 280 285
Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu
290 295 300
Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn
305 310 315 320
Gly Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe
325 330 335
Thr Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu
340 345 350
Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr
355 360 365
Gly Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser
370 375 380
Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn
385 390 395 400
Asn Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser
405 410 415
Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp
420 425 430
Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Gly Tyr His Lys Ser Gly
435 440 445
Ala Ala Gln Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val
450 455 460
Gln Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val
465 470 475 480
Ser Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly
485 490 495
Ala Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly
500 505 510
Pro Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu
515 520 525
Ser Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val
530 535 540
Asp Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr
545 550 555 560
Asn Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln
565 570 575
Asn Val Ser Tyr Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile
580 585 590
Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro
595 600 605
Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro
610 615 620
Leu Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile
625 630 635 640
Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp
645 650 655
Lys Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val
660 665 670
Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro
675 680 685
Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe
690 695 700
Ala Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr
705 710 715 720
Arg Tyr Leu Thr Arg Asn Leu
725
<210> 460
<211> 727
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 460
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg
130 135 140
Ile Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp
145 150 155 160
Ser Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser
165 170 175
Gln Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp
180 185 190
Thr Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Glu Gly
195 200 205
Ala Asp Gly Val Gly Ser Ser Ser Gly Asn Trp His Cys Asp Ser Gln
210 215 220
Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu
225 230 235 240
Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser
245 250 255
Gly Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp
260 265 270
Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp
275 280 285
Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu
290 295 300
Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn
305 310 315 320
Gly Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe
325 330 335
Thr Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu
340 345 350
Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr
355 360 365
Gly Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser
370 375 380
Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn
385 390 395 400
Asn Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser
405 410 415
Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp
420 425 430
Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn
435 440 445
Gln Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val
450 455 460
Gln Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val
465 470 475 480
Ser Thr Thr Val Thr Gln Asn Leu Asn Ser Met Leu Ile Trp Pro Gly
485 490 495
Ala Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly
500 505 510
Pro Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu
515 520 525
Ser Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val
530 535 540
Asp Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr
545 550 555 560
Asn Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln
565 570 575
Ser Ala Gln Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile
580 585 590
Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro
595 600 605
Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro
610 615 620
Leu Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile
625 630 635 640
Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp
645 650 655
Lys Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val
660 665 670
Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro
675 680 685
Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe
690 695 700
Ala Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr
705 710 715 720
Arg Tyr Leu Thr Arg Asn Leu
725
<210> 461
<211> 727
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 461
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg
130 135 140
Ile Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp
145 150 155 160
Ser Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser
165 170 175
Gln Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp
180 185 190
Thr Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Glu Gly
195 200 205
Ala Asp Gly Val Gly Ser Ser Ser Gly Asn Trp His Cys Asp Ser Gln
210 215 220
Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu
225 230 235 240
Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser
245 250 255
Gly Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp
260 265 270
Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp
275 280 285
Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu
290 295 300
Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn
305 310 315 320
Gly Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe
325 330 335
Thr Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu
340 345 350
Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr
355 360 365
Gly Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser
370 375 380
Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn
385 390 395 400
Asn Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser
405 410 415
Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp
420 425 430
Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Gly Tyr His Lys Ser Gly
435 440 445
Ala Ala Gln Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val
450 455 460
Gln Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val
465 470 475 480
Ser Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp Pro Gly
485 490 495
Ala Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly
500 505 510
Pro Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu
515 520 525
Ser Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val
530 535 540
Asp Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr
545 550 555 560
Asn Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln
565 570 575
Ala Asn Tyr Gly Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile
580 585 590
Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro
595 600 605
Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro
610 615 620
Leu Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile
625 630 635 640
Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp
645 650 655
Lys Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val
660 665 670
Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro
675 680 685
Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe
690 695 700
Ala Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr
705 710 715 720
Arg Tyr Leu Thr Arg Asn Leu
725
<210> 462
<211> 727
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 462
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg
130 135 140
Ile Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp
145 150 155 160
Ser Lys Pro Ser Thr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser
165 170 175
Gln Gln Leu Gln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp
180 185 190
Thr Met Ser Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Glu Gly
195 200 205
Ala Asp Gly Val Gly Ser Ser Ser Gly Asn Trp His Cys Asp Ser Gln
210 215 220
Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu
225 230 235 240
Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser
245 250 255
Gly Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp
260 265 270
Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp
275 280 285
Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu
290 295 300
Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn
305 310 315 320
Gly Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe
325 330 335
Thr Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu
340 345 350
Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr
355 360 365
Gly Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser
370 375 380
Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn
385 390 395 400
Asn Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser
405 410 415
Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp
420 425 430
Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Asn Gly Ser Gly Gln Asn
435 440 445
Gln Gln Thr Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val
450 455 460
Gln Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val
465 470 475 480
Ser Thr Thr Val Thr Gln Asn Leu Asn Ser Met Leu Ile Trp Pro Gly
485 490 495
Ala Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly
500 505 510
Pro Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu
515 520 525
Ser Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Gly Arg Asp Asn Val
530 535 540
Asp Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr
545 550 555 560
Asn Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln
565 570 575
Ala Asn Tyr Gly Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile
580 585 590
Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro
595 600 605
Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro
610 615 620
Leu Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile
625 630 635 640
Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp
645 650 655
Lys Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val
660 665 670
Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro
675 680 685
Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe
690 695 700
Ala Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr
705 710 715 720
Arg Tyr Leu Thr Arg Asn Leu
725
<210> 463
<211> 502
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<220>
<221> 其他特征
<222> (218)..(226)
<223> Xaa可以是任何天然存在的氨基酸
<220>
<221> 其他特征
<222> (263)..(268)
<223> Xaa可以是任何天然存在的氨基酸
<220>
<221> 其他特征
<222> (315)..(319)
<223> Xaa可以是任何天然存在的氨基酸
<220>
<221> 其他特征
<222> (352)..(355)
<223> Xaa可以是任何天然存在的氨基酸
<400> 463
Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro
1 5 10 15
Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly
20 25 30
Gly Ser Ser Asn Asp Asn Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly
35 40 45
Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp
50 55 60
Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn
65 70 75 80
Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Asp Asn Asn Gly
85 90 95
Val Lys Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Thr
100 105 110
Asp Ser Asp Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Glu Gly
115 120 125
Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly
130 135 140
Tyr Leu Thr Leu Asn Asp Gly Ser Gln Ala Val Gly Arg Ser Ser Phe
145 150 155 160
Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn
165 170 175
Phe Gln Phe Ser Tyr Glu Phe Glu Asn Val Pro Phe His Ser Ser Tyr
180 185 190
Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln
195 200 205
Tyr Leu Tyr Tyr Leu Ser Lys Thr Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa
210 215 220
Xaa Xaa Leu Lys Phe Ser Val Ala Gly Pro Ser Asn Met Ala Val Gln
225 230 235 240
Gly Arg Asn Tyr Ile Pro Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser
245 250 255
Thr Thr Val Thr Gln Asn Xaa Xaa Xaa Xaa Xaa Xaa Trp Pro Gly Ala
260 265 270
Ser Ser Trp Ala Leu Asn Gly Arg Asn Ser Leu Met Asn Pro Gly Pro
275 280 285
Ala Met Ala Ser His Lys Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser
290 295 300
Gly Ser Leu Ile Phe Gly Lys Gln Gly Thr Xaa Xaa Xaa Xaa Xaa Asp
305 310 315 320
Ala Asp Lys Val Met Ile Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn
325 330 335
Pro Val Ala Thr Glu Ser Tyr Gly Gln Val Ala Thr Asn His Gln Xaa
340 345 350
Xaa Xaa Xaa Gln Ala Gln Thr Gly Trp Val Gln Asn Gln Gly Ile Leu
355 360 365
Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile
370 375 380
Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu
385 390 395 400
Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile Leu Ile Lys
405 410 415
Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys
420 425 430
Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu
435 440 445
Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu
450 455 460
Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala
465 470 475 480
Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg
485 490 495
Tyr Leu Thr Arg Asn Leu
500
<210> 464
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 464
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Asn Val Ser Tyr Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 465
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 465
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Met Val Asn Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 466
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 466
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Asn Val Gly Thr Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 467
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 467
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Gln Asp Ala Ser Leu Leu Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 468
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 468
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Asn Gly Ser Gly Gln Asn Gln Gln Thr Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Gly Met Ser Phe Thr Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 469
<211> 9
<212> PRT
<213> 依赖性细小病毒属腺相关病毒血清型9
<400> 469
Asn Gly Ser Gly Gln Asn Gln Gln Thr
1 5
<210> 470
<211> 18
<212> PRT
<213> 依赖性细小病毒属腺相关病毒血清型9
<400> 470
Arg Val Ser Thr Thr Val Thr Gln Asn Asn Asn Ser Glu Phe Ala Trp
1 5 10 15
Pro Gly
<210> 471
<211> 14
<212> PRT
<213> 依赖性细小病毒属腺相关病毒血清型9
<400> 471
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val
1 5 10
<210> 472
<211> 13
<212> PRT
<213> 依赖性细小病毒属腺相关病毒血清型9
<400> 472
Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln Thr
1 5 10
<210> 473
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VR-IV蛋白基序
<220>
<221> 其他特征
<222> (1)..(1)
<223> Xaa为Gly或Val
<220>
<221> 其他特征
<222> (2)..(2)
<223> Xaa为Tyr或Ile
<220>
<221> 其他特征
<222> (3)..(3)
<223> Xaa为His或Ile
<220>
<221> 其他特征
<222> (5)..(5)
<223> Xaa为Ser或Ile
<220>
<221> 其他特征
<222> (7)..(7)
<223> Xaa为Ala或Val
<400> 473
Xaa Xaa Xaa Lys Xaa Gly Xaa Ala Gln
1 5
<210> 474
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> VR-V蛋白基序
<220>
<221> 其他特征
<222> (1)..(1)
<223> Xaa为Ser、Leu、His、Asn或Ala
<220>
<221> 其他特征
<222> (2)..(2)
<223> Xaa为Thr、Met、Lys、Gly或Asn
<220>
<221> 其他特征
<222> (3)..(3)
<223> Xaa为Ser、Thr、Met或Ile
<220>
<221> 其他特征
<222> (4)..(4)
<223> Xaa为Ser、Pro、Phe、Met或Asn
<220>
<221> 其他特征
<222> (5)..(5)
<223> Xaa为Phe、Ser、Pro 或Leu
<220>
<221> 其他特征
<222> (6)..(6)
<223> Xaa为Ile、Val或Thr
<400> 474
Xaa Xaa Xaa Xaa Xaa Xaa
1 5
<210> 475
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> VR-VII蛋白基序
<220>
<221> 其他特征
<222> (1)..(1)
<223> Xaa为Val、Leu、Gln、Cys或Arg
<220>
<221> 其他特征
<222> (2)..(2)
<223> Xaa为Ser、His、Gly、Cys或Asp
<220>
<221> 其他特征
<222> (3)..(3)
<223> Xaa为Tyr、Ser、Leu、Gly或Asn
<220>
<221> 其他特征
<222> (4)..(4)
<223> Xaa为Ser、Leu、His、Gln或Asn
<220>
<221> 其他特征
<222> (5)..(5)
<223> Xaa为Val、Ile或Arg
<400> 475
Xaa Xaa Xaa Xaa Xaa
1 5
<210> 476
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> VR-VIII蛋白基序
<220>
<221> 其他特征
<222> (1)..(1)
<223> Xaa为Ser、Asn或Ala
<220>
<221> 其他特征
<222> (2)..(2)
<223> Xaa为Val、Met、Asn或Ala
<220>
<221> 其他特征
<222> (3)..(3)
<223> Xaa为Tyr、Val、Ser或Gly
<220>
<221> 其他特征
<222> (4)..(4)
<223> Xaa为Tyr、Thr、Met、 Gly或Asn
<400> 476
Xaa Xaa Xaa Xaa
1
<210> 477
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> VR-IV变体
<220>
<221> 其他特征
<222> (1)..(1)
<223> Xaa为Gly、Ser或Val
<220>
<221> 其他特征
<222> (2)..(2)
<223> Xaa为Tyr、Gln或Ile
<220>
<221> 其他特征
<222> (3)..(3)
<223> Xaa为His、Trp、Val或Ile
<220>
<221> 其他特征
<222> (4)..(4)
<223> Xaa为Lys或Asn
<220>
<221> 其他特征
<222> (5)..(5)
<223> Xaa为Ser、Gly或Ile
<220>
<221> 其他特征
<222> (6)..(6)
<223> Xaa为Gly或Arg
<220>
<221> 其他特征
<222> (7)..(7)
<223> Xaa为Ala、Pro或Val
<220>
<221> 其他特征
<222> (8)..(8)
<223> Xaa为Ala或Arg
<220>
<221> 其他特征
<222> (9)..(9)
<223> Xaa为Gln或Asp
<400> 477
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5
<210> 478
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> VR-IV变体
<220>
<221> 其他特征
<222> (1)..(11)
<223> Xaa为任意氨基酸
<220>
<221> 其他特征
<222> (8)..(11)
<223> Xaa可能存在可能存在或多达4个残基可能不存在
<400> 478
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10
<210> 479
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> VR-V变体
<220>
<221> 其他特征
<222> (1)..(8)
<223> Xaa为任意氨基酸
<220>
<221> 其他特征
<222> (5)..(8)
<223> Xaa可能存在或多达4个残基可能不存在
<400> 479
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5
<210> 480
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> VR-VII变体
<220>
<221> 其他特征
<222> (1)..(7)
<223> Xaa为任意氨基酸
<220>
<221> 其他特征
<222> (4)..(7)
<223> Xaa可能存在或多达4个残基可能不存在
<400> 480
Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5
<210> 481
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> VR-VIII变体
<220>
<221> 其他特征
<222> (1)..(6)
<223> Xaa为任意氨基酸
<220>
<221> 其他特征
<222> (3)..(6)
<223> Xaa可能存在或多达4个残基可能不存在
<400> 481
Xaa Xaa Xaa Xaa Xaa Xaa
1 5
<210> 482
<211> 745
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白
<400> 482
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ser Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Gly Tyr His Lys Ser Gly Ala Ala Gln Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ser Ala
580 585 590
Ser Asn Val Asn Ala Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln
595 600 605
Gly Ile Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln
610 615 620
Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro
625 630 635 640
Ser Pro Leu Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile
645 650 655
Leu Ile Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn
660 665 670
Lys Asp Lys Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val
675 680 685
Ser Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp
690 695 700
Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val
705 710 715 720
Glu Phe Ala Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile
725 730 735
Gly Thr Arg Tyr Leu Thr Arg Asn Leu
740 745
<210> 483
<211> 745
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白.
<400> 483
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ser Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Gly Tyr His Lys Ser Gly Ala Ala Gln Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Ala Ala Ser
580 585 590
Pro Thr Thr Thr Ala Ala Gln Ala Gln Thr Gly Trp Val Gln Asn Gln
595 600 605
Gly Ile Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln
610 615 620
Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro
625 630 635 640
Ser Pro Leu Met Gly Gly Phe Gly Met Lys His Pro Pro Pro Gln Ile
645 650 655
Leu Ile Lys Asn Thr Pro Val Pro Ala Asp Pro Pro Thr Ala Phe Asn
660 665 670
Lys Asp Lys Leu Asn Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val
675 680 685
Ser Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp
690 695 700
Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Asn Asn Val
705 710 715 720
Glu Phe Ala Val Asn Thr Glu Gly Val Tyr Ser Glu Pro Arg Pro Ile
725 730 735
Gly Thr Arg Tyr Leu Thr Arg Asn Leu
740 745
<210> 484
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白.
<400> 484
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Gly Tyr His Lys Ser Gly Ala Ala Gln Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Arg Thr Ser Thr Thr Asp Thr Gln Asn
485 490 495
Asn Asn Ser Glu Phe Ala Trp Pro Ala Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
<210> 485
<211> 736
<212> PRT
<213> 人工序列
<220>
<223> 重组AAV衣壳蛋白.
<400> 485
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15
Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
20 25 30
Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro
35 40 45
Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
85 90 95
Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly
100 105 110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro
115 120 125
Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly
145 150 155 160
Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175
Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro
180 185 190
Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Met Ala Ser Gly Gly Gly
195 200 205
Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser
210 215 220
Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile
225 230 235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255
Tyr Lys Gln Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn
260 265 270
Ala Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285
Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300
Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320
Gln Val Lys Glu Val Thr Asp Asn Asn Gly Val Lys Thr Ile Ala Asn
325 330 335
Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Asp Tyr Gln Leu
340 345 350
Pro Tyr Val Leu Gly Ser Ala His Glu Gly Cys Leu Pro Pro Phe Pro
355 360 365
Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asp
370 375 380
Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400
Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Glu
405 410 415
Phe Glu Asn Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430
Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445
Lys Thr Ile Gly Tyr His Lys Ser Gly Ala Ala Gln Leu Lys Phe Ser
450 455 460
Val Ala Gly Pro Ser Asn Met Ala Val Gln Gly Arg Asn Tyr Ile Pro
465 470 475 480
Gly Pro Ser Tyr Arg Gln Gln Val Val Ser Gly Asp Asp Thr Gln Asp
485 490 495
Ala Gly Leu Glu Leu Asn Ile Ala Gly Ala Ser Ser Trp Ala Leu Asn
500 505 510
Gly Arg Asn Ser Leu Met Asn Pro Gly Pro Ala Met Ala Ser His Lys
515 520 525
Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly
530 535 540
Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile
545 550 555 560
Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser
565 570 575
Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln
580 585 590
Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln
595 600 605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620
Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met
625 630 635 640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655
Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr
660 665 670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700
Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val
705 710 715 720
Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735
Claims (77)
1.一种重组腺相关病毒(rAAV)衣壳蛋白,所述衣壳蛋白在亲本序列的VR-IV位点、VR-V位点、VR-VII位点和VR-VIII位点中的一个或多个位点处包含变体多肽序列,其中所述亲本序列包含与SEQ ID NO:463至少95%、至少98%、至少99%或100%相同的序列。
2.如权利要求1所述的衣壳蛋白,其中所述变体多肽序列是亲心性变体多肽序列。
3.如权利要求1或权利要求2所述的衣壳蛋白,其中所述衣壳蛋白在所述亲本序列的所述VR-IV位点处包含变体多肽。
4.如权利要求3所述的衣壳蛋白,其中所述VR-IV位点的所述变体多肽具有序列:
-X1-X2-X3-X4-X5-X6-X7-X8-X9-
其中:
a)X1是G、S或V;
b)X2是Y、Q或I;
c)X3是H、W、V或I;
d)X4是K或N;
e)X5是S、G或I;
f)X6是G或R;
g)X7是A、P或V;
h)X8是A或R;并且
i)X9是Q或D(SEQ ID NO:477)。
5.如权利要求3所述的衣壳蛋白,其中所述VR-IV位点的所述变体多肽包含选自SEQ IDNO:6-104的氨基酸序列。
6.如权利要求3所述的衣壳蛋白,其中所述VR-IV位点的所述变体多肽包含选自GYHKSGAAQ(SEQ ID NO:6)、VIIKSGAAQ(SEQ ID NO:7)、GYHKIGAAQ(SEQ ID NO:8)、SQVNGRPRD(SEQ ID NO:33)和GYHKSGVAQ(SEQ ID NO:9)的氨基酸序列。
7.如权利要求3所述的衣壳蛋白,其中所述VR-IV位点的所述变体多肽包含氨基酸序列GYHKSGAAQ(SEQ ID NO:6)或相对于GYHKSGAAQ(SEQ ID NO:6)包含至多1、2、3或4个氨基酸取代的序列。
8.如权利要求1-7中任一项所述的衣壳蛋白,其中所述衣壳蛋白在所述亲本序列的所述VR-IV位点处包含变体多肽。
9.如权利要求8所述的衣壳蛋白,其中所述VR-V位点的所述变体多肽具有序列:
-X1-X2-X3-X4-X5-X6-
其中:
a)X1是S、L、H、N或A;
b)X2是T、M、K、G或N;
c)X3是S、T、M或I;
d)X4是S、P、F、M或N;
e)X5是F、S、P或L;并且
f)X6是I、V或T(SEQ ID NO:474)。
10.如权利要求8所述的衣壳蛋白,其中所述VR-V位点的所述变体多肽包含选自SEQ IDNO:105-203的氨基酸序列。
11.如权利要求8所述的衣壳蛋白,其中所述VR-V位点的所述变体多肽包含选自LNSMLI(SEQ ID NO:105)、NGMSFT(SEQ ID NO:106)、HKTFSI(SEQ ID NO:107)和SMSNFV(SEQ IDNO:108)的氨基酸序列。
12.如权利要求8所述的衣壳蛋白,其中所述VR-V位点的所述变体多肽包含氨基酸序列LNSMLI(SEQ ID NO:105)或相对于LNSMLI(SEQ ID NO:105)包含至多1、2、3或4个氨基酸取代的序列。
13.如权利要求1-12中任一项所述的衣壳蛋白,其中所述衣壳蛋白在所述亲本序列的所述VR-VII位点处包含变体多肽。
14.如权利要求13所述的衣壳蛋白,其中所述VR-VII位点的所述变体多肽具有序列:
-X1-X2-X3-X4-X5-
其中:
a)X1是V、L、Q、C或R;
b)X2是S、H、G、C或D;
c)X3是Y、S、L、G或N;
d)X4是S、L、H、Q或N;并且
e)X5是V、I或R(SEQ ID NO:475)。
15.如权利要求13所述的衣壳蛋白,其中所述VR-VII位点的所述变体多肽包含选自SEQID NO:204-302的氨基酸序列。
16.如权利要求13所述的衣壳蛋白,其中所述VR-VII位点的所述变体多肽包含选自RGNQV(SEQ ID NO:204)、VSLNR(SEQ ID NO:205)、CDYSV(SEQ ID NO:206)和QHGHI(SEQ IDNO:207)的氨基酸序列。
17.如权利要求13所述的衣壳蛋白,其中所述VR-VII位点的所述变体多肽包含氨基酸序列RGNQV(SEQ ID NO:204)或相对于RGNQV(SEQ ID NO:204)包含至多1、2或3个氨基酸取代的序列。
18.如权利要求1-17中任一项所述的衣壳蛋白,其中所述衣壳蛋白在所述亲本序列的所述VR-VII位点处包含多肽。
19.如权利要求18所述的衣壳蛋白,其中所述VR-VIII位点的所述变体多肽具有序列:
-X1-X2-X3-X4-
其中:
a)X1是S、N或A;
b)X2是V、M、N或A;
c)X3是Y、V、S或G;并且
d)X4是Y、T、M、G或N(SEQ ID NO:476)。
20.如权利要求18所述的衣壳蛋白,其中所述VR-VIII位点的所述变体多肽包含选自SEQ ID NO:303-401的氨基酸序列。
21.如权利要求18所述的衣壳蛋白,其中所述VR-VIII位点的所述变体多肽包含选自ANYG(SEQ ID NO:305)、NVSY(SEQ ID NO:303)、SMVN(SEQ ID NO:304)和NVGT(SEQ ID NO:306)的氨基酸序列。
22.如权利要求18所述的衣壳蛋白,其中所述VR-VIII位点的所述变体多肽包含氨基酸序列ANYG(SEQ ID NO:305)或相对于ANYG(SEQ ID NO:305)包含至多1或2个氨基酸取代的序列。
23.如权利要求18所述的衣壳蛋白,其中所述VR-VIII位点的所述变体多肽包含氨基酸序列NVSY(SEQ ID NO:303)或相对于NVSY(SEQ ID NO:303)包含至多1或2个氨基酸取代的序列。
24.如权利要求1所述的衣壳蛋白,其中所述衣壳蛋白包含与选自SEQ ID NO:402-410的序列至少95%相同的氨基酸序列。
25.如权利要求1所述的衣壳蛋白,其中所述衣壳蛋白包含与SEQ ID NO:402至少95%、至少98%、至少99%或100%相同的氨基酸序列。
26.根据权利要求1所述的衣壳蛋白,其中所述衣壳蛋白包含与SEQ ID NO:403至少95%、至少98%、至少99%或100%相同的氨基酸序列。
27.根据权利要求1所述的衣壳蛋白,其中所述衣壳蛋白包含与SEQ ID NO:404至少95%、至少98%、至少99%或100%相同的氨基酸序列。
28.如权利要求1所述的衣壳蛋白,其中所述衣壳蛋白包含与SEQ ID NO:406至少95%、至少98%、至少99%或100%相同的氨基酸序列。
29.如权利要求1所述的衣壳蛋白,其中所述衣壳蛋白包含与SEQ ID NO:409至少95%、至少98%、至少99%或100%相同的氨基酸序列。
30.如权利要求1所述的衣壳蛋白,其中所述衣壳蛋白包含与SEQ ID NO:483至少95%、至少98%、至少99%或100%相同的氨基酸序列。
31.如权利要求1-23中任一项所述的衣壳蛋白,其中所述衣壳蛋白是AAV5/AAV9嵌合衣壳蛋白。
32.如权利要求31所述的衣壳蛋白,其中所述衣壳蛋白包含来自AAV5衣壳蛋白的至少一个区段。
33.如权利要求31或32所述的衣壳蛋白,其中所述衣壳蛋白包含:
a)包含与SEQ ID NO:411或SEQ ID NO:412至少95%相同的序列的第一区段;
b)包含与SEQ ID NO:413或SEQ ID NO:414至少95%相同的序列的第二区段;
c)包含与SEQ ID NO:415或SEQ ID NO:416至少95%相同的序列的第三区段;
d)包含与SEQ ID NO:417或SEQ ID NO:418至少95%相同的序列的第四区段;
e)包含与SEQ ID NO:419或SEQ ID NO:420至少95%相同的序列的第五区段;
其中至少一个区段来自AAV5衣壳蛋白且至少一个区段来自AAV9衣壳蛋白。
34.如权利要求31所述的衣壳蛋白,其中所述嵌合衣壳蛋白包含与选自SEQ ID NO:445-462的序列至少95%相同的氨基酸序列。
35.如权利要求31所述的衣壳蛋白,其中所述衣壳蛋白包含与SEQ ID NO:457至少95%、至少98%、至少99%或100%相同的氨基酸序列。
36.如权利要求31所述的衣壳蛋白,其中所述衣壳蛋白包含与SEQ ID NO:459至少95%、至少98%、至少99%或100%相同的氨基酸序列。
37.如权利要求31所述的衣壳蛋白,其中所述衣壳蛋白包含与SEQ ID NO:445至少95%、至少98%、至少99%或100%相同的氨基酸序列。
38.如权利要求31所述的衣壳蛋白,其中所述衣壳蛋白包含与SEQ ID NO:446至少95%、至少98%、至少99%或100%相同的氨基酸序列。
39.如权利要求31所述的衣壳蛋白,其中所述衣壳蛋白包含与SEQ ID NO:447至少95%、至少98%、至少99%或100%相同的氨基酸序列。
40.如权利要求31所述的衣壳蛋白,其中所述衣壳蛋白包含与SEQ ID NO:448至少95%、至少98%、至少99%或100%相同的氨基酸序列。
41.一种重组腺相关病毒(rAAV)衣壳蛋白,所述衣壳蛋白包含与SEQ ID NO:463至少95%、至少98%、至少99%或100%相同的序列。
42.如权利要求41所述的衣壳蛋白,其中所述变体多肽序列是亲心性变体多肽序列。
43.如权利要求41或42所述的衣壳蛋白,其中所述衣壳蛋白包含来自AAV5衣壳蛋白的至少一个区段。
44.如权利要求41-43中任一项所述的衣壳蛋白,其中所述衣壳蛋白包含:
f)包含与SEQ ID NO:411或SEQ ID NO:412至少95%相同的序列的第一区段;
g)包含与SEQ ID NO:413或SEQ ID NO:414至少95%相同的序列的第二区段;
h)包含与SEQ ID NO:415或SEQ ID NO:416至少95%相同的序列的第三区段;
i)包含与SEQ ID NO:417或SEQ ID NO:418至少95%相同的序列的第四区段;
j)包含与SEQ ID NO:419或SEQ ID NO:420至少95%相同的序列的第五区段;
其中至少一个区段来自AAV5衣壳蛋白且至少一个区段来自AAV9衣壳蛋白。
45.如权利要求41-44中任一项所述的衣壳蛋白,其中所述嵌合衣壳蛋白包含与选自SEQ ID NO:421-444的序列至少95%相同的序列。
46.如权利要求45所述的衣壳蛋白,其中所述衣壳蛋白包含与SEQ ID NO:434至少95%、至少98%、至少99%或100%相同的氨基酸序列。
47.如权利要求45所述的衣壳蛋白,其中所述衣壳蛋白包含与SEQ ID NO:438至少95%、至少98%、至少99%或100%相同的氨基酸序列。
48.如权利要求45所述的衣壳蛋白,其中所述衣壳蛋白包含与SEQ ID NO:441至少95%、至少98%、至少99%或100%相同的氨基酸序列。
49.一种重组腺相关病毒(rAAV)病毒体,所述病毒体包含:a)如权利要求1至48中任一项所述的衣壳蛋白;和b)包含编码一种或多种基因产物的核苷酸序列的异源核酸。
50.如权利要求49所述的rAAV病毒体,其中所述rAAV病毒体与包含所述亲本序列的AAV病毒体相比,在心脏细胞中表现出增加的转导效率。
51.如权利要求49或50所述的rAAV病毒体,其中所述rAAV病毒体与包含所述亲本序列的AAV病毒体相比,在诱导多能干细胞来源的心肌细胞(iPS-CM)中表现出增加的转导效率。
52.如权利要求49-51中任一项所述的rAAV病毒体,其中所述rAAV病毒体与包含所述亲本序列的AAV病毒体相比,在人心脏成纤维细胞(hCF)中表现出增加的转导效率。
53.如权利要求52所述的rAAV病毒体,其中所述人心脏成纤维细胞位于心脏的左心室中。
54.如权利要求51所述的rAAV病毒体,其中所述rAAV病毒体在100,000的感染复数(MOI)下在iPS-CM细胞中表现出增加至少2倍的转导效率。
55.如权利要求51所述的rAAV病毒体,其中所述rAAV病毒体在75,000的感染复数(MOI)下在iPS-CM细胞中表现出增加至少2倍的转导效率。
56.如权利要求49-55中任一项所述的rAAV病毒体,其中所述rAAV病毒体在C57BL/6J小鼠中表现出增加至少2倍的心脏转导效率,其中所述小鼠被注射2.5E+11vg/只小鼠的病毒体剂量。
57.如权利要求49-55中任一项所述的rAAV病毒体,其中所述rAAV病毒体在C57BL/6J小鼠中表现出增加至少1.5倍的心脏转导效率,其中所述小鼠被注射2E+11vg/只小鼠的病毒体剂量。
58.如权利要求49-55中任一项所述的rAAV病毒体,其中所述rAAV病毒体在C57BL/6J小鼠中表现出增加至少2倍的心脏转导效率,其中所述小鼠被注射1E+11vg/只小鼠的病毒体剂量。
59.如权利要求49-58中任一项所述的rAAV病毒体,其中所述rAAV病毒体与包含所述亲本序列的AAV病毒体相比,在肝细胞中表现出降低的转导效率。
60.如权利要求49-59中任一项所述的rAAV病毒体,其中所述rAAV病毒体与包含所述亲本序列的AAV病毒体相比,表现出改善的NAb逃避。
61.如权利要求49-60中任一项所述的rAAV病毒体,其中所述rAAV病毒体表现出所述rAAV病毒体对心脏细胞比对肝细胞的选择性增加。
62.如权利要求49-61中任一项所述的rAAV病毒体,其中所述rAAV病毒体表现出所述rAAV病毒体对iPS-CM细胞比对肝细胞的选择性增加。
63.如权利要求49-62中任一项所述的rAAV病毒体,其中所述衣壳蛋白包含与SEQ IDNO:404至少95%、至少98%、至少99%或100%相同的序列。
64.如权利要求49-62中任一项所述的rAAV病毒体,其中所述衣壳蛋白包含与SEQ IDNO:483至少95%、至少98%、至少99%或100%相同的序列。
65.一种药物组合物,所述药物组合物包含如权利要求49-64中任一项所述的rAAV病毒体和药学上可接受的载剂。
66.一种编码如权利要求1-64中任一项所述的衣壳蛋白的多核苷酸。
67.一种转导心脏细胞的方法,所述方法包括使所述心脏细胞与根据权利要求49-64中任一项所述的rAAV病毒体接触,其中所述rAAV病毒体转导所述心脏细胞。
68.如权利要求67所述的方法,其中所述心脏细胞是心肌细胞。
69.如权利要求67或68所述的方法,其中所述rAAV病毒体与包含AAV9衣壳蛋白序列的AAV病毒体相比,在所述细胞中表现出增加的转导效率。
70.如权利要求67-69中任一项所述的方法,其中所述rAAV病毒体与包含AAV9衣壳蛋白序列的AAV病毒体相比在75,000的感染复数(MOI)下在所述细胞中表现出增加至少2倍的转导效率。
71.一种将一种或多种基因产物递送至心脏细胞的方法,所述方法包括使所述心脏细胞与如权利要求49-64中任一项所述的rAAV病毒体接触。
72.如权利要求71所述的方法,其中所述心脏细胞是心肌细胞。
73.一种治疗有此需要的受试者的心脏病理的方法,所述方法包括向所述受试者施用治疗有效量的如权利要求49-64中任一项所述的rAAV病毒体或如权利要求61所述的药物组合物,其中所述rAAV病毒体转导心脏组织。
74.如权利要求73所述的方法,其中所述一种或多种基因产物包括MYBPC3、DWORF、KCNH2、TRPM4、DSG2、PKP2和/或ATP2A2。
75.如权利要求73所述的方法,其中所述一种或多种基因产物包括CACNA1C、DMD、DMPK、EPG5、EVC、EVC2、FBN1、NF1、SCN5A、SOS1、NPR1、ERBB4、VIP、MYH7和/或Cas9。
76.如权利要求73所述的方法,其中所述一种或多种基因产物包括MYOCD、ASCL1、GATA4、MEF2C、TBX5、miR-133和/或MESP1。
77.一种试剂盒,所述试剂盒包含如权利要求67所述的药物组合物和使用说明书。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063012703P | 2020-04-20 | 2020-04-20 | |
US63/012703 | 2020-04-20 | ||
PCT/US2021/027979 WO2021216456A2 (en) | 2020-04-20 | 2021-04-19 | Adeno-associated virus with engineered capsid |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115997011A true CN115997011A (zh) | 2023-04-21 |
Family
ID=78269888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180043726.1A Pending CN115997011A (zh) | 2020-04-20 | 2021-04-19 | 具有工程化衣壳的腺相关病毒 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230220014A1 (zh) |
EP (1) | EP4139443A4 (zh) |
JP (1) | JP2023522106A (zh) |
KR (1) | KR20230004719A (zh) |
CN (1) | CN115997011A (zh) |
AU (1) | AU2021259422A1 (zh) |
BR (1) | BR112022021134A2 (zh) |
CA (1) | CA3180202A1 (zh) |
CO (1) | CO2022016592A2 (zh) |
IL (1) | IL297391A (zh) |
MX (1) | MX2022012855A (zh) |
WO (1) | WO2021216456A2 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112022023106A2 (pt) | 2020-05-13 | 2023-01-17 | Voyager Therapeutics Inc | Redirecionamento de tropismo de capsídeos de aav |
US20230241249A1 (en) * | 2020-07-07 | 2023-08-03 | The Board Of Regents Of The University Of Texas System | Adeno-associated virus vector for dwarf open reading frame |
KR20230043869A (ko) | 2020-08-07 | 2023-03-31 | 스페이스크래프트 세븐, 엘엘씨 | Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법 |
WO2023060264A1 (en) | 2021-10-08 | 2023-04-13 | Dyno Therapeutics, Inc. | Capsid variants and methods of using the same |
WO2023091934A1 (en) * | 2021-11-16 | 2023-05-25 | California Institute Of Technology | Adeno-associated virus compositions having preferred heart and skeletal muscle enrichment |
TW202404993A (zh) | 2022-04-11 | 2024-02-01 | 美商特納亞治療股份有限公司 | 具經工程化蛋白殼之腺相關病毒 |
WO2024038345A1 (en) * | 2022-08-19 | 2024-02-22 | Lubrizol Advanced Materials, Inc. | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes |
WO2024064863A2 (en) * | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors |
WO2024191778A1 (en) | 2023-03-10 | 2024-09-19 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3561062A1 (en) * | 2013-09-13 | 2019-10-30 | California Institute of Technology | Selective recovery |
WO2015164757A1 (en) * | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
WO2017100671A1 (en) * | 2015-12-11 | 2017-06-15 | California Institute Of Technology | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) |
MX2020010466A (es) * | 2018-04-03 | 2021-01-08 | Vectores de virus que evitan anticuerpos. | |
CN112040988A (zh) * | 2018-04-27 | 2020-12-04 | 海德堡大学 | 修饰的aav衣壳多肽用于治疗肌肉疾病 |
WO2020068990A1 (en) * | 2018-09-26 | 2020-04-02 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
-
2021
- 2021-04-19 CA CA3180202A patent/CA3180202A1/en active Pending
- 2021-04-19 JP JP2022563387A patent/JP2023522106A/ja active Pending
- 2021-04-19 AU AU2021259422A patent/AU2021259422A1/en active Pending
- 2021-04-19 IL IL297391A patent/IL297391A/en unknown
- 2021-04-19 CN CN202180043726.1A patent/CN115997011A/zh active Pending
- 2021-04-19 WO PCT/US2021/027979 patent/WO2021216456A2/en active Application Filing
- 2021-04-19 KR KR1020227040546A patent/KR20230004719A/ko unknown
- 2021-04-19 EP EP21793043.7A patent/EP4139443A4/en active Pending
- 2021-04-19 BR BR112022021134A patent/BR112022021134A2/pt not_active Application Discontinuation
- 2021-04-19 US US17/996,611 patent/US20230220014A1/en active Pending
- 2021-04-19 MX MX2022012855A patent/MX2022012855A/es unknown
-
2022
- 2022-11-17 CO CONC2022/0016592A patent/CO2022016592A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021216456A2 (en) | 2021-10-28 |
BR112022021134A2 (pt) | 2023-02-14 |
EP4139443A4 (en) | 2024-08-14 |
AU2021259422A1 (en) | 2022-12-08 |
US20230220014A1 (en) | 2023-07-13 |
CA3180202A1 (en) | 2021-10-28 |
JP2023522106A (ja) | 2023-05-26 |
KR20230004719A (ko) | 2023-01-06 |
EP4139443A2 (en) | 2023-03-01 |
IL297391A (en) | 2022-12-01 |
CO2022016592A2 (es) | 2022-11-29 |
WO2021216456A3 (en) | 2021-12-02 |
MX2022012855A (es) | 2023-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115997011A (zh) | 具有工程化衣壳的腺相关病毒 | |
US12104165B2 (en) | Adeno-associated virus with engineered capsid | |
WO2018222503A1 (en) | Adeno-associated virus with variant capsid and methods of use thereof | |
JP7432621B2 (ja) | 選択的遺伝子調節のための組成物および方法 | |
US20220088143A1 (en) | Angiogenic conditioning to enhance cardiac cellular reprogramming of fibroblasts of the infarcted myocardium | |
JP2022522196A (ja) | ラミノパシーを処置するための組成物および方法 | |
JP7408838B2 (ja) | コドン最適化されたgla遺伝子およびその使用 | |
JP2024050766A (ja) | 改変ウイルスカプシド | |
WO2023200742A2 (en) | Capsids for plakophillin-2 gene therapy | |
IL297437A (en) | Anti-hemoglobin (hjv) antibodies for the treatment of myelofibrosis | |
US20230103731A1 (en) | Gene vector control by cardiomyocyte-expressed micrornas | |
TW202404993A (zh) | 具經工程化蛋白殼之腺相關病毒 | |
WO2024215655A1 (en) | Cardioprotective bag3 therapies | |
EA046157B1 (ru) | Композиции и способы селективной регуляции экспрессии генов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |